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Rheumatoid arthritis (RA) is a common, chronic, autoimmune, inflammatory disease
characterized by persistent synovitis that results in the progressive destruction ofjoints. The
cellular and molecular basis of the inflammation is complex and multifactorial. During the
progression of the disease many types of cells are activated, which in turn secrete a variety of
mediators, including cytokines, which initiate and perpetuate the disease.
Rat adjuvant-induced unilateral arthritis is a well established RA disease model and
use of this model has facilitated the understanding of the pathology of joint inflammation.
The model closely mimics the pathology of human RA, including histopathological changes,
cell infiltration, as well as hypersensitivity and swelling of the joint. Measurements of
spontaneous pain and hypersensitivity states are assessed in this model. However, no
objective measure of joint hypersensitivity is used to assess experimental arthritic joint pain
in laboratory rodents. To that end, the pressure application device (PAD) was developed to
align pre-clinical measures to those used clinically and help the translation of animal studies
to human conditions. PAD was able to detect FCA-induced hypersensitivity in mice and
rats, observed as a decrease in limb withdrawal thresholds (LWTs) of around 60% and 40%
respectively, compared with basal levels in normal joints. PAD subsequently detected
prednisolone analgesia in both species, which was abolished after dosing ceased. PAD also
showed significant reversal of evoked mechanical hypersensitivity in arthritic animals
treated with morphine or celecoxib, which was comparable to that measured by the weight
distribution readout. PAD provides a novel, accurate behavioural tool for detecting localised
primary mechanical hypersensitivity in two animal models of chronic inflammatory joint
pain.
The infiltration of cells and release of inflammatory proteins in the synovial tissue
and joint space is a key characteristic of synovitis. Measuring the levels of these in the
synovial fluid can provide information about the underlying pathophysiology of joint
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disease. Furthermore changes occurring in the synovial fluid can be used as biomarkers of
disease; therefore the joint perfusion method was developed to evaluate the inflammatory
protein and cell content of rat knee joints, to further validate the adjuvant-induced arthritis
model, as well as to determine the effects of inflammatory insults or the effect of anti¬
inflammatory, analgesic or anti-rheumatic drugs. This technique proved to be reliable and
consistent when perfusing the joint cavity, and regular volumes of sample were easily
collected. This technique is therefore a valuable addition to protocols which use
homogenates of entire joints to assess inflammatory mediator content.
The temporal expression patterns of cytokines and inflammatory cells in the knee
joints of rats following induction of arthritis were determined using the novel perfusion
technique. Cytokine expression altered over time as arthritis progressed from the acute to
the more "chronic" phase. The proportion of inflamed joints that contained detectable levels
of each mediator measured was significantly increased during the study. This suggests that it
may be the presence of the protein, even at low levels, that is important for the development
and maintenance of joint inflammation and hypersensitivity. In addition, significant
correlations between measures of joint swelling or mechanical hypersensitivity and levels of
cytokines in inflamed joints were seen. Prednisolone did not affect the absolute levels of
cytokines in inflamed joints, although it reduced the percentage of inflamed joints that
contained detectable levels of ILla and IL6. This suggests that the steroid appears to have
an all-or-none effect in terms of cytokine expression levels in this study.
The roles of ILip and IL6 in joint pain and inflammation were assessed. The
contribution of the activity of primary afferent fibres to joint pain and hypersensitivity after
administration of intra-articular ILip or IL6 was investigated by recording action potentials
from primary afferent nerves innervating the knee joint. IL1 p caused a transient increase in
the frequency of basal neural discharge by 88% within three hours. It also decreased the
threshold of mechanical stimulation required to evoke neural activity by 50% between one
and four hours after injection. In contrast, IL6 did not affect the frequency of basal neural
vi
discharge or the mechanical threshold. Neither ILip nor IL6 affected the neural discharge
frequency to mechanical stimulation above the threshold. The induction of basal neural
activity resembles the occurrence of spontaneous pain during inflammation, such as that
measured by the incapacitance tester as a result of intra-articular IL1 p or IL6. A reduction in
the LWT, measured by PAD, following ILip or IL6 occurred within a few hours, similar to
the decrease in the mechanical threshold to von Frey hairs in primary afferents after ILip, as
a result of neuronal sensitization. Although ILip or IL6 did not cause swelling of the joint,
they did induce mechanical hypersensitivity within a couple of hours, which lasted for up to
four days. Intra-articular IL1 p or IL6 had no effect on joint structure, bone or cartilage.
ILip and IL6 evoked increases in the expression of ILip, IL6 and TNFa within the first
eight hours, and additionally elevated levels of ILla, IL2, IL4 (IL6-treated only) and IL10
(ILlp-treated only) from day one post administration. ILip also resulted in recruitment of
inflammatory cells into the synovial cavity one day after administration.
In conclusion, this study has developed and validated two novel techniques to study
experimental joint pain and inflammation in rodents; the behavioural measure of joint
mechanical hypersensitivity, PAD; and the joint perfusion technique to assess inflammatory
mediator and cell content of synovial fluid. These methods have been used alongside other
techniques to show the temporal cytokine expression patterns during adjuvant-induced
arthritis and the relationship of these to swelling and hypersensitivity of the joint. The roles
of ILip and IL6 in evoking joint pain and hypersensitivity were also investigated. This data
supports the hypothesis that ILip and IL6 are directly involved in the development of joint
pain, but cannot alone elicit swelling or joint damage at doses sufficient to evoke
hypersensitivity. Furthermore, similarities between this animal model of joint disease and
human RA have been demonstrated that further validate the model as a valuable pre-clinical
tool to study the inflammatory process of human RA. Moreover, consolidation of these
similarities helps improve the confidence of novel drug screening using this model prior to
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This chapter will give an overview of historical and more recent work surrounding
the main themes of this thesis, including the pathology of arthritis, the roles of immune cells
and cytokines in this disease as well as commonly used experimental models ofjoint disease.
In addition, central and peripheral mechanisms of inflammatory pain and nociception will be
discussed alongside the roles of various mediators and receptors involved in these processes.
1.1 ARTHRITIS
Arthritis can be divided according to its primary pathology into rheumatoid arthritis
(RA) and osteoarthritis (OA).
1.1.1 OSTEOARTHRITIS
OA is a slowly progressing degenerative disease that mainly affects synovial joints
through non-immune processes. It is commonly associated with one joint, and is usually the
result of "wear and tear". The main clinical symptoms are joint swelling, stiffness, reduced
function and a decrease in quality of life due to persistent, chronic pain (Scott, 2006). In
OA, cartilage of the affected joint gradually roughens and becomes thin, the bone underneath
thickens and at the edge of the joint it grows outward (see Figure 1.1). The synovium
produces extra fluid resulting in joint swelling. The capsule and ligaments slowly thicken
and contract to stabilize the joint as it changes shape. Muscles around the joint weaken and
become wasted. In severe OA, the cartilage can degrade completely, so it no longer covers
the thickened bone ends causing them to touch and start to wear away. The loss of cartilage,
the wearing of bone and the bony overgrowth at the edges can change the shape of the joint,





RA is a common chronic autoimmune, inflammatory disease characterized by
persistent synovitis that results in progressive destruction of affected joints. Its prevalence
within the general population of the UK is 1.16% in women and 0.44% in men (Symmons et
al., 2002), these figures show a decrease since 1961, when the last age- and sex- specific
estimates of the prevalence of RA were published (Lawrence, 1961). The disease can occur
at any age, but it is most common in those aged 40 - 70 years, its incidence increasing with
age. Pain is the most prominent symptom associated with arthritis (Anderson et al., 1994;
Heiberg & Kvien, 2002; Kazis et al., 1983; McKenna & Wright, 1985) and a common basis
for primary care consultation (Mantyselka et al., 2001; Rekola et al., 1993; Uhlig et al.,
2002). From a random sample of 120 RA patients, 47% ranked pain relief as the most
desirable objective of their treatment (Gibson & Clark, 1985).
The past decade has seen major transformations in the treatment of RA in terms of
both approach and choice of drugs. Previously, initial management consisted mainly of non¬
steroidal anti-inflammatory drugs (NSAIDs), which reduce joint inflammation, with the hope
of improving the associated pain; then disease modifying anti-rheumatic drugs (DMARDs)
were prescribed once clear evidence of erosions were seen. More recently, DMARDs have
been introduced to treatment regimes much earlier following diagnosis, and are used in
combination therapy in patients with the potential for progressive disease (Lee & Weinblatt,
2001), as they not only improve inflammatory symptoms, but also slow the progression of
the underlying pathology and joint destruction.
RA is a systemic inflammatory disease, it can affect many tissues and organs (Scott,
2006) and causes general ill health. However, it principally attacks the joints, producing a
progressive synovitis that often progresses to destruction of the articular cartilage and
erosion of the bone due to persistent inflammation of the joint (see Figure 1.1). RA is a
polyarthritis and is usually present in multiple joints; in synovial joints the inflammation is
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symmetrical, with joints on both sides of the body equally affected (Scott, 2006). Although
the cause of RA remains unknown, autoimmunity appears to play a pivotal role in its
chronicity and progression (Glynn, 1968).
B C
Figure 1.1 Comparison of a normal joint (A), a severe RA knee joint (B) and a severely deformed
knee joint due to OA (C). The normal joint has a thin synovial lining and smooth surfaces on the bone
and cartilage. The RA joint shows a marked thickening of the synovial membrane, due to the
infiltration of inflammatory cells, which also invade surrounding tissues and the joint space. The
principal features of OA include loss of articular cartilage, new bone formation in the subchondral
region, and formation of new cartilage and bone at the joint margins (adapted from
ArthritisResearchCampaign, 2004).
Anatomy of the knee joint and changes during RA
The synovium serves as a source of nutrients for cartilage as the cartilage itself is
avascular (Gray, 1918). In addition, synovial cells (synoviocytes) synthesize joint lubricant
such as hyaluronic acid, as well as collagens and fibronectin that constitute the structural
framework of the synovial interstitum (Gray, 1918). In a normal joint the synovial lining
consists of a very thin membrane, just a few cells thick, which isolates the largely acellular
joint space (Bathon, 2005). During RA, synovitis or inflammation of the synovium occurs,
involving a significant thickening of the synovial membrane as a result of a marked increase
in macrophage-like and fibroblast-like synoviocytes as well as the invasion of inflammatory
cells, mostly polymorphonuclear (PMN) leukocytes, into the synovial membrane and joint
space (Bathon, 2005).
The subintimal area of synovium is where the synovial blood vessels are located;




































inflammatory cells, including T and B lymphocytes, macrophages and mast cells (Harris,
1990). This is accompanied by angiogenesis, the growth of new blood vessels, which supply
nutrients and oxygen to the augmented inflammatory cell mass, thus contributing to the
perpetuation of synovitis (Taylor & Feldmann, 2004). However, the new blood vessel
network is dysfunctional and fails to restore tissue oxygen homeostasis, so the rheumatoid
joint remains a hypoxic environment (Mapp et al., 1995).
One of the characteristic features of RA is the formation of pannus, the tissue
formed at the boundary of the cartilage and the synovial lining (Rosenberg, 1999). It is a
fibrocellular mass of synovium consisting of both synoviocytes and inflammatory cells. The
aggressive front of pannus overgrows healthy cartilage from the border with the synovium
and destroys local articular structures. Within the pannus tissue, mediators are released,
including neuropeptides, cytokines, oxygen radicals and lysosomal and matrix
metalloproteinase (MMP) enzymes that perpetuate the inflammation and which cause
cartilage destruction and bone erosion (Chu et al., 1992). After the cartilage has been
destroyed the pannus bridges the apposing bones and eventually ossifies (Rosenburg, 1999).
The joint cartilage consists of chondrocytes embedded in a highly structured matrix;
it is a resilient tissue that absorbs considerable impact and stress. Chondrocytes are
connective tissue cells that produce and maintain the cartilaginous matrix. In cartilage from
RA patients, the collagen is impaired both structurally and functionally due to the production
of proteolytic enzymes both by synovial lining cells and the chondrocytes themselves.
During RA the synthesis of the matrix components are reduced and the breakdown of the
cartilage matrix is enhanced. PMNs within the synovial fluid also contribute to cartilage
breakdown (Bathon, 2005). In RA, the bone becomes eroded by the invading synovium via
release of mediators such as prostaglandins (PGs) and proteases by the synovial cells and
osteoclasts (multinucleated cells that degrade and reabsorb bone, which are involved in the
natural turnover of bone tissue).
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The synovial cavity is normally a space filled with hyaluronic acid and very few
cells, however, in RA large amounts of fluid collect which are filtrates of plasma with high
protein content. The synovial fluid is highly inflammatory in RA joints.
Cellular component of RA
During the course of RA, the normally acellular synovium becomes heavily
infiltrated by a wide variety of cells which migrate from proliferating blood vessels.
Variable numbers of T cells, B cells, plasma cells, macrophages, dendritic cells (antigen-
presenting cells), fibroblasts, granulocytes and endothelial cells are dispersed throughout the
synovium (Haraoui et al., 1991; Harris, 1990; Muller-Ladner et al., 1997; Tak, 2000), see
Figure 1.2 and 1.3 for a summary.
After the initiating event ofRA, an influx ofCD4+ T cells into the synovium begins
(Goronzy & Weyand, 1995). CD4 is a glycoprotein, part of the immunoglobulin (Ig) family,
expressed on the surface of T helper cells, regulatory T cells and dendritic cells. On T cells,
CD4 is the co-receptor for the T cell receptor; it amplifies the signal by the T cell receptor by
recruiting tyrosine kinases essential for activating many molecules involved in the signalling
cascade of an activated T cell. T cells recruited to the synovium are activated and release
several cytokines, which activate monocytes, macrophages and fibroblasts. Although there
appear to be large numbers of CD4+ T cells in the synovium throughout the disease course,
they are mostly inactive in the chronic phase of the disease (Firestein & Zvaifler, 2002).
This is shown by the fact that T-cell derived-cytokines are present in low levels (Smeets et
al., 1998) compared with macrophage and fibroblast-derived cytokines within the synovium
(Firestein et al., 1990). Moreover, experimental T-cell directed therapies have had limited
success (Fox, 1997).
Fibroblast- and macrophage-like cells accumulate in the lining layer of the
synovium (Barland et al., 1962; Ghadially & Roy, 1966) where they produce large amounts
of proinflammatory cytokines, chemokines and angiogenic molecules which activate signal
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transduction pathways and transcription factors, which, in turn control the transcription of
further pro- and anti-inflammatory cytokines (Sweeney & Firestein, 2004). This maintains
the inflammatory cells in an activated state promoting the maturation of newly recruited
monocytes and macrophages, resulting in a positive feedback cycle, perpetuating the
inflammatory reaction.
Synovial tissue macrophages are multifunctional cells that have biological functions
that may be either destructive or protective (Burmester et al., 1997). When activated they
demonstrate increased expression and transcription of interleukin (IL) ip, tumour necrosis
factor (TNF) a and the monocyte chemo-attractant protein. Macrophages and fibroblasts
appear to be largely responsible for creating a self-perpetuating state of chronic
inflammation in which continuing T cell participation may not be critical once the
inflammatory reaction has begun (see Figure 1.3; Bathon, 2005).
In contrast to the rheumatoid synovial tissue of patients with RA, which is infiltrated
with lymphocytes and macrophages, the predominant cell type in the synovial fluid is
neutrophils (Chatham et al., 1993). Neutrophils are recruited in large numbers to the
rheumatoid synovium via expression of adhesion molecules on endothelial cells. This
process is enhanced by cytokines, specifically IL8, a potent and specific chemo-tactic
stimulus for neutrophils (Caswell et al., 1999). Neutrophils are seen at the site of the
cartilage-pannus junction (CPJ), where synovial tissue penetrates the degrading cartilage.
Here they contribute to joint destruction (Mohr & Menninger, 1980). Far more neutrophils
accumulate in synovial exudates than in surrounding tissue. They produce various cartilage
degrading enzymes including MMPs (Choy & Panayi, 2001). Activated neutrophils in the
synovial fluid release oxygen free radicals, resulting in damage to the joint via breakdown of



















































Figure 1.2. The process of synovial inflammation in RA. Exposure of genetically predisposed
patients to an unknown trigger initiates a cascade of events leading to an autoimmune response, in
which many inflammatory mediators are involved, including interleukins, tumour necrosis factor,
fibroblast growth factors, platelet-derived growth factors, monocyte- and neutrophil-stimulating
peptides, granulocyte macrophage - colony stimulating factor, PGs and nitric oxide (NO). Illustration





Figure 1.3. Macrophages and fibroblasts are adjacent to one another in the synovial intimal lining
and produce cytokines that can activate either themselves or their neighboring cells. Pro¬
inflammatory cytokines (+) and anti-inflammatory proteins (-) are indicated (Diagram from Firestein,
2003).
B cells, dendritic cells, T cells and macrophages form lymphoid-like structures
within the synovial membrane and produce antibodies (Smolen et al., 2005), including
rheumatoid factor, an antibody against IgG. These auto-antibodies form immune complexes
and are deposited in the cartilage of RA patients (Cooke et al., 1975). The stimulus for
maturation of B cells to Ig secreting plasma cells was thought to be CD4+ T cells; however,
as stated above, T cells are not activated in the chronic phase of RA. IL6 however is also a
potent stimulus for this maturation (Hirano, 1992); thus, IL6 from synovial fibroblasts is
likely to be providing the T cell independent stimulus for continuous plasma cell activation
and rheumatoid factor production (Bathon, 2005). Plasma cells have been implicated in joint
destruction at the CPJ (Kobayashi & Ziff, 1975).
Chondrocytes are activated by IL1 and TNF, resulting in the production of
proteolytic enzymes, therefore contributing to the destruction of their own cartilage matrix
(Borden et al., 1996). Chondrocyte derived cells are known to appear in the proliferating
pannus (Allard et al., 1987). In contrast with enzyme-mediated cartilage degradation, bone
destruction depends on osteoclasts (Gravallese, 2002); these cells are not present in the
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inflamed joints of non-destructive arthritis. Osteoclasts are formed by fusion with
monocytes.
Increased numbers ofmast cells have been found in the synovial tissue and fluid of
patients with RA (Tetlow & Woolley, 1995), especially at the site of cartilage erosion
(Bromley et al., 1984). Mast cells are found in connective tissue, and contain numerous
basophilic granules and release substances such as heparin and histamine in response to
injury or inflammation of bodily tissues. Local accumulations ofmast cells were observed in
approximately 50% of chronic RA synovial tissue samples from the CPJ (Tetlow &
Woolley, 1995); evidence of cell activation was present in most samples. Furthermore, mice
that lack mast cells are resistant to inflammatory erosive arthritis induced by arthritogenic
serum (Lee et al., 2002). Mast cells contain many inflammatory mediators, which if released
could contribute to the rheumatoid lesion. They are the major source of tissue histamine and
raised levels of histamine have been recorded both in the peripheral blood and synovial fluid
of patients with RA (Partsch et al., 1982).
1.2 CYTOKINES IN RA
Cytokines are small protein molecules produced by many cells that modulate the
function of other cell types, see below for more detail and Table 1.1 for a summary.
Cytokine production is stimulated by numerous factors, including endotoxin, immune
complexes, toxins, physical injury and inflammatory processes such as other cytokines
(Billingham, 1987). Cytokines have effects in acute and chronic inflammation. They can act
on the same cell that produces them in an autocrine fashion; on cells in the immediate
vicinity, for example in joint spaces via a paracrine effect; or alternatively by an endocrine




Cytokines are produced during immune and inflammatory responses, and secretion
of these mediators is transient and closely regulated. They are not stored within cells, but are
produced and secreted as necessary. Many cell types make and release multiple cytokines,
and each protein is pleiotropic, in that it has a variety of actions on a variety of different cell
types. They are multi-functional; each cytokine may have both positive and negative
regulatory actions. Cytokines mediate their effects by binding to specific cell-surface
receptors on target cells; these receptors can be regulated by both endogenous and exogenous
signals. Despite their pleiotropic effects, cytokines can be divided into five groups, based on
their major functions, or the nature of the target cell (Collins, 1999):
• Cytokines that regulate lymphocyte function: regulate activation, growth and
differentiation of lymphocytes, includes IL2, IL4, IL10 and transforming growth factor p
(TGFp).
• Cytokines involved with natural immunity, includes TNFa, IL1 (3, interferon (IFN) a, IFNp
and IL6
• Cytokines that activate inflammatory cells', includes IFNy, TNFa, TNFp, IL5, IL10 and
IL12.
• Chemokines: characterized by chemo-tactic activity for leukocytes.
• Cytokines that stimulate haematopoiesis: mediate immature leukocyte growth and
differentiation. Includes IL3, IL17, granulocyte macrophage - colony stimulating factor
(GM-CSF), Monocyte - CSF, granulocyte - CSF and stem cell factor.
The levels of pro-inflammatory cytokines are elevated in the joints and blood of
patients with RA (Chikanza et al., 1995a; Eastgate et al., 1988; Houssiau, 1995; Houssiau et
al., 1988; Ozaki et al., 2001; Saxne et al., 1988). Anti-inflammatory cytokines also exist,
including IL10 and IL4, which cooperate to inhibit the production of pro-inflammatory
mediators. Anti-inflammatory cytokines are also elevated in the joints of patients with RA.
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In chronic inflammation, such as RA, an imbalance between pro- and anti-inflammatory
mediators develops, resulting in cellular damage and destruction of cartilage and bone.
There are many pro- and anti-inflammatory cytokines known to be involved in RA,
but for the purpose of this thesis only IL1, IL2, IL4, IL6, IL10, GM-CSF, IFNy and TNFa
will be described, see Table 1.1 and Figures 1.2 and 1.3 for a summary of some key
mediators and their roles in RA.
Effects IL1 TNFa IL6 GM-CSF IFNy
MC/MP activation T t — t T
Mononuclear cell infiltration T T t T ^T-cells only
Synovial vascularization
— — 1? —
Synovial fibrosis/ hyperplasia t r f? — 1
Cartilage breakdown T T |? f? 1
Bone resorption T T t? It




Table 1.1. Possible roles of some pro-inflammatory cytokines in the RA joint (table modified from
Rickard & Gowen, 1993).
1.2.1 TUMOUR NECROSIS FACTOR a (TNFa)
TNFa is produced primarily by monocytes and macrophages, but also by T cells, B
cells, Natural Killer cells and fibroblasts (Tracey & Cerami, 1994) and its production can be
stimulated by several factors, including lipopolysaccharide (LPS), IL1, GM-CSF, TNFa
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itself, hypoxia, oxygen radicals and complement activation. TNFa is a potent cytokine,
which exerts a diverse range of effects. It is an autocrine stimulator as well as a potent
paracrine inducer of other inflammatory cytokines including IL1, IL6, IL8, GM-CSF and
MMPs and collagenase (Brennan et cil., 1989; Butler et al., 1995). Furthermore, it induces
the production of PGs, increases the expression of adhesion molecules and may facilitate
osteoclastogenesis and bone resorption (Dayer et al., 1985; Lader & Flanagan, 1998).
TNFa is found in high levels in RA synovial fluid and pannus (Field et al., 1991)
and its expression has been positively correlated with synovitis and erosions (Field et al.,
1991; Neidel et al., 1995). Several lines of evidence suggest a crucial role for TNFa in
initiating inflammatory arthritis (Feldmann et al., 1996); TNFa transgenic mice, which
express human TNFa constitutively, can spontaneously develop an inflammatory,
destructive polyarthritis (Keffer et al., 1991). Furthermore, inhibiting TNFa activity
constitutively by monoclonal antibodies in these animals prevents the development of
spontaneous arthritis in mice (Keffer et al., 1991). In addition, TNFa knockout mice are
resistant to the development of experimental synovitis (Henderson & Pettipher, 1989;
Hultgren et al., 1998). During collagen-induced arthritis (CIA) in mice, blocking TNFa with
a soluble TNF-receptor fusion protein or with monoclonal antibodies ameliorates disease
activity and reduces the severity of joint damage (Williams et al., 1992; Wooley et al.,
1993b). Moreover, intra-articular injection of TNFa can directly induce joint inflammation
and damage in rats (Campagnuolo et al., 2003).
Clinically, anti-TNFa treatment potently inhibits arthritis (Feldmann & Maini,
2003). Currently three TNF antagonists are approved for the treatment of RA: infliximab (a
chimeric monoclonal antibody to TNF), adalimumab (a human monoclonal antibody to
TNF) and etanercept (a fusion protein of the p75 receptor; for reviews see Alldred, 2001;
Emery, 2001; Furst et al., 2003; Goldenberg, 1999; Hochberg et al., 2003; Jobanputra et al.,
2002). All three treatments have proved efficacious in patients who failed to respond
sufficiently to methotrexate treatment. Infliximab and adalimumab are antibodies to TNFa,
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whereas etanercept mimics one of the endogenous TNFa receptors, thus binding free TNFa
protein. They work by binding to TNFa and preventing it from interacting with receptors on
cell surfaces. This blocks the processes described above, decreasing the overactivity of the
immune system (particularly in the joints), helping to relieve joint pain and swelling, and
slowing down or even stopping joint damage caused by RA.
1.2.2 INTERLEUKIN 2 (IL2)
IL2 is a T cell-derived cytokine which is present at relatively low levels in the joints
of RA patients, compared with levels of macrophage- and fibroblast-derived products
(Firestein et al., 1990). Results from IL2 studies in arthritis are conflicting;
immunohistochemical analysis of tissue sections from RA patients revealed lymphokine
expression in 0.1-0.3% of T cells, particularly IL2 and DFN y (Steiner et al., 1999).
Furthermore, considerable IL2-like activity is detected in the synovial fluid but not in the
peripheral blood (Boyum, 1968; Lefkovits & Waldmann, 1979; Wood et al., 1983). In vitro
production of IL2 in cultures of synovial fluid lymphocytes has been reported as diminished
(Bolhuis et al., 1978) and enhanced (McKenna et al., 1986; Wood et al., 1983).
Furthermore, IL2-responsiveness of synovial fluid lymphocytes has been shown to be
increased by some groups (Gillis et al., 1978), but reduced by others (Taetle & Royston,
1980). Adjuvant-induced arthritis in rats, a T-cell dependent disease, leads to T-cell
activation and proliferation, processes in which the de novo expression of the IL2 receptor
plays a pivotal role. Intra-peritoneal EL2-PE40, a cytotoxic IL2-Pseudomonas endotoxin
fusion protein, proved to be an effective and specific modifier of adjuvant arthritis, based on
clinical, histological and radiographic assessment (Case et al., 1989).
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1.2.3 INTERLEUKIN 4 (IL4)
IL4 is an anti-inflammatory cytokine produced by CD4+ T cells and participates in
the differentiation and growth of B cells (Isomaki & Punnonen, 1997). In vitro IL4 inhibits
the activation of T cells which, in turn, decreases the production of IL1 and TNFa and
inhibits cartilage damage (van Roon et al., 1996). Furthermore, IL4 inhibits the production
and functions of IL6 and IL8 (Ralph et al., 1992; Sugiyama et al., 1995; Vannier et al.,
1992), induces T helper cells and inhibits MMP production. In cultures of synovium
samples from patients with RA, IL4 increased the expression of IL1 receptor antagonist
(Vannier et al., 1992) and soluble TNFa receptors (Joyce et al., 1994) both of which reduce
inflammation (Chomarat et al., 1995). Recombinant IL4 has been tested in patients with
RA; however, the clinical efficacy of the treatment has been disappointing, perhaps due to
the short half life of the substances (Choy & Panayi, 2001).
1.2.4 INTERLEUKIN 10 (IL10)
IL10 is another anti-inflammatory cytokine which is produced by monocytes,
macrophages, B cells and T cells. It inhibits the production of several other cytokines,
including IL1 and TNFa and the proliferation of T cells in vitro (Isomaki & Punnonen,
1997). IL10 can also reverse the cartilage degradation mediated by antigen-stimulated
mononuclear cells from patients with RA (van Roon et al., 1996). Although IL10 is found in
the synovial fluid of these patients (Cush et al., 1995; Isomaki et al., 1996), the amount may
be insufficient to suppress inflammation (Katsikis et al., 1994). Like IL4, recombinant IL10
has been tested in patients with RA, in a phase I dose-ranging study in patients with active
RA, administration of recombinant human IL-10 at a dose of 5 pg kg"1 by daily subcutaneous
injection resulted in a trend towards improvement in disease activity, compared with placebo
recipients, after 4 weeks of administration (Maini et al., 1997).
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1.2.5 GRANULOCYTE MACROPHAGE - COLONY STIMULATING
FACTOR (GM-CSF)
GM-CSF is a growth factor synthesized by macrophages, fibroblasts, endothelial
cells and activated lymphocytes (Groopman et al., 1989). As well as promoting the growth
and differentiation of granulocytes and macrophages, it is known to have several other pro¬
inflammatory roles, including increasing the secretion of IL1, TNFa and prostaglandin E2
(PGE2) release from macrophages (Fischer et al., 1988; Heidenreich et al., 1989) as well as
amplification of cartilage destruction by IL1 and TNF (Alvaro-Gracia et al., 1989).
1.2.6 INTERFERON y (IFNy)
It is likely that IFNy, as a T cell-derived cytokine, is involved in the early stages of
RA. IFNy specifically inhibits TNFa mediated matrix degradation therefore lack of IFNy
and over-production of TNFa by tissue macrophages suggests that the destructive actions of
TNFa proceed almost unopposed. In bone and cartilage IFNy inhibits matrix resorption by
blocking osteoclast precursor proliferation and multinucleated osteoclast formation and by
reducing MMP synthesis respectively. IFNy appears to have no more therapeutic value than
placebo in the management of RA, because its effectiveness is dependent upon disease stage
and its ability to block only the actions of TNFa and not those of IL1 (Veys et al., 1997).
1.3 INTERLEUKIN 1 tlL1)
1.3.1 FORMATION
There are two distinct related IL1 glycoproteins, ILla and ILip, which are encoded
by separate genes; in most human tissues ILip messenger ribonucleic acid (mRNA)
predominates (Arai et al., 1990). The gene which encodes ILip is not spontaneously
expressed but can be stimulated by LPS, complement components or ILip itself. ILla and
ILip are synthesized as 31 kilo Dalton (kD) precursors (pro-ILl) and converted to 17 kD
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active glycoproteins, by interleukin converting enzyme (ICE), also known as caspase-1,
which is present in many cell types. Pro-ILla can be found on the surface of cells in a
biologically active form, whereas pro-ILip requires cleavage for its optimal secretion and
biological activity (Dinarello, 1994a). IL1 can be produced and released by a range of cells
including macrophages, fibroblasts, keratinocytes, T- and B-lymphocytes, astrocytes,
microglia, endothelial cells, smooth muscle cells and chondrocytes.
1.3.2 RECEPTORS
There are two main receptors of the IL1 family, IL1 receptor type I and type II (IL1
RI and IL1 RII respectively), they are encoded by a common receptor gene (Sims et al.,
1995). Both receptors have a single transmembrane domain, and the extracellular portions of
each receptor are homologous (26-28%) and contain three Ig-like domains. However,
whereas the IL1 RI has a long cytosolic domain (213 amino acids; Sims et al., 1988) that of
the IL1 RII is relatively short (29 amino acids; McMahan et al., 1991). It is therefore not
surprising that IL1 RII is not involved in cell-signalling pathways (Sims et al., 1993).
IL1 RI is an 8 kD glycoprotein found at low levels on nearly all cells. It is heavily
glycosylated and blocking the glycosylation sites reduces the binding of IL1 (Mancilla et al.,
1992). Primary cells usually express less than 200 and in some cases less than 50 receptors
per cell; IL1 signal transduction has been observed in cells expressing less than 10 per cell
(Dinarello, 1994b). However, the number of cell surface receptors rises rapidly on exposure
to inflammatory mediators including IFNy, IL1, IL2, IL4, PGE2, platelet derived growth
factor (PDGF), vitamin D3, phorbol esters and promoters of inflammation e.g. LPS
(Akahoshi et al., 1988; Koch et al., 1992a). In some cells IL1 down-regulates the number of
its own surface receptors by a decrease in mRNA half life (Akahoshi et al., 1988; Koch et
al., 1992b; Ye etal., 1992).
17
Chapter 1: introduction
IL1 RII is found primarily on the surface of neutrophils, monocytes and B
lymphocytes (McMahan et al., 1991) and like the IL1 RI, the number of receptors is
increased during inflammation by several mediators including IL1, PGE2 and IL4 (Re et al.,
1994). IL1 RII can be shed from the cell surface and is often found as a soluble receptor in
the circulation, here is acts as a "decoy" receptor; it has a much higher affinity for IL1 than
IL1 RI and such binding is irreversible, thus is thought to be a regulatory mechanisms for
excess IL1 in inflammatory conditions (Colotta et al., 1993). However, soluble forms of
both receptors have been detected in human inflammatory fluids and experimental cell
culture supernatants (Colotta et al., 1996; Symons et al., 1991; Symons et al., 1990).
1.3.3 SIGNAL TRANSDUCTION
There are less than 100 cell surface IL1 receptors on most cells, and less than 5% of
these need to be occupied for a biological response, therefore IL1 signal transduction is
highly efficient and greatly amplified (Dinarello, 1994a). The most likely mechanisms for
signal amplification is multiple and sequential phosphorylations or dephosphoylations of
kinases, which result in nuclear translocation of transcription factors and activation of
proteins participating in translation ofmRNA.
Within a few minutes of binding to cells, IL1 induces several biochemical events,
responses include hydrolysis of guanyltriphosphate-binding protein with no associated
increase in adenyl cyclase (AC; O'Neill et al., 1990), activation of AC (Chedid & Mizel,
1990; Mizel, 1990), hydrolysis of three phospholipids by non-phosphatidylinositol
phospholipase C (PLC; Kester et al., 1989; Rosoff et al., 1988) and release of arachidonic




IL1 does not stimulate hydrolysis of phosphatidylinositol or an increase in
intracellular calcium. Some IL1 signalling events are prominent in different cells, post-
receptor signalling mechanisms may therefore provide cellular specificity.
1.3.4 REGULATION
Modulation or inhibition of the effects of IL1 can be achieved by reducing the
amount ofILip released, down-regulation of IL1 receptors, antagonism of IL1 at a receptor
level, modulation of its actions by anti-inflammatory cytokines, or inhibition of ICE to
decrease the amount of active IL1 (3 released from its inactive pre-cursor form.
IL1 Receptor Antagonist
An endogenously released inhibitor of IL1 activity was detected in the serum of
humans injected with LPS (Andersson et al., 1992) and in the urine of patients with
monocytic leukaemia (Seckinger et al., 1987), this is the IL1 receptor antagonist (ILIRa). It
is a 17 kD protein which is more closely related to ILip (26% homology) than ILla (18%
homology), and can bind the same receptors (Evans & Robbins, 1994; Graves et al., 1990;
Priestle et al., 1989; Vigers et al., 1994). However, IL1 Ra cannot initiate an intracellular
signalling cascade (Evans & Robbins, 1994), thus it competes with ILip for its receptor and
acts as a competitive antagonist.
ILIRa reduces the severity of a number of inflammatory diseases including
adjuvant-induced arthritis in rats (Schwab et al., 1991). Levels of ILIRa increase in
inflammatory diseases in animals and humans (Fischer et al., 1992) and therefore may act to
regulate the biological effects of IL1. However, the levels are deficient relative to total
production of IL1 (Bresnihan & Cunnane, 1998; Chikanza et al., 1995b; Firestein et al.,
1994), therefore the administration of exogenous recombinant ILIRa restores the balance
between IL1 and ILIRa and is a therapeutic approach that has been investigated in recent
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years. Natural and recombinant IL1 Ra were shown to inhibit IL1 mediated bone resorption
and PGE2 production (Seckinger et al., 1990). Anakinra has been approved for the treatment
of RA (for review see Furst, 2004); it improved clinical symptoms with a 10% reduction in
the number of swollen joints in patients as well as slowing the progression of the disease
(Bresnihan et al., 1998). However, the lack of an impressive clinical response, despite
reductions in disease progression, may indicate that there is a difference between cytokines
involved in pain and inflammation and cytokines involved in joint destruction.
Immunohistological studies indicate IL1 is present in 90% of cells at the CPJ, the majority
macrophages. In addition, 65% of chondrocytes in the superficial layer of the articular
cartilage adjacent to the pannus also contain IL1. Similar studies reveal the presence of IL1
Ra in less than 10% of the cells in the above locations, yet a 50% inhibition of IL1 activity
requires approximately 100-fold excess of IL1 Ra (Arend et al., 1990; Seckinger et al.,
1990).
Soluble IL1 receptor accessory protein
A human soluble IL1 receptor accessory protein (IL1 RAcP) has been described that
is recruited to IL1 RI (Greenfeder et al., 1995). The formation of a complex including IL1,
IL1 RI and IL1 RAcP appears to be essential for the initiation of IL1 signal transduction
(Martin & Falk, 1997). This is supported by evidence that a cell line containing a functional
IL1 RI but not expressing complete IL1 RAcP is unable to respond to IL1 stimulation
(Korherr et al., 1997; Wesche et al., 1997). The inhibition or reduction of this molecule
could therefore modulate IL1 responses, as shown by Smeets et al. (2005). The latter paper
demonstrates that he sILlRAcP ameliorates experimental arthritis without affecting T cell




IL4 was found to down regulate the LPS-evoked production of IL1 by human
peripheral monocytes in a dose-dependent manner (Essner et al., 1989; te Velde et al., 1990)
as well as up regulating the production of ILIRa protein four-fold and the expression of
ILIRa mRNA two-fold in the same in vitro preparation as above (Vannier et al., 1992). In
addition, studies using monoclonal antibodies have demonstrated that IL-4 antagonized the
action of IL-1 by inducing expression and release of IL-1R II (Colotta et al., 1993), thus
reducing the effects of IL1.
IL10, IL 13 and TGFp act in similar ways to IL4, down regulating IL1 production
and up regulating IL1 Ra production (Burd et al., 1995; Colotta et al., 1996; de Waal
Malefyt et al., 1991; Girard et al., 1996; Jenkins et al., 1994; Vannier et al., 1996).
Inhibition of Interleukin converting enzyme
Inhibition of ICE would result in a reduction in the amount of biologically active IL1
produced. The tetrapeptide ICE inhibitor YVAD blocked the increased expression of
cyclooxygenase (COX) 2 and the production PGE2 in the central nervous system (CNS) of
rats following peripheral inflammation or intrathecal injection of IL1 (Samad et al., 2001).
In addition, the irreversible tetrapeptide ICE inhibitor, YVAD-CMK, strongly reduced IL 1
and IL18 production in human OA cartilage explants (Saha et al., 1999). However this
compound is not effective when administered orally. In contrast, pralnacasan (HMR
3480/VX-740) is an orally bioavailable pro-drug of RU 36384/VRT-18858 which inhibits
LPS-induced IL1 release by human peripheral blood mononuclear cells in vitro (Loher et al.,
2004; Rudolphi et al., 2003). In vivo, oral administration of pralnacasan in mice inhibited
LPS-evoked elevation of serum IL1 by up to 80%. In CIA, prophylactic treatment with
pralnacasan delayed the onset of forepaw inflammation, and reduced disease severity by 50-
70%. Furthermore, pralnacasan significantly reduced forepaw inflammation and progression
of arthritis when administered to mice with established arthritis reducing the incidence of
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cartilage damage by >60% and bone erosion by >80%, compared with vehicle-treated mice
(Ku et al., 2001). Moreover, pralnacasan treatment significantly ameliorated
histopathological damage of the knee joint in two mouse models of OA (CIA and
spontaneous OA in STR/1N mice; Rudolphi et al., 2003).
RU 36384/VRT-18858 is the first potent, selective, non-peptide inhibitor of ICE in
phase II clinical trials for RA (Wollheim, 2001). An initial Phase Ella clinical program has
shown that pralnacasan is well tolerated in healthy volunteers and patients with RA.
However, the trial was suspended after animal toxicology suggested likely pralnacasan-
associated liver abnormalities after nine-month exposure to high doses of the drug.
Decoy receptors
Development of recombinant human IL1 RI has provided a possible drug treatment
for RA, it has been tested in phase 1 trials of patients with active RA, however the efficacy
of this agent has not proved promising (Drevlow et al., 1996). The lack of efficacy of
recombinant human IL1 RI might be the result of complex interactions occurring within the
IL1 signal transduction system. In addition to binding IL1, soluble receptors also bind IL1
Ra; this interaction might complicate the therapeutic use of soluble IL1 receptors,
particularly type 1 receptors, as its affinity for IL1 Ra is greater than for ILip or ILla (Arend
et al., 1994).
1.3.5 ROLE OF IL1 IN INFLAMMATION AND RA
IL1|3 plays an important role in the pathophysiology of RA by contributing to
inflammation as well as joint destruction. Most clinical and pre-clinical evidence relating to
the role of IL1 in inflammation and RA relates to ILip. Infusion of ILip induces and
exacerbates arthritis in animal models (Horn et al., 1988; Horn et al., 1990; Schwab et al.,
1991). However, continuous infusion of ILla in rabbit knees for two weeks also induced
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arthritis with changes similar to those seen in RA (Feige et al., 1989) indicating a separate
effect of ILla.
Elevated plasma levels of IL1|3 have been demonstrated to positively correlate with
measures of disease activity (Eastgate et al., 1988) and radiographic progression over one
year (Hopkins et al., 1988). Concentrations of ILip are higher in joint tissue biopsies from
patients with joint erosions than those with non-erosive disease (Fong et al., 1994) but at
present the measurement of ILla in plasma offers little clinical value.
IL1 is a key mediator of synovial inflammation. It is responsible for:
• Triggering the recruitment ofPMNs, lymphocytes and monocytes into the joint
• The activation of macrophages, resulting in release of proteases (Bresnihan & Cunnane,
1998)
• stimulating T- and B-cell proliferation and differentiation (Dinarello, 2002)
• Enhancing the proliferation of fibroblasts, leading to pannus formation.
IL1 plays a key role in cartilage and bone destruction during RA. A primary action
of IL1 is the stimulation ofMMP synthesis by articular chondrocytes, synovial macrophages,
fibroblasts, invading macrophages and neutrophils, which causes proteoglycan degradation,
which in turn drives cartilage destruction (Gurr et al., 1988). Furthermore reactive oxygen
species are released which are efficient factors in cartilage matrix destruction as previously
described. A further effect of IL1 on chondrocytes is to inhibit proteoglycan synthesis and
the production ofMMP inhibitors preventing the normal maintenance of cartilage (Bresnihan
et al., 1998; Eastgate et al., 1988; van de Loo et al., 1995; van de Loo et al., 1992; Van Lent
et al., 1995). In experimental models, this loss of cartilage has been shown to occur early in
the disease progress (van den Berg, 2001). In addition, erosion of the cartilage surface is
mediated by the formation of pannus and increased migration of PMNs in to the synovial
tissue; IL1 has an important role in driving these processes. In addition, IL1 is a potent
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stimulator of synoviocytes, chondrocytes and osteoblasts, cells responsible for bone
formation.
The effects of IL1 on bone resorption are mediated indirectly through interaction of
osteoprotegrin (OPG) and osteoprotegrin ligand (OPG-L) and their effects on osteoclasts.
OPG stimulates induction of osteoclast differentiation and activation. When bound to OPG-
L bone resorption is inhibited, thus OPG-L/OPG balance determines the relative degree of
erosion. IL1 acts directly on T cells and osteoclasts to increase expression of OPG-L, which
then stimulates the differentiation of osteoclast precursors to mature osteoclasts; furthermore,
it increases their resorptive activity (Gravallese & Goldring, 2000; Kong et al., 1999). IL1
has been shown to induce osteoblast apoptosis and may thereby prevent new bone formation,
which is particularly important when repair is required (Lemonnier et al., 2001; Tsuboi et
al., 1999).
IL1 initiates the production of COX-2, PLA2 and inducible nitric oxide synthase
(iNOS). This accounts for the large amount of PGE2, platelet activating factor (PAF) and
nitric oxide (NO) produced by cells exposed to IL1 or in animals or humans injected with
IL1. Furthermore, de novo synthesis of COX-2 was enhanced by IL1 [3 in rheumatoid
synovial explant cultures and cultured rheumatoid synoviocytes (Crofford et al., 1994). The
PG products of COX-2 contribute to pain and inflammation and high levels of NO kill
chondrocytes, the cells responsible for cartilage remodelling (Notoya et al., 2000). COX-2 is
up regulated in rats with adjuvant-induced arthritis (Sano et al., 1992) and in the synovium
of patients with RA (Crofford et al., 1994).
Intra-articular injection of IL1 in rabbits induces a transient infiltration of
neutrophils into the joint space, followed by mononuclear cell infiltration (Pettipher et al.,
1986). Loss of proteoglycans from the articular cartilage also follows IL1 injection into the
joint (Pettipher et al., 1986). In addition, it has been shown that CIA in mice is accelerated
by subcutaneous injection of IL1 (Horn et al., 1988).
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In contrast, it has also been observed that injection of IL1 into the knee joints of rats
with adjuvant-induced arthritis leads to a reduction in inflammation and joint destruction
(Jacobs et cil., 1988). This effect was observed with both pre-treatment and administration of
IL1 once the arthritis was present. A similar study was carried out in Streptococcal Cell
Wall (SCW) arthritis, and demonstrated anti-inflammatory effects of IL1 (Schwab et al.,
1991). Furthermore, it has been demonstrated that intra-venous or subcutaneous IL1 inhibits
carageenan-induced paw oedema in a dose-dependent manner (Drelon et al., 1994; Drelon et
al., 1992; Nakamura et al., 1988). In Nakamura's studies oedema inhibition is concominant
with the increase of plasma levels of adrenocorticotophic hormone and corticosterone, and
hence anti-inflammatory actions of IL1 may be, at least in part, explained by pituitary-
adrenal axis simulation.
Numerous experimental studies provide evidence that proinflammatory cytokines
induce or facilitate inflammatory as well as neuropathic pain or hyperalgesia. Direct
receptor-mediated actions of cytokines on afferent nerve fibres have been reported as well as
cytokine effects involving further mediators. For example, electrophysiological recording
from rat DRGs during topical application of IL1(3 resulted in an increase in the discharge
rate, increased mechanosensitivity of the DRG units (Ozaktay, 2006). Furthermore, brief
applications of ILlp to nociceptive neurons yielded a potentiation of heat-activated inwad
currents and a shift of activation thresholds towards lower temperatures without altering
intracellular calcium levels, the effect was not mediated by G-protein coupled receptors but
was mediated by activation of protein kinases (Obreja et al., 2002; for review of cytokines





IL6 is produced from a single gene encoding a product of 212 amino acids, which is
cleaved at the N-terminus to produce a 184 amino acid peptide with a molecular weight of
between 23 and 32 kD (Yasukawa et al., 1987). Extensive posttranslational modifications
occur and may account for the variability of the end product.
IL6 production has been documented from many cells, including fibroblasts
(Weissenbach et al., 1980), endothelial cells (Corbel & Melchers, 1984), keratinocytes
(Baumartn et al., 1984), monocytes/macrophages (Aarden et al., 1987; Baumann et al.,
1984), lymphocytes (Hirano et al., 1985), mast cells (Plaut et al., 1989), synoviocytes
(Guerne et al., 1989) a variety of tumour cell lines (Hirano et al., 1986), and many more.
However, synoviocytes, T cells and B lymphocytes are the primary sources of IL6 within the
synovium (Guerne et al., 1989; Hirano et al., 1988).
1.4.2 RECEPTORS
Specific binding of IL6 has been demonstrated in a range of cells. However, IL6
also binds soluble receptors (sIL6R). Normal (non-tumour) cells express only a few hundred
IL6 receptors each (Van Snick, 1990); IL6 Rs have been found on T and B lymphocytes as
well as macrophages. Interestingly, the expression of IL6Rs is regulated differentially in B
and T lymphocytes. T cells down regulate IL6Rs upon activation, whereas B cells acquire
them only at the final stages of maturation (Zhang et al., 1988), indicating that IL6 acts early
in T cell activation and late in B cell responses.
The sIL6R is a 55 kD protein generated from differential RNA splicing or
proteolytic cleavage and shedding of cell surface bound receptors (Jones et al., 2001;
Mullberg et al., 1993). Production of sIL6Rs is increased in RA as well as other
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inflammatory conditions (De Benedetti et al., 1994; Pignatti et al., 2003). Synovial fluid
levels of sIL6R are elevated in RA compared with OA (De Benedetti et al., 1994).
1.4.3 SIGNAL TRANSDUCTION
The cytokine-cytokine receptor complex binds to a cell surface glycoprotein (gp),
gpl30 (Kishimoto et al., 1995). Cellular activation results from the activation of gpl30; the
intracellular domain of the 80 kD receptor plays no role in the transduction of the IL6 signal
(Taga et al., 1989). Following binding of IL6 to the receptor, and subsequent association of
gpl30, the Janus kinase (JAK) family protein tyrosine kinase(s) are activated and tyrosines
are phosphorylated on various cellular proteins including gpl30 itself. The activated
tyrosine kinases, in turn, phosphorylate and activate the signal transducer and activator of
transcription family proteins, after a complex series of intercellular events the downstream
effects of IL6 are seen (Inoue et al., 1997).
1.4.4 REGULATION
IL6 is not produced constitutively by normal cells, but its expression is rapidly
induced by viral infections (Cayphas et al., 1987; Frei et al., 1989; Sehgal et al., 1988), LPS
(Nordan & Potter, 1986), and a variety of other stimuli including pro-inflammatory
cytokines such as IL1 a and P (Shalaby et al., 1989), TNFa (Van Damme et al., 1987), IFNy
(Sanceau et al., 1989; Shalaby et al., 1989), PDGF (Kohase et al., 1987), IL3 and GM-CSF
(Van Snick, 1990). However, not all cells respond in the same way to all these factors, for
example IL1 is the most potent inducer of IL6 in fibroblasts but induces very little IL6 in
bone marrow cells, which respond highly to IL3 or GM-CSF.
The different effects of IL6 may be partly mediated by the level of sIL6R, it could be
the level of this receptor, rather than IL6 itself, that determines the biological response.
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1.4.5 ROLE OF IL6 IN INFLAMMATION AND RA
Despite high levels of IL6 production in joints and serum from patients with RA, in
animals with experimental arthritis, and the correlation with disease activity or radiological
joint damage (Hirano et al., 1988; Houssiau et al., 1988; Swaak et al., 1988), the role of IL6
during inflammation is largely unclear. Levels of IL6 decrease after effective treatment with
DMARDs (Dasgupta et al., 1992; Kotake et al., 1996). However, the precise pathogenic
role of IL6 is controversial because it has both pro- and anti-inflammatory properties in vitro.
IL6 acts synergistically with IL1 and TNFa to augment the production and release of
MMPs and increase the production of tissue inhibitor of MMP from human synovial
fibroblasts (Ito et al., 1992). Therefore IL6 may modulate the balance between MMPs and
inhibitors of MMPs at sites of inflammation in RA; it is this imbalance that may result in
joint and cartilage destruction.
IL6 is produced by osteoblasts and chondrocytes and is induced by pro¬
inflammatory cytokines (Guerne et al., 1990; Hierl et al., 1998; Littlewood et al., 1991). In
bone, IL6 is an autocrine and paracrine factor that plays a role in osteoclast-mediated bone
resorption (Ishimi et al., 1990; Roodman et al., 1992). IL6 does not appear to have a direct
effect in stimulating bone resorption mediated by mature osteoclasts (al-Humidan et al.,
1991; Bertolini et al., 1994). In cartilage, IL6 along with other pro-inflammatory cytokines
has been shown to be significantly up regulated in OA versus normal joints (Moos et al.,
1999). Synovial fluid with high levels of IL6 promotes osteoclast activation and was shown
to promote osteoclast cell formation when added to co-cultures of osteoblasts and bone
marrow cells (Kotake et al., 1996). The degree of activation correlates with joint damage in
these patients (Kotake et al., 1996).
IL6 is a potent B-cell growth and differentiation factor. Within the joint, IL6
stimulates the differentiation of B cells to plasma cells (Hirano et al., 1986), which may
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account for the high levels of rheumatoid factor. In addition, IL6 stimulates proliferation
and differentiation ofT lymphocytes into cytotoxic T cells (Okada et al., 1988).
Another pro-inflammatory action of IL6 is the stimulation of hepatocytes to produce
acute phase proteins (APP), which is generally measured by the concentration of C-reactive
protein (CRP). IL6 is the only cytokine responsible for triggering APP release (Castell et al.,
1988), mediating the innate immune response. Furthermore, IL6 promotes leukocyte
chemotaxis (Taga & Kishimoto, 1997), by inducing the expression of intercellular adhesion
molecule-1 (ICAM-1) and other adhesive ligands.
IL6 knockout mice are protected against joint inflammation and destruction in both
collagen- and antigen-induced models of arthritis (Alonzi et al., 1998; de Hooge et al., 2000;
Ohshima et al., 1998). This protection was seen despite the expression of both TNFa and
IL1 in the inflamed synovium (Ohshima et al., 1998), demonstrating the importance of IL6
in these models of disease. Furthermore, an IL6 receptor neutralizing antibody suppressed
the onset and reduced the severity ofCIA in mice (Takagi et al., 1998).
The above observations suggest that inhibition of the activity of IL6 in patients with
RA may be of clinical benefit. IL6 blockade using a monoclonal antibody was well-tolerated
and resulted in significant improvement in clinical scores and laboratory parameters in a
small number of patients with RA (Wendling et al., 1993). A recent therapeutic trial of an
anti-IL6 receptor monoclonal antibody in patients with active RA resulted in a significant,
dose-dependent reduction in disease activity (Choy et al., 2002).
However, there is also evidence that IL6 has anti-inflammatory effects. In vitro IL6
can reduce inflammation by suppressing IL1 and TNFa production and by inducing the
release of IL1 Ra and soluble TNFa receptors (Taga & Kishimoto, 1997). Hence it has been
argued that IL6 may regulate rather than mediate inflammation. In addition in zymosan-
induced arthritis, IL6 knockout mice had increased cartilage degradation, which occurred in
spite of reduced joint swelling and normal production of IL1, TNF and NO (van de Loo et
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al., 1997). IL6 may therefore have both deleterious and protective effects in inflammatory
arthritis.
Limited research on arthritis can be conducted in patients due to ethical constraints.
Most research is carried out in laboratory animals; hence, there have been several
experimental models of joint inflammation developed to mimic human joint diseases. The
next section will review some commonly used models of inflammatory arthritis, their
advantages and disadvantages as well as the similarities to human conditions.
1.5 EXPERIMENTAL ANIMAL MODELS OF RA
Rodent models of RA serve as valuable tools to investigate the underlying
mechanisms at early, intermediate and late stages of joint disease (for review see Sakaguchi
and Sakaguchi, 2005 and Wooley, 2004). Several animal models of joint inflammation have
been developed and characterised, although none of these mimic the exact aetiology of RA
in humans, which probably involves several different initiating factors. However, they can
provide a valuable insight to help unravel the mechanisms of pain and inflammation as well
as the progression of the disease itself. Most experimental RA in animals is produced with
an inducing agent, however, the advancements in genetics mean genetically altered mice can
be engineered which spontaneously develop RA-like disease.
1.5.1 ADJUVANT-INDUCED ARTHRITIS
Jules Freund (1947) introduced a mixture of mineral oils, heat killed mycobacterium
and emulsifying agents, known as Freunds complete adjuvant (FCA: Freund, 1956; Freund,
1947). This concoction proved to be an efficient enhancer of cell-mediated and humoral
immune responses towards antigens with which it was emulsified. The first model of
polyarthritis was developed by Storerk et al (1954) who reported that joint lesions developed
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in rats after immunization with FCA and rat spleen tissue. He suspected that the spleen
tissue was arthritogenic, but Pearson and Wood (1959) found that injection of rats intra-
dermally at the tail base with complete adjuvant alone induced a chronic, lapsing-remitting
arthritis involving multiple joints, this is the poly-arthritis adjuvant arthritis model (Pearson,
1956; Stoerk et al, 1954). Although this initially manifested as a profound inflammation at
the site of injection, it also resulted in a delayed T-cell mediated hypersensitivity reaction
(Pearson & Wood, 1959; Wall, 1984) with multiple joint involvement and subsequent
development of lesions of the eyes, ears, nose, skin, genitals, spleen, liver and bone marrow
as well as lymph node enlargement and severe weight loss. Adjuvant-induced polyarthritis
has many disadvantages, particularly the widespread systemic disease which causes severe
discomfort and stress to the animal (Butler et al., 1992; Stein et al., 1988).
The model was subsequently refined to a monoarthritic model in the ankle joint of
rats, removing some of the complications of the model. Most refined models use local
injection of FCA into (Butler et al., 1992) or around the tibiotarsal joint (Donaldson et al.,
1993; Grubb et al., 1991). In addition, it was noted that increasing doses of FCA resulted in
symmetry of joint inflammation across the body following direct injection to the rat ankle
joint (Donaldson et al., 1993), which was more humane than polyarthritis, yet mimicked
human RA more closely. Subsequently the unilateral model was extended to the knee joint,
which is now a well characterized model of experimental arthritis in rats and mice (Gauldie
et al., 2004; Wilson et al., 2006).
Heat shock proteins have been implicated in the pathogenesis of arthritis in humans
and rodents. The 65 kD mycobacterial heat shock protein in FCA may be the primary
autoantigen in this experimental model (van Eden et al., 1988). Furthermore, it has been
shown that a specific epitope of mycobacterial heat shock protein 65 corresponding to
certain amino acids is recognised by rat T cells (van Eden et al., 1988).
FCA-induced arthritis shares many features with human RA including genetic
linkage, synovial CD4+ T cells and T cell dependence (see Table 1.2; Goodson et al., 2003).
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However, one of the major differences between the adjuvant arthritis model and human RA
is simply that the inciting agent is known in the model.
It is the adjuvant-induced arthritis model that will be used throughout this thesis, as
it has been the most extensively studied and characterized in this laboratory in the past,
therefore experimental work in this thesis can be correlated with and supplemented by
previous research, with the aim of reducing the number of animals needed for the studies, in
line with Home Office requirements and the 3 R's.
Adjuvant Rheumatoid
arthritis Arthritis
Acute and Peripheral joints ++ ++
recurrent arthritis Spinal joints + ++
Chronic deforming arthritis ++ ++
Skin lesions + 0
Clinical Genital lesions ++ 0
Eye lesions + +
Progressive and destructive joint disease ++ ++
Skin and s.c. nodules Rheumatoid nodules ++ ++
Vasculitis only + 0
Acute and sub-acute synovitis ++ ++
Primarily mononuclear cell ++ ++
Immune response
mediated T-cell dependent ++ ++
B-cell dependent ++ ++
Pathologic
Invasion of bone and joint space by pannus ++ ++
Bursitis and tendonitis ++ ++
Osteitis and Fibrous ++ +
periostitis ankylosis Bony + +
Changes in serum proteins ++ ++
Rheumatoid factor 0 ++
0 =almost never, + = rarely, ++ = common
Table 1.2 The clinical and general pathological features of RA and poly-adjuvant-induced arthritis.
The model used during this thesis was monoarthritis, which does not include the widespread, systemic
features noted in this table. Examination of the table reveals the only real difference between adjuvant
arthritis and RA are the absence of rheumatoid factor in adjuvant-arthritis and the lack of genital or
skin lesions in RA. Despite these differences an overwhelming number of features occur in both
diseases (modified from Pearson (1966).
1.5.2 RAT STREPTOCOCCAL CELL WALL (SCW) ARTHRITIS
Schwab and colleagues described SCW arthritis in the 1970s and subsequently
Schwab and Wilder separately characterized important features of this model (Schwab,
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1995; Wilder, 1988). Intra-peritoneal injection of SCW mix induces a chronic, severe
erosive arthritis in female Lewis rats. However, male Lewis rats are less susceptible, and
there are vast differences between strains of rats (Wilder, 1988), so although it is a good
model for human RA, there are limitations on animal strain, but the unknown genetic
mechanisms for this variation may help elucidate human susceptibility to RA.
1.5.3 COLLAGEN INDUCED ARTHRITIS (CIA)
CIA is a model of RA that is induced in susceptible mouse strains following
intradermal immunization with collagen-II emulsified in an adjuvant; it is an extensively
studied animal model of RA because it shares both immunological and pathological features
of human RA (Stuart et al., 1985). Following immunization with collagen type II animals
develop an erosive, polyarticular arthritis mediated by an autoimmune response (Courtenay
et al., 1980). The significance of this model is that collagen type II is the major constituent
protein of cartilage at sites of inflammation in RA. Unlike the models of adjuvant- and
antigen-induced arthritis which are largely, if not entirely, mediated by T cells, CIA permits
the study of synovitis induced by antibodies and propagated by T cells specific to a major
glycoprotein found only in cartilage (Myers et al., 1997).
1.5.4 MOUSE TRANSGENIC AND KNOCKOUT MODELS OF RA
Deletion or introduction of genes for particular receptors, signalling molecules,
cytokines or other factors help test the role of these genes in immunologic mechanisms of
arthritis. In addition, spontaneous inflammation sometimes occurs, which not only provides
another model for the study of arthritis, but can help provide insights into immune regulation
and mechanisms of autoimmunity (Kannan et al., 2005). For example, mice with altered
cytokine formation or responsiveness, including overexpression of human TNFa or IL1
(Keffer et al., 1991; Kontoyiannis et al., 1999; Niki et al., 2001) or a deficiency of ILIRa
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(Horai et al., 2000) can result in the development of arthritis in mice. In addition, there is a
group of mice that spontaneously develop chronic arthritis as a result of a single gene
mutation. An example of this includes mice with mutations at the Fas gene, although it is
still unknown how altering a gene which impairs activation of induced cell death causes
arthritis (Sakaguchi and Sakaguchi, 2005).
Work detailed in later chapters of this thesis will cover pain and nociception. The
next section will therefore give a background to research in this field, and go on to describe
peripheral and central mechanisms, as well as key mediators involved in inflammatory pain.
1.6 PAIN AND NOCICEPTION
The sensation of pain helps an organism detect potentially damaging external stimuli
and avoid tissue damage from these stimuli (Sherrington, 1906). In addition, pain
encourages an organism to protect the damaged area to aid repair and avoid further damage.
A century ago Sherrington (1906) proposed there were specialized receptors to detect painful
(noxious) stimuli in cutaneous tissue (Sherrington, 1906). From Sherrington's work the
terms nociceptors and nociception eventually emerged (Burgess & Perl, 1967). According
to Sherrington's model, nociceptors have characteristic thresholds or sensitivities that
distinguish them from other sensory nerve fibres (Sherrington, 1906).
However, the term pain not only includes the neural sensation of noxious stimuli, but
also the CNS's subjective perception of the sensation, and therefore pain experiences differ
drastically among humans. Furthermore, we cannot assume that non-human animals
experience the same "pain" that we do, merely that they experience nociception.
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1.6.1 DISCOVERY AND CLASSIFICATION OF NOCICEPTORS
Early psychophysicists provided the first evidence that pain was a distinct sense
from touch and was mediated by specialized sensory organs (von Frey, 1894; von Frey,
1922). Electrophysiological studies demonstrated the existence of primary sensory neurons
that can be excited by noxious heat, cold, pressure or irritant chemicals, but not by innocuous
stimuli such as warming or light touch (Burgess & Perl, 1967). Furthermore, it was
observed that a variety of sensory nerves innervate peripheral tissues, with different
functions. It was shown that thin myelinated (AS fibres) and unmyelinated axons (C-fibres)
were mostly activated by noxious stimuli, whereas the largest myelinated fibres (AP-fibres)
responded to innocuous stimuli (Clarke et al., 1935; Gasser & Erlanger, 1927; Heinbecker et
al., 1932; Zotterman, 1933). However, asubstantial proportion of cutaneous and somatic
afferent A-fire nociceptors conduct in the AP-fibre conduction velocity range (for review see
Djouhri and Lawson, 2004). Recently, Djouhri et al. (2006) demonstrated that spontaneous
pain arising in inflammatory and neuopathic pain models is related to the rate of spontaneous
neural discharge of c-fibres. C-fibres have small fibre diameter (0.4-2 pm), A5-fibres having
medium fibre diameter (2-6 pm), and Ap fibres have the largest diameter (>10 pm; Millan,
1999). The conduction velocities of the different types of nerve fibre differ: C-fibres
conduct at less than 2ms"1; A5 fibres between 3 and 30 ms"1 and AP between 35 and 100 ms"1
(Erlanger & Gasser, 1937). Myelin is an electrically insulating phospholipid layer that
surrounds the axons of many neurons. The main consequence of a myelin layer (or sheath)
is an increase in the speed at which impulses propagate along the myelinated fibre. Along
unmyelinated fibres, impulses move continuously as waves, in contrast, in myelinated fibres
they propagate by saltation.
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In the nai've knee joint the above fibres have been further classified into 4 groups
according to their responsiveness to mechanical stimulation (Schaible & Schmidt, 1983b):
• Group I: nerves excited by innocuous movement.
• Group II: nerves weakly excited by innocuous movement while noxious movements lead
to pronounced neural discharge.
• Group III: nerves that respond consistently only to noxious joint movements.
• Group IV: nerves that cannot be excited by any joint movement.
Approximately 70% of A8 and C-fibres belong to groups III and IV (Schaible & Grubb,
1993).
Another study used anatomical and histological methods to study the innervation of
41 cat knee joints, and classified the articular nerve endings into four groups (Freeman &
Wyke, 1967):
• Type 1 endings correspond to those previously described as Ruffini endings - slowly
adapting cutaneous mechanoreceptors
• Type II endings were regarded as modified Pacinian corpuscles - rapidly adapting
mechanoreceptors found in the mesenteries and near joints
• Type III endings were those with the description of Golgi tendon organs - a
proprioceptive sensory organ located at the insertion of skeletal muscle fibres into the
tendons of skeletal muscle
• Type IV endings were believed to be a system of free nerve endings and plexuses for
nociception - uncapsulated, unspecialized, afferent nerve endings frequently found in the
skin - responsible for detecting temperature, mechanical stimuli (such as pressure),
nociception and information regarding touch.
However, the main criteria used to classify nociceptors is the stimulus that activates
them; Bessou and Perl (1969) reported the response characteristics of a population of C-
fibres innervating skin on the hind limb of a cat, they showed that approximately half of
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these were activated by innocuous mechanical stimulation. The other 50%, the nociceptors,
can be divided into 2 groups, 80% of which were activated by intense mechanical
stimulation, high temperatures and chemical stimulation, these were called polymodal
nociceptors. The remaining 20% responded only to noxious mechanical stimulation, these
were called mechanonociceptors (Heppelmann, 1997; Heppelmann et al, 1988a;
Heppelmann et al., 1988b; Hildebrand et al., 1991).
A further classification system for nociceptive afferents includes molecules
expressed on the cell surface, molecules stored and those released from nociceptive
afferents. The expression of receptors for neurotrophic factors is of particular interest, as
these factors may regulate the sensitivity of nociceptive afferents in adult animals (Bennett et
al., 1998a). Unmyelinated nociceptors fall into 2 groups, one of which expresses peptides
including substance P and calcitonin gene related peptide (CGRP; 50% of C fibres; 20% of
A8 fibres). This group mediates the neurogenic inflammation induced by small vasoactive
peptides, either directly or indirectly via mast cell degranulation and the subsequent release
of histamine. The second group is nonpeptidergic, i.e. does not express substance P or
CGRP (see Figure 1.4). Furthermore, non-peptidergic neurons and axons are characterised
by their binding of the plant lectin IB4 from Griffonia simplicifolia (Silverman & Kruger,
1988). Most peptidergic neurons express the tyrosine kinase receptor A (TrkA), suggesting
that they depend on nerve growth factor (NGF) for survival (Averill et al., 1995). In
contrast, most IB4-positive dorsal root ganglion (DRG) cells do not express TrkA (Molliver
et al., 1995), but express one of the glial cell line-derived neurotrophic factor family
receptors (GFRal-4) together with receptor tyrosine kinase RET (Bennett et al., 1998b;
Orozco et al., 2001). These nociceptors contain a distinctive phosphatase called thiamine
monophosphatase or fluoride-resistant acid phosphatase (FRAP+; Knyihar-Csillik & Csillik,
1981). They also express a subset of purinergic receptors (P2X3), which are activated by
adenosine triphosphate (ATP), see Section 1.6.4 for more details; Willis and Coggeshall,
1991; Chen et al., 1995; Molliver et al., 1995). Another unique feature of nociceptors in this
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group is a high density of tetrodotoxin-resistant (TTX-r) sodium channels (Willis and
Coggeshall, 1991). The third group is myelinated and therefore can be characterized based
on its neurofilaments (NF200; Julius & McCleskey, 2006). These nociceptors contain
CGRP and other peptides (Julius & McCleskey, 2006). Their membrane expresses receptors
for neurotrophins belonging to the NGF family Transient Receptor Potential Vanilloid 2
receptor (TRPV2R; see Section 1.6.2; Julius & McCleskey, 2006).
A series of complex electrical and chemical events occurs between the occurrence of
a noxious stimulus and the subjective experience of pain. These comprise four distinct
processes: transduction, transmission, modulation and perception.
• Transduction, or receptor activation, is the process by which the external noxious
stimulus is converted into electrophysiological activity in nociceptive primary afferent
neurons.
• Transmission is the process by which this information is relayed to areas of the CNS
concerned with pain. The first stage of transmission is the conduction of impulses along
primary afferent neurons (first order neurons) to the dorsal horn of the spinal cord where
they synapse onto second order neurons, intrinsic to the CNS. From here a network of
neurons ascends the spinal cord to the brainstem and thalamus. Finally, connections are
made with higher centres of the brain (third order neurons) concerned with the
perceptive affective responses associated with pain. However, nociceptive activity does
not always result in pain perception (equally, pain may be experienced in the absence of
nociception); data from human microneurography experiments show that a single
impulse or even low frequency discharge in a single nociceptive afferent appears to be
insufficient to evoke a sensation ofpain (Van Hees & Gybels, 1972).
• Therefore a process of signal modulation is needed if this system is capable of
interfering in this pathway; the modulatory site about which most is known is the dorsal
horn of the spinal cord.
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• The final process is perception, in which the pain message is relayed to the brain,
producing a subjective usually unpleasant sensory experience, which has affective,
defensive and perceptive components (Beaulieu & Rice, 2002).
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1.6.2 EXCITATION OF NOCICEPTORS
Noxious stimuli are detected when the peripheral terminals of nociceptive primary
afferents are depolarised to the threshold for an action potential. The resting membrane
potential of such fibres is approximately -70 mV in the normal state (Eccles & Krnjevic,
1959; Koketsu, 1956; Woodbury & Patton, 1952). Depolarisation occurs either as a result of
an increased permeability of the membrane to ions such as sodium (Na+) and calcium (Ca2+),
or a reduced permeability to potassium ions (K+; Bevan, 1996b). The action potentials are
transmitted along the axon to the CNS, where they may be perceived as pain, as described
above.
Mechanical excitation
Mechanoreceptors that respond to low intensity mechanical stimulation or to normal
joint movements have conduction velocities in the A|3 range (35 - 100 ms~'). These sensors
have proprioceptive functions which enable the position of the joint to be established as well
as responding to vibration within the structure (Schaible & Schmidt, 1988). Movements
beyond the normal range, or applied forces beyond certain thresholds are perceived as
painful and these stimuli activate a separate population of A5-fibres, the
mechanonociceptors. Furthermore, there are afferents which do not respond to innocuous
or noxious movement, namely the "mechano-insensitive afferents" (Schaible & Grubb,
1993). These fibres do not appear to be important for encoding mechanical stimuli in the
normal joint, but they may be required, or have altered function, during inflammation of the
joint.
Among sensory modalities, mechano-sensation has been the most elusive with
regard to the identification of molecules that mediate stimulus detection and transduction.
Recent electrophysiological studies have shown primary sensory neurons from rat dorsal
root or trigeminal ganglia retain sensitivity to mechanical stimuli when dissociated and
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placed in culture; this has enabled experiments to show that mechanically sensitive DRG
neurons can be divided into high and low threshold classes based on their responses to
stimuli of graded intensity (Cho et al., 2002; Drew et al., 2002).
However, much of what is known has been from studies in non-mammalian systems,
including the Eschericia coli mechano-sensitive channel of large conductance (MscL;
reviewed by Sukharev et al., 1997). Purified MscL proteins form functional mechano-
sensitive channels when reconstituted into artificial lipid bilayers (Hase et al., 1995)
indicating that stretching the lipid bilayer directly opens the channel.
The genetic manipulation of Caenorhabditis elegans results in it being insensitive to
touch (Tavernarakis & Driscoll, 1997). One of the genes required by C.elegans for
mechano-sensitivity is thought to encode a mechano-sensitive ion channel homologous to the
amiloride-sensitive, voltage-insenstive sodium channel; amiloride is well known to inhibit
mechano-sensitive ion channels in mammalian systems (Hamill et al., 1992; Kellenberger
and Schild, 2002). Acid-sensing ion channels (ASIC) represent a H+-gated subgroup of the
degenerin/epithelial Na+ channel family of cation channels, are thought to be involved in
mechanotransduction, but more work is required to fully determine their role in this process
(for review see Wemmie et al., 2006).
Using frog oocytes as a model system, it has been shown that mechanical
stimulation can release ATP from the cell, promoting autocrine activation of P2Y receptors
on the cell's surface. In vivo, mechanical force might therefore promote ATP release from
one or more cell types in the periphery, where it could activate purinergic receptors on
nearby nociceptor terminals (Nakamura & Strittmatter, 1996). Furthermore, a cRNA derived
from sensory neurons which renders Xenopus oocytes mechanosensitive was found to
encode a P2Yi receptor (for review see Burnstock et al., 2000).
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In addition, a member of the TRP family of receptors, TRPA1, has been proposed as
a candidate for mechanotransduction. In vitro knockdown studies have shown that TRPA1
was a promising candidate for the mechanosensitive transduction channel of hair cells in the
inner ear (Corey et al., 2004). OSM-9 and OCR2 are members of the TRP family needed for
avoidance of nose touch and high osmolality and are coexpressed in ciliary mechanosensory
endings (Colbert et al., 1997; Tobin et al., 2002). No mechanoreceptor potential C
(NOMPC) mediates rapidly adapting receptor currents in bristle mechanoreceptor epithelia
and is expressed in C.elegans mechanosensory neurons that detect variations in substrate
texture (Sawin et al., 2000; Walker et al., 2000).
There are now several more proteins with potential roles in mechanotransduction
(for review see Goodman et al., 2004) and further investigation of these receptors or mice
lacking their expression will increase knowledge of the transduction mechanisms, but for
now, the exact characteristics ofperipheral mechanonociceptors remain elusive.
Thermal excitation
Sensory neurons are ale to detect a wide range of temperatures. Temperatures
outside the normal physiological range are perceived as painful, these signals are transmitted
by thermanociceptors.
Noxious heat
In sensory ganglia dissociated in culture, approximately 45% of small- to medium-
diameter neurons exhibit heat evoked membrane currents with a "moderate" threshold of
45°C, whereas another 5 - 10% of cells respond with a "high" threshold of ~52°C (Caterina
et al., 1997; Cesare & McNaughton, 1996; Nagy & Rang, 1999). The former corresponds to
C and type II A8 nociceptors, and the latter to type I A5 nociceptors. Recent studies suggest
that this is mediated via a cation selective ion channel that is also gated by capsaicin the
selective ingredient of chilli peppers.
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In the mid-19th century, the principal pungent component of peppers of the genus
Capsicum was isolated and named capsaicin (Thresh, 1946). Several decades later, it was
proposed that capsaicin acted selectively on sensory neurons, resulting in the sensation of
pain. The structure of capsaicin was revealed as an acylamide derivative of homovanillic
acid, 8-mcthyl-iV-vanillyl-6-noneamidc (Nelson, 1991). Later, it was demonstrated that
capsaicin was capable of preventing the sensation of painful stimuli in animals, as well as
activating sensory neurons (Jancso et al., 1967; Szolcsanyi et al., 1988). Capsaicin has been
a valuable tool, as a functional marker for nociceptors. Studies of capsaicin action have
provided insights into the activation of primary afferent nociceptors and have revealed the
efferent role of some nociceptors, acting to evoke inflammation or smooth muscle
contraction (Maggi, 1995; Szolcsanyi, 1996). Moreover, an appreciation of the mechanisms
by which capsaicin desensitises neurons has provided a rational basis for the use of capsaicin
and related compounds, such as resiniferatoxin, in the treatment of painful disorders
ranging from diabetic neuropathy to arthritis, although use of an antagonist to the receptor
would be more beneficial.
Genetic methods have been used to assess the roles of the TRJPV1R in thermo- and
chemo-nociception (Caterina et al., 2000; Davis et al., 2000). Mice bearing targeted
deletions within the TRPV1 gene were examined for thermal sensitivity at numerous levels
of the pain pathway, including cultured sensory neurons, primary afferent fibres (skin-nerve
preparation), spinal cord dorsal horn neurons and animal behaviour. At each level,
significant deficits were observed in heat sensitivity. However, it is clear that these mice are
not completely insensitive to thermal nociception suggesting that TRPV1 mediates some, but
not all, aspects of thermal nociception. It has been hypothesised that the remaining thermal
sensation is mediated by another member of the TRP family (Julius, 2004). TRPV2 has 50%
homology to TRPV1, but it has no capsaicin binding site (Caterina et al., 1999). It is
sensitive to heat >50°C and is probably expressed in high-threshold heat-sensitive small
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myelinated nociceptors units (AS; Caterina et al., 1999; Lewinter et al., 2004; Ma, 2001).
The discovery and cloning of the TRPV1 channel revealed that it was sensitive to not only
capsaicin, but also high temperatures (>42°C) and protons, pH is <6 (Caterina et al., 1997).
Hyperalgesic neural responses, such as c-fos expression in the dorsal horn of the
spinal cord induced by inflammation, are blocked by capsazepine (Kwak et al., 1998), a
TRPV1 antagonist. However, capsazepine at micromolar concentrations, which are
necessary to inhibit capsaicin-evoked responses in most tissues, also blocks voltage-
dependent calcium channels (Docherty et al., 1997; Kuenzi & Dale, 1996), voltage-
dependent potassium channels (Kuenzi & Dale, 1996) as well as nicotinic acetylcholine
receptors (Liu & Simon, 1997).
It has been speculated that other than voltage and protons, an endogenous ligand for
TRPV1 may exist. Three different classes of lipids, all derived from the metabolism of
arachidonic acid, have recently been characterised that can activate TRPV1; these are the
endocannabinoid anandamide, some lipoxygenase products of arachidonic acid, and N-
arachidonoyldopamine. The levels of endocannabinoids are elevated in pain (Rice et al.,
2002; Walker & Huang, 2002) an observation that has led to speculation that they play an
important role in the regulation of pain processing and nociceptive neuronal excitability in
pathophysiological situations.
The endogenous cannabinoid receptor agonist anandamide is a powerful vasodilator
when studied in isolated vascular preparations. Anandamide-evoked vasodilatation is
capsaicin-sensitive and accompanied by release of CGRP (Zygmunt et al., 1999). The
selective CGRP-receptor antagonist 8-37 CGRP, but not the cannabinoid (CB) 1 receptor
antagonist SR141716A, inhibited the vasodilator effect of anandamide. Other endogenous
(2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP
55,940) CB1 and CB2 receptor agonists could not mimic the action of anandamide. The
45
Chapter 1: Introduction
vanilloid receptor antagonist capsazepine, inhibited anandamide-induced vasodilatation and
release of CGRP. Moreover, in patch-clamp experiments on cells expressing TRPV1,
anandamide induced a capsazepine-sensitive current in whole cells and isolated membrane
patches (Zygmunt et al., 1999).
Products of lipoxygenase enzymes are able to activate TRPV1 (Hwang et al., 2000).
These are released during inflammation (Samuelsson, 1983) and cause hyperalgesia when
injected intra-dermally in the rat paw (Levine et al., 1984). In addition, products of
lipoxygenase activity often function as intracellular second messengers in neurons (Kim &
Oh, 2004). 12- hydroperoxy eicosatetraenoic acids (HPETE) activated single-channel
current that were blocked by capsezipine in isolated membrane patches. Furthermore, the
current-voltage curve of a single-channel currents activated by 12-HPETE is outwardly
rectifying, identical to that obtained with capsaicin (Kim & Oh, 2004). Other products of
lipoxygenase also activate TRPV1, including 15-HPETE, 5- and 15-hydroxyeicosatetraenoic
acids (5- and 15- HETEs) and leukotriene (LT) B4 (Kim & Oh, 2004). PGs sensitise
nociceptive fibres, which suggest a possible effect on TRPV1, but they fail to activate the
channel (Kim & Oh, 2004).
There are receptors in the skin that respond to mild changes in temperature. Warm
receptors are predominantly found on unmyelinated fibres, are highly sensitive to gentle
warming to their punctuate receptive fields. These fibres have been shown to signal
exclusively the quality and intensity of warmth sensation (Johnson et al., 1979). Another
member of the TRP family of receptors responsible for this warm sensation is TRPV3 (33°C
threshold; Peier et al., 2002b; Smith et al., 2002; Xu et al., 2002). Warm receptors conduct
almost exclusively in the C-fibre range and are also spontaneously active at normal skin
temperature and show linear increase in discharge as skin temperature increases up to 46°C.




Compared with our understanding of noxious heat sensation, less is known about
cold receptors. Depending on the study and experimental system, approximately 10-15% of
C and A5 fibres respond to application of cold stimulus (Bessou & Perl, 1969; Hensel &
Zotterman, 1951; Kress et al., 1992). Furthermore, it was noted that cultured sensory
neurons produced responses to cold or menthol application with properties similar to those of
the TRPV1 channel, this new channel was cloned and termed the cold- and menthol-
sensitive channel (CMR1 or Transient Receptor Potential Menthol 8; TRPM8; McKemy et
al., 2002; Peier et al., 2002a; for review see Dhaka et al., 2006 or Reid, 2005). TRPM8 is
activated by moderate to strong cooling from 28° C to 8° C, independent of the rate of
direction of temperature change (Handwerker, 2006; McKemy et al., 2002). Studies of cold
or menthol responses in nerve fibres in cultured sensory neurons have produced several
models to explain how cold and menthol promote neuronal depolarization, including
inhibition of background (or leak conductance's - a major determinant of membrane resting
potential) potassium channels, inhibition of Na+/K+ ATPases, activation of Na+-selective
epithelial sodium channel/ degenerin channels, and activation of Ca2+ permeable channels
(Askwith et al., 2001; Braun et al., 1980; Pierau et al., 1974; Reid & Flonta, 2001a; Reid &
Flonta, 2001b; Suto & Gotoh, 1999).
A second novel cold-activated TRP channel has been characterised, TRPA1 (17°C
threshold; activated at a broad range of temperatures 12°C - 24°C ;Peier et al., 2002a; Story
et al., 2003). TRPA1 is expressed in either AS- and/or C-fibres; it is coexpressed with
CGRP, substance P and TRPV1, all of which is consistent with a role in cold nociception





Nociceptors can be activated by some chemical irritants acting via specific
pharmacological receptors at their terminals to produce an acutely painful response. During
inflammation, in inflamed tissues, a variety of chemical mediators are released that are able
to directly or indirectly activate primary afferent nociceptors leading to more chronic pain.
The mechanism by which inflammatory agents excite or sensitise nociceptors is described in
Section 1.6.4 in more detail.
1.6.3 NOCICEPTORS INNERVATING THE NORMAL AND INFLAMED
KNEE JOINT
There is extensive literature on sensory nerve innervations in a wide variety of
tissues throughout the body including skin (Bessou & Perl, 1969; Torebjork & Hallin, 1974),
joints (Heppelmann, 1997; Mapp, 1995; Schaible & Schmidt, 1983a), cornea (Belmonte et
al., 1991; Belmonte & Giraldez, 1981; Giraldez et al., 1979), skeletal muscles (Mense &
Meyer, 1985), airways (Fox et al., 1993), viscera (Cervero, 1994) and teeth (Greenwood et
al., 1972). Only the articular afferent innervation of the knee joint, in particular nociceptors,
will be discussed further, due to the relevance to experimental work carried out.
Early comprehensive studies of the anatomy of the knee joint were carried out in
cats (Freeman & Wyke, 1967; Gardner, 1944; Skoglund, 1956). More recently, electron
microscope studies have provided a detailed morphological analysis of the nociceptive
afferent endings innervating the joint (Fleppelmann et al., 1988a). Although the cat knee
joint has been the most extensively studied and documented, studies examining the
innervation of other species' knee joints have also been carried out, including rats
(Hildebrand et al., 1991) humans (Biedert et al., 1992; Halata et al., 1985) and mice
(Ebinger et al., 2001). These studies have shown that the pattern of innervation, the types of
fibres and the ratio of myelinated to unmyelinated fibres are very similar between species.
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The most notable difference between the species was the absolute number of fibres
innervating the joint, but this is dependent on animal size.
The articular branches that exit the saphenous nerve on the medial aspect of the limb
supply the knee joint. The knee joint innervation arises primarily from two articular nerves,
the posterior articular nerve (PAN) and the medial articular nerve (MAN).
Electrophysiological recordings during experimental work in this thesis record from the
MAN, therefore further discussions will focus on this articular nerve.
The MAN branches from the saphenous nerve and traverses the antro-medial aspect
of the thigh and runs alongside the descending genicular artery and vein, to the medial aspect
of the knee joint. At this point the nerve divides into two branches and spreads out to
innervate the medial and antero-medial aspects of the fibrous capsule of the knee joint, the
medial collateral ligament, the medial part of the annular ligament attached to the medial
meniscus, the ligamentum patellae and the infrapatellar fat pad , and the medial part of the
patellar periosteum (Freeman & Wyke, 1967).
The MAN of the cat contains approximately 630 afferent and 500 unmyelinated
sympathetic efferent fibres. Of the afferents the majority are A8- and C-fibres (groups III
and IV; 20% and 70% respectively). The remaining are Ap-fibres (Langford & Schmidt,
1983). Approximately 60% of knee joint innervation may be classified as nociceptive
(Heppelmann, 1997). In the rat, a large PAN and a small MAN can be identified. The PAN
is composed of approximately 400 axons, about 80% of which are unmyelinated. All
myelinated fibres are sensory; they range in size between 1-8 pm. Approximately one-third
of the unmyelinated axons represent afferents (Hildebrand et al., 1991).
From their peripheral terminals, articular afferents extend long axons up to the cell
bodies in the DRG.
In addition to sending axons to the periphery, articular nociceptors project axons
from the DRG into the dorsal horn of the spinal cord. Using retrograde labelling of axons in
the cat it has been shown that afferents of the MAN enter the spinal cord via L5 and L6
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(Craig et al., 1988; Skoglund, 1956). Once in the dorsal horn these afferents have projections
into different layers of laminae.
1.6.4 INFLAMMATORY PAIN
An injury or site of inflammation can heighten the level of pain experienced by
increasing the sensitivity of nociceptors to thermal, mechanical and chemical stimuli. This is
partly a result of the production and release of chemical mediators into the micro-
environment from primary sensory terminals and non-neuronal cells, including immune cells
and platelets (Bevan, 1999). These mediators either directly activate nociceptors or sensitise
the primary afferents to other stimuli.
Due to the excitatory and sensitising effects of inflammatory mediators, nociceptors
innervating inflamed tissues have an increased basal rate of discharge, a reduced threshold
for activation and an augmented response to stimuli. Furthermore, during inflammation
more nociceptors are excited by any given stimulus and nociceptors that were previously
inactive are now activated (Coggeshall et al., 1983; Guilbaud et al., 1985; Schaible &
Schmidt, 1985; Schaible & Schmidt, 1988).
There are two phenomena that occur in inflammatory conditions, and the
nomenclature used here will be that defined by the International Association for the Study of
Pain (LASP) subcommittee on taxonomy; hyperalgesia is 'an increased response to a
stimulus that is normally painful and should not be associated with a lowering of threshold';
whereas allodynia is commonly used when referring to 'pain due to a stimulus that does not
normally produce pain' (Merskey & Bogduk, 1994; see Figure 1.5). These enhanced pain
states arise from both peripheral and central mechanisms of altered pain transmission.
Hyperalgesia exists both at the site of injury and in the uninjured surrounding tissue,
these are known as primary and secondary hyperalgesia respectively (Lewis, 1942).
Secondary hyperalgesia can be partly explained by enhanced synaptic responses of second-
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order neurons in the spinal cord to their normal afferent input (central sensitisation;
Koltzcnburg, 2000; LaMotte et al., 1991; Torebjork et ah, 1992). However, there are also
indications that peripheral mechanisms play a role, including the axon reflex (Serra et al.,
1998). Local axon reflexes depolarise other branches of the same sensory axon and result in
more widespread release of inflammatory mediators, this is mediated by peptidergic C-
fibres, and includes enhanced pain from mechanical but not heat stimuli (Ali et al., 1996).
Multiple intracutaneous injections of lidocaine after a nearby capsaicin injection block the
spreading of the axon reflex and also the development of punctuate hyperalgesia (LaMotte et
al., 1991; Serra et al., 1998).
Figure 1.5. Noxious stimuli can sensitise the neural response to subsequent stimuli. The normal pain
response as a function of stimulus intensity is depicted by the curve on the right, where even strong
stimuli are not experienced as pain. However, a traumatic injury can shift the curve to the left. Then,
noxious stimuli become more painful (hyperalgesia) and typically painless stimuli are experienced as
pain (allodynia; illustration redrawn and adapted from Gottschalk & Smith, 2001).
Peripheral mechanisms
Injury or inflammation results in the local release of chemicals that mediate or
facilitate the inflammatory process, including bradykinin (BK), PGs, LTs, 5-
hydroxytryptamine (5-HT; serotonin), histamine, substance P, thromboxanes, PAF,
adenosine, ATP, protons and free radicals. Cytokines, such as IL1 and TNF, and






can directly activate nociceptors, while others act indirectly via inflammatory cells, which in
turn, release algogenic agents. Other mediators lead to a sensitisation of the nociceptor's
response to natural stimuli and therefore play a role in primary hyperalgesia.
Bradykinin (BK)
Several lines of evidence suggest BK plays a critical role in inflammatory pain (for
review see Dray, 1997). BK is released as a result of tissue injury and is present in
inflammatory exudates. In addition, it has been shown to evoke pain in humans when
administered intradermally, intra-arterially, intravenously or intraperitoneally. Furthermore,
administration of BK in the region of the receptive field of unmyelinated and myelinated
nociceptors results in an evoked response in these fibres (Beck & Handwerker, 1974),
however, this response undergoes tachyphylaxis upon repeated applications. BK not only
activates nociceptors, but also sensitises them to heat stimuli (Khan et al., 1992; Lang et al.,
1990), however, unlike the evoked response, the sensitisation does not undergo
tachyphylaxis (Manning et al., 1991).
This BK-induced excitation in inflamed rat skin is thought to occur through B2
receptors, since a B2-receptor antagonist blocks the effect on C-fibre nociceptors, while Bl-
receptor antagonists have no effect (Banik et al., 2001). However, conflicting reports
suggest that B1-receptors do play a role in BK-induced afferent sensitisation (Reeh & Sauer,
1997). BK receptors are coupled to guanyl-nucleotide binding proteins (GPCR) and result in
a second messenger signalling cascade. The BK B2 receptor activation pathway on sensory
neurons results in the activation of PLC which cleaves membrane lipids to form inositol
triphosphate (IP3) and diacylglycerol (DAG). DAG activates protein kinase-C (PKC) which
can phosphoylate membrane ion channels, including TRPV1 and receptors leading to




Mast cell degranulation releases PAF, which evokes 5-HT release from platelets. 5-
HT rapidly depolarises the cell membrane by binding to specific ligand-gated ion-channel
linked receptors. 5-HT causes pain when applied to a human blister base (Richardson &
Engel, 1986), when injected into human skin (Schmelz et al., 2003) and can activate
nociceptors in the rat (Lang et al., 1990) and a population of mechanically-insensitive
afferents (Schmelz et al., 2003). Furthermore, 5-HT can potentiate the pain induced by BK
and hence the response of nociceptors to BK. In addition, it has been shown to excite and
sensitise group III and IV afferents to mechanical stimulation in the cat knee joint and the rat
ankle joint (Birrell et al., 1990; Herbert & Schmidt, 1992). There are many subtypes of 5-
HT receptors and several of these are implicated in pain (for review see Zemlan et al., 1988).
Protons
The pH of the surrounding skin tissue decreases following skin incision, (Woo et al.,
2004). The protons responsible for the drop in pH may play a role in activating and
sensitising nociceptors. Pain and hyperalgesia to mechanical stimuli are produced in humans
following continuous cutaneous administration of low pH solutions (Steen & Reeh, 1993)
and this pain is potentiated by co-administration of low pH with inflammatory mediators in
humans (Steen et al., 1996). This correlates with the observation that protons selectively
activate nociceptors and produce sensitisation of nociceptors to mechanical stimuli. (Steen
et al., 1996; Steen etal., 1995).
Specific channels have been identified that respond to protons. In the DRG, ASIC 3
mediates acid-evoked pain and hyperalgesia. ASIC receptors have been implicated as the
major mediators of proton-induced cutaneous pain in humans (Jones et al., 2004). However,










Figure 1.6. Receptors, nociception and inflammation. This figure shows the mediators that activate





During tissue injury, mast cells can release histamine when activated by substance P
from nociceptor terminals. Histamine can lead to a variety of responses including
vasodilatation and oedema. Furthermore, histamine application causes excitation of
nociceptors. Canine polymodal visceral receptors in vitro are excited by histamine at high
concentrations (Koda et al., 1996) and histamine potentiates the response of nociceptors to
BK and heat (Mizumura et al., 1995), suggesting that under conditions of inflammation
histamine may play a role in the production of hyperalgesia. Mechanosensitive cutaneous
nociceptors in rat and humans respond only weakly to histamine (Lang et al., 1990).
However, a subpopulation of mechanosensitive C fibres is vigorously excited by histamine
in human microneurography experiments (Schmelz et al., 1997). However, application of
histamine to human skin produces a sensation of itch rather than pain (Simone et al., 1991),
and intradermal injection of histamine in mice is used to induce itch (Bell et al., 2004).
Arachidonic acid metabolites
Arachidonic acid is metabolised into a number of compounds collectively known as
eicosanoids: PGs, thromboxanes (Txs) and LTs. The eicosanoids are generally not thought
to activate nociceptors directly, but instead they sensitise nociceptors in skin and viscera to
heat, mechanical stimuli and other endogenus chemicals (for reviews see Cunha & Ferreira,
2003; Schaible et al., 2002). However, there are exceptions, including PGE2 and
prostacyclin (PGI2), which have been shown to directly excite as well as sensitise joint
afferent nociceptors (Birrell et al., 1991; Grubb et al., 1991; Heppelmann et al., 1986;
Schaible & Schmidt, 1988). Furthermore, PGE2 activates C-fibre mechano- heat- sensitive
nociceptors and a subpopulation of mechano-insensitive afferents (Schmelz et al., 2003).
PGI2 has a much greater role in sensitisation of nociceptors; in the rat ankle joint PGI2 and
the more stable agonist cicaprost sensitised the majority of nociceptors (80-90%) to
mechanical stimulation (Birrell et al., 1991). PGE2 and PGI2 act on specific cell surface
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receptors to increase AC activity intracellularly. AC mediated increases in intracellular
cyclic adenosine mono-phosphate (cAMP) have been implicated in nociceptor sensitisation
(Levine & Tawoi, 1994). PGs reduce the threshold for activation of voltage-sensitive TTX-r
sodium current specific nociceptors, increase intracellular cAMP and increase the
excitability of sensory neurons (Bevan, 1996a; England et al., 1996; Gold et al., 1996). PGs
are synthesized by the constitutively expressed COX-1 and by the inducible COX-2, which
is increased during inflammatory conditions (Ballou et al., 2000).
LT D4 and B4, produced by lipoxygenase enzymes, may play a role in producing
mechanical hyperalgesia (Levine et al., 1984) and in sensitisation to mechanical stimuli
(Martin et al., 1987).
Adenosine and adenosine phosphates
During inflammation and tissue injury, adenosine, adenosine monophosphate,
adenosine diphosphate and ATP are released into the extracellular space and activate
nociceptors. Adenosine and its phosphates have been reported to induce pain when applied
to a human blister base or are administered by intra-arterial or intradermal injections
(Bleehen & Keele, 1977). The adenosine receptor family comprises four subtypes: Ai, A2a,
A2b and A3 (Fredholm et al., 2001). In animals, adenosine enhances the response to
formalin, via the A2 receptor. Animals lacking the A2 receptor are hypoalgesic to heat
stimuli (Ledent et al., 1997). The role of adenosine receptors in nociception is complex and
may involve different mechanisms in the CNS and in peripheral tissues. For example, spinal
administration of adenosine receptor agonists produces antinociception in a variety of animal
models of pain through the activation of spinal Ai and to a lesser extent through A2 receptors
(Holmgren et al., 1986; Sawynok, 1998). Adenosine can produce analgesic or
pronociceptive effects (Doak & Sawynok, 1995) through activation of Al and A2 receptors
respectively (Doak & Sawynok, 1995; Tawoi & Levine, 1990).
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A number of lines of evidence suggest a role of ATP as a peripheral mediator of
pain. Increased levels of ATP are found at sites of inflammation and can activate
nociceptors. ATP-induced pain is dependent on capsaicin-sensitive neurons and repeated
topical application of capsaicin reduces the ATP-induced pain. In human microneurography
experiments, injection of ATP in the receptive field of nociceptors results in responses in
more than 60% of mechano-responsive and mechanic-insensitive C fibres. However, ATP
does not sensitise the C fibres to mechanical or heat stimuli (Hilliges et al., 2002). It has
been found that ATP acts directly on the terminals of peripheral sensory nerves (Dowd et al.,
1998), through what is thought to be a receptor complex made up of P2X2 and P2X3
subtypes (Lewis et ah, 1995). Moreover, knockout mice lacking the P2X3 receptor, showed
a modest reduction in hind paw licking and lifting after intraplantar formalin (Cockayne et
ah, 2000).
Receptors for ATP are found in both the DRG and the periphery and are composed
of two major classes, the P2X (ligand-gated cation channels) and P2Y groups (GPCR)
(Abbracchio & Burnstock, 1994). P2X3 and P2X2/3 have very restricted distribution patterns;
they are only expressed in the cell bodies of thin myelinated and unmyelinated sensory
afferents (Chen et ah, 1995; Lewis et ah, 1995). Dose-dependent pain behaviour is observed
when P2X agents are intradermally injected in rodents (Bland-Ward & Humphrey, 1997),
and enhanced pain behaviours to formalin are seen in rats (Sawynok & Reid, 1997).
Administration of a P2X antagonist reversed the mechanical hyperalgesia produced by
inflammation. Furthermore, the C-fibre sensitisation produced by a P2X agonist is blocked
by a P2X antagonist (Wu et ah, 2004). In addition, the P2X7 receptor is present on mast
cells, which during inflammation release a large number of pro-LTs.
Excitatory amino acids
Evidence exists that suggest a role of peripheral metabotropic glutamate receptors in
nociception and inflammatory pain (see Carlton, 2001). Peripheral application of glutamate
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activates nociceptors, and peripheral administration of ligands binding to glutamate receptors
induces pain behaviour in animals. For example, intraplantar injection of glutamate in the
rat hind paw produces mechanical hyperalgesia (Carlton et al., 1995). A subsequent study
demonstrated that intraplantar injection of the specific glutamate receptor agonists NMDA,
AMPA or kainate results in mechanical hyperalgesia and allodynia that can be blocked by
appropriate antagonists (Zhou et al., 1996). Similarly, intra-articular injection of excitatory
amino acids in the rat knee joint (Lawand et al., 1997) or the tail (Carlton et al., 1998) results
in thermal hyperalgesia and mechanical allodynia that is attenuated by local administration
of NMDA or non-NMDA receptor antagonists (Lawand et al., 1997; Carlton et al., 1998).
Furthermore glutamate activates and sensitises nociceptors in rat glaborous skin (Du et al.,
2001). An involvement of peripheral glutamate receptors in formalin-induced pain
behaviours and glutamate-induced thermal hyperalgesia has been demonstrated (Davidson et
al., 1997).
Endogenous sources of glutamate in the periphery include plasma, macrophages,
epithelial cells and dendritic cells.. In addition, peripheral processes of the primary afferents
contain glutamate, and nociceptor stimulation can cause the peripheral release of glutamate
from the terminals of these afferents (deGroot et al., 2000).
Acetylcholine
Non-neuronally released acetylcholine (ACh) acting on peripheral cholinergic
receptors may have a modulatory role on nociception. Nicotine has a weak excitatory effect
on C-fibre nociceptors, and induces a mild sensitisation to heat but no alterations in
mechanical responsiveness. However, muscarine desensitises C-fibre nociceptors to
mechanical and thermal stimuli (Bernardini et al., 2001), therefore nicotinic and muscarinic




The vanilloid receptor, TRPV1 is expressed only in a minority of IB4-
positive nerve cells in mice (Zwick et al., 2002) and IB4-positive neurons are less responsive
to heat, capsaicin and protons than their IB4-negative counterparts (Dirajlal et al., 2003;
Stucky & Lewin, 1999). In rat this distinction is less obvious, as about half of both IB4-
positive and IB4-negative cells express TRPV1 (Caterina et al., 1997; Guo et al., 2001; Guo
et al., 1999; Michael & Priestley, 1999). Axonal transport of TRPV1 mRNA is induced by
inflammation; the proportion of TRPV1-labelled unmyelinated axons in the periphery is
increased by almost 100% (Carlton & Coggeshall, 2001) and the sensitivity of primary
afferents to capsaicin increases (Tohda et al., 2001). Studies using TRPV1 knockout mice
show a crucial role for the receptor in thermal hyperalgesia and swelling (Caterina et al.,
2000; Keeble, 2004).
Neuropeptides
Activated peptidergic C-fibres release neuropeptides such as substance P and CGRP,
which in turn cause local increases in blood flow and endothelial permeability (McMurdo et
al., 1997), leading to recruitment of more blood-borne immune cells to the site for tissue
repair. The release of substance P and CGRP is not confined to the immediate vicinity of the
injury because depolarised nerve endings activate local axon reflexes resulting in more
widespread release of these mediators (Helyes et al., 2003; Langley, 1921). CGRP and
substance P released from sensory neurons contribute to further sensitisation of nerve
endings via stimulation of production of prostaglandins by surrounding cells.
Voltage-gated sodium channels
Sodium channel blockers are powerful analgesics at low concentrations (Strichartz et
al., 2002). Two sodium channels, Nav1.8 and Nav 1.9 are selectively expressed within the
peripheral nervous system, predominantly in nociceptive sensory neurons. Nav 1.7 is found
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in both sympathetic and nociceptive sensory neurons and has been shown to play a critical
role in inflammatory pain using nociceptor-specific knockout mice (Nassar et al., 2004).
Studies of DRG neurons from mice lacking theNav1.8 gene indicate this channel accounts
for almost all TTX-resistant current during action potentials in these neurons (Akopian et al.,
1999). Behavioural studies of these mice revealed a complete absence of responses to a tonic
noxious mechanical stimulus and attenuated primary thermal hyperalgesia evoked by
intraplantar injection of NGF (Akopian et al., 1999; Kerr et al., 2001). Inhibiting the
expression of Nav1.8 protein using antisense oligonucleotides also reduces primary
hyperalgesia produced by intraplantar PGE2 or FCA in rats (Khasar et al., 1998; Porreca et
al., 1999).
Central Mechanisms
The dorsal horn of the medulla and spinal cord are the major sites of termination of
nearly all sensory afferents. Central axons of primary afferents ascend or descend one or
two segments in Lissauer's tract before terminating in specific regions of the grey matter of
the spinal cord. The dorsal horn was divided into ten laminae based on histology (Rexed,
1952; for review see Willis and Coggeshall 1991). Unmyelinated C-fibre nociceptors
terminate principally in lamina II (the subsantia gelatinosa; Willis and Coggeshall, 1991;
Millan, 1999). Small myelinated A5 nociceptors terminate mainly in the superficial dorsal
horn (lamina I). Nociceptors from joint terminate in lamina I as well as more deeply in
lamina VI and VII. Large fibre, low threshold mechanoceptors terminate mainly in lamina
III and IV, or more rostrally in the dorsal column nuclei of the medulla oblongata (Todd &
Koerber, 2006).
The terminations of primary afferent nociceptors transmit information to second
order neurons in the dorsal horn. These can be divided into two classes, namely; nociceptor
specific (Besson and Chaouch, 1987) or wide dynamic range neurons that have different
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response properties to afferent input and differentiatial distributions in regions of the dorsal
horn (Willis and Coggeshall, 1991).
Neurotransmission from the dorsal horn encompasses:
• Excitatory transmitters released from the central terminals of primary afferent
nociceptors;
• Excitatory transmission between neurons of the spinal cord;
• Inhibitory transmitters released by interneurons within the spinal cord;
• Inhibitory transmitters released from supraspinal sources.
Glutamate is the main CNS neurotransmitter and plays a major role in nociceptive
transmission in the dorsal horn. Glutamate acts at AMPA, NMDA and kaniate receptors.
The release of substance P, which coexists in primary afferents with glutamate, occurs
following cutaneous thermal, mechanical or chemincal noxious stimuli and is potentiated by
peripheral inflammation.
The increased C-fibre activity during inflammation increases the excitability of
second order spinal neurons via release of glutamate and substance P. Experimentally,
repeated stimulation of primary afferent C-fibres above a threshold rate induces a cumulative
increase in the action potential firing of dorsal horn neurons in vivo (Mendell, 1966). This is
called wind-up, which effectively increases the gain of afferent inputs (Kress & Reeh,
1996). In addition, brief high frequency stimulation induces a long-term increase in
excitatory synaptic transmission onto superficial dorsal horn neurons which outlasts the
period of stimulation. This strengthens the efficacy of synaptic transmission, in a similar
way to long-term potentiation of the hippocampus (Ji et al, 2003), and is called central
sensitisation.
Some work has also shown that following peripheral nerve injury the central
terminals of peripheral AP-fibres sprout novel synapses in more superficial layers of the
dorsal horn, more commonly associated with nociceptive transmission (Lekan et al., 1996),
although more recently this work was repeated and found not to be the case (Hughes et al.,
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2003). There may also be changes in neurotransmitters, receptors, ion channels and
intracellular signalling in the CNS which may exist during chronic pain states.
Primary afferent nociceptors relay to projection neurons in the dorsal hom, which
cross the spinal cord and ascend to supraspinal sites, and contribute to both affective and
sensory aspects of pain (for review see Hunt and Mantyh, 2001). Projection neurons activate
multiple higher centres, including the nucleus reticularis gigantocellularis, from here neurons
project to the thalamus, and also activate the nucleus raphe magnus and periaquadual gray
(PAG; Millan, 1999) of the midbrain.
Descending fibres from the PAG project also project to the nucleus raphe magnus
and adjacent reticular formation. These neurons activate descending inhibitory neurons that
are located in these regions and terminate in the dorsal horn of the spinal cord. Descending
projections also arise from a number of brainstem sites, including the locus ceruleus.
Several other sites within the limbic system receive projections from the spinal cord, such as
the amygdaloid and septal nuclei (Fields et al., 2006).
Some supraspinal structures which are involved in pain processing include the
thalamus, cortical structures (including motor, premotor, parietal, frontal, occipital, insular
and anterior cingulated regions), the PAG of the midbrain, which receives projections from a
number of brain regions, including the amygdale, frontal and insular cortex and
hypothalamus and acts in concert with the rostral ventromedial medulla (RVM) to provide
descending pain modulation.
However, this thesis will focus on peripheral mechanisms of pain and inflammation;
hence will not discuss central mechanisms further, although they clearly play important roles




The studies detailed in later chapters of this thesis were designed to test several
hypothesis concering the mechanisms which lead to inflammation and pain of an inflamed
joint. Firstly, it was expected that there would be significantly increased levels of known
key inflammatory mediators in synovial cavities during the acute and chronic stages of
adjuvant-induced arthritis, to which we could attribute the chronic pain, swelling and joint
destruction seen during the model. These mediators, including TNFa, ILip and IL6, are
present in human arthritic joints and in other animal models of inflammatory joint disease.
Once a suitable perfusion technique had been developed to enable sampling ofjoint fluid and
therefore measurement of cytokine levels within the joint space, a 21-day time course of
adjuvant-induced unilateral arthritis was carried out. Samples from ipsilateral and
contralateral joints were taken and later assayed for cytokine levels. Blood samples were
also taken to determine whether systemic levels of these mediators were elevated, which was
expected based on previous evidence. A further hypothesis at this stage was that the levels
of inflammatory mediators in the joints and in the blood would correlate to measues of joint
swelling and hypersensitivity.
Chapters 6 and 7 were designed as a result of data generated in chapter 5. It was
hypothesised from the expression levels ofILip and IL6 in the knee joints during adjuvant-
induced arthritis, and their stong correlation to the weight distribution readout during this
time course, that they were directly involved in the induction of mechanical hypersensitivity
both by direct actions on peripheral sensory nerves and via indirect actions on these primary
afferents, probably via the release of secondary messengers. It was anticipated that intra¬
articular administration of either of these compounds would increase the electrical
excitability of peripheral afferents, decreasing the mechanical threshold required to induce
neural activity, increasing the rate of basal discharge and increasing the frequency of action
potentials triggered to a suprathreshold stimulus. Furthermore, we hypothesised that ILip
and IL6, at the pharmacological doses administered, would initiate joint destruction,
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including cartilage and potentially bone erosion, thus resulting in a chronic joint
inflammation, including behavioural signs of swelling and hypersensitivity.
1.8 AIMS OF THE STUDIES
The primary aim of this thesis was to investigate the roles of specific pro¬
inflammatory cytokines in the development and maintenance ofjoint pain and inflammation.
In order to achieve this two novel techniques were developed and validated with the view to
using them alongside existing methods. A new behavioural tool to measure mechanical
hypersensitivity directly across the knee joint which would add to current readouts was
developed in collaboration with Dr Harry Brash, a medical physicist. This device was
validated by determining whether it could detect changes in hypersensitivity of knee joints of
rats and mice as a result of an inflammatory insult, and subsequently whether it was able to
detect the reversal of hypersensitivity in animals treated with a range of gold-standard
analgesic drugs. Secondly, a perfusion technique designed to improve the collection of
synovial fluid from rat knee joints and to allow more accurate assessment of the
inflammatory mediator and cell content of the joint cavity was developed. The perfusion
technique was used to investigate the temporal expression patterns of inflammatory
cytokines and cells in the knee joints of rats with adjuvant-induced arthritis, and the effect of
the steroid prednisolone on these levels. Finally, the effects of IL1P or IL6 on
■ acute and chronic joint swelling, hypersensitivity and joint destruction
■ the release of other pro- and anti-inflammatory cytokines
■ primary sensory afferent neural activity and sensitivity
were assessed using the two new techniques, as well as established methods including in vivo
electrophysiological recording from primary afferent nerves innervating the rat knee joint,
histological processing of normal and ILip- or IL6-injected joints, the weight distribution
readout and a measure of joint swelling.
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All experiments described in this thesis were performed in accordance with the
regulations and guidelines of the Scientific Procedures Act (1986) under the Personal
Licence number PIL 60/9007 and Project Licence, PPL 60/2750 until Aug 05, then PPL
60/3496. Animals used in these studies were housed at licensed animal facilities within the
School of Biomedical and Clinical Laboratory Sciences and experiments were performed in
licensed laboratories within the Division of Neuroscience at The University of Edinburgh.
Joint perfusate samples were frozen and assayed for inflammatory mediator content at
GlaxoSmithKline (Harlow, UK).
In these studies a total of 522 adult male Wistar rats and 24 adult male C57 Black-6
(C57BL/6) mice were used. All animals were purchased from Charles River (UK). Animals
were kept on a 12-hour light/dark cycle and maintained on standard animal feed and had
access to water ad libitum at all times.
2,1 MODELS OF EXPERIMENTAL ARHTRITIS
2.1.1 THE RAT FCA MODEL OF ARTHRITIS
Induction of unilateral arthritis
A localised chronic inflammation was induced in rats by intra-articular (i.art)
injection of Freund's Complete Adjuvant (FCA, 1 mg ml"1; heat killed Mycobacterium
tuberculosis suspended in heavy liquid paraffin (HLP) oil with Monooleate adjuvant; Sigma,
UK) into the left knee (stifle) joint under transient halothane anaesthesia (3% in oxygen).
FCA (150 pi) was injected using a 26-gauge needle (Microlance, UK) inserted into the joint
space through the patella tendon just below the patella. Once the animals recovered, they
were housed in a cage (maximum four per cage) until they were used.
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Induction of Bilateral Arthritis
A bilateral chronic inflammation was induced in rats by i.art injection of FCA (5 mg
ml"1 heat killed Mycobacterium tuberculosis suspended in HLP oil with Monooleate
adjuvant; MAFF, UK) into the left knee joint under transient halothane anaesthesia (3% in
oxygen). FCA (100 pi; 500 pg) was injected using a 26-gauge needle (Microlance, UK)
inserted into the joint space through the patella tendon just below the patella. Once the
animals recovered, they were housed in a cage (maximum four per cage) until they were
used.
2.1.2 CYTOKINE-INDUCED JOINT INFLAMMATION
A mild short-lived inflammation was induced in rats by i.art injection of
recombinant rat ILip or IL6 (Bioclone, USA) into the left knee joint under transient
halothane anaesthesia (3% in oxygen). ILip or IL6 (100 pi; 1, 3 or 10 pg) was injected
using a 26-gauge needle (microlance, UK) inserted into the joint space through the patella
tendon just below the patella. Once the animals recovered, they were housed in a cage
(maximum four per cage) until they were used. Basal measurements of weight distribution,
PAD LWT and knee joint diameter were made prior to administration of ILip, IL6 or
vehicle (t=0). The weight distribution between the hind limbs was assessed two, four and six
hours post-ILip or vehicle; PAD LWT measurements were made three, five and seven hours
post-ILl P or vehicle. Measurements for body weight, joint diameter, weight distribution and
PAD LWT were then made 24, 48, 72, 96, 144 and 168 hours post-ILip or vehicle.
2.1.3 THE MURINE MODEL OF UNILATERAL ARTHRITIS
Male C57BL6 mice were injected with FCA (i.art; 20 pi; 200 pg). Briefly,
injections were carried out during transient halothane anaesthesia (3% in oxygen) and a
small incision was made over the left knee joint to allow visualisation of the patella tendon.
FCA (20 pi) was injected under the patella tendon and directly into the joint space of the
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knee joint using a 30-gauge needle mounted on a 50 pi Hamilton syringe. Once the animals
recovered, they were housed in a cage (maximum eight per cage) until they were used.
2.2 ASSESSMENT OF ARTHRITIS
The single i.art injection of FCA produces a mild to moderate chronic inflammation
that persists for up to 90 days (Wilson et al., 2006). During this time, the general health of
the animals remains good, as shown by their ability to eat, gain weight, groom and move
around the cage as normal (Donaldson et al., 1993; Gauldie et al., 2004). Between the
induction of arthritis and their use for joint perfusions or behavioural assessments, the
animals' general health and mobility was observed by me and the Named Animal Care
Worker. The level of inflammation and hypersensitivity associated with the experimental
arthritis was determined prior to their use in further experiments; see Table 2.1 for
experimental use times.
Experimental use Days post arthritis-induction
Joint perfusions FCA: 1-21 days
ILip, IL6, saline: 1-10 days
Histology FCA or HLP: 14-21
ILip, IL6, saline: 1-10 days
Behavioural Studies FCA or HLP: 1-28
ILip, IL6, saline: 1-7
Table 2.1 Experimental use times for joint perfusions, histological processing and behavioural studies
ofFCA-, HLP-, ILip-, IL6-, or saline-injected rats.
2.2.1 SWELLING
The degree of joint inflammation was determined by measuring the diameter of the
ipsilateral and contralateral joints using digital micro-callipers (Mitutoyo, Japan; see Figure
2.1). FCA (150 pg), ILip or IL6 (1, 3 and 10 pg) injections resulted in a unilateral
inflammation, restricted only to the ipsilateral joint, showing no spread to the contralateral
side. However, studies designed to investigate the nature of the contralateral inflammation
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using 500 ug FCA, resulted in both ipsilateral and contralateral swelling, the contralateral
spread having a delayed onset of 10-14 days. Ipsilateral joint diameters were compared with
contralateral measurement and the basal diameter, measured prior to intra-articular
injections.
Hi
Figure 2.1 Photograph of the digital micro-callipers used to measure knee joint diameter of rats and
mice.
2.2.2 WEIGHT DISTRIBUTION
The mechanical hypersensitivity as a result of i.art injections was determined by
comparing the distribution of body weight between the two hind limbs using a dual channel
weight averager (Linton Instruments; Clayton et al., 1997). Briefly, the instrument consists
of two force transducers capable ofmeasuring the weight applied on each limb over a three
second period. The rats were restrained for a short period in a clear Perspex box, which
aligned the body so that each hind limb was placed on a transducer plate, with the fore limbs
resting on a slope for support (see Figure 2.2). The force on each transducer was measured
and given as a digital readout in grams for each limb. Using the contralateral joint as an
internal control, the weight distribution could be expressed as a ratio (ipsilateral:
contralateral) or as a percentage change from baseline. Usually, the animal distributed its
weight equally between the two hind limbs prior to induction of joint inflammation, and then
as arthritis develops the injected limb carried less weight than the contralateral joint.
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Figure 2.2 Photograph of the incapacitance tester used to assess mechanical hypersensitivity of rats.
A similar device with a smaller Perspex box and transducer plates is used for mouse measurements.
2.2.3 PRESSURE APPLICATION
A second method was also used to assess mechanical hypersensitivity of the joints,
involving direct application of pressure to the joint. This novel apparatus, the Pressure
Application Device (PAD) was developed and validated during my PhD and therefore makes
a separate chapter (Chapter 4) in this thesis in which all the details are included.
2.3 IN VIVO RECORDING FROM AFFERENT NERVES
2.3.1 ANAESTHESIA AND SURGICAL PROCEDURES
Rats were initially anaesthetised with intra-peritoneal (i.p.) injection of pentobarbital
sodium (60 mg ml"1; 0.1ml kg "'). Once fully anaesthetised, when no paw withdrawal
reflexes occurred when the foot was pinched (areflexic), the animal was laid on its back and
its core body temperature maintained at 37°C using an automated heating blanket (Harvard
Apparatus Limited, UK) attached to a thermistor probe inserted into the rectum.
A small midline incision was made in the neck to expose the trachea, which was
cannulated (cannula outer diameter (OD) 2.0 mm, Portex, UK) to allow the facilitation of
breathing, or if required, artificial ventilation using a ventilator (Harvard Apparatus Limited
UK). The right carotid artery was cannulated (cannula OD 0.75 mm) to allow the continual
monitoring and recording of arterial blood pressure (BP) through a pressure transducer (Bell
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and Howell, UK) attached to a Powerlab/ 8sp (ADInstruments, UK), connected to a personal
computer running Chart 5.01 (ADInstruments, UK) software.
The medial aspect of the right hind limb was exposed by cutting the skin. The right
femoral vein was cannulated (cannula OD 0.63 mm) to administer anaesthetic; deep
anaesthesia and fluid levels were maintained throughout the experiment with an intravenous
(i.v.) infusion of pentobarbital (375pi hr"1; 7.5 mg hr"1; 0.3-0.6 mg kg"1 min"1) diluted 1:3 in
saline (20 mg ml"1). The infusion was adjusted regularly depending on reflexes, which were
checked regularly by squeezing the intact paw for reflex withdrawal.
2.3.2 DISSECTION OF THE MEDIAL ARTICULAR NERVE
Extracellular recordings were performed on a portion of the MAN innervating the
left knee joint (Freeman & Wyke, 1967; Gardner, 1944). The left hind limb was fixed to a
support using plaster of Paris and a small incision was made on the medial aspect in order to
expose the MAN where it branches from the saphenous nerve. The skin was secured with
cotton stitches to a small brass ring to form a pouch which was filled with HLP oil to create
an electrically isolated system (see Figure 2.3). The saphenous nerve was cut centrally to
prevent interference from efferent neural activity. In addition, input from skin afferents was
reduced by separating as much skin as possible from the knee joint. The MAN was dissected
out from the surrounding tissue using fine forceps and placed over bipolar platinum/iridium







The left knee is fixed to a
support and the overlying
skin excised and attached
to a brass ring to form a




Figure 2.3 Photograph of the experimental set up for recording neural activity from sensory afferents
in the MAN innervating the rat knee joint. The left knee joint was fixed to a support and the skin cut
and tied to a small brass ring to form a pool, into which HLP was poured to produce an electrically
isolated system. .
2.3.3 RECORDING FROM THE MAN
Afferent activity was recorded by laying the dissected MAN nerve bundle over the
bipolar Pt/Ir electrodes. The raw nerve signal was passed through a pre-amplifier and an
amplifier (Neurolog NL 103 and NL 105 respectively; signal amplified x 10 000). The
signal was then displayed on an oscilloscope (Gould 1604), filtered (100 Hz low pass and
1000 Hz high pass; Neurolog, NL 115), and the voltage discriminated signal passed through
a Micro 1401 interface (Cambridge Electronic Design (CED), UK) connected to a loud
speaker and a personal computer (PC) running Spike 2 software (CED, UK; version 5.11).
Electrical events were recorded online by setting both positive and negative trigger levels.
These were saved as data files for off-line analysis. In addition, keyboard markers were
written into the file whilst recording to identify drug injections or test points. Figure 2.4
illustrates the experimental set-up. Units were characterised only to mechanical stimulation,
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Figure 2.4 A schematic diagram of signal processing during neural recording illustrating the
equipment used to record, store and analyse the neural activity from the sensory afferents innervating
the rat knee joint.
2.3.4 DRUG ADMINISTRATION
Drugs were administered via an i.art injection into the left knee joint. Recombinant
rat ILip (0.1 pg in 100 pi) or IL6 (0.1 pg in 100 pi) were administered i.art into the left knee
joint two hours after the nerve recording began, to allow the nerve to stabilise following the
preparatory surgery, and to allow two control tests to be carried out. The electrode was
lowered, reducing the tension of the nerve, in order to prevent damage during movement of
the joint during the injection, and then raised immediately after. A volume of 100 pi was
administered into the knee joint using a 25-gauge needle. The drugs used in this study,




The threshold to mechanical stimulation was determined using a range of six
calibrated von Frey hairs, 0.96, 2.35, 4.64, 7.37, 12.5 and 20.9 g (Stoelting, Scientific
Marketing Associates, UK); once the nerve responded to a fibre, no higher forces were
applied. Two tests were carried out 30 minutes apart before (control; -60 and -30 minutes)
administration of ILip, IL6 or saline and then 15, 30, 60, 90, 120, 150, 180, 210 and 240
minutes after.
In a separate series of experiments, the discharge evoked by 0.98, 12.5 or 20.9 g von
Frey hairs was measured at regular intervals before and after i.art administration of IL1 (3, IL6
or saline. The receptive field of the nerve was located by probing with a plastic tip 1 mm in
diameter, and a specific location for repeated stimuli was marked to ensure accurate repeated
applications of the fibres. The von Frey filament was applied for a five second period and
then removed. Two tests were carried out 30 minutes apart before (control; -60 and -30
minutes) administration of ILip, IL6 or saline and then 15, 30, 60, 90, 120, 150, 180, 210
and 240 minutes after.
2.3.6 BASAL NEURAL ACTIVITY RECORDED FROM THE NERVE
Changes in basal discharge frequency were studied following administration of ILip
(0.1 pg in 100 pi ;n=8), IL6 (0.1 pg in 100 pi ;n=8) or vehicle (100 p n=5); 300 second time
periods were used to assess the firing frequency at two time points prior to ILip, IL6 or
vehicle administration (t= -60 and -30 minutes) and then again 15, 30, 60, 90, 120, 150, 180,
210 and 240 minutes after ILip, IL6 or vehicle administration.
2.3.6 DATA SORTING
Once the experiment was recorded on the PC, the neural data was analysed using
Spike 2 software (see Figure 2.5a). The recorded waveform was scanned for action
potentials that exceeded the noise band and then rescanned and waveform templates used to
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represent the individual spikes that make up the responses. Once this was achieved, the
response of each unit was displayed on individual channels (see Figure 2.5b). Data was
generally displayed in histogram format, showing the total number of impulses in one
second, providing data on the absolute discharge (impulses) and frequency (impulses s"1).
2.3.7 DATA ANALYSIS
Responses to mechanical stimulations were determined by comparing the action
potential discharge frequency or the absolute number of action potentials recorded during the
test period with that of the basal discharge recorded prior to mechanical stimulation. Data
are expressed as either the change in mean action potential frequency (Ax; impulses s"1;
Equation 1) or the change in the absolute number of action potentials evoked over the
duration of the response (A£x; impulses; Equation 2) between that of the test period and that
of the control period immediately prior to the test. If no clear response was observed the
afferent activity present was measured for 15 s after the injection.
^X X test ~ X control Equation 1
X Yjjest ~ y. control Equation 2
Definitions:
Yl- The total number of action potentials counted in the control (15 s) or test periods,
ZXco«r™/or Zfev respectively (expressed as impulses).
X : The frequency of action potential discharge in the control (15 s) or test periods
(expressed as impulses s"1).
Therefore,
X control yycontrol/ tcontrol
X test ~~ 2]%test / ^test
Where changes in spontaneous action potential discharge were studied following
i.art administration of compounds, 300 second time periods were used to assess the discharge
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frequency at two time points prior to substance administration (-60 and -30 minutes;
controls) and then again at 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes after.
The mechanical threshold to von Frey filaments was used to assess the affect of i.art
ILip, IL6 or saline on primary afferent sensitivities. Two control measurements were made
30 minutes apart before injection of compounds into the synovial cavity (-60 and -30
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Figure 2.5 Spike traces showing (a) the raw filtered neural signal (top) and the BP trace (bottom) for
an i.a. injection of lpg Capsaicin and (b) the individual fibre patterns of two units in the bundle during
the same injection and the spike shapes of the 2 units in the recording.
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2.4 RAT KNEE JOINT PERFUSION
As the development of this novel technique comprised a significant portion of the
overall project, it is covered in a separate chapter in this thesis. Full details of the method
are provided in chapter 4.
2.4.1 THE PERFUSION NEEDLES
A needle perfusion system was constructed by binding a 25- and a 23-gauge needle
(Microlance, UK) together using epoxy putty, with the bevels of the needles positioned on
the outside edges facing away from one another (see Figure 2.6). The tips of the needles
were set 1-1.5 mm apart. The needles were connected to a Watson-Marlow roller pump via
silicone rubber perfusion tubing (internal diameter 1 mm, external diameter 4.2 mm, Watson
Marlow, UK).
Figure 2.6 The perfusion needles and the perfusion system managing inflow and outflow from the
knee joint space. A Watson-Marlow pump controlled the rate of saline infusion and sample extraction
(100 pi min"1) from the joint.
2.4.2 PERFUSION OF THE KNEE JOINT
Rats were anaesthetised with i.p. urethane (ethyl carbamate; 0.6 ml lOOg"1 body
weight; 25% w v"1 solution; single i.p. injection) or sodium pentobarbital (1 ml kg"1 body
weight; 60 mg ml"' solution; single i.p. injection maintained with i.v. 375 pi hr"1 20 mg ml"1
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solution). Once fully anaesthetised the animal was placed on its back on an automated
heating blanket (Harvard Apparatus Limited, UK) and its core body temperature maintained
at 37°C via a thermistor probe positioned in the rectum.
The limbs of the rat were flexed over a 20 ml glass vial, with the patella facing
directly upwards and were held in place with tape. The perfusion needles were inserted to a
depth of approximately 3 mm into the joint and held in place with the aid of a clamp attached
to the table. The 23-gauge needle was connected to the Watson-Marlow roller pump via
silicone rubber perfusion tubing and sterile saline was infused at a constant rate of 100 pi
min"1. After infusion of 100 pi of sterile saline, the outflow tubing was connected to the 25-
gauge needle, to minimise pressure build-up within the joint space. Fluid was infused and
withdrawn at a constant rate until a 250 pi sample was collected in a 1.5 ml centrifuge tube.
Samples were immediately frozen and stored at -20°C. Approximately 75% of joint
perfusions resulted in successful sample collection. Problems that resulted in collection
failure included inconsistent outflow of solution from the joint space or incorrect needle
placement. Samples that were contaminated with blood were not used.
2.4.3 CYTOKINE ASSAY OF JOINT SAMPLES
ELISA Assay
PGE2, TNFa and ILlp content of samples were measured using commercially
available ELISA kits (PGE2: Amersham Biosciences, UK; rat ILlp and TNFa: BioSource
International, Camarillo, USA), according to the manufacturers' protocol. The ELISA assay
for PGE2 was carried out by Ms Penny Staton at GlaxoSmithKline, Harlow, UK.
Briefly, 50 or 100 pi aliquots of sample were pipetted into the wells of a microtiter
plate pre-coated with an antibody specific for rat IL-ip, TNFa or PGE2 and incubated for
between 1 and 3 h at room temperature. After washing, a different biotinylated anti-rat IL-
lp, TNFa or PGE2 antibody was added and incubated at ambient temperature for 1 h.
Streptavidin-peroxidase (HRP) was added and incubated for 30 - 45 min. After a third
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incubation and washing to remove all unbound enzyme, colour was developed by addition of
stabilized chromogen (tetramethylbenzidine), a stop solution added after 30 minutes and the
intensity of the coloured product quantified by a 96-well spectrophotometer at 450 nm
(Thermo Labsystems Multiskan Ascent plate reader running Ascent software Version 2.6).
The minimum detection limit of the assay was 3, 4 and 50 pg ml"1 for ILlp, TNFa and PGE2
respectively.
ELISA Data Analysis
Standard curves were plotted using the aliquoted serial dilutions of a positive control
solution for calibration. Unknown sample cytokine concentrations were calculated from the
curve.
Luminex Bead Array Assay
Perfusates were analysed for multiple analytes using a multi-cytokine bead array
detection system. Rat ILla, IL1|3, IL2, IL4, IL6, IL10, IFNy, GM-CSF and TNFa were
measured using a Bio-Rad rat 9-plex kit, according to the manufacturer's instructions
(Biorad, USA). A monocolonal antibody directed against the desired analyte is covalently
coupled to dyed 5.5 pm polystyrene beads (2.5xl06 beads ml"1 cytokine"1). The conjugated
beads were exposed to 50 pi of sample or standard solutions containing a known amount of
cytokine, in a 96-well filter plate and incubated overnight at 4°C, protected from light. After
a series of washes with 5% bovine serum albumin (BSA) in phosphate buffered saline (PBS)
and vacuum filtration (Millipore, USA) to remove unbound protein, a biotinylated detection
antibody specific for a different epitope on the analyte was added to the reaction, After
incubation, the unbound antibody was removed; the reaction mixture was detected by the
addition of streptavidin-phycoerythrin (streptavidin-PE; Europa Bioproducts, UK), which
binds to the biotinylated detection antibodies. Following three washes and vacuum filtration,
the beads were re-suspended in 200 pi 5% BSA in PBS; the plate was stored at 4°C in the
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dark until analysis, up to a maximum of 24 hours later. The reaction mixture was read using
a Luminex Data Collector in a Luminex xMAP 100 (Luminex, USA).
Luminex Data analysis
Excel data files were generated by the Luminex containing individual bead numbers
and the associated median fluorescence intensities. Standard curves were plotted to calculate
the relative amount of each cytokine in samples, using the aliquoted serial dilutions of a
positive control solution for calibration. Cytokine concentrations of unknown samples were
calculated from the curve.
2.4.4 TOTAL CELL COUNTS OF PERFUSION SAMPLES
Total inflammatory cell counts of perfusion samples were determined using 10 pi of
sample collected from rat knee joints as described above but with 3.15% sodium citrate in
the sterile saline infusion solution. Samples were viewed in a haemocytometer using a light
microscope. Initially undiluted samples were examined, but due to the red blood cell content
of some samples, it was necessary to dilute the samples with saline with added Zappoglobin
(1-2 drops per 20 ml saline; a red blood cell lysing agent). All cells remaining could be
identified as white blood cells (inflammatory), and were counted, and multiplied up by the
dilution factor and 10, 000 (as a 10 pi sample used) to calculate the total number of
inflammatory cells in 1 ml of joint perfusion sample. Inflammatory cell count analysis was
carried out at The Queens Medical Research Institute, Little France, Edinburgh in
collaboration with the laboratory of Prof. Adriano Rossi.
2.4.5 BLOOD SAMPLE COLLECTION
Blood samples were taken from the tail vein after perfusion of the knee joints was
complete. These were collected in EDTA-coated capillary tubes (Sarstedt Microvette, UK)
and centrifuged (Eppendorf Centifuge, Model 5414) at 12000 revolutions per minute (rpm)
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for ten minutes. The plasma was removed and placed in a 1 ml centrifuge tube and frozen at
-20° C. Blood samples were later assayed for multiple cytokines using the Luminex assay.
2.5 HISTOLOGICAL PROCESSING
The left knee joints of rats were injected with IL1P (1 pg; n=12) or IL6 (1 pg; n=12)
under transient halothane anaesthesia (3% in oxygen). On days 1, 2, 4 and 7 post-ILl(3 or -
IL6 three animals were killed and the hind limbs surgically removed and fixed in formalin.
Animals were killed by rising carbon dioxide concentrations in a chamber, and both the left
and right knee joints removed and fixed in 10% formal saline. All tissues were then
processed (post-fixed, decalcified and paraffin embedded), sectioned (3 pm sections) and
mounted on glass slides by Professor Donald Salter (Department of Pathology, University of
Edinburgh). Paraffin-embedded sections of rat knee joints were stained using haematoxylin
and eosin (H&E), and covered with glass coverslips using Pertex mountant. The sections
were subsequently examined using light microscopy by Prof. Donald Salter, at The
Department of Pathology, Royal Infirmary of Edinburgh
2.6 STATISTICAL ANALYSIS
Data was collected and analysed using Microsoft Excel, GraphPad Prism and
GraphPad Instat software. Data is expressed as mean ± standard error of the mean (SEM)
where appropriate. Unpaired t-tests were used to analyse the differences between the means
of two normally distributed groups. When the sample size for each group was small, or data
was not normally distributed the non-parametric Mann-Whitney U-test was performed. For
paired data the Student's paired t-test (parametric) orWilcoxon U-test (non-parametric) tests
were used. To determine whether statistically significant differences existed between group
mean values a one-way analysis of variance (ANOVA) was done and a post-hoc test (Dunns
multiple comparison) performed if the result was deemed to be significant. The means of
two or more groups of non-parametric data were analysed with a Kruskal-Wallis test and a
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post-hoc analysis done using Dunn's multiple comparison. Correlations between normally
distributed groups were determined using Linear (Pearson) correlation and non-parametric
data were compared using a Spearman Rank Correlation. To compare the relative
proportions in a population between two groups the Fisher's Exact test was used. Where the
effects of drug-treatment were assessed, area under the curve (AUC) values were calculated
during the dosing period and compared with that of vehicle-treated groups. AUC values
were calculated for individual animals on each day during the dosing period. The baseline
was taken as the measurement on the day prior to drug treatment. AUC values were
compared with vehicle using a Kruskal Wallis non-parametric ANOVA. In all cases the null
hypothesis was rejected at the 0.05 level. Therefore P < 0.05 was considered statistically
significant and where possible the calculated P value was quoted to show the proximity to
the 0.05 limit.
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Chapter 3 - Development of an automated pressure
withdrawal threshold readout (PAD) to assess
mechanical hypersensitivity of rat and mouse knee
joints
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3.1 INTRODUCTION
One of the main symptoms of arthritis is joint pain (Anderson et al., 1994; Heiberg &
Kvien, 2002; Kazis et al., 1983; McKenna & Wright, 1985); quantification of this is useful in
determining the mechanisms of pain and evaluating the effects of anti-arthritic, analgesic or anti¬
inflammatory drugs. Pain is not a single sensory experience, and thus a wide variety of models
have been developed to represent different types of pain. Although acute thermal and
mechanical assays exhibit adequate validity for many analgesics (Taber, 1973), acute pain is not
a clinically relevant situation, particularly for RA patients. Thus, a number of animal models of
"chronic" joint pain have been developed, including adjuvant-induced arthritis, as discussed in
Section 1.5.1.
Measurements of spontaneous pain as well as hypersensitivity states, such as
hyperalgesia or allodynia, are assessed in these models. A range of behavioural tests are used to
determine nociceptive thresholds to thermal, mechanical or electrical stimuli (for review see Le
Bars et al., 2001). Spontaneous measures of pain in laboratory animals include assessment of
weight-bearing by the affected foot (Clayton et al., 1997; Min et al., 2001; Schott et al., 1994),
locomotor activity, foot position and gait analysis, either subjectively or with the use of a
computer (Clarke et al., 1997; Coderre & Wall, 1988; Gegout-Pottie et al., 1999; Otsuki et al.,
1986; Wang et al., 2000) and paw elevation time of a rat walking on a rotating cylinder (Tonussi
& Ferreira, 1992).
The incapacitance tester (Clayton et al., 1997) consists of two force transducers on
which the animals' hind limbs are positioned; the device is able to provide an objective, non-
evoked assessment of pain by measuring the average weight placed independently on each hind
limb. Naive rodents distribute their weight evenly across both hind limbs under normal
conditions (Kobayashi et al., 2003). Following induction of joint inflammation, animals
redistribute their weight in order to place less weight on the affected joint, as a guarding
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mechanism to protect the limb and prevent further injury during tissue repair. Results based on
the incapacitance tester were found to be less variable and more graded that those of a subjective
grading of animal stance (Schott et al., 1994).
Mechanical stimulation of the paw using von Frey filaments (Chaplan et al., 1994) or
the Randall-Selitto apparatus (analgesymeter; Randall & Selitto, 1957) is commonly used to
assess inflammatory pain. However, although these methods appear to measure arthritic pain,
there are problems associated with their use as an index of pain in a particular joint, such as the
knee. For example, testing sensitivity of the paw to assess pain in the knee joint is indirect.
Recently, home-made calibrated forceps which apply a gradually increasing pressure to
the paw until the animal withdraws the paw or vocalises have been used to assess pain (Gauriau
& Bernard, 2004; Yu et al., 2002). These devices consist of two strain gauges attached to the
inner arms of large forceps. The strain gauges are electrical resistors; the resistance varies
linearly according to the strain applied, and the withdrawal threshold is automatically recorded
when the animal withdraws the paw. One study has used a similar technique on the knee joint
(Neugebauer & Li, 2002), but used vocalisation as the test endpoint rather than limb withdrawal,
which meant that supraspinal responses, rather than basic spinal nociceptive reflexes were being
investigated. Application of a compression or squeeze force to the joint is more relevant than
punctate mechanical stimulation of the skin overlying the joint with von Frey filaments, which is
more likely to stimulate skin nociceptors, rather than nociceptors in the joint.
Animal models are designed to mimic human disease, so it is crucial that they represent
human arthritic pain, and that the assessments of this pain used in the laboratory accurately
reflect those used clinically. Pain is "subjective" if reported from patient self-report
questionnaires or "objective" if data is interpreted from laboratory, imaging and physical
examination (Sokka, 2003). Patient self-report questionnaires have been developed to facilitate
qualitative and quantitative assessment of pain status and functionality of arthritic joints and
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have proven valuable in gaining new understandings of mechanisms and control of pain
(Anderson, 2001; Bellamy, 1989; Bellamy et al., 1988; Fries et al., 1980; Hunt et al., 1985;
Huskisson, 1974; Meenan et al., 1980; Melzack, 1975; Ware & Sherboume, 1992).
Furthermore, quantitative pain measures from patient questionnaires provide information to
recognize if patients improve or worsen over time. For example, the self-report health
assessment questionnaire contains a scale of 20 activities of daily living in eight categories,
designed to assess functional disability with four response options for the patient:
• "without difficulty" (0)
• "with some difficulty" (1)
• "with much difficulty" (2)
• "unable to do" (3)
Efforts to assess pain in patients through objective external measures have not been
successful in providing reliable quantitative data (Sokka, 2003). Furthermore, the most effective
predictor of mortality in patients with RA is found in a patient questionnaire, rather than in data
from physical examination, laboratory tests or radiography (Pincus et al., 1994; Pincus et al.,
1984). However, with the inability to communicate verbally with experimental animals,
physical behavioural measures of pain are the only way to assess experimental hypersensitivity.
Three functional measures used for assessing RA patients in the clinic include "grip
strength" (Lee et al., 1974), the "button test" (Clawson et al., 1971) and "walk time" (Deodhar et
al., 1973). The "grip test" uses a BP cuff inflated to 20 mm of mercury. The patient is asked to
squeeze as hard as possible, triplicate measurements are taken for each hand, and the average
value used as the grip strength value. To assess "walking time" patients are asked to walk at a
"normal" pace for a set distance; the test is timed using a stopwatch. The "button test" uses a
standard commercially available board; patients are asked to button and unbutton five shirt
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buttons attached to the board as quickly as possible, the process is timed. When performed
according to a standard protocol (Pincus & Callahan, 1992) these methods are among the most
reproducible measures in clinical rheumatology (Pincus et al., 1994; Pincus et al., 1987).
A dolorimeter is an instrument which applies progressive pressure to the joints of
patients who are asked to report when they first experience pain and when the pain becomes
unbearable. Dolorimeters have been used for many years to measure the pain threshold, which
is more accurately assessed than pain itself. The dolorimeter has proven to be of great value in
research concerning pain thresholds and behaviours (Langley et al., 1983). Furthermore, the
dolorimeter was found to be more sensitive than a modified Ritchie index in measuring the
degree of joint tenderness and equally as sensitive in detecting tender joints. The Ritchie
articular index is generally accepted as a standard subjective method for measuring joint
tenderness in RA (Ritchie et al., 1968) and is widely used in evaluating the response to anti¬
rheumatic therapy during clinical trials. The Ritchie articular index allocates one of four grades
of tenderness to patients' joints:
• "Not tender" (0)
• "Tender" (1)
• "Tender and winced" (2)
• "Tender, winced and withdrew" (3).
The dolorimeter was able to detect changes in joint tenderness in a drug withdrawal study,
whereas the Ritchie index was not (Langley et al., 1983).
In this chapter the development and use in our laboratory of a novel behavioural readout,
capable of being used in both mice (Strickland et al., 2005) and rats is described. The pressure
application device (PAD) uses similar principles to the clinical pressure dolorimeter and was
designed to apply a gradually increasing squeeze directly across a knee joint until the rodent
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shows signs of pain or discomfort, as evidenced by withdrawal of the limb, or rarely
vocalisation. At this "end point" a quantitative value of the maximum force applied prior to
limb withdrawal is recorded, and this value provided an objective measure of the withdrawal
threshold. The aim of the study was to evaluate accuracy, sensitivity, and reliability of the novel
device designed to measure knee joint hypersensitivity in rats and mice with experimentally-
induced arthritis, in comparison with untreated joints. PAD was also used to determine whether
it could detect reversal of hyperalgesia by analgesics known to be clinically effective in relieving
the pain of arthritis.
A dose-response study using prednisolone (Pyne et al., 2004; Song & Buttgereit, 2006),
and other studies using morphine (Caldwell et al., 2002; Dickenson & Kieffer, 2006) and
celecoxib (Schnitzer et al., 2005; Hawkey, 2001), were performed to investigate the
reproducibility and sensitivity of PAD in rats, whilst comparing the device to the already
established weight distribution readout. A smaller study was carried out in mice, in which only
the effects of prednisolone were investigated.
3.2 MATERIALS AND METHODS
3.2.1 PAD- KNEE JOINTWITHDRAWAL THRESHOLD MEASUREMENT
PAD was designed and constructed by Dr Harry Brash, a medical physicist at The
University of Edinburgh, working in collaboration with our laboratory on this project. PAD
consists of a force transducer mounted on a unit fitted to the experimenter's thumb (see Figure
3.1). The thumb unit is connected to a recording base unit containing the control panel and
digital readout display. The rat apparatus has a force transducer with a range of 0-1500 g
(Honeywell, FSG-15N1A, Farnell, UK) and the diameter of the circular contact area is 8 mm;
the area of the surface is therefore 50.3 mm2. Due to the difference in size between mice and
rats, a second force transducer was developed for use in murine studies, which had a force range
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of 0-500 g (Honeywell, FSL05N2C, Farnell, UK) and a 5 mm diameter contact area, hence a
19.6 mm2 area. All measurements were made in Edinburgh, UK, therefore all values are
comparable, as gravity was consistent.
Animals were lightly, but securely held (rats) or scruffed (mice) by Mrs Susan Bond for
the rat studies or by Mr Iain Strickland during the mouse study. The operator (myself) placed
the thumb unit on one side of the animal's knee joint and the forefinger on the other. A
gradually increasing force was applied across the joint by squeezing, and the force in grams
applied was displayed on the digital screen. The test endpoint was when the animal reflexly
withdrew its limb or on the rare occasion when the animal vocalised prior to limb withdrawal.
The peak gram force (gl) applied immediately prior to limb withdrawal was recorded by the base
unit, and was designated the limb withdrawal threshold (LWT). Three measurements were made
at one minute intervals and the mean LWT was calculated. Both ipsilateral (left) and
contralateral (right) limb measurements were made.
(a) (b) (c)
Figure 3.1 Presentation of the pressure application device (PAD), (a) The portable control unit with
digital display and thumb attachment and PAD in use measuring the LWT of (b) rat and (c) mouse.
3.2.2 STUDY DESIGN AND DRUG TREATMENT
A pilot study was performed in rats to determine whether PAD could detect
hypersensitivity following i.art (left - ipsilateral) FCA in comparison with naive animals. The
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study also compared values for PAD with those obtained in the same animals using the
incapacitance tester. Baseline values for body weight, weight distribution, PAD LWT and knee
joint diameters were measured prior to induction of the joint inflammation (on day 0), and were
repeated 2-3 times weekly until day 28.
Subsequently, a drug-treatment study was carried out to investigate whether PAD was
able to detect the reversal of joint hypersensitivity and how this differed in rats treated with three
different types of drug, an opioid, a steroid and an NSAID. Baseline values for body weight,
weight distribution, PAD LWT and knee joint diameters were measured, prior to induction of
joint inflammation (left - ipsilateral joint). Measurements were made two or three times a week
until 10 days post-FCA, when animals were randomly assigned into treatment groups. Drugs
were administered subcutaneously (s.c.) in a volume of 2 ml kg"1 between days 14 and 18; drugs
were administered blindly by Mrs Susan Bond. Prednisolone (1, 3 or 10 mg kg"1; Rioja et al.,
2004) was injected once per day; whereas morphine (3 mg kg"1; Wilson et al., 2006), celecoxib
(15 mg kg"1; Pinheiro & Calixto, 2002) and vehicle (ethanol 5%, Polyethylene Glycol (PEG)
45% and distilled water 50%) were given twice a day. One hour after dosing blind behavioural
assessments were made by myself following a strict protocol in order to give animals a rest
period between the weight distribution and the PAD measurements. Briefly, animals were
weighed and their weight distribution assessed by taking three consecutive readings before being
returned to their cage. Five minutes later, animals had the sensitivity of the ipsilateral and
contralateral knee joints assessed using PAD, with three readings taken. Finally the knee joint
diameters were measured. Further behavioural assessments were carried out once the dosing
period was complete, on days 21, 24 and 28.
A smaller study was carried out in mice as the focus of our laboratory is mainly on rat
models of inflammation. However, PAD was developed for mice, due to the increasing use of
genetically modified mice in science. For the murine study only prednisolone (1 mg kg"1) or
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vehicle was used. Drugs were administered blind (s.c.) by Mr Iain Strickland once a day in a
volume of 3 ml kg"1. All groups were assessed for behavioural changes daily during the dosing
period one hour after dosing on days 13-17 post-FCA (left - ipsilateral joint). Further
behavioural assessments were carried out on day 21, once the dosing ended.
3.3 RESULTS
In all the studies performed, i.art injection of FCA had no adverse effects on the general
health of the animals. They continued to feed and gain weight normally throughout the studies
(see Figure 3.2) and there was no significant difference in body weight between any of the FCA-
injected and sham animals at any time point in rats or mice, or between vehicle- and drug-treated
animals (P>0.05, Kruskal-Wallis).
91































*FCA + Vehicle (n=8)
-B-FCA + Celecoxib (n=8)
-*-FCA + Morphine (n=8)
-A-FCA + Pred 1 mg kg"1 (n=7)
-♦-FCA + Pred 3 mg kg"1 (n=8)
-s-FCA + Pred 10 mg kg"1 (n=8)
-©-Sham (n=8)
10 20



















-■-FCA + Pred (n=8)
-b-FCA + Vehicle (n=8)
-&-Sham (n=8)
10 15 20 25
Time post FCA (days)
Figure 3.2 The effect of i.art FCA on body weights of animals during (a) the rat pilot study, (b) the rat
prednisolone, morphine and celecoxib drug study and (c) the murine study. Although there were no
significant differences in body weight between FCA-injected and sham animals (P>0.05, Kruskal Wallis),
there was a trend for FCA-injected animals to have slightly lower body weights following FCA injection.
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3.3.1 FCA-INDUCED HYPERSENSITIVITY IN RATS - PILOT STUDY
Pressure application device - PAD
Prior to induction of joint inflammation (on day 0) the average ipsilateral LWT was 710
± 41 gf (n=16) and the average contralateral LWT was 790 ± 39 gf (n=16), these were not
significantly different from each other (P>0.05, paired t-test). There was also no significant
difference between the ipsilateral LWTs of the two study groups at this time point (P>0.05,
Mann Whitney).
On day 1, following i.art FCA, the average ipsilateral LWT, decreased by 57% to 316 ±
45 gf (n=8), this was significantly lower than both the day 0 value (P<0.05, Wilcoxon) and the
sham group at the same time point (P<0.05, Mann Witney; see Figure 3.3). Despite being
untreated the ipsilateral LWT of sham animals increased significantly by 57% to 1028 ± 48 gf
(n=8; P<0.05, Wilcoxon) on day 1 compared with day 0 values. Similar increases were seen in
contralateral joints of both groups over the first 24 hours of the study (see Figure 3.3).
Subsequently, this measurement remained relatively steady at approximately 1000 gf for the
duration of the study in all contralateral joints, and ipsilateral joints of sham animals. The
average ipsilateral LWT of FCA-injected rats was significantly lower than sham and
contralateral joints on each test day over the full 28 day time course studied (P<0.05, two-way
ANOVA).
Incapacitance Tester -Weight Distribution
On day 0, the average weight placed on ipsilateral and contralateral hind limbs in rats
was 96 ± 3 g and 98 ± 3 g respectively, resulting in a ratio of 0.98 ± 0.03 (n=16). There was no
significant difference between the two groups (P>0.05, Mann Whitney). The ratio of weight
distribution between the hind limbs for FCA injected rats decreased by 70% (to 0.29 ± 0.05;
n=8; see Figure 3.3) on day 1, which corresponds to 40 ± 4 g and 140 ± 5 g placed on ipsilateral
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and contralateral limbs respectively. The ratio was significantly less than that in sham animals
(P<0.05, Mann Whitney), which had a ratio of 1.05 ± 0.02 (ipsilateral = 116 ± 4 g and
contralateral = 110 ± 4 g; n=8; see Figure 3.3) at this time point. The ratio remained
significantly reduced in FCA-injected animals compared with the sham group on each test day
up until and including day 28 (P>0.05, two-way ANOVA). There were no significant changes
observed in the sham group at any time point in this behavioural readout (P>0.05, Kruskal
Wallis).
Joint Swelling
Basal measurements of joint diameter were 9.92 ± 0.08 mm and 9.85 ± 0.12 mm for
ipsilateral and contralateral knee joints respectively (n=16). These values did not differ
significantly from one another (P>0.05, Wilcoxon), with no significant differences observed
between the two groups (P>0.05, Mann Whitney). On day 1, the average ipsilateral knee joint
diameter of FCA-injected rats increased to 13.11 ± 0.06 mm (n=8), compared with 10.12 ± 0.1
(n=8) in sham animals; this was a statistically significant increase (P<0.05, Mann Whitney; see
Figure 3.3). The swelling remained significant in comparison with sham animals on days 1, 2, 5,
7 and 9 post-FCA (P<0.05, two-way ANOVA). However, thereafter the values returned towards
basal levels and no further significant differences were observed (P>0.05, two-way ANOVA).
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Figure 3.3. The (a) PAD LWTs, (b) absolute values of weight distribution on each hind limb (in grams),
(c) knee joint diameters and (d) ratio of weight distribution between hind limbs of sham and FCA-injected
(150 /tg) rats over a 28 day pilot study. PAD detected hypersensitivity in FCA-injected animals, similar
and comparable to that measured by the incapacitance tester. * represents statistical significance (P<0.05)
comparing the groups at each time point using a two-way ANOVA and a Bonferroni post-hoc test.
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3.3.2 PREDNISOLONE, MORPHINE AND CELECOXIB STUDY IN RATS
Pressure application device - PAD
There were no significant differences between the PAD ipsilateral LWTs of any groups
prior to the induction of arthritis (n=56; P>0.05, Kruskal-Wallis). There were no differences
between the average ipsilateral (1068 ± 23 gf) and contralateral (1037 ± 21 gf) LWTs of animals
on day 0 (n=56; P>0.05, Wilcoxon; see Figure 3.4). Measurements were made on days 2, 4, 7
and 10 to determine that hypersensitivity was present prior to drug treatment. On each of these
days the ipsilateral PAD LWTs of all FCA-injected animals (n=47; one rat was excluded from
the study as it was found to have an existing limb injury that appeared to affect the behavioural
measurements in this study) were significantly less than sham (n=8, P< 0.05, two-way ANOVA)
and were not statistically different from values observed in the pilot study (P> 0.05, Mann
Whitney).
On day 10 arthritic rats were randomly assigned into one of six treatment groups:
• celecoxib 15 mg kg"1 (n=8)
• morphine 3 mg kg"1 (n=8)
• prednisolone 1 mg kg"1 (n=7),
• prednisolone 3 mg kg"1 (n=8)
• prednisolone 10 mg kg"1 (n=8).
Drugs were administered daily between days 14 and 18, and behavioural assessments were made
one hour after drug injections. AUC values were calculated for each individual animal to
observe any drug induced reversal of hypersensitivity (analgesia) over the five day dosing
period. Values were calculated using day 10 values as a baseline to observe changes from day
10 through until day 18. Results showed that PAD detected a significant analgesic effect, (i.e. an
increase in LWT towards levels measured in sham animals) of morphine, celecoxib and
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prednisolone (3 and 10 mg kg"1; P< 0.05, Kruskal Wallis, compared with vehicle, see Figure 3.5
and 3.6). The dose of morphine used here produced no obvious motor effects at the time of
behavioural testing which could interfere with the withdrawal reflexes.
Further PAD LWT measurements were taken on days 21, 24 and 28 after drug-treatment
had ended. In all groups any analgesic effect of the compound previously administered was
absent; there was no significant difference from the vehicle-treated group (P>0.05, Kruskal
Wallis). No changes were seen in contralateral LWTs at any time during this study.
Incapacitance Tester -Weight Distribution
There were no significant differences between the weight distribution ratio of any
animals prior to the induction of arthritis (n=56; P>0.05, Kruskal-Wallis; see Figure 3.4). The
actual weights placed on each hind limb on this day were 64.0 ± 0.8 g and 63.0 ± 0.8 g on
ipsilateral and contralateral limbs respectively. Measurements were made on days 2, 4, 7 and
10, to determine hypersensitivity was present prior to drug treatment regimes. On each of these
days the weight distribution ratio of all FCA-injected animals (n=47) was significantly less than
those of naive controls (P< 0.05, two-way ANOVA, n=8), and was not significantly different
from those values in the pilot study (P> 0.05, Mann Whitney, see Figure 3.4).
On day 10, arthritic rats were randomly assigned into one of six treatment groups, as
described above. Drugs were injected (s.c.) daily between days 14 and 18, and behavioural
assessments were made one hour after drug injections. AUC values were calculated from daily
measurements for the dosing period as described above and showed that the FCA-induced
hypersensitivity was significantly attenuated by celecoxib (n=8), morphine (n=8) and
prednisolone at 3 (n=8) and 10 mg kg"1 (n=8) (P<0.05, Kruskal Wallis, compared with vehicle),
but not by 1 mg kg"1 (n=7) prednisolone (P>0.05, Kruskal Wallis; see Figure 3.5 and 3.6).
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Further measurements were made on days 21, 24 and 28, after drug-treatment had
ended. In all groups any analgesic effect of the compound previously administered was absent;
there was no significant difference from the vehicle-treated group (P>0.05, Kruskal-Wallis).
Joint inflammation
There were no significant differences between the ipsilateral joint diameters of animals
prior to the induction of arthritis (n=56; P>0.05, Kruskal-Wallis, see Figure 3.4). There were no
differences between the average ipsilateral (8.81 ± 0.13 mm) and contralateral (8.97 ± 0.09 mm)
knee joint measurements of animals on day 0 (n=56; P>0.05, Wilcoxon). Measurements were
made on days 2, 4, 7 and 10 prior to start of the dosing period. On days 2, 4, and 7 the ipsilateral
joint diameters of all FCA-injected animals (n=47) were significantly higher than those of sham
(n=8, P< 0.05, two-way ANOVA: see Figure 3.4) and were not statistically different to values
observed in the pilot study (P< 0.05, Mann Whitney).
Administration of morphine (3 mg kg"1), celecoxib (15 mg kg"1) and 3 or 10 mg kg"1
prednisolone had no effect on FCA-induced joint swelling. However, prednisolone at 1 mg kg"1
significantly reduced the average ipsilateral knee joint diameter (P<0.05, Kruskal-Wallis,
compared with vehicle) during the dosing period (see Figure 3.5 and 3.6). No changes in
contralateral joint diameters were observed in any group over this time period.
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Figure 3.4 The (a) PAD LWTs, (b) absolute values in grams of weight placed on each hind limb, (c) knee
joint diameters and (d) ratio of weight distribution between the hind limbs of sham and FCA-injected (150
Hg) rats from day 0 up until and including day 10, prior to drug treatment. * represents statistical
significance (P<0.05) comparing the groups at each time point using a two-way ANOVA and a
Bonferroni post-hoc test.
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Figure 3.5 The (a) ipsilateral PAD LWTs, (c) weight distribution ratios and (e) ipsilateral knee joint
diameters of prednisolone- and vehicle-treated arthritic and sham (control) rats and the corresponding
AUC graphs during the dosing period (b, d and f respectively). The drug dosing period was between days
14 and 18 as indicated by the box on the graphs. Statistical analysis was carried out to compare the AUC
values for the drug-treated group in comparison with vehicle; * represents statistical significance
(P<0.05), determined by a Kruskal Wallis test.
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Figure 3.6 The (a) ipsilateral PAD LWTs, (c) weight distribution ratios and (e) ipsilateral knee joint
diameters of morphine-, celecoxib- and vehicle-treated arthritic and sham (control) rats and the
corresponding AUC graphs for the three readouts during the dosing period (b, d and f respectively). The
drug dosing period was between days 14 and 18 as indicated by the box on the graphs. PAD was able to
detect the analgesic effect in groups treated with both drugs compared with vehicle. Statistical analysis
was carried out to compare the AUC values for the drug-treated group with that of vehicle-treated animals;
* represents statistical significance (P<0.05) determined by a Kruskal Wallis test.
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Correlation of PAD LWT with weight distribution readout
In order to determine the strength of the correlation between the results obtained from
the two pain readouts, a Spearman's linear regression analysis was performed. The mean PAD
ipsilateral LWT for each group was plotted against the mean ratio of weight distribution of the
same group, with results from all experimental days included. A strong positive correlation
















Spearman r = 0.91
P< 0.0001 ***
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Figure 3.7. The correlation of the absolute ipsilateral LWT, as measured by PAD, and the ratio of the
weight distribution between the hind limbs, measured by the incapacitance tester, in rats. There was a
strong positive correlation between the two measures. The Spearman Linear Correlation factor was 0.91,
which was highly significant (P<0.0001).
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3.3.3 MURINE STUDY - FCA-INDUCED HYPERSENSITIVITY
Pressure application device - PAD
Prior to FCA-induced joint inflammation (on day 0) there were no significant
differences between the groups' ipsilateral PAD LWT (P>0.05, Kruskal-Wallis); the values were
402 ± 16 gf (n=8), 400 ± 16 gf (n=8) and 437 ± 16 gf (n=8). There were no differences between
the average ipsilateral (414 ± 10 gf) and contralateral (386 ± 14 gf) LWTs of animals, prior to
arthritis induction (n=24; P>0.05, Wilcoxon).
The ipsilateral LWT of the FCA-injected groups decreased by 57% to 175 ± 6 gf (n=8)
and 63% to 148 ± 16 gf (n=8) one day after injection. These LWTs were significantly lower
than the sham group (P<0.05, Kruskal Wallis; see Figure 3.8) at this time point, indicating that
PAD is able to detect hypersensitivity in mice following induction of joint inflammation.
Following sham surgery, the average LWT of the control group dropped by 30% over the same
24 hour period to 307 ± 19 gf (n=8), a significant reduction from the day 0 value (P<0.05,
Wilcoxon). However, this decrease was not sustained, and the value had increased towards
basal values by day 3, and was no longer statistically different from baseline thresholds (P>0.05,
Kruskal Wallis). Ipsilateral LWTs remained significantly lower in both FCA-injected groups in
comparison with the sham animals on each day post-FCA (P<0.05, two-way ANOVA) up to and
including day 10. Furthermore, ipsilateral PAD LWTs for FCA and vehicle-treated animals
were significantly decreased compared with contralateral readings on each day post FCA.
Incapacitance Tester -Weight Distribution
The average baseline ratio of weight distribution between ipsilateral and contralateral
limbs in mice was 1.0 ± 0.1 (n=24); this resulted from 9.9 ± 0.3 g and 9.8 ± 0.3 g on the
ipsilateral and contralateral hind limbs respectively. There were no significant differences
between the ratios of the three groups (P<0.05, Kruskal-Wallis).
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There was a 36% reduction (to 0.65 ± 0.09; n=16) in FCA-injected animals' weight
distribution ratio on day 1. This was significantly lower than that of sham animals (P<0.05,
Mann Whitney, see Figure 3.8), which was 1.0 ± 0.03 (n=8), illustrating that the weight
distribution readout is able to detect FCA-evoked hypersensitivity in mice. The ratio remained
significantly reduced in FCA-injected animals compared with the sham group up until and
including day 10 (P<0.05, two-way ANOVA), when drug treatment groups were assigned.
There were no changes observed in the sham group at any time point in this behavioural readout
(P<0.05, Kruskal-Wallis).
Joint Inflammation
Baseline knee joint diameters averaged 4.02 ± 0.02 mm (n=24) and 4.01 ± 0.02 (n=24)
mm before FCA, these values were not significantly different (F>0.05, Wilcoxon). Intra¬
articular FCA evoked a significant swelling in all animals (n=16) compared with the sham group
(n=8) on each day post FCA (P<0.01, two-way ANOVA; see Figure 3.8). No changes in knee
joint diameter were seen in the sham group, or in the contralateral joints of FCA-treated animals
at any time point (P>0.05, Kruskal-Wallis).
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Figure 3.8 The (a) PAD LWTs, (b) absolute values in grams of weight placed on each hind limb, (c) knee
joint diameters and (d) weight distribution ratios of sham and FCA-injected (200 fig) mice from day 0 up
until and including day 10, prior to drug treatment. * represents statistical significance (P<0.05),
determined by a Kruskal Wallis test.
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3.3.4 MURINE STUDY - PREDNISOLONE INDUCED ANALGESIA
Pressure application device - PAD
FCA-injected mice had a significantly lower average PAD LWT on day 10 in
comparison with the sham group, values were 137 ± 17 gf (n=16) and 349 ± 34 gf respectively
(n=8; P<0.01, Mann Whitney). On day 10, FCA-injected mice were randomly assigned to one
of two treatment groups:
• prednisolone (1 mg kg"1)
• vehicle.
Drugs were administered (s.c.) blind by Mr Iain Strickland, once a day between days 13 and 17
in a volume of 3 ml kg"1; behavioural assessments were made one hour after drug administration.
AUC values calculated for the prednisolone- and vehicle-treated groups between days 10 and 17
showed that prednisolone induced significant analgesia compared with the vehicle-treated group,
as measured by PAD (P<0.05, Mann Whitney; see Figure 3.9). The largest individual reversal
was observed on the final day of dosing, day 17, where the prednisolone-treated FCA group had
an average PAD LWT of 310 ± 38 gf (n—8), which was 61% higher that LWTs in vehicle-treated
mice (n=8). Following termination of drug-treatment, the ipsilateral LWT of prednisolone-
treated animals returned to values near those of the vehicle-treated group. However, no
significant difference between LWTs of FCA-injected and sham animals was detected (P>0.05,
Kruskal Wallis). No changes were noted in contralateral LWTs in any group at any time during
this study (P>0.05, Kruskal Wallis).
Incapacitance Tester -Weight Distribution
The average weight distribution ratio on day 10 for the FCA-injected mice was 0.64 ±
0.08 (n=16), which resulted from 7.9 ± 0.4 g on the ipsilateral joint and 11.2 ± 0.4 g on the
contralateral side. The ratio was significantly lower in FCA-treated animals than the sham
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group, in which the ratio of weight distribution between the two joints was 1.03 ± 0.02 (P<0.05,
Mann Whitney; n=8). On day 10, FCA-injected mice were randomly assigned into one of two
treatment groups; 1 mg kg"1 prednisolone or vehicle. Drugs were administered (s.c.) once a day
between days 13 and 17; behavioural assessments were made one hour after injections. AUC
values calculated for the prednisolone- and vehicle-treated groups between days 10 and 17
showed that there was significant analgesia as a result of prednisolone treatment, as determined
by the incapacitance tester (P<0.05, Mann Whitney; see Figure 3.9). Following termination of
drug-treatment, the weight distribution ratios of the drag-treated group returned to near those of
the vehicle-treated animals, which was not significantly different than the values for sham
animals.
Joint Inflammation
Prior to commencement of prednisolone treatment, average ipsilateral joint diameters in
FCA treated animals was 6.53 ± 0.45 mm (n=16), in contrast values for control (sham) animals
was 4.21 ±0.11 mm (n=8). There were no significant differences between the groups (P>0.05,
Mann Whitney). Prednisolone-treatment (1 mg kg"1) caused a reduction in joint swelling;
although the AUC values for this period were not significantly reduced compared with vehicle-
treated mice, see Figure 3.9. Following termination of drag-treatment, the joint diameters of the
drug-treated group remained lower than those of the vehicle-treated animals, however no
statistical significance was evident (P>0.05, Mann Whitney). Furthermore, ipsilateral joint
diameters in the FCA-injected animals were not significantly greater than sham values (P>0.05,
Mann Whitney). No changes were observed in contralateral joint diameters at any time point
during this study (P>0.05 Kruskal Wallis).
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Correlation of the PAD LWT with the weight distribution readout
In order to determine the strength of the correlation between the results obtained from
the two hypersensitivity readouts in mice, a Spearman's linear regression analysis was carried
out. The PAD ipsilateral LWT for each group was plotted against the ratio of weight
distribution of the same group, with results from all experimental days included. A strong
positive correlation between the results obtained from the two different readouts was observed
(see Figure 3.10; Spearman r =0.79; PcO.OOOl).
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Figure 3.9 The (a) ipsilateral PAD LWTs, (c) weight distribution ratios and (e) knee joint diameters of
FCA-injected (200 /tg) or sham mice from day 10. Prednisolone (1 mg kg"1) was administered (s.c.) on
days 13 to 17 inclusive. AUC values for (b) PAD LWT, (d) weight distribution ratios and (f) joint
diameters showed that prednisolone caused significant analgesia in both pain readouts. However, no
significant difference in joint diameter was shown in this study as a result of prednisolone, at this dose.
Statistical analysis was carried out on AUC data to compare the values for the FCA-injected groups to that
of sham animals; * represents statistical significance (P<0.05), determined by Mann Whitney tests.
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Figure 3.10 Correlation of the absolute ipsilateral LWT, as measured by PAD, and the ratio of the weight
distribution between the hind limbs, measured by the incapacitance readout, in mice. There was a strong
positive correlation between the two readouts; the Spearman Linear Correlation factor was 0.79, which
was highly significant (PcO.OOOl).
3.4 DISCUSSION
A novel behavioural tool for assessing joint pain in two experimental rodent models of
chronic inflammation has been developed and assessed. The results of these studies indicate that
PAD provides a reliable, quantitative measurement of localised, FCA-induced mechanical
hypersensitivity in the knee joint of rats and mice. PAD was also able to detect the analgesic
action of prednisolone in mice and rats; and morphine- and celecoxib-induced analgesia in rats.
Furthermore, a strong correlation between the weight distribution readout and the PAD
measurements were made in both species, illustrating that PAD is a simple behavioural test that
will be a valuable instrument for assessing hypersensitivity in the joint.
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STIMULUS AREA AND NOCICEPTOR ACTIVATION
Pressure exerted onto the skin may activate nociceptive afferents in several tissues,
depending on the surface area of the object used. Contact with a punctate object such as a
needle may exclusively activate nerve endings in the skin, in particular C fibres. Because
deformation of the skin can be achieved with very small forces (Garell et al., 1996; Garnsworthy
et al., 1988; Khalsa et al., 1997), these stimuli have little effect on afferents in deeper tissues. In
contrast, a preferential activation of deep afferents is possible if pressure is exerted on a larger
area of skin and the contact surface is rounded or padded (Treede et al., 2002). According to
experiments using topical local anaesthesia, the contribution of cutaneous afferents to pain
evoked by blunt pressure is minimal (Kosek et al., 1995). This evidence adds support to the use
of PAD as a measure of pain in deeper tissues such as the joint itself, rather than overlying skin.
This is in contrast to von Frey hairs, which as a punctate stimulus, activate skin afferents rather
than those innervating the joint capsule and surrounding tissues.
Typical naive LWTs for rats and mice were approximately 1045 gf and 400 gf
respectively. These values are considerably higher than those seen in the paw using calibrated
forceps or the Randall and Selitto device (Baamonde et al., 2004; Cook & Moore, 2006; Luis-
Delgado et al., 2006; Walker et al., 2003), which is probably due to the difference in the size and
gross anatomy of the paw and the knee joint, in addition to the surface area over which the
pressure is applied using the different devices. Using the Randall and Selitto device paw
withdrawal thresholds in nai've rats have ranged between 22 and 90 g, depending on sex, strain
and size of the animals (Cicala et al., 2000; Magari et al., 2003). Others have modified the
Randall and Selitto analgesymeter to measure pain thresholds of the ankle joint, and report much
higher withdrawal thresholds, of around 150 g in naive rats (Magari et al., 2003). Studies using
calibrated forceps to determine withdrawal thresholds of paws indicate much higher values, in
the region of 500 g in naive rats (Luis-Delgado et al., 2006). Yu et al (2002) reported
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vocalisation thresholds to compression force applied to the knee joint at approximately 1800 g in
normal rats and falling to about 500 g following i.art FCA, using calibrated forceps, which
again, is comparable to the values recorded in our study.
Neugebauer et al. (2002) report that pressure stimuli >1500 g 30 mm " applied to the
knee joint with calibrated forceps was noxious, as it consistently evoked hind limb withdrawal
reflexes in awake rats. When converted to gf mm"2, our study which uses a circular disc with an
area of approximately 50 mm2, and showed LWTs in the region of 1000 gf in naive rat joints, the
values of pressure are 20 gf mm"2 or 600 gf 30 mm"2 for nai've rats. In mice the LWTs were also
in the region of 20 gf mm"2 or 600 gf 30mm"2, although the circular contact area was
approximately 20mm2. This indicates that the same pressure (20 gf mm"2) is noxious in rats and
mice when the joint is stimulated with PAD. However, the data from PAD is not routinely
presented as a force per unit area (pressure), as it cannot be assumed that the entire surface of the
disc is in contact with the joint, furthermore in inflamed joints the deformation of the joint onto
the disc is different to that in nai've animals. PAD measurements are therefore more accurately
expressed as a force, in gram force.
PAD VS. CLINICAL MEASURES OF JOINT PAIN
Clinically, joint pain is assessed either subjectively using the Ritchie Articular index or
objectively using a dolorimeter (Langley et al., 1983; Ritchie et al., 1968). The Ritchie articular
index allocates one of four grades of tenderness in patients' joints. Previous studies carried out
in this laboratory used a similar subjective scale of joint hypersensitivity (Gauldie et al., 2004).
However, a quantitative measure which mimics the pressure dolorimeter would considerably
improve assessments of experimental joint pain by providing an objective measure. The
dolorimeter uses a gradually increasing force, applied in a perpendicular plane across the joint
margin, to assess localised hypersensitivity of a human joint. The dolorimeter can be used on
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different joint types and has been adopted in clinical studies assessing osteoarthritis of the knee
(Ottillinger et cil., 2001) as well as the pain associated with fibromyalgia (Gracely et al., 2003).
Currently no objective measure of joint hypersensitivity is used to assess experimental arthritic
joint pain in laboratory rodents. To that end, PAD was developed to align pre-clinical measures
to those used clinically and help the translation of animal studies to human conditions.
PAD VS. ALTERNATIVE DEVICES TO MEASURE EXPERIMENTAL JOINT PAIN
Calibrated forceps have been used as a means of mechanical stimulation during
electrophysiological recording (Li & Neugebauer, 2004; Neugebauer & Li, 2002), to measure
knee joint or paw pain in experimental inflammation (Han et al., 2005; Luis-Delgado et al.,
2006; Yu et al., 2002) and to induce primary inflammatory hyperalgesia in deep tissues. These
involved direct application of the forceps to muscle or to the knee joint of rats (Cui et al., 1999;
Skyba et al., 2005). However, although the technique is reported to be an easy to use, reliable
method of assessing nociceptive withdrawal thresholds, they also show a steady increase in paw
withdrawal threshold over a 9 day period that was highly correlated to an increase in weight gain
over this time (Luis-Delgado et al., 2006). The authors suggest that the modification of pain
sensitivity was due to increased size of the paw (Luis-Delgado et al., 2006). This problem does
not arise with PAD, although the LWT tended to increase over time as the animals gained
weight, this wasn't significant, and no correlation to the body weight of the rats was observed.
In addition, the weight distribution readout is also affected by the weight; although the ratio
remains steady throughout the study, the actual weight placed on each hind limb increases as a
result in the increase in the total weight of the animal over the time period of the study. For
these reasons it is imperative to include a sham control group to compare all results to, to
account for changes in PAD LWT and weight distribution data due to the gain in weight
experienced by the animals over a chronic study such as those in this chapter.
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An initial increase in LWT was noted in ipsilateral joints of naive rats and contralateral
joints of all rats, however, it was not significant and levels plateaued off after two days. In
contrast, an initial decrease in LWT was observed in mice. This was seen in ipsilateral and
contralateral joints in all three groups; however, it only proved to be a significant reduction from
basal levels in ipsilateral knee joints, presumably as a result of the skin incision, which was
necessary for intra-articular injection or sham surgery.
The authors in these studies reported several problems with the forcep style of device,
including variation caused by the operator due to finger placement on the forceps, and inaccurate
values of withdrawal thresholds, as the calibrated reading given is a function of the force applied
by the experimenter and the resistance offered by the joint. PAD is calibrated directly across the
force transducer and directly records the precise force placed across the knee joint, up until the
point of withdrawal. As PAD uses a single force transducer worn on the experimenter's thumb,
the amount of operator variation will only occur in the placement of the transducer on the knee
joint of the animal being tested. However this is only a minor issue as the large surface area of
the PAD thumb attachment removes potential inaccuracy in focusing on an exact point on the
joint, which happens in the case of small forceps tips. A further advantage of PAD is the ability
to change the size of the pressure application surface and the force range of the transducer,
allowing the device to be used in several species as well as the possibility of assessing other
joints and paws.
In this study, we chose to validate PAD by comparing the results to the current standard
measure of hypersensitivity, the weight distribution readout. However, PAD is designed to
measure evoked mechanical hypersensitivity of the joint, whereas the incapacitance tester is
typically considered a measure of spontaneous pain. However, due to the fact that the animals
are required to stand in the Perspex box and are moved from their home-cage, the incapacitance
tester cannot truly be described as a measure of spontaneous pain, and most likely incorporates
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aspects of evoked and ongoing, spontaneous pain, as evidenced by the strong degree of
correlation between the two measures in this thesis. Therefore, it is possible to confidently
validate a new device for measuring evoked mechanical hypersensitivity, in this case PAD,
against the weight distribution readout, given that there is no other current standard measure for
this parameter. PAD is thus an easy to use device allowing us to perform rapid, reproducible
measurements. The absence of a significant difference between the ipsilateral and contralateral
LWT in naive animals, together with the low variability, indicates that PAD could use the
contralateral joint as an internal control, an idea originally proposed by Randall and Selitto
(1957).
DETECTION OF HYPERSENSIVITY AND SUBSEQUENT ANALGESIA
PAD was able to detect FCA-induced hypersensitivity in both mice and rats, observed as
a decrease in LWTs of around 60% and 40% respectively, compared with the basal levels in
normal joints. This hypersensitivity in the acute stage of the arthritis was mimicked by the
significant inflammation observed following FCA injection. The ability of PAD to detect FCA-
evoked hypersensitivity provides an excellent experimental model in which to test the analgesic
properties of novel compounds over a period of stable inflammation between days 13 and 18
post-FCA.
Prednisolone, a standard positive control in drug screening (Pyne et cil., 2004), was
studied over a five day period to check whether the drug would lead to a resolution of FCA-
induced hypersensitivity as a correlate to the analgesia we would expect to see in man (Pyne et
al., 2004). PAD detected prednisolone analgesia, in both species over the five days of dosing,
which was abolished after dosing ceased. PAD also showed significant reversal of evoked
mechanical hypersensitivity in arthritic animals treated with the opioid morphine and the
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cyclooxygenase-2 inhibitor, celecoxib, which was comparable to that seen in the weight
distribution readout.
Results in mice and rats show strong correlations between the two behavioural
assessments. These results suggest that both techniques have the ability to detect a joint
hypersensitivity, which can be attenuated using gold-standard analgesics. PAD has the added
advantage of assessing the hypersensitivity of the joint at the site of the inflammation, in a
similar fashion to the clinical dolorimeter (Langley et al., 1983)
CONCLUSIONS
In conclusion, the present study shows that PAD provides a novel, accurate behavioural
tool for detecting a localised primary mechanical hypersensitivity in two animal models of
chronic inflammatory joint pain. PAD is the first tool designed to measure both primary and
secondary hypersensitivity objectively. It can be used in various experimental pain models and
could be extended for use in other species. Results from these pilot studies suggest PAD will aid
the screening of novel analgesics designed to improve chronic inflammatory pain.
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Chapter 4 - Development and validation of a joint
perfusion system to enable assessment of
inflammatory mediator and cell content of rat knee
joints
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4.1 INTRODUCTION
Inflammatory joint diseases such as RA are regulated by complex interactions
involving many mediators, including prostanoids and cytokines (see Chapter 1). The
infiltration of cells into the synovial tissue and joint space is another key characteristic of
synovitis, which combined with the release of inflammatory mediators and degradative
enzymes, eventually leads to cartilage and bone destruction (for reviews see Sweeney &
Firestein, 2004).
Measuring the levels of these mediators in the synovial fluid from patients can
provide information about the underlying pathophysiology of joint disease (Kubota et al.,
1998), for example the severity and current activity (Alstergren et al., 1998; Chang & Israel,
2005; Rooney et al., 1990) as well as inter-individual variations in disease (Ulfgren et al.,
2000) and effectiveness of drug-treatments (for review see Barrera et al., 1996).
Furthermore changes occurring in the synovial fluid can be used as biomarkers of disease, as
has already been demonstrated in RA for plasma levels of inflammatory proteins (Eastgate et
al., 1988; Houssiau et al., 1988).
Fluid samples from human joints have been analysed for inflammatory mediator
content from both healthy volunteers and patients with joint diseases. These studies revealed
the importance of particular cytokines, including TNFa, ILip, and IL6, which are now
targets for DMARDs (for review see Christodoulou & Choy, 2006; Zwerina et al., 2005).
Furthermore, increases in virtually all the prostanoids were detected in synovial fluid from
human joints (Egg, 1984; Trang et al., 1977), but notably PGE2, which has been associated
with erosion of bone and cartilage in RA (Dayer et al., 1976; Fulkerson & Damiano, 1983;
Robinson et al., 1975a; Robinson et al., 1975b).
Although some studies have investigated the fluid from joints, most research has
been focused on the inflammatory mediators within the synovial membrane. One reason for
this is the technical difficulty of trying to measure cytokine levels in such a viscous material
as synovial fluid. Several studies have assessed cytokine gene expression levels in the
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synovial membrane, rather than the actual protein content, both in human clinical samples
(Firestein et al., 1990; Wagner et al., 1997) and in animal models of arthritis (Patten et al.,
2004; Rioja et al., 2004; Thornton et al., 1999). In addition, PGE synthase, the enzyme
responsible for the conversion of COX-derived PGH2 to PGE2 has been detected in synovial
tissues of patients with RA (Westman et al., 2004).
The early time course for the release of key mediators cannot be determined using
human synovial fluid samples, as patients rarely report to the clinic until the disease has
progressed and is causing chronic pain and swelling (Cohen et al., 1995). Even then,
repeated sampling from individuals is difficult and most patients are prescribed drugs, to
improve their symptoms and quality of life, which interfere with inflammatory regulatory
processes and cytokine expression. Therefore animal models of joint disease can be used to
study the early events in the inflammatory process and the effects of drugs on inflammatory
markers can be measured under controlled conditions.
Rat adjuvant-induced unilateral arthritis is a well established RA disease model
(Bileviciute et al., 1993; Billingham, 1987; Mapp et al., 1993) and use of this model has
facilitated the understanding of the time-course of the pathology in clinical RA (see Section
1.5.1). The model closely mimics the pathology of human RA, including histopathological
changes, cell infiltration, hypersensitivity and swelling of the affected joint (Donaldson et
al., 1993; Pelegri et al., 1995; Wilson et al., 2006). Previous studies in animal models of
joint inflammation have investigated the time course of cytokine protein or gene expression
using homogenates of entire joints or paws from rats post mortem (Magari et al., 2003;
Marinova-Mutafchieva et al., 1997; Patten et al., 2004; Rioja et al., 2004; Smith-Oliver et
al., 1993; Thornton et al., 1999). A major limitation of these studies is that such sampling
always includes bone, synovial tissue, synovial fluid and surrounding muscles and
connective tissue, which will not allow the origin of any analytes to be determined. Others
have surgically dissected and lavaged knee joints in order to collect the synovial fluid from
dead animals (Keeble et al., 2005; Singh et al., 1997; Vale et al., 2004). As yet, no studies
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appear to have been carried out by perfusing saline through the intact joint space and
collecting samples from intact anaesthetised animals.
The initial aim of this study was to develop a perfusion method to sample the
synovial fluid and to use it to study the effects of a joint insult on the temporal release
pattern for PGE2, ILip and TNFa concentrations and inflammatory cell infiltrate levels in
the joint. During this study joint perfusates were assayed for particular cytokines and




In order to determine the effect of anaesthetic agents on inflammatory mediators in
joints, control experiments were performed. Firstly, five naive rats were anaesthetised with
urethane (ethyl carbamate; 0.6 ml 100 g"1 body weight; 25% w v"1 solution; single i.p.
injection) and five with sodium pentobarbital (1 ml kg"1 body weight; 60 mg ml"1 solution;
single i.p. injection maintained with i.v. 375 p\ hr"1 20 mg ml"1 solution). Animals were
placed on automated heating blankets connected to a thermistor probe inserted in the rectum
to maintain their body temperature at 37°C. No other procedures were carried out for seven
hours, at which point perfusion needles were inserted into left and right knee joints and a 250
p\ sample collected. The samples were frozen immediately at -20°C, stored in a freezer and
later assayed using the Luminex assay.
Effect of the perfusion needles in the joint space
To investigate whether the perfusion needles had any effects on synovial cytokine
content, six animals were anaesthetised with urethane (as described above) and the perfusion
needles inserted into both knee joints once the animals were fully anaesthetised. The needles
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were held in position for seven hours, and then a 250 p\ sample was collected. The sample
was frozen and stored at -20°C and later assayed using ELISAs.
Effect of joint perfusion on the concentration of analyte
Two naive rats were anaesthetised with urethane (as described above) and a basal
joint perfusate sample taken immediately. Recombinant rat ELip (100 /xl of 10 ng ml"1) was
infused over one minute. One hour later a second sample was taken; this was repeated
hourly until six or seven hour's post-ILlp infusion. The samples were frozen and stored at -
20°C and later assayed for ELip content using an ELISA to determine whether the sample
contained the same amount of ILip that was initially infused.
IL1p and TNFa in normal and FCA-injected joints
Basal samples from normal animals (n=16) were compared with basal samples from
rats treated with FCA (i.art) 14 days earlier (n=14). All animals were anaesthetised using
urethane, as described above. Samples were collected and then frozen and stored at -20°C
for later analysis with ELISAs for rat TNFa and ELI p.
PGE2 expression over a 21-day FCA time course
Basal samples were taken from rats 1, 3, 5, 7, 10, 14, 16, 18 and 21 days post-FCA
(n=4 per day, n=36 in total) and compared with PGE2 baseline values from naive rats (n=4).
Samples were frozen at -20° C and later assayed using an ELISA for PGE2.
Total inflammatory cell counts
Joints were perfused with 3.15% sodium citrate in sterile saline and the perfusate
collected from five naive rat knee joints, five FCA-injected (150 p.g; 14-day post FCA)
ipsilateral and contralateral joints and three FCA-injected (500 /xg; 14-day post-FCA)
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ipsilateral and contralateral joints. Undiluted samples were viewed by light microscopy in a
haemocytometer. If red blood cells or a high number of inflammatory cells were present,
samples were diluted in saline, with added Zappoglobin, as per the manufacturer's
instructions (1 drop per 20 ml).
4.3. RESULTS
4.3.1 ANAESTHETIC EFFECTS
Samples from naive animals (n=5) which received no treatment during seven hours
of urethane anaesthesia, showed a slight trend towards increased levels of inflammatory
mediators. However, the increases were not statistically significant for ILla, ILip, IL2, IL4,
IL6, IL10, GM-CSF, IFNy, or TNFa compared with samples obtained immediately after
induction of anaesthetic (P>0.05, Kruskal Wallis; see Table 4.1). In contrast, those animals
anaesthetised with pentobarbital (n=5), had significantly higher levels of GM-CSF and TNFa
(P<0.05, Kruskal Wallis) after seven hours, in comparison with naive joints, see Table 4.1.
IL1a ILip IL2 IL4 IL6 IL10 GM-CSF IFNy TNFa
Basal 0.9 1.2 0.2 0.3 3.2 1.9 0.2 0.2 0.3
Mean ± SEM
±0.6 ±1.2 ±0.2 ±0.3 ±3.2 ±1.3 ±0.2 ±0.2 ±0.3
(pg ml"1; n=10)
Urethane 2.6 0 0 0 0 0 1.0 0.3 36.6
Mean ± SEM ±1.1 ±0
±0 ±0 ±0 ±0 ±0.6 ±0.3 ±20.9
(pg ml"1; n=5)
Pentobarbital 1.4 0.2 0.1 0 0 6.2 1.7 * 0.1 44.2 *
Mean ± SEM





Table 4.1. The concentrations (pg ml"1) of nine cytokines in normal (untreated) rat knee joint
perfusate samples from animals anaesthetised for seven hours with either urethane (n=5) or
pentobarbital (n=8), or samples taken immediately after urethane anaesthesia (basal; n=10). Kruskal
Wallis tests were performed to determine the differences between the cytokine concentrations in joints
of rats anaesthetised with each anaesthetic and basal levels. Pentobarbital anaesthesia caused a
significant elevation of GM-CSF and TNFa; statistical significance (P<0.05 compared with basal
levels) indicated by *.
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4.3.2 EFFECT OF THE PERFUSION NEEDLES IN THE JOINT SPACE
Joint perfusion samples from knee joints in which the perfusion needles had been in
place for seven hours in anaesthetised rats (n—6) showed increased levels of TNFa and ILip,
as measured by ELISA (see Figure 4.1). However, the levels were not significantly different
from basal samples taken from the same rats immediately after needle insertion (P>0.05,























Basal (n=6) 7h (n=6)
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Basal (n=6) 7h (n=6)
Figure 4.1 The concentrations of (a) TNFa and (b) ILip measured in perfusates from joints
immediately after needle insertion (basal) and seven hours (7h) later. Cytokines were assayed using
an ELISA, and although there was an apparent increase in both proteins in two samples at the 7h time
point; the median value (n=6) was not significantly different to basal samples (P>0.05, Mann
Whitney). The horizontal lines on the graphs represent the median values in each group.
4.3.3 EFFECTS OF PERFUSION ON THE CONCENTRATION OF ANALYTE
A study was performed to determine if any of the infused solution leaked from the
joint space prior to withdrawal of samples. Recombinant rat ILip (1000 pg in 100 /xl) was
infused into the joint and samples were collected hourly. In both cases the full amount (1000
pg) administered was recovered in the first two samples. In fact, more than the administered
amount of ILip was recovered (see Table 4.2).
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Animal 1 Animal 2
IL1P Amount of IL1 p Amount of
concentration IL1 p concentration IL1 p
(pg ml"1; 250 pi) (pg in 250//I) (pg ml1; 250 pi) (pg in 250 //I)
1 hr 2000 500 2000 500
2 hr 2000 500 2000 500
3 hr 200 50 356 89
4 hr 544 136 216 54
5 hr 350 87.5 210 52.5
6 hr 458 114.5 200 50





(147% of adminstered dose) (125% of administered dose)
Table 4.2 The ILip concentrations in each 250 gl sample collected, up to six or seven hours post-
infusion of ILip (1000 pg) . The amount of ILip protein in each sample was calculated and summed,
to show that little or no leakage from the joint space occurred; in fact, more ILip was present in the
perfusate in comparison with the amount initially injected.
4.3.4 TNFa AND IL1p IN NORMAL AND FCA-INJECTED JOINTS
Fourteen days after rats received FCA (150 pg; n=14), the ipsilateral (injected) joint
showed significantly higher levels of both TNFa (/><0.05, Mann Whitney) and ILip
(P<0.05, Mann Whitney) compared with samples from naive joints (n=16), as measured by































Normal (n=16) FCA (n=14)
Figure 4.2 The concentrations of (a) TNFa and (b) ILip in normal (untreated; open bar) and FCA-
injected (closed bar) joints 14 days after arthritis induction. There were negligible levels of either
protein in naive joints, but a significant increase in their expression was seen in inflamed joints
(P<0.05, Mann Whitney); statistical significance (P<0.05) represented by *.
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4.3.5 PGE2 EXPRESSION OVER A 21-DAY FCA TIME COURSE
FCA (150 pg) caused a biphasic expression of PGE2 within the ipsilateral joint
cavity, see Figure 4.3. Basal levels, measured in naive joints, were 1865.2 ± 214.0 pg ml"1
(n=4). The initial peak of expression occurs at day 3 and the second peak at day 10.
However, none of the PGE2 levels at any time point proved to be significantly elevated in
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Figure 4.3 The concentration of PGE2 in FCA-treated (150 pig; closed bar) and normal (untreated;
open bars) joints (n=4 on each day). There was a biphasic expression pattern, peaking on days 3 and
10, although the increase was not statistically significant overall (P>0.05, Kruskal-Wallis).
Contralateral joint levels of PGE2 also increased following i.art FCA, although at
each time point they remained lower than ipsilateral joint levels. Prior to induction of joint
inflammation, the levels of PGE2 in contralateral joints was 1486 ± 687.1 pg ml" ; this
increased to a peak of 3853.0 ± 1310.4 pg ml"1 one day after FCA. Further measurements
were less than basal measurements, and none of the contralateral PGE2 levels were
significantly different from day 0 readings (P>0.05, Kruskal Wallis).
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4.3.6 TOTAL INFLAMMATORY CELL COUNTS
Total inflammatory cell counts from normal animals and those injected with FCA
(n=7) 21 days prior to sampling are shown in Figure 4.4. Normal joints (n=5) had no
inflammatory cells detectable, whereas all other samples had measurable levels. However,
only the high dose FCA ipsilateral (500 pg; n=3) joints proved to have a significantly greater
number of inflammatory cells (4.8 ± 0.06 x 106 cells ml"1) than normal joints (P<0.05, Mann
Whitney). The ipsilateral joint contained a higher number of inflammatory cells than the
contralateral joint in rats injected with both doses of FCA. However, ipsilateral and
contralateral joints' inflammatory cell counts in rats injected with the higher dose of FCA
had increased levels in comparison with those injected with the low dose FCA.
*
Figure 4.4. The effects of low (150 pg) and high (500 pg) dose FCA on total inflammatory cell
counts from joint perfusates. Naive joints contained no detectable inflammatory cells (0), whereas all
other joints contained increased levels, although only high dose ipsilateral joints proved to have a
significantly greater number of inflammatory cells in comparison with normal joints (P<0.05, Mann
Whitney); statistical significance represented by *.
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4.4 DISCUSSION
The aim of this study was to develop a method for sampling synovial fluid from the
knee joints of anaesthetized rats. The technique was validated by determining whether an
inflammatory response was evoked by the experimental protocol, including the anaesthetic
and the perfusion needles themselves. The efficiency of the system was also investigated,
i.e. whether any of the infused solution leaked from the joint space. Finally, the novel
perfusion technique was used to quantify inflammatory cell and mediator content within the
rat synovial cavity.
This technique proved to be reliable and consistent when perfusing the joint cavity
and regular volumes of sample were easily collected. There were no problems with
measuring inflammatory protein content due to high sample viscosity, a problem previously
reported with the analysis of synovial fluid. This technique is therefore a valuable addition
to protocols which use homogenates of entire joints to assess inflammatory mediator content.
It was established that the choice of anaesthetic may play a role in initiating an
inflammatory response within the knee joint. Urethane, a hypnotic anaesthetic agent
commonly used for laboratory animals did not affect levels of any of the mediators measured
over a seven hour period. In contrast, pentobarbital (pentobarbitone), a short-acting
anaesthetic which must be maintained by i.v infusion, therefore requiring further surgical
preparation of the animal, was associated with increases in GM-CSF and TNFa after
continuous administration during the day. I suspect that there was neither a pro¬
inflammatory effect of pentobarbital nor an anti-inflammatory effect of urethane, merely that
the extra surgical preparation required to cannulate a vein for continuous administration of
pentobarbital to maintain the level of anaesthetic required for the duration of the perfusion
lead to a systemic inflammatory response, which was subsequently detected in the joint
perfusate samples from rats anaesthetised with pentobarbital. In order to determine if this
was the cause of the increased levels of TMFa and GM-CSF in basal samples from
pentobarbital-anaesthetised rats, a further study could be conducted in which the
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pentobarbital anaesthetic was administered regularly via i.p. injections rather than
intravenous delivery. It was therefore decided to use urethane for joint perfusion
experiments, given that it provides an extended period of anaesthesia with minimal
physiological changes (Sapru & Krieger, 1979), without the need for invasive surgical
preparation. Furthermore, pentobarbital can cause respiratory depression in rats, whereas
urethane causes minimal cardiopulmonary disturbances (Field et al., 1993; Wixson et al.,
1987). Hypoxia, under pentobarbital anaesthesia, may cause release of inflammatory
mediators, as seen in this study.
Once it had been established that urethane had no adverse effects on the system, it
was necessary to evaluate any inflammatory component resulting from insertion of the
needles and the presence of the needles in the joint over seven hours. It was observed that a
few rats showed increased TNFa or ILip levels, but the changes occurred in only 20% of
animals and were not statistically significant.
This study has demonstrated that very little, if any, solution perfused into the joint is
lost into the surrounding tissue, and that the perfusate can all be recovered through the
effusion tubes. This was confirmed by injection of Evans blue dye into the joint cavity and
later dissection of the tissue. Although this study was not designed to show the effects of the
exogenous inflammatory protein on the joint, ILip caused de novo release of natural ILip, as
shown by the fact that levels of ILip in the perfusate were 20 - 40% greater than the initial
dose administered.
Adjuvant-induced arthritis is a widely used model of inflammatory joint disease, and
it was therefore important that samples collected via perfusion of the joint contained
detectable cytokine levels in comparison with naive joints and FCA-injected inflamed joints.
Levels of both the cytokines measured in this study, ILip and TNFa, increased substantially
14 days after the initial insult to the joint. A 34-fold elevation of TNFa levels, and a 42-fold
increase for ILip levels occurred. This is in agreement with previous studies using
homogenised rat joints (Smith-Oliver et al., 1993; Szekanecz et al., 2000).
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Other key mediators which play vital roles in the pathophysiology of joint
inflammation, such as PGE2 showed a trend toward increased expression levels.
Previously PGE2 had been identified in other inflammatory models, such as whole
homogenates of rat paws treated with intra-plantar carageenan (Guay et al., 2004), as well as
supernatants of ex vivo cultured human synovium (Robinson et al., 1975a; Robinson et al.,
1975b) and monolayers of dissociated synovial cells taken from collagen-induced arthritic
rats, but not non-arthritic rats (Robinson et al., 1975a; Robinson et al., 1975b).
However, of notable interest in this study, is the presence of PGE2 in samples from
naive joints. There are two COX isoforms; the relative amount of each isoform expressed in
individual tissues varies and is modulated under pathological conditions. It is therefore
possible that the PGE2 detected in normal joints was present prior to the needles being
inserted, however, it is also possible that arachidonic acid from the joint tissue was
metabolised to PGE2 as a result of the mechanical stimulation caused by the needles (Ferreira
& Vane, 1967). However, PGE2 also plays a role in bone homeostasis (Kawaguchi et al.,
1995); so it may be that the levels detected in normal joints may represent endogenous
prostanoids. This could be confirmed by analysing the PGE2 content of whole homogenised
joints which have not undergone an injection or other procedure. If PGE? is present in these
samples, then it is likely that the PGE2 detected in the present study was in the joint prior to
the needle insertion.
Finally, the total number of inflammatory cells present in the joint perfusate samples
was investigated. Not surprisingly it was found that FCA-injected joints contained higher
levels of inflammatory cells than normal rat knee joints, as previously reported (Santos &
Tipping, 1994). However, of particular interest are the inflammatory cell counts from
contralateral, non-injected limbs. Contralateral effects arising from a unilateral insult is a
well documented phenomenon. In general, the changes in behaviour, magnitude of
biochemical fluctuations or histopathological lesions in the contralateral joint are less than
those observed on the injected joint (for review see Shenker et al., 2003). Total
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inflammatory cell count data from this study are in agreement with this finding, and although
the lower dose of FCA used here does not elicit behavioural signs of inflammation or
hypersensitivity in the contralateral joint, there is evidence of infiltration of inflammatory
cells. Furthermore, the higher dose of FCA induced contralateral invasion of inflammatory
cells to similar levels seen in the ipsilateral side of low dose FCA injected animals,
indicating the onset of contralateral spread with higher FCA levels (Donaldson et al., 1993;
Shenker et al., 2003).
In summary, a novel method for sampling synovial fluid content via perfusing the
joint cavity has been devised and used successfully for obtaining samples for subsequent
analysis of cytokine and prostanoid levels during adjuvant-induced arthritis. This method
has the advantage of enabling the contents of synovial fluid to be investigated alone, without
the contamination of the surrounding tissue. We have also shown that it can be employed to
elucidate the temporal expression pattern of PGE2 during the development and progression
of rat-adjuvant arthritis and revealed its value in measuring cellular components of
inflammation.
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Chapter 5 - The effect of adjuvant-induced arthritis on
the expression of inflammatory cells and cytokines in
the synovial cavity
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5.1 INTRODUCTION
The complex actions and interactions of inflammatory proteins that drive the immune
response in the joint are still not fully understood, although it is known that cytokines, in
particular, TNFa, ILip and IL6, are important in the development and maintenance of RA
(Brennan et al., 1992; Choy & Panayi, 2001; Feldmann et al, 1990). The expression levels of
these molecules are elevated in the synovium of RA patients (Chikanza et al., 1995a; Eastgate et
al., 1988; Houssiau, 1995; Houssiau et al., 1988; Ozaki et al., 2001; Saxne et al., 1988). TNFa
and IL6 are involved in inflammation, differentiation, proliferation of T and B cells and bone
resorption (Campbell et al., 2003; Ishihara & Hirano, 2002). ILip is involved during the
induction of inflammation, modification of the immune response and activation of osteoclasts
(Dayer, 2003; Seckinger et al., 1990).
Synovial biopsies from knee joints of RA patients analysed for cytokine
immunolocalisation or mRNA levels identified a variable pattern (Alsalameh et al., 1999;
Barrera et al., 2001; Deleuran, 1996; Dolhain et al., 1998; Kirkham et al., 1999; Ulfgren et al.,
2000). Although TNFa was present at high levels in some RA patients, it was undetectable in
approximately half of patients. This absence of TNFa in some patients and the fact that anti-
TNFa therapy is not efficacious in all cases of RA suggests multiple pathways and factors are
involved. Moreover, the cytokine network may vary at different stages of the disease; therefore
repeated sampling in large groups of RA patients is needed to shed more light on this issue.
However, in patients with active RA, synovial fluid levels of IL6 have been reported to be
between 160 and 660 pg ml"1 (Matsumoto et al., 2006; McNiff et al., 1995). Considerably
higher levels (nearly 3000 pg ml"1) have been reported in synovial fluid of patients with juvenile
idiopathic arthritis (JIA; de Jager et al., 2006). Several studies have investigated the levels of
ILip in the synovial fluid of RA patients; levels were approximately 360 pg ml"1 (McNiff et al,
1995), whereas they were reportedly only 15 pg ml"1 in patients with JIA (de Jager et al., 2006).
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Finally, TNFa levels have in patients with active RA and JIA ranged from 13 to 562 pg ml"1
(McNiff et al., 1995; de Jager et al., 2006).
Moreover, changes to the levels of proinflammatory cytokines in the blood are also seen
n patients with inflammatory arthritis. De Jager et al. (2006) report that levels of ILip, IL6 and
TNFa in normal, healthy controls were 1.2, 0 and 1.1 pg ml"1 respectively. In contrast, serum
levels of these proteins in arthritic patients have been reported to be 81-100, 440- 572, 6-1200 pg
ml"1 (Danis et al., 1992; de Jager et al., 2006; Syesson et al., 2002).
There is a need for new treatments, perhaps based on the antagonism of a combination
of several inflammatory mediators. However, RA progresses over the course of years, making
studying the effects of the disease course on cytokine expression difficult. Animal models of
RA are widely used to gain insights into the pathogenic mechanisms of inflammation, processes
of autoimmunity and during the preclinical development of new therapeutic agents. Rodent
models of RA avoid these limitations, since the disease progresses over a period of a few weeks
and serial sampling is more viable. However, none of the rodent models exactly mimic human
RA.
Glucocorticoids, such as prednisolone, despite having a number of side effects, are
potent and commonly used anti-inflammatory agents used to treat human RA. They are known
to down-regulate pro-inflammatory cytokine production such as IL1|3 and TNFa normally
produced by macrophages and monocytes (Kunicka et al., 1993). In the present study,
prednisolone was used to investigate the effect of steroid treatment on cytokine production in the
arthritic rat knee joint.
The primary aim of this study was to characterise the dynamics of key pro- and anti¬
inflammatory cytokine expression in the knee joints of rats with adjuvant induced arthritis and
compare these to behavioural measures of swelling and mechanical hypersensitivity. Secondly,
133
Chapter 5: FCA effect on cytokines in the joint




Normal joint and blood cytokine levels and cell counts
The body weights, joint diameters and weight distribution between the hind limbs were
assessed prior to the perfusion of untreated joints (n=ll). Samples were immediately frozen and
stored at -20° C, and later assayed for multiple cytokines using the Luminex assay. Blood
plasma samples were taken after perfusions of the knee joints were complete. In order to
determine the total inflammatory cell count of perfusate samples, 50 pi was removed from the
joint perfusate sample prior to freezing and transferred to a new centrifuge tube. A total
inflammatory cell count was conducted.
Effect of FCA on joint and blood cytokine levels and inflammatory cell counts
Body weights, joint diameters and weight distribution between the hind limbs were
assessed in rats prior to induction of joint inflammation (day 0). FCA (150 pg) was injected into
the left (ipsilateral) knee joint under transient halothane anaesthesia (n=100).
Animals were assessed for changes in body weight, weight distribution and joint
diameter (ipsilateral and contralateral) prior to the perfusion of the joint. The ipsilateral and
contralateral knee joints from eight FCA-injected animals were perfused 2, 5, 7, 10, 14, 16, 18,
and 21 days post-FCA (n=8 per day, n=64 in total), and from four FCA-injected rats on days 1,
3, 4, 8, 9, 11, 12, 15 and 17 (n= 4 per day, n=36 in total). Samples were immediately frozen and
stored at -20° C, and later assayed for multiple cytokines using the Luminex assay. Blood
plasma samples we're taken after perfusions of the knee joints were complete. In order to
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determine the total inflammatory cell count of joint perfusate samples, 50 fil was removed from
the perfusate sample prior to freezing and transferred to a new 1 ml centrifuge tube. A total
inflammatory cell count was conducted.
Effect of prednisolone on FCA-evoked joint inflammation
Body weights, joint diameters and weight distribution between the hind limbs were
assessed in rats prior to induction of joint inflammation (day 0). FCA (150 yttg) was injected into
the left (ipsilateral) knee joint under transient halothane anaesthesia (n=54). The knee joints
from six FCA-injected animals were perfused 3, 7 and 10 (n=18 in total) days post-FCA. On
day 13, all remaining arthritic rats (n=36) were injected (s.c.) with prednisolone (10 mg kg"1); the
ipsilateral and contralateral knee joints of six of these rats were perfused one hour later. On days
14 (n=30), 15 (n=24), 16 (n=18) and 17 (n=12) the protocol was repeated and the joints of six
rats were perfused daily one hour after prednisolone treatment. On day 21 the knee joints of the
final six rats were perfused. All samples were frozen and stored at -20° C, and later assayed for
multiple cytokines using the Luminex assay.
5.3. RESULTS
5.3.1. NORMAL ANIMALS
Cytokine content of untreated rat knee joints
In general, cytokine levels in normal joint perfusate samples (n=10) were below the
level of detection of the assay. However, some samples did contain detectable levels of some
cytokines (see Table 5.1).
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Cytokine ILla ILip IL2 IL4 IL6 IL10 GM-CSF IFNy TNFa
Concentration 0.9 1.2 0.2 0.3 3.2 1.9 0.2 0.2 0.3
(pg ml"1)
±0.6 ± 1.2 ±0.2 ±0.3 ±3.2 ± 1.3 ±0.2 ±0.2 ±0.3




detectable 2 1 1 I 1 2 1 1 1
levels
Table 5.1 The concentrations of each cytokine (in pg ml"1), the total number of rats sampled and the
number of joints that contained detectable levels of each analyte in normal (untreated) rat knee joints.
Detection limit of the assay was 2 pg ml"1: this data represents anything <2 =0 and anthing greater han 2
pg ml"1 averaged. Note: it was not the same samples that contained measurable concentrations of each
cytokine.
Cytokine content of untreated rat plasma
Blood samples from normal rats showed negligible levels of eight of the nine cytokines
measured, however levels of TNFa were 4.7 ± 4.7 pg ml"1 as a result of one sample containing


















Figure 5.1 Levels of cytokines in blood samples from normal (untreated; n=ll) rats. All cytokines
assayed were below the detection threshold of the assay, except for TNFa which had a concentration of
approximately 4 pg ml"1.
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5.3.2 EFFECT OF FCA ON LEVELS OF CYTOKINE EXPRESSION IN THE BLOOD
AND JOINT CAVITIES
Behavioural assessments
FCA had no adverse effects on the animals' general health, as evidenced by the fact that
animals continued to feed and gain weight normally throughout the study (see Figure 5.2a). On
days 16, 18 and 21-post FCA, the body weights of the rats were significantly higher than day 0
(P<0.05, Kruskal Wallis).
Before induction of arthritis the ipsilateral and contralateral knee joint diameters were
9.7 ±0.1 mm (n=64) and 9.8 ±0.1 mm (n=64) respectively, these values did not differ
significantly (P>0.05, Mann Whitney). Following FCA, the ipsilateral joint was significantly
swollen (13.8 ± 0.4 mm on day 2 post-FCA; n=8) in comparison with the contralateral joint (9.7
± 0.2 mm on day 2 post-FCA; n=8; P<0.05, Mann Whitney). The ipsilateral joint diameter
remained significantly higher than that of the contralateral joint until the end of the study
(P<0.05, Kruskal Wallis; see Figure 5.2b). No changes in contralateral joint diameters occurred
in comparison to the basal values at any time (P>0.05, Kruskal Wallis).
I.art FCA evoked mechanical hypersensitivity of the ipsilateral joint, as measured by the
incapacitance tester. Prior to induction of joint inflammation, the weights carried by the two
hind limbs were 102.6 ± 3.1 g (n=64) and 104.3 ± 3.3 g (n=64). However, following
administration of FCA the weights on the ipsilateral and contralateral hind limbs were 23.3 ± 2.7
g (n=8) and 132.9 ± 5.9 g (n=8) respectively; these were significantly different from each other
(P<0.05, Kruskal Wallis). The weights on the two hind limbs remained significantly different
from one another for the duration of the study (P<0.05. Kruskal Wallis; see Figure 5.2c). The
associated ratio of the weight distribution between the hind limbs on day 0 was 0.99 ± 0.0
(n=64); two days after FCA the ratio was 0.19 ± 0.0 (n=8), this was significantly lower than the
137
Chapter 5: FCA effect on cytokines in the joint
basal measurement (f<0.05, Mann Whitney), and remained significantly reduced up to and
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Figure 5.2 Measurements of (a) body weight, (b) knee joint diameter, (c) the weight placed on each hind
limb and (d) the associated ratio of weight distribution between the ipsilateral and contralateral hind limbs
of rats injected with FCA on day 0 (150 /xl; n=8). The ipsilateral joints were significantly swollen and
hypersensitive from day one post FCA until the end of the study on day 21 (P<0.05, Kruskal Wallis;
represented by *).
Cytokine content of ipsilateral joints
Joint perfusates from rats injected with FCA (150 /xl; on day 0) were analysed for
multiple cytokine content using the Luminex Assay. ELla, ILip, EL2, IL4, IL6, IL10, GM-CSF,
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IFNy and TNFa concentrations of the samples were measured. Data are grouped into three day
blocks, to reduce variations in temporal expression patterns between different rats.
Interleukin 1a
The concentration of ILla in the ipsilateral (injected) joint was significantly elevated
compared with values from normal joints in untreated rats on each test day until the end of the
study on day 21 (n=9-21; P<0.05, Kruskal Wallis; see Figure 5.3a). The peak ELla
concentration occurred between days 16 and 18, when the level was 56.7 ± 19.2 pg ml"1 (n=17).
See Figure 5.3b for the scatter of ILla concentrations from ipsilateral joints. The proportion of
ILla-positive samples on particular days were compared with those of untreated joints (day 0)
using the Fisher's Exact test (see Figure 5.3c). In each time group, the proportion of ILla-
positive joints was significantly greater than in normal joints (P<0.05, Fisher's Exact test).
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Figure 5.3 (a) Concentrations of ILla in ipsilateral perfusate samples (n=10-21) and (b) the ranges of
ILla levels in perfusates from ipsilateral joints following FCA; the horizontal bar on the graph indicates
the median concentration, (c) The percentage of ipsilateral knee joints that were positive for ILla, i.e.
they contained detectable levels of ILla. Statistical significance (P<0.05) is represented by *, statistical
analysis for figure (a) was carried out to compare concentrations on each day post FCA with levels in
normal joints (day 0) using the Kruskal Wallis test. The Fisher's Exact test was used to analyse the
differences in the proportion of samples that had detectable levels of the protein in (c).
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Interleukin 1(3
The level of ILlfi in inflamed joints was significantly elevated in comparison with
values from normal joints between days 1-3 (n=19), 4-6 (n=12) and 10-12 (n=19) post-FCA
(P<0.05, Kruskal Wallis; see Figure 5.4a). The peak IL1 [3 concentration (385.4 ± 203.9 pg ml"1)
occurred between days four and six. See Figure 5.4b for the scatter of ILip concentrations from
ipsilateral joints. The proportion of ILl|3-positive samples on particular days were compared
with those of untreated joints (day 0) using the Fisher's Exact test (see Figure 5.4c). In each
time group, apart from between days 13-15 post-FCA, the proportion of ILip-positive joints was
significantly greater than in normal joints (/J<0.05, Fisher's Exact test).
Interleukin 6
The concentration of IL6 in ipsilateral joint perfusates was not significantly different
from normal joints at any time point post-FCA (n=9-20; P>0.05, Kruskal Wallis; see Figure
5.5a). See Figure 5.5b for the scatter of EL6 concentrations from ipsilateral joints. The
proportion of EL6-positive samples on particular days were compared with those of untreated
joints (day 0) using the Fisher's Exact test (see Figure 5.5c). In each time group, the proportion
of IL6-positive joints was significantly greater than in normal joints (/J<0.05. Fisher's Exact
test).Between days 1-3 post-FCA, the proportion of IL6-positive joints was significantly higher
than in normal joints (P<0.05, Fisher's Exact test).
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Figure 5.4 (a) Concentrations of IL1 (3 in ipsilateral perfusate samples (n=10-21) and (b) ranges of IL1(3
levels in perfusates from ipsilateral joints following FCA; the horizontal bar on the graph indicates the
median concentration, (c) The percentage of ipsilateral knee joints that were positive for ILlp, i.e. they
contained detectable levels of ILip. Statistical significance (F<0.05) is represented by *, statistical
analysis for figure (a) was carried out to compare concentrations on each day post FCA with levels in
normal joints (day 0) using the Kruskal Wallis test. The Fisher's Exact test was used to analyse the
differences in the proportion of samples that had detectable levels of the protein in (c).
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Figure 5.5 (a) Concentrations of IL6 in ipsilateral perfusate samples (n=8-20) and (b) the ranges of IL6
levels in perfusates from ipsilateral joints following FCA; the horizontal bar on the graph indicates the
median concentration, (c) The percentage of ipsilateral knee joints that were positive for IL6, i.e. they
contained detectable levels of IL6. Statistical significance (P<0.05) is represented by *, statistical analysis
for figure (a) was carried out to compare concentrations on each day post FCA with levels in normal joints
(day 0) using the Kruskal Wallis test. The Fisher's Exact test was used to analyse the differences in the
proportion of samples that had detectable levels of the protein in (c).
143
Chapter 5: FCA effect on cytokines in the joint
Interleukin 10
The levels of IL10 in ipsilateral joint perfusates were not significantly different from
those of normal joints at any time point post-FCA (n=9-21; P>0.05, Kruskal Wallis; see Figure
5.6a). See Figure 5.6b for the scatter of 11.10 concentrations from ipsilateral joints. The
proportion of ILlO-positive samples on particular days were compared with those of untreated
joints (day 0) using the Fisher's Exact test (see Figure 5.6c). Between 4 and 6 days post-FCA
the proportion of ILlO-positive joints was significantly higher than in normal joints (F<0.05,
Fisher's Exact test).
Tumour Necrosis Factor a
The concentration of TNFa was significantly elevated in FCA-injected joints compared
with normal joints between days 1 and 3 post-FCA (n=19; P>0.05, Kruskal Wallis; see Figure
5.7a). The peak TNFa concentration occurred between days 1-3 post-FCA, when the
concentration was 14.9 ± 3.7 pg ml"1. See Figure 5.7b for the scatter of TNFa concentrations
from ipsilateral joints. The proportion of TNFa-positive samples on particular days were
compared with those of untreated joints (day 0) using the Fisher's Exact test (see Figure 5.7c).
Until day 15 post-FCA the proportion of TNFa-positive joints was significantly higher than in
normal joints (F<0.05, Fisher's Exact test).
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Figure 5.6 (a) Concentrations of IL10 in ipsilateral perfusate samples (n=8-21) and (b) ranges of IL10 in
perfusates from ipsilateral joints following FCA; the horizontal bar on the graph indicates the median
concentration, (c) The percentage of ipsilateral knee joints that were positive for IL10, i.e. they contained
detectable levels of IL10. Statistical significance (P<0.05) is represented by *, statistical analysis for
figure (a) was carried out to compare concentrations on each day post FCA with levels in normal joints
(day 0) using the Kruskal Wallis test. The Fisher's Exact test was used to analyse the differences in the
proportion of samples that had detectable levels of the protein in (c).
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Figure 5.7 Concentrations of TNFa in (a) all perfusate samples (n=8-21) and (b) in perfusates from joints
that were positive for TNFa following FCA (n=5-10); the horizontal bar on the graph indicates the median
concentration, (c) The percentage of ipsilateral knee joints that were positive for TNFa, i.e. they
contained detectable levels of TNFa. Statistical significance (P<0.05) is represented by *, statistical
analysis for figure (a) was carried out to compare concentrations on each day post FCA with levels in
normal joints (day 0) using the Kruskal Wallis test. The Fisher's Exact test was used to analyse the
differences in the proportion of samples that had detectable levels of the protein in (c).
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Interleukin 2 and 4, Granulocyte-Macrophage CSF and Interferon y
Levels and spread of IL2, IL4, GM-CSF and EFNy in FCA-injected and normal
(untreated; day 0) knee joints of rats and the percentage of joints containing IL2, IL4, GM-CSF
and IFNy are shown in Table 5.2.
Cytokine content of contralateral joints
In addition to changes in cytokine expression in the FCA-injected joint, increases in
levels of cytokines in contralateral joints also occurred (see Figure 5.9). However, at each time
point the levels were lower in the contralateral side compared with the ipsilateral joint. Some
increases proved to be significant, in comparison with levels in normal joints, see Figure 5.8
(P<0.05, Kruskal Wallis).
Correlation of behavioural assessments with cytokine contents of ipsilateral joint
perfusates
In order to determine whether any of the cytokines assayed in the ipsilateral joint
perfusion samples were significantly correlated with the behavioural measures (knee joint
swelling and hypersensitivity) Spearman rank correlation factors were calculated (see Figure
5.9). ILla, ILip, IL4 and IL10 showed strong positive correlations with the ipsilateral knee
joint diameter (P<0.05).
Correlations between levels of ILla, ILip, IL6 and TNFa in ipsilateral joint perfusates
and the ratio of weight distribution on the hind limbs are shown in Figure 5.10. The correlations
between these two parameters were significant (P<0.05, Spearman r).
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Day IL2 IL4 GM-CSF IFNy
Levels in 0 0.2 ±0.2 0.3 ±0.3 0.1 ±0.1 0.2 ± 0.2
ipsilateral joint
perfusates
(n=10) (n=10) (n=10) (n=19)
1-3 87.2 ±47.3 10.2 ±7.3 7.8 ± 3.1* 1441.0 ±890.0
(Mean +SEM; (n=21) (n=15) (n=10) (n=21)
pg ml"1) 4-6 4.5 ±2.5 20.0 ±9.4 3.3 ±1.2 728.5 ±728.3
All data
(n=12) (n=13) (n=5) (n=12)
7-9 21.9 ±9.9 2.1 ± 1.6 2.5 ±0.9 70.2 ± 66.5
(n=9) (n=6) (n=4) (n=9)
10-12 16.9 ±5.9 4.8 ±3.7 1.9 ±0.5 1573.0 ± 1090.0
(n=19) (n=9) (n=8) (n=19)
13-15 8.2 ±2.6 1.0 ± 1.0 1.5 ±0.9 11.2 ± 4.8
(n=12) (n=10) (n=4) (n=12)
16-18 42.6 ± 22.4 33.8 ±33.8 2.4 ± 1.1 2609.0 ± 1857.0
(n=19) (n=5) (n=7) (n=17)
19-21 8.7 ±4.0 0.2 ±0.2 2.0 ±0.4 3754.0 ±2570.0
(n=ll) (n=13) (n=7) (n=l 1)
Range of levels 0 0-1.63 0-2.57 0- 1.47 0-1.7
in ipsilateral
joint perfusates
(n=10) (n=10) (n=10) (n= 10)
1-3 0-732 0-107.7 0-31.7 0-12558
(pg ml"1) (n=21) (n=15) (n= 10) (n=21)
4-6 0-24 0-107.7 0-7.1 0 - 8740
(n=12) (n=13) (n=5) (n=12)
7-9 0-96 0-9.95 0-4.03 0-601.3
(n=9) (n=6) (n=4) (n=12)
10-12 0-96 0-33.17 0-3.01 0-17298
(n=19) (n=9) (n=8) (n=19)
13-15 0-19 0 - 9.95 0-3.0 0-35.4
(n=12) (n=10) (n=4) (n=12)
16-18 0-434 0-169.2 0-8.0 0-31539
(n=19) (n=5) (n=7) (n=17)
19-21 0 - 34.3 0-2.58 0-3 0 - 24600
(n=l 1) (n=13) (n=7) (n=l 1)
Percentage of 0 10 10 10 10
joints containing
0 pg ml"1
1-3 57* 20 80* 52*
4-6 25 46 80* 17
7-9 78* 29 75* 22
10-12 53* 22 75* 37
13-15 50 10 50 33
16-18 74* 20 57 53*
19-21 45 8 86* 36
Table 5.2 Levels of IL2, IL4, GM-CSF and IFNy in ipsilateral joints of normal (untreated; day 0; grey
bars; n=10-21) and FCA-injected rats (150 fig). The ranges of concentrations measured in joint perfusates
and the percentage of joints that contained >0 pg ml"1 for each of the latter are included. Statistical
significance (P<0.05) is represent by *.
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Figure 5.8 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in joint perfusates from contralateral (uninjected; n= 9-20) rat knee joints following FCA (150 p\)
injection into the ipsilateral joint on day 0. Statistical analysis was carried out to compare the
concentration in each time block with the levels in normal joints using the Kruskal Wallis test; statistical
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Figure 5.9 Correlation plots for ipsilateral joint diameter against the concentration of (a) ILla, (b) ILip,
(c) IL4 and (d) IL10 in ipsilateral joint perfusates. Figures include the linear regression line and the values
for Spearman r correlation factor, and the associated P value.
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Figure 5.10 Correlation plots for the ratio of weight distribution between the hind limbs and the ipsilateral
joint cytokine concentrations of (a) ILla, (b) ILip, (c) IL6 and (d) TNFa. Significant negative
correlations occurred (P<0.05). Graphs include the linear regression plot and the values for Spearman r
correlation factor, and the associated P value.
Cytokine content of blood samples
Induction of arthritis caused cytokine levels in blood plasma to increase in comparison
with levels in blood from normal animals, however, none of the increases were statistically
significant (P>0.05, Kruskal Wallis; see Figure 5.11).
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Figure 5.11 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in blood plasma samples from rats injected with FCA (150 /tg; on day 0; n= 8-19). Statistical
analysis was carried out to compare the concentration in each time block with the levels in normal joints
(day 0) using the Kruskal Wallis test; statistical significance (P<0.05) is represented by *.
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Correlation of behavioural assessments with cytokine content of blood samples
No significant correlations between the cytokine content of blood samples and the joint
swelling or hypersensitivity occurred in this study.
Inflammatory cell content of joints
Total inflammatory cell counts were carried out in joint perfusate samples from
ipsilateral and contralateral knee joints of normal and FCA-injected rats (n=3 on each day).
Increased numbers of inflammatory cells were counted on days 7, 10 and 21 in ipsilateral joints,
but only on day 21 in contralateral joint perfusate samples. However, none of the increases were
significant in comparison with samples from normal animals (P>0.05, Kruskal Wallis; see
Figure 5.12).
> 5]
0 1 2 5 7 10 12 14 21
Time post FCA (days)
■ ipsilateral (n=3) □Contralateral (n=3)
Figure 5.12 Total inflammatory cell counts in ipsilateral and contralateral joint perfusate samples from
normal (day 0) and FCA-injected (150 /xg; n=3) rat knee joints. No statistical differences in total cell
counts were measured between FCA-injected and normal rat knee joints (F>0.05, Kruskal Wallis).
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5.3.4 EFFECT OF PREDNISOLONE ON FCA-EVOKED INFLAMMATORY
RESPONSE
Behavioural Assessments
FCA had no adverse effects on the rats' general health. Animals continued to feed and
gain weight normally throughout the study. Data from days 0-9 are not shown, as no differences
were seen between the values in this study and those in the FCA time course described in
Section 5.3.2 (P>0.05, two-way ANOVA). No significant differences in body weight were
measured between days 10 and 17 during drug treatment (P>0.05, Kruskal Wallis; see Figure
5.16a).
Ten days after FCA the ipsilateral knee joint was significantly swollen (12.3 ± 0.5 mm;
n=6) in comparison with the contralateral joint (9.9 ± 0.0 mm; n=6; P<0.05, Mann Whitney).
Prednisolone was administered on days 13 - 17 once daily (10 mg kg-1; s.c.). During
prednisolone treatment swelling of the ipsilateral joint decreased, and by day 14 was no longer
significantly swollen (11.3 ± 0.2 mm; n=6) compared with the contralateral joint (9.9 ±0.1 mm;
n=6; P>0.05, Kruskal Wallis; see Figure 5.16b).
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Figure 5.16 The (a) body weights and (b) knee joint diameters of the ipsilateral and contralateral limbs of
rats injected with FCA on day 0. The joints were significantly swollen on day 10, prior to prednisolone
administration between days 13 and 17 post-FCA. From day 14 onwards, the ipsilateral joint was no
longer significantly swollen in comparison with the contralateral knee joint (n=6; P<0.05, Kruskal
Wallis). Statistical significance (P<0.05) is represented by *.
Cytokine Content of joints - Ipsilateral
Joint perfusates from rats injected with FCA on day 0 were analysed for cytokine
content using the Luminex Assay. Concentrations of ILla, ILlp, IL2, IL4, IL6, EL10, GM-CSF,
IFNy and TNFa were measured. Data from day 10 until day 17 are shown, as data from days 0-
9 showed no significant differences from the FCA study above (Section 5.3.2; P>0.05, two-way
ANOVA). Prednisolone (10 mg kg"1) was administered daily (s.c.) between days 13 and 17.
Ipsilateral and contralateral joints were perfused approximately one hour after prednisolone
injection.
Interleukin 1a
No significant differences were observed between levels of ELla on day 10 (n=6; 21.3 ±
2.9 pg ml"1; pre-prednisolone treatment) and any day during the drug-treatment regime in
inflamed joints (P>0.05, Kruskal Wallis; see Figure 5.17a). Further data analysis was carried
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out, in which all values below the level of detection of the assay (i.e. ILla-negative joints) were
removed from the data set to determine the effect of prednisolone treatment on the proportion of
joints expressing ILla protein. The ILla content of ILla-positive FCA-injected joints was not
significantly different during prednisolone administration in comparison with the day 10, pre-
treatment value (n=2-4; P>0.05, Kruskal Wallis; see Figure 5.17b). There were between one
and four ILla-negative joints in each time group; the proportion of "responder" samples on
particular days was compared with those of pre-prednisolone treated levels (day 10) using the
Fisher's Exact test (see Figure 5.17c). On day 16 the proportion of ILla-positive joints was
significantly less than in non-drug treated joints (F<0.05, Fisher's Exact test).
Interleukin 1(3
No significant differences were observed between levels of ILip on day 10 (n=6; 27.3 ±
4.7 pg ml" ; pre-prednisolone treatment) and any day during the drug-treatment regime in
ipsilateral joints (P>0.05, Kruskal Wallis; see Figure 5.18a). The ILip content of ELlp-positive
FCA-injected joints was not significantly different during prednisolone administration in
comparison with the day 10, pre-treatment value (n=5-6; P>0.05, Kruskal Wallis; see Figure
5.18b). There was only one ILlp-negative joint, on day 16. Prednisolone treatment had no
effect on the proportion of ILip-positive joints (P>0.05, Fisher's Exact test; see Figure 5.18c).
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Figure 5.17 Concentrations of ILla in (a) all joint perfusate samples and (b) in joints that were positive
for ILla content in pre-prednisolone treated rats (open symbols) and prednisolone-treated rats (closed
symbols); the horizontal bar on the graph indicates the median concentration, (c) The percentage of FCA-
injected (ipsilateral) knee joints that were positive for ILla, i.e. contained detectable levels of this
cytokine. Statistical significance (P<0.05) is represented by *. Statistical analysis for (a) and (b) were
carried out to compare concentrations on each day post FCA with levels on day 10 using the Kruskal
Wallis test. The Fisher's Exact test was used to analyse the differences in proportion of samples that had
detectable levels of the protein in (c).
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(a) Drug dosing
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Figure 5.18 Levels of ILip in (a) all joint perfusate samples and (b) in joints that were positive for ILip
content in pre-prednisolone treated rats (open symbols) and prednisolone-treated rats (closed symbols); the
horizontal bar on the graph indicates the median concentration, (c) The percentage of FCA-injected
(ipsilateral) knee joints that were positive for ILip, i.e. contained detectable levels of this cytokine.
Statistical significance (P<0.05) is represented by *. Statistical analysis for (a) and (b) were carried out to
compare concentrations on each day post FCA with levels on day 10 using the Kruskal Wallis test. The
Fisher's Exact test was used to analyse the differences in proportion of samples that had detectable levels
of the protein in (c).
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Interleukin 6
No significant differences between the concentration of IL6 before prednisolone
treatment (day 10; n=6; 142.1 ± 67.3 pg ml"1) and any day during the drug-treatment regime
were seen (P>0.05, Kruskal Wallis; see Figure 5.19a). The IL6 content of IL6-positive FCA-
injected joints was not significantly different during prednisolone administration in comparison
with the day 10 levels (n=l-3; P>0.05, Kruskal Wallis; see Figure 5.19b). There were between
three and five IL6-negative joints during prednisolone treatment. The Fisher's Exact test
showed that prednisolone significantly reduced the proportion of IL6-positive joints on days 15
- 17 post FCA (following 3-5 days of prednisolone treatment; P>0.05, Fisher's Exact test; see
Figure 5.19c).
Interleukin 10
No significant differences were observed between concentrations of IL10 in ipsilateral
knee joints of FCA-injected animals on day 10 (58.0 ± 32.8 pg ml"1; n=6; pre-prednisolone
treatment) and any day during the drug-treatment regime (F>0.05, Kruskal Wallis; see Figure
5.20a). The IL10 content of ILlO-positive FCA-injected joints was not significantly different
during prednisolone administration in comparison with the day 10, pre-treatment value (P>0.05,
Kruskal Wallis; see Figure 5.20b) and prednisolone had no significant effect on the proportion of
ILlO-positive joints (P>0.05, Fisher's Exact test), although there were between one and five
ILlO-negative joints during prednisolone treatment (see Figure 5.20c).
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Figure 5.19 Levels of IL6 in (a) all joint perfusate samples and (b) in joints that were positive for IL6
content in pre-prednisolone treated rats (open symbols) and prednisolone-treated rats (closed symbols); the
horizontal bar on the graph indicates the median concentration, (c) The percentage of FCA-injected
(ipsilateral) knee joints that were positive for IL6, i.e. contained detectable levels of this cytokine.
Statistical significance (P<0.05) is represented by *. Statistical analysis for (a) and (b) were carried out to
compare concentrations on each day post FCA with levels on day 10 using the Kruskal Wallis test. The
Fisher's Exact test was used to analyse the differences in proportion of samples that had detectable levels
of the protein in (c).
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Figure 5.20 Levels of IL10 in (a) all joint perfusate samples and (b) in joints that were positive for IL10
content in pre-prednisolone treated rats (open symbols) and prednisolone-treated rats (closed symbols); the
horizontal bar on the graph indicates the median concentration, (c) The percentage of FCA-injected
(ipsilateral) knee joints that were positive for IL10, i.e. contained detectable levels of this cytokine.
Statistical significance (P<0.05) is represented by *. Statistical analysis for (a) and (b) were carried out to
compare concentrations on each day post FCA with levels on day 10 using the Kruskal Wallis test. The
Fisher's Exact test was used to analyse the differences in proportion of samples that had detectable levels
of the protein in (c).
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Tumour Necrosis Factor a
No significant differences were observed between TNFa concentrations in ipsilateral
(FCA-injected) joints on day 10 (31.8 ± 8.8 pg ml"1; n=6; pre-prednisolone treatment) and any
day during the drug-treatment regime (P>0.05, Kruskal Wallis; see Figure 5.21a). The TNFa
content of TNFa-positive FCA-injected joints was not significantly different during
prednisolone administration in comparison with the day 10, pre-treatment value (P>0.05,
Kruskal Wallis). However, prednisolone administration significantly reduced the proportion of
TNFa-positive joints on day 15 post-FCA (P>0.05, Fisher's Exact test; see Figure 5.21c).
Interleukin 2 and 4, Granulocyte-Macrophage CSF and Interferon y
Concentrations of IL2, DL4. GM-CSF and EFNy in ipsilateral joints of FCA-injected
animals on day 10 (pre-prednisolone treatment) and during drug administration (days 13-17) are
shown in Table 5.3. No significant differences between pre-treatment levels and values during
prednisolone-treatment occurred (P>0.05, Kruskal Wallis).
Cytokine content of joints- Contralateral
In rats with established arthritis (day 10) perfusates from contralateral joints contained
detectable levels of cytokines (see Figure 5.22). Treatment with prednisolone (10 mg kg"1) had
no significant effect (P <0.05, Kruskal Wallis).
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Figure 5.21 Levels of TNFa in (a) all joint perfusate samples and (b) in joints that were positive forTNFa
content in pre-prednisolone treated rats (open symbols) and prednisolone-treated rats (closed symbols); the
horizontal bar on the graph indicates the median concentration, (c) The percentage of FCA-injected
(ipsilateral) knee joints that were positive for TNFa, i.e. contained detectable levels of this cytokine.
Statistical significance (P<0.05) is represented by *. Statistical analysis for (a) and (b) were carried out to
compare concentrations on each day post FCA with levels on day 10 using the Kruskal Wallis test. The
Fisher's Exact test was used to analyse the differences in proportion of samples that had detectable levels
of the protein in (c).
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All data 14 3.6 ±1.7 22.7 ± 15.4 7.8 ± 4.8 5.6 ±2.3
(n=5) (n=5) (n=5) (n=5)
15 0.9 ±0.9 11.6 ± 11.6 4.7 ±4.7 2.1 ±2.1
(n=6) (n=6) (n=6) (n=6)
16 0.5 ±0.5 4.4 ±4.4 5.6 ±3.5 5.6 ±1.8
(n=6) (n=6) (n=6) (n=6)
17 0.9 ±0.9 3.8 ±3.8 2.5 ±2.5 6.2 ± 2.0






















Positive joints 14 6.0 ± 1.7 56.8 ±20.8 19.5 ± 1.3 9.4 ±0.5
only
(n=3) (n=2) (n=2) (n=3)
15 5.3 ±0.0 69.8 ±0.0 28.2 ±0.0 12.4 ±0.0
(n=l) (n=l) (n=l) (n=l)
16 3.0 ±0.0 26.3 ± 0.0 16.8 ±0.1 8.4 ±0.1
(n=l) (n=l) (n=2) (n=4)
17 5.6 ±0.0 22.5 ±0.0 14.8 ±0.0 9.4 ±0.7
(n=l) (n=l) (n=l) (n=4)
Percentage of
positive joints
10 50 50 67 50
13 66 50 50 83
14 60 40 40 60
15 17 17 17 17
16 17 17 33 67
17 17 17 17 67
Table 5.3 Concentrations of IL2, IL4, GM-CSF and IFNy in FCA-injected (ipsilateral) knee joints before
prednisolone treatment (grey bars) and during prednisolone administration (days 13-17). The values for
levels in positive joints only and the percentage of joints that were positive for each of the cytokines are
also shown. No significant changes occurred.
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Figure 5.22 Levels of (a) ILla, (b) ILlp, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in contralateral (un-injected) knee joints from FCA-treated animals (n=6) before prednisolone
treatment (day 10; open bars) and during prednisolone administration (days 13-17; closed bars).
Statistical analysis was carried out to compare concentrations on each day during drug treatment with
levels pre-treatment (day 10) using the Kruskal Wallis test.
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5.4 DISCUSSION
The primary aim of this study was to identify temporal expression patterns of a)
cytokines and b) inflammatory cells in the knee joints of rats following induction of arthritis
using the novel perfusion technique, described in Chapter 4. Once it had been established that
FCA significantly increased expression of the ILla, ELip, TNFa and GM-CSF and tended to
increase (although not significantly) levels of IL6, IL10, IL2, IL4 and IFNy, a second study was
conducted during which a glucocorticosteroid, prednisolone, was administered daily. Joint
perfusions were performed one hour later, in order to determine whether the anti-inflammatory
steroid had an effect on the levels of inflammatory proteins induced by FCA. This time point
was chosen for the perfusions as the maximum analgesia in the behavioural assessments was
observed. The inclusion of vehicle-treated animals was considered, but was decided to be
unnecessary in terms of controlling against the FCA-induced inflammation, due to the fact that
the inflammatory process arising from the injection of FCA arises in part as a result of the
injection itself, the increase in intra-articular pressure, the vehicle and the bacterial substance
within the FCA.
Cytokine expression altered over time as FCA-induced arthritis progressed from the
acute to the more "chronic" phase. The proportion of inflamed joints that contained detectable
levels of all mediators (except EL4) measured was significantly increased during the study. This
suggests that it may be the presence of the protein, even at low levels, that is important for the
development and maintenance of joint inflammation and hypersensitivity. In addition,
significant correlations between measures of joint swelling or mechanical hypersensitivity and
levels of cytokines in inflamed joints were seen. Furthermore, trends towards increased
concentrations of all mediators measured in blood plasma were elevated in comparison to
normal joints, although none of these were found to correlate with behavioural signs of arthritis.
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Cytokines are locally-produced proteins known to be involved in many biological
functions, including inflammation, bone remodelling, cell growth and activation (for review see
Christodoulou & Choy, 2006). It is therefore not surprising that they play a role in joint
inflammation during autoimmune diseases such as RA, and that anti-cytokine therapies are being
successfully used in the clinic to slow the progression of the disease and joint destruction and
provide effective analgesia.
INTERLEUKIN 1a
ILla levels remained significantly elevated for the duration of the experiment,
indicating that ILla may be involved in sustaining the inflammatory response in this model
following the initial insult. Furthermore, between 80 and 100% of joints contained detectable
levels of this protein at all time points post-FCA, this implies that ILla is important for the
development of adjuvant-arthritis. In accord, the transgenic mouse line which overexpresses
human ILla exhibits a severe arthritic phenotype (Niki et al., 2004). Furthermore, levels of
ILla in the inflamed joint were strongly correlated with functional measures of mechanical
hypersensitivity and joint swelling. Similarly, in patients with RA, plasma ILla levels
significantly correlate with the Ritchie Articular Index, analogue pain scores and duration of
morning stiffness (Eastgate et al., 1991). However, ILlp mRNA and protein production greatly
exceeds that of ILla clinically in RA joints (Dinarello, 1994c). The levels of ILla protein in
joint exudates from arthritic rats in this study are in agreement; the maximum levels of the two
cytokines were 60 pg ml"' and 400 pg ml"1 respectively.
INTERLEUKIN 1p
In contrast to ILla, significantly increased ILip expression occurred only in the acute
phase and declined toward basal values within ten days, despite the persistence of the clinical
symptoms. However, the proportion of joints that were ILip-positive was high throughout the
study, between 60 and 100% and hence it is a valid drug target effective in a high proportion of
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patients, perhaps those that do not respond to TNFa therapy. A strong correlation between
levels of ILip in the joint and the swelling occurred, moreover, ILip antagonists reduce swelling
of arthritic joints in patients (Bresnihan et al., 1998). The level of ILip in inflamed joints was
strongly correlated with mechanical hypersensitivity, which is in agreement with similar studies
in patients (Alstergren et al., 1998). In patients with RA, levels of DLip in synovial fluid was
approximately 360 pg ml"1 (McNiff et al., 1995), which are comparable to levels measured in the
joint perfusates of adjuvant-injected rat joints during the first week of joint inflammation.
INTERLEUKIN 6
IL6 protein and mRNA have been detected in human RA synovial tissue (Hirano et al.,
1988; Houssiau et al., 1988), although no statistically significant increases in IL6 protein were
measured at any time point in this study, there was a trend showing that the peak protein
expression was in the acute phase and levels remained very low thereafter. Moreover, no
correlation between levels in the joint or in plasma and joint swelling was observed, although
IL6 plasma levels have been previously shown to correlate with footpad swelling in adjuvant-
induced arthritic Lewis rats treated with cyclosporin A or indomethacin (Leisten et al., 1990).
However, IL6 in perfusates was highly correlated with mechanical hypersensitivity in the rats
suggesting it may be directly involved in the development of alterations in "nociception" as a
result of joint inflammation (for a review on the role of EL6 in pain and nociception see De
Jongh et al., 2003). Although IL6 is known to be a key mediator in joint inflammation and RA,
less than 50% of inflamed joints contained the protein at any time point during this study. In a
double-blind randomised controlled clinical trial treating RA patients with the IL6 receptor
antagonist, tocilizumab, a maximum of 63% of patients achieved American college of
rheumatology 20 (ACR; see below; McQuay & Moore, 2002) with tocilizumab monotherapy
(Maini et al., 2006). This could suggest that IL6 may not have had a predominant role in the rest
of the RA population of patients.
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The ACR endpoint for effective treatment of RA states that patients must have:
1. 20% improvement in tender joint count
2. 20% improvement in swollen joint count
3. 20% improvement in three of the following:
■ Global disease activity assessed by observer
■ Global disease activity assessed by patient
■ Patient assessment of pain
■ Physical disability score (like health assessment questionnaire)
Levels of IL6 in inflamed joints in the present study are comparable to that seen clinically in RA
patients; the levels have been reported to be between 160 and 600 pg ml"1 in human synovial
fluid (Matsumoto et al., 2006; McNiff et al., 2006), whereas the peak expression of IL6 protein
was approximately 200 pg ml"1 in rat joints following FCA. Therefore, although IL6 reduction
by novel therapies may improve RA, it is likely there will be a proportion of "non-responders",
as there is for current TNFa and IL1 [3 antagonists. Perhaps a combination of several cytokine
antagonists would prove to be more efficacious and have more widespread benefit to more
patients, although this may result in increased risk of infection due to more widespread
immunosuppression.
TUMOUR NECROSIS FACTOR a
TNFa, like ILip, is present in synovial fluid of patients with RA (Di Giovine et al.,
1988; Hopkins & Meager, 1988). Similar levels of TNFa protein in collagen-injected mouse
joints were seen as in this study; the levels in the mouse joints peaked at 35 pg ml"1 (Rioja et al.,
2004). The concentrations detected in the present study were lower, but Rioja et al used whole
homogenised joints, including surrounding tissue as well as synovial fluid. It would therefore be
expected that values should be higher, taking into account all TNFa in the joint and synovial
cavity. Moreover, clinically levels of TNFa in synovial fluid from patients with RA have been
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reported between 13 and 562 pg ml"1 (McNiff et al., 1995; de Jager et al., 2006), whereas levels
in the present study, measured in joint perfusate samples peaked at approximately 15 pg ml"1.
Levels of TNFa in inflamed joints in the present study were significantly correlated with joint
swelling and hypersensitivity. In accord, neutralising monoclonal antibodies of TNFa reduce
joint swelling in rabbits with antigen induced arthritis (Lewthwaite et al., 1995) and inhibition of
TNFa production abolished ankle joint swelling in rats with established experimental arthritis
(Conway et al., 2001). Other studies have also shown the importance of TNFa in the
development of inflammatory hyperalgesia and carageenan-induced knee joint pain (Cunha et
al., 1992; Junger & Sorkin, 2000; Tonussi & Ferreira, 1999). The proportion of joints that were
TNFa-positive was dramatically increased during the first two weeks of the study, between 60
and 80%. TNFa antagonists provide impressive protection against pain and joint swelling in
most RA patients (Maini & Taylor, 2000; Charles et al., 1999; Edwards, 1999; Fox, 2000;
Garrison & McDonnell, 1999; Kavanaugh et al., 2000; Lorenz et al., 2000; Moreland et al.,
2000), however, it is also evident that anti-TNFa therapy is not effective in all RA patients
(Smolen & Steiner, 2003), nor does it control arthritis in all affected joints of good responders.
The lower levels of expression of the three key pro-inflammatory cytokines, ILip, TNFa
and IL6, in the "chronic" phase during this study suggest other factors may maintain this phase
of the response. Other studies have followed the progression of FCA-induced joint
inflammation for up to 90 days, and the physical symptoms persist throughout this duration
(Wilson et al., 2006). However, it may be that higher levels of specific mediators are needed to
induce joint inflammation or arthritis but that lower levels are sufficient to maintain the
inflammation.
ANTI-INFLAMMATORY CYTOKINES
IL4 and IL10, Th2 helper cell-derived cytokines, have been previously demonstrated in
RA joints, although the expression levels of IL4 are relatively low, despite the abundance of T
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cells (Chen et al., 1993; Miyata et al., 2000; Simon et al., 1994; Ulfgren et al., 1995). In other
animal models of arthritis, IL4 levels have been found to be low or negligible, in agreement with
our results (Schmidt-Weber et al., 1999). It is possible that the lack of IL4 -producing CD4+
Th2 cells contributes to the pathogenesis of RA, and this has led to suggestions that IL4 may be
a useful therapeutic agent (Miossec et al., 1990).
In contrast IL10 had increased levels (although not statistically significant) of expression
throughout the disease course in this study, which is in agreement with human studies of RA-
affected joints (Wagner et al., 1997). IL4 and IL10 have been employed in clinical trials for the
treatment of RA and despite efficacy in animal models (Tarner et al., 2002), a Phase I trial of
recombinant IL4 in RA, although well tolerated, did not reveal significant clinical benefit (van
den Bosch, 1998). In contrast, IL10 initially seemed to be beneficial (Weinblatt, 1999) and led
to pronounced increases of circulating TNFa receptors and ILIRa (Maini et al., 1997).
However, thrombocytopenia occurred in some patients and efficacy was not discerned in
subsequent studies. The development of both IL4 and IL10 for RA was discontinued but it may
still be possible that the combination of both cytokines, or other T helper cell-derived products,
could lead to a more marked improvement (van Roon et al., 2002). Alternatively, local
administration, for example into the joint space, may reduce the associated side effects, whilst
still providing efficacious improvement ofRA.
CONTRALATERAL SPREAD OF CYTOKINE EXPRESSION
Surprisingly, contralateral joints also showed increased expression of the nine cytokines
measured, although absolute levels remained lower than in the inflamed joint at all time points.
Contralateral joint inflammation as a result of a unilateral inflammatory insult is a well
documented occurrence (Donaldson, 1999; Shenker et al., 2003), although behavioural signs of
this crossover are not usually evident with the dose of adjuvant used here (Donaldson et al.,
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1993). It may be that the inflammation which occurs in the contralateral knee joint is not
sufficient to initiate swelling or hypersensitivity. Histological processing from this joint has also
shown that no changes are seen in the contralateral joint in rats injected with 150 /xg FCA
(previous unpublished work from this laboratory). However, pain and inflammation of the joint
arises not only from cytokines within the joint, but via neural mechanisms peripherally and
centrally, which may explain the lack of symptoms in the contralateral limb, despite the fact that
inflammatory proteins and cells are present within the joint. Alternatively, mild discomfort in
the contralateral joint may exist but is outweighed by more severe hypersensitivity in the
inflamed joint. When higher doses of FCA are used, neural mechanisms may result in more
widespread hypersensitivity and oedema. The "on" and "off' cells in the rostral ventromedial
medulla (RVM) of the brain are involved in pain processes. "Off' cells exert net inhibitory
effect on nociception, they cease firing prior to withdrawal to noxious heat. In contrast "on"
cells have a net facilitatory effect on nociception; they begin firing immediately prior to limb
withdrawal to a noxious heat stimulus. The organisation of the RVM suggests that "on" and
"off' cells function as a unit that exerts global, rather than topographical, discrete control over
pain transmission. This may help explain mild sensitisation and contralateral effects, which may
exist in other joints of the body, but were only noted here only in the knee joint, as no other areas
were studied.
EFFECT OF PREDNISOLONE ON JOINT INFLAMMATION
Prednisolone did not affect the absolute levels of cytokines in inflamed joints, although
it reduced the percentage of inflamed joints that contained detectable levels of ILla and LL6.
This suggests that the steroid appears to have an all-or-none effect in terms of cytokines. This is
in contrast to other studies, in which prednisolone reduced joint swelling through a mechanism
associated with a reduction in ILip and IL6 protein and mRNA expression levels in CIA and
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SCW arthritis (Rioja et al., 2004). However, Rioja and colleagues administered prednisolone
immediately after induction of joint arthritis, therefore perhaps preventing the production of
cytokines, rather than stopping or reducing their expression once already present when
administered over a five day period. Clinically, effective prednisolone treatment is associated
with a marked reduction in macrophage infiltration in the RA synovial tissue after two weeks of
treatment (Gerlag et al., 2004; Haringman et al., 2005). Although no inflammatory cell counts
were measured here, their inflammatory products were, and were not reduced. The predominant
effect of corticosteroids is to switch off multiple inflammatory genes (encoding cytokines,
chemokines, adhesion molecules, inflammatory enzymes, receptors and proteins) that have been
activated during the chronic inflammatory process. At higher concentrations glucocorticoids
have additional effects on the synthesis of anti-inflammatory proteins and postgenomic effects
(Barnes, 2006). Perhaps the duration of prednisolone administration was not sufficient in the
present study to see effects on inflammatory mediators, despite the fact that the swelling of the
joint was reduced within the week. This could be confirmed by dosing rats with established
arthritis with prednisolone over a longer period, several weeks, perfusing the joints and assaying
the perfusate for cytokines. Additionally, the n numbers used here were relatively low (six per
day), if these were increased, more effect may be seen on absolute cytokine levels, however due
to ethical reasons, the aim of reducing animal use, as well as financial and time limitations, this
was not possible for the purpose of this thesis.
SUMMARY
In conclusion, these studies have demonstrated the application of the novel joint
perfusion method for sampling synovial fluid and assayed the perfusates for cytokines over a
three week period of adjuvant-induced arthritis. As well as revealing additional information
regarding the expression patterns of cytokines during adjuvant-induced arthritis, similarities
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between this animal model of joint disease and human RA have been demonstrated that further
validate the model as a valuable pre-clinical tool to study the inflammatory process of human
RA. Moreover, consolidation of these similarities helps improve the confidence of novel drug
screening using this model prior to use in the clinic.
Table 5.4 A summary of changes in cytokine expression profiles within adjuvant-injected rat knee joints
and the important relationships between these levels and behavioural measures ofjoint swelling and
hypersensitivity
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Chapter 6 - The role of IL1B in joint pain and
inflammation
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6.1 INTRODUCTION
ILip is a key mediator of synovial inflammation, responsible for
• Triggering the recruitment of PMNs, lymphocytes and monocytes into the joint
• Activation of macrophages, resulting in release of proteases (Bresnihan et al., 1998)
• Stimulation of T- and B-cell proliferation and differentiation (Dinarello, 2002)
• Enhancing the proliferation of fibroblasts, leading to pannus formation.
IL1 [3 plays an important role in the pathophysiology of joint inflammation and RA by
contributing to the inflammatory process as well as joint destruction; levels of LFlp are higher in
joint tissue biopsies from patients with joint erosions than those with non-erosive RA (Fong et
al., 1994). Inhibition of EL1(3 with recombinant ILIRa reduces the extent of inflammation in RA
in patients (Bresnihan et al., 1998) and lessens inflammation and bone resorption in various
experimental models of arthritis (Feige et al., 2000; Joosten et al., 1996; Kuiper et al., 1998;
Wooley et al., 1993a; Wooley et al., 1993b).
Infusion of ELip (s.c.) induces and exacerbates arthritis in mouse and rat models of joint
inflammation (Horn et al., 1988; Horn et al., 1990; Schwab et al., 1991). Furthermore, i.art
injection of ELip in rabbits induces a transient infiltration of neutrophils into the joint space,
followed by mononuclear cell infiltration which lasts a few days, and loss of proteoglycans from
the articular cartilage (Pettipher et al., 1986). In addition, i.art IFip induced a significant dose-
dependent increase in inflammation, bone resorption and the number of osteoclasts in rat knee
joints and was accompanied with mild cartilage degradation (Bolon et al., 2004).
In contrast, it has also been reported that injection of DLlp into the knee joints of rats
with established adjuvant-induced arthritis reduced inflammation and joint destruction (Jacobs et
al., 1988). This effect was observed with administration of IFlp prior to adjuvant and
administration during established arthritis. Furthermore, it has been shown that i.v. or s.c. IFip
inhibits carageenan-induced paw oedema in a dose-dependent manner in rats (Drelon et al.,
176
Chapter 6: IL113 in joint pain and inflammation
1994; Drelon et al., 1992; Nakamura et al., 1988). The inhibition of oedema is concomitant with
the increase of plasma levels of adrenocorticotophic hormone and corticosterone, hence anti¬
inflammatory actions of ELI [3 may be, at least in part, explained by pituitary-adrenal axis
simulation (Nakamura et al., 1988). It has also been suggested that the anti-inflammatory effect
of pro-inflammatory cytokines injected into inflamed tissues is mediated by the liberation of
endorphins from inflammatory cells (Czlonkowski et al., 1993).
The aims of this study were to:
■ Determine whether ILip could induce acute and/or "chronic" joint swelling,
hypersensitivity and joint destruction
■ To assess the release of other pro- and anti-inflammatory cytokines as a result of i.art
ILip
■ To determine the effect of ILip on primary sensory afferent neural activity and
sensitivity using in vivo electrophysiological recording.
6.2 METHODS
All methods were carried out as described in Chapter 2.
Perfusion of the knee joint in anaesthetised rats was carried out as described in Section
2.4. To determine the acute effects of ILip on the release of pro- and anti-inflammatory
cytokine release, the left knee joints of six normal (untreated) rats were perfused to collect basal
samples. Then recombinant rat ILip (1 pig in 100 /xl; n=6) or vehicle (100 pi 1 sterile saline; n=6)
was perfused into the joint over one minute. One, two, three, four, five, six and seven hours later
a 250 nl sample was collected via perfusion of the joint, the sample was frozen and stored at -
20° C.
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To evaluate the effects of ILip on the cytokine content of the joint over a ten day period,
ILip (1 pg in 100 pi, n=15) or vehicle (100 p\ sterile saline; n=15) were administered via i.art
injection under transient halothane anaesthesia (3% in oxygen). Animals were allowed to
recover, and the ipsilateral (injected) knee joints of three rats were perfused on days 1, 2, 4, 7
and 10 post-LLip (n=3 per day) or vehicle (n=3 per day). Total inflammatory cell counts of joint
perfusate samples were carried out as described in Section 2.4.2, samples were then frozen and
stored at -20° C and later assayed for a range of nine cytokines (ELla, ELip, IL2, IL4, EL6, EL 10,
GM-CSF, EFNy and TNFa) using the Luminex assay as described in Section 2.4.3.
6.3. RESULTS
6.3.1. EFFECT OF IL1p ON BASAL NEURAL DISCHARGE OF PRIMARY
AFFERENT NERVES
The basal neural discharge frequency of primary afferents innervating normal rat knee
joints was 0.01 ± 0 impulses s"1 (n=13 rats, 32 units; 60% of units were inactive at this time).
This increased to 0.08 ± 0.04 (n=8 rats; 23 units; 40% of units were inactive at this time) or 0.07
± 0.04 impulses s"1 (n=5 rats; 9 units; 55% of units were inactive at this time) 30 minutes after
i.art ILip (0.1 pg) or vehicle respectively, these were not significantly different (P>0.05, Mann
Whitney). Between 30 and 150 minutes the basal neural discharge frequency declined towards
basal levels in vehicle-injected joints but increased towards a peak 180 minutes after ILip
administration. The frequency was 0.26 ± 0.06 impulses s"1 (n=8 rats, 23 units; 0% of units were
inactive at this time), which was significantly higher than that of vehicle-treated joints at this
time point (P<0.05, Mann Whitney; see Figure 6.1).
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Figure 6.1 Basal neural activity (impulses s"1) in fibres of the MAN in normal rat knee joints injected with
ILip (n=23 units; 8 rats; 0.1 gg; closed bar) or vehicle (n=9 units; 5 rats; open bar; sterile saline) at time
t=0 (arrow). ILip resulted in a significant increase in spontaneous action potential discharge frequency in
comparison with vehicle-injected joints 180 minutes after administration (* P<0.05, Mann Whitney).
6.3.2 EFFECT OF IL1p ON THE MECHANICAL THRESHOLD OF PRIMARY
AFFERENT NERVES
The mechanical threshold for activation of primary afferent nerves innervating the
normal rat knee joint was 5.20 ± 0.64 g (n=13 rats, 32 units). Following ILip there was a
significant reduction in the threshold to mechanical stimulation with von Frey airs in comparison
with vehicle-injected joints between 60 and 210 minutes post injection (P<0.05, two-way
ANOVA). However, by 240 minutes the effect had diminished (see Figure 6.2). The afferents
included in this analysis probably include a mixture of nociceptors and low threshold mechano-
sensitive afferents.
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Figure 6.2 Mechanical threshold of primary afferent nerves in normal rat knee joints injected with ILip
(n=23 units; 8 rats; 0.1 pg; closed bar) or vehicle (n=9 units; 5 rats; open bar; sterile saline) at time t=0
(arrow). ILip resulted in a significant decrease in mechanical threshold to von Frey hairs in comparison
with vehicle-injected joints between 60 and 210 minutes after injection (* P<0.05, Two-way ANOVA).
6.3.3 EFFECT OF IL1p ON DISCHARGE FREQUENCY AND ACTION POTENTIAL
COUNT TO MECHANICAL STIMULATION
The evoked response of primary afferents innervating the normal rat knee joints to 0.98,
12.5 and 20.9 g von Frey hairs were 0.05 ± 0.03, 2.69 ± 0.66 and 3.63 ± 0.95 impulses s"1
respectively (n=12 rats; 35 units). Following ILip (0.1 pg\ n=6) or vehicle (n=6), no significant
changes to the evoked discharge frequency or total action potential count occurred (/J>0.05, two-
way ANOVA; see Figure 6.3).
6.3.4 EFFECT OF ILip ON JOINT SWELLING AND MECHANICAL
HYPERSENSITIVITY
I.art ILip had no adverse effects on the animals' general health as demonstrated by the
fact that the animals continued to feed and gain weight normally throughout the study (see
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Figure 6.4a). Four, five, six and seven days post-ILl|3 the body weights of the rats were
significantly higher than day 0 (P<0.05, Kruskal Wallis). There was no significant difference in
body weight between the FL1(3 and vehicle-injected animals at any time point (P>0.05, two-way
ANOVA).
Joint swelling
Before the i.art injection, the ipsilateral and contralateral knee joint diameters were 9.1 ±
0.1 mm (n=24) and 9.1 ±0.1 mm (n=24) respectively, which were not significantly different
(P>0.05, Mann Whitney). Following IL1(3 (1, 3 or 10 /xg; n=6 at each dose) there was no
significant difference in joint diameter in comparison with those of vehicle-injected joints (n=6)
at any time point (P>0.05, two-way ANOVA; see Figure 6.4b). No changes in contralateral
joint diameters occurred in comparison to the basal values at any time during this study (P>0.05,
Kruskal Wallis).
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Figure 6.3 The evoked frequency and total action potential count during five seconds of mechanical
stimulation of primary afferent nerves innervating normal rat knee joints. Stimulation with (a) and (b)
0.98 g, (c) and (d) 12.5 g and (e) and (f) 20.9 g von Frey hairs in normal joints and following ILip (n-20
units; 6 rats; 0.1 /xg; closed bar) or vehicle (n=15 units; 6 rats; open bar; sterile saline) at time t=0. ILip
had no effect on the evoked discharge frequency to mechanical stimulation by these von Frey hairs in
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Figure 6.4. The (a) body weight and (b) ipsilateral knee joint diameters of ILip- and vehicle-injected rats
over a seven day study. ILip (1, 3 or 10 pg\ n=6) had no effect on ipsilateral or contralateral knee joint
diameters in comparison with vehicle-injected (sterile saline) rats at any time during this study (n=6; *
P>0.05, two-way ANOVA). Statistical analysis was performed to compare the body weight or joint
diameter of the two groups on each day using the two-way ANOVA and a Bonferroni post-hoc test.
Mechanical hypersensitivity measured by the incapacitance tester
Prior to injection of ILip, the weights on the two hind limbs were 65.0 ± 3.3 g (n=24)
and 62.4± 2.8 g (n=24), with an associated ratio (ipsi:contra) of 1.1 ± 0.0. However, following
administration of 1, 3 and 10 pg ILip, the weights on the ipsilateral and contralateral hind limbs
were significantly different from each other until 96 hours post-injection (P<0.05. Kruskal
Wallis; see Figure 6.5 a, b and c). The associated ratio of the weight distribution between the
hind limbs decreased by 23.6 ±0.1 (n=6), 52.8 ± 0.1 (n=6) and 36.4 ± 0.1 % (n=6) in rats treated
with 1, 3 and 10 /xg ILip respectively by four hours post administration. The ratio remained
significantly reduced in comparison with vehicle-injected joints (n=6) until four days post-ILip
(P<0.05, two-way ANOVA; see Figure 6.5d).
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Figure 6.5 The absolute weight placed on the ipsilateral (injected) and contralateral hind limbs of rats
injected with (a) 1 pg, (b) 3 pg and (c) 10 pg ILip (n=6 at each dose) on day 0 after basal measurements
were made and (d) the associated ratio of weight distribution between the hind limbs for ILip- and
vehicle-injected (n=6; sterile saline) rats. All doses of ILip caused significant mechanical
hypersensitivity of the joint from two hours post administration (* P<0.05, two-way ANOVA). Statistical
analysis was performed to determine whether the difference between the weight on the ipsilateral and
contralateral hind limbs were significantly different (a, b, and c) or whether the ratio of weight distribution
was significantly reduced in ILip-injected rats compared with vehicle-injected animals using a two-way
ANOVA.
Mechanical hypersensitivity measured by PAD
Before induction of inflammation, the ipsilateral and contralateral LWTs were 409.4 ±
13.19 gf (n=24) and 443.0 ± 19.2 gf (n=24) respectively, which were not significantly different
(P>0.05, Kruskal Wallis). However, following ILip (1, 3 and 10 pg-, n=6 at each dose) the
ipsilateral LWTs were significantly reduced in comparison with vehicle-injected rats (P<0.05,
two-way ANOVA; see Figure 6.6). The ipsilateral LWTs remained significantly reduced until
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seven, five and 24 hours post IL1|3 for 1, 3 and 10 /xg respectively (P<0.05, two-way ANOVA).
No changes in the LWT of contralateral joints were observed at any time during this study
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Figure 6.6 Ipsilateral LWTs of rats injected with 1, 3 or 10 /xg ILip (n=6 at each dose) or vehicle (n=6;
sterile saline; at t=0) following baseline measurements. The highest dose of ILip administered evoked the
longest duration of mechanical hypersensitivity (as measured by PAD); the ipsilateral LWT was
significantly reduced in comparison with vehicle-treated rats until one day post-ILip (* P<0.05, two-way
ANOVA).
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Time (hours) Drug administered i.art into ipsilateral knee joint at t=0
Vehicle (n=6) 1 MSILIP (n=6) 3 jig ILip (n=6) 10 /xg ILip (n=6)
0 492.0 ± 63.6 399.7 ±21.8 420.2 ± 29.7 405.7 ±46.8
3 448.3 ±32.8 390.2 ±54.8 475.8 ± 60.4 443.3 ±44.8
5 418.5 ±44.3 510.0 ±62.7 429.7 ±45.7 500. ± 37.7
7 430.5 ± 28.7 476.8 ±56.8 492.7 ± 47.5 623.8 ±57.4
24 595.8 ±43.6 533.5 ±47.9 381.8 ±52.6 437.7 ±41.1
48 406.8 ±69.8 372.3 ±28.5 455.3 ±39.5 653.7 ± 16.7
72 429.2 ± 55.3 408.8 ±72.4 512.3 ±41.0 707.0 ±51.9
96 67.5 ±49.3 410.3 ±33.6 474.5 ± 26.9 491.8 ±62.1
120 455.2 ±93.3 479.2 ± 82.9 624.7 ± 46.9 632.7 ±46.0
144 406.5 ±63.1 604.7 ±57.7 586.7 ±90.7 632.0 ±93.5
168 473.2 ± 36.4 710.3 ±49.2 627.2 ± 64.4 537.5 ±71.7
Table 6.1. Contralateral LWTs for ILip- (1, 3 and 10 /xg; n=6 at each dose) and vehicle-injected (n=6;
sterile saline) rats. No significant difference in contralateral LWTs occurred between ILlp-injected and
vehicle-treated animals at any time during this study (P>0.05, two-way ANOVA). The grey box indicates
the pre-ILip or vehicle baseline values.
6.3.5 EFFECT OF IL1p ON ACUTE CYTOKINE RELEASE IN THE JOINT SPACE
The acute (up to seven hours) effects of ILip (1 /xg; n=6) on the production of
inflammatory mediators in the joints was investigated and compared with vehicle-injected joints
(n=6). ILip significantly increased the expression of ILip, IL6 and TNFa in ipsilateral joint
perfusates in comparison with levels in vehicle-injected joints (P<0.05, two-way ANOVA, see
Figure 6.7).
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Figure 6.7 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in normal joints (t=0) perfused with ILip (1 /xg; n=6; closed bars) or vehicle (sterile saline; n=6;
open bars) and sampled hourly until seven hours post-administration. ILip caused significant increases in
ILip, IL6 and TNFa production in comparison with vehicle-injected joints (* P<0.05 two-way ANOVA).
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6.3.6 EFFECT OF IL1(3 ON "CHRONIC" CYTOKINE RELEASE AND
INFLAMMATORY CELL INFILTRATION IN THE JOINT SPACE
The "chronic" (up to ten days) effects of IL1(3 (1 /xg; n=3) on the production of
inflammatory mediators in the joints was investigated and compared with vehicle-injected joints
(n=3). It was found that ILip significantly increased levels of ILla, ILip, IL2, IL6, IL10 and
TNFa, in ipsilateral joint perfusates in comparison with levels in vehicle-injected joints (P<0.05,
two-way ANOVA, see Figure 6.8).
The "chronic" effects of ILip (1 /xg; n =3) on inflammatory cell infiltration into the joint
space was investigated and compared with vehicle-injected joints (n=3). ILip induced a
significant increase in the total number of inflammatory cells (0.55 ± 0.43 x 106 cell ml"1) in the
joint perfusate sample on day one after administration in comparison with levels in vehicle-
injected joints (0 ± 0; n=3; P<0.05, two-way ANOVA). No cells were detectable at any other
time point during this study.
6.3.7 EFFECT OF IL1p ON HISTOLOGY OF THE NORMAL JOINT
I.art IL 1P resulted in a marked influx of inflammatory cell infiltrate from day one after
administration, as shown in Figure 6.9. This effect decreased by day 4 and by day 7 no
abnormalities were observed. At no time did ILip (1 /xg; n=3 on days 1, 2, 4 and 7) cause
cartilage or bone erosion.
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Figure 6.8 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in normal joints (t=0) injected with ILip (1 /ig; n=3) or vehicle (100 /xl sterile saline; n=3) and
sampled daily until ten days post-administration. ILip resulted in significant increases in ILla, ILip, IL2,
IL6, IL10 and TNFa production in comparison with vehicle-injected joints (* P<0.05 two-way ANOVA).
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Figure 6.9 Summary of histology from (a) and (b) normal (untreated) and (c) and (d) IL1 P-injected (day 1
post IL1P; 1 pg; n=3) rat knee joints respectively. The normal joint shows an acellular joint space, thin
synovial membrane and smooth, healthy cartilage, (e) The normal and (f) IL1 P-injected (day 1 post ILIP;
1 pg; n=3 on days 1, 2, 4 and 7) synovium of a rat knee joint. PMNs and macrophages infiltrate the joint
space and synovium, although no structural changes to the joint occurred as a result of ILip (n=3).
Midline sections stained with H&E.
Abbreviations: JS, joint space; C, cartilage; T, tibia; F, femur; SM, synovial membrane.
Scale bars: (a) 500pm, (b) 250 pm, (c) 500 pm, (d) 250 pm (e and f) 50 pm.
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6.4 DISCUSSION
The aims of these studies were to investigate the role of DLip in joint pain and
inflammation. The contribution made by primary afferent fibres to mechanical hypersensitivity
of the joint after administration of i.art ILip was investigated by recording action potentials from
primary afferent nerves innervating the knee joint. I.art ILip caused a transient increase in the
frequency of basal neural discharge by 88% within three hours. It also decreased the threshold
of mechanical stimulation required to evoke neural activity by 50% between one and four hours
after injection. However, ILip did not alter the firing frequency to mechanical stimulation
above the threshold. The induction of spontaneous neural activity coincides with the occurrence
of spontaneous pain during inflammation, such as that measured by the incapacitance tester as a
result of i.art IL1P in the present study. The present results are similar to those of others, who
report that intra-plantar injection of ILip induced changes in sensitivities and the receptive field
of DRG neurons (Fukuoka et al., 1994). A reduction in the LWT following ILip occurred
within a few hours, similar to the decrease in the mechanical threshold to von Frey hairs in
primary afferents, probably as a result of neuronal sensitisation.
IL1 p AND PGs
ILip is a potent nociceptive agent (Ferreira et al., 1988) that induces the release of PGs
(Dayer et al., 1979; Handwerker & Neher, 1976; Mizel et al., 1981) which sensitise nociceptors
in humans and animals (Ferreira, 1972; Schaible & Schmidt, 1988). This is probably the way
ILip acts in the present study, given that the effects were not immediate, although there may be
direct stimulatory action on certain sensory nerves (Follenfant et al., 1989). Evidence also
suggests that BLIP may increase the release of peptides from peptidergic neurons. It increased
the Substance P-like immunoreactivity in the culture medium of primary cultured rat DRG cells
(Inoue et al., 1999). The latter effect was calcium dependent and significantly inhibited by
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ILIRa, COX inhibitors and dexamethasone (Inoue et al., 1999). The roles of PGs, BK,
Substance P, or other mediators could be investigated by giving enzyme inhibitors of these
compounds, or receptor antagonists during the present study design. A further investigation
which may prove interesting, to determine if the effects of IL1 (1 on sensory nerves is dose-
dependent, would be to increase the doses of ILip administered during the electrophysiological
recordings. This was not carried out during this thesis due to financial and time limitations.
IL1 p AND HYPERSENSITIVITY
Although ILip did not cause swelling of the joint, it did induce mechanical
hypersensitivity within a couple of hours, which lasted for up to four days. Previously, i.art
ILip has been shown to evoke swelling of the joint, although at higher doses than those used in
the present study (90 /xg rather than 10 /xg; Chandrasekhar et al., 1990). However, it is evident
from the results in Chapter 5 that ILip alone is not entirely responsible for inflammatory joint
swelling. Furthermore, mice that spontaneously develop arthritis and are additionally ILip -/-
develop milder forms of arthritis than do IL1P+/+ arthritic mice, with swelling occurring in only
a few digits in those mice lacking ILip (Hata et al., 2004). In addition, neutralisation of ILip
did not reduce joint swelling in mice with SCW arthritis, whereas anti-TNFa treatment did
(Kuiper et al., 1998). Not all rats respond to ILip to the same degree, which may indicate
differences in the number or location of the receptors between individuals, and this may explain
why anti-ILip treatment is not effective in all RA patients, and why not all inflamed joints
contain ILip (see Chapter 5).
Previous studies have provided evidence that proinflammatory cytokines induce or
facilitate inflammatory as well as neuropathic pain or hyperalgesia. Direct receptor-mediated
actions of cytokines on afferent nerve fibres have been reported as well as cytokine effects
involving further mediators. For example, electrophysiological recording from rat DRGs during
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topical application of IL 1 p resulted in an increase in the discharge rate, increased
mechanosensitivity of the DRG units (Ozaktay, 2006). Furthermore, brief applications of ILip
to nociceptive neurons yielded a potentiation of heat-activated inwad currents and a shift of
activation thresholds towards lower temperatures without altering intracellular calcium levels,
the effect was not mediated by G-protein coupled receptors but was mediated by activation of
protein kinases (Obreja et al., 2002; for review of cytokines and pain see Sommer & Kress,
2004).
IL1 p AND COX-2
IL1[3 stimulates the production of COX-2 and the subsequent release of PGs (Bernheim
et al., 1980; Crofford et al., 1994; Cunha et al., 1992; Zucali et al., 1986). The fact that PGs
ultimately sensitise joint nociceptors suggests ILip as an important inflammatory
hypernociceptive mediator. In fact, ILip was the first cytokine reported to mediate
inflammatory nociception in experimental animals (Ferreira et al., 1988). Ferreira et al (1988)
reported that ILip, even at picomolar doses, produced a severe mechanical hypernociception
that apparently depends on the release of prostanoids, as local pre-treatment with indomethacin
blocked its effects. The peripheral pro-nociceptive action of ILip is mediated by a complex
signalling cascade and secondary production of NO, BK or PGs (for review see Poole et al.,
1999). However, ILip can excite nociceptive fibres in the DRG in vivo within one minute of
plantar administration of ILip between 100 pg and 1 jig, indicating a more direct action
(Fukuoka et al., 1994). ILip applied to nociceptors in the skin-nerve preparation resulted in a
facilitation of heat-evoked release of CGRP from peptidergic neurons (Opree & Kress, 2000),
indicating that ILip may play a important role in thermal hyperalgesia during inflammation or
injury.
193
Chapter 6; IL1/3 in joint pain and inflammation
IL1p AND JOINT EROSION
Inflammation and skeletal destruction in arthritis are determined by interactions between
numerous pro- and anti-inflammatory molecules. ILip and TNFa are two key players that work
co-operatively to promote joint inflammation. ILip and TNFa exhibit synergism in vitro when
inducing production of PGE2 (Berenbaum et al., 1996; Meyer et al., 1990), IL6 (Harigai et al.,
1991), or EL8 (Rathanaswami et al., 1993) by human synovial fibroblasts. ILip and TNFa also
act synergistically to recruit leukocytes into rabbit joints in vivo (Henderson & Pettipher, 1989).
It has been proposed that synergism between these two cytokines results from reciprocal positive
feedback cycles by which ILip induces TNFa production (Ikejima et al., 1990) and vice versa
(Turner et al., 1989); ILip has also been shown to induce expression of itself (Schindler et al.,
1990). In the present study DLip had no effect on bone or cartilage, which is in contrast to other
studies which found that both ILip and TNFa yielded mild inflammation, and evoked significant
bone resorption, osteoclasts and cartilage matrix loss (Bolon et al., 2004; Campagnuolo et al.,
2003). However, the dose used in the present study was at the lower end of those used by
others; although it did induce functional signs of inflammation, further cytokine release and
changes in the primary afferent activity. In rabbits, ILip (5 /xg; i.art) failed to cause significant
proteoglycan loss from cartilage, although it did induce inflammatory cell recruitment
(Henderson & Pettipher, 1989), in accord with our results.
IL1p AND CYTOKINE RELEASE
ILip-evoked mechanical hypersensitivity that was accompanied by an increase in the
expression of ILip, IL6 and TNFa within the first eight hours, and additionally with elevated
levels of ILla, IL2 and IL10 from 24 hours post-ILlp. Increases in TNFa were observed within
an hour of ILip administration, whereas IL6 expression was delayed until six hours after ILip
injection. ILip induced IL2 receptor up-regulation and production of IL2 in vitro, and also
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induced IL6 mRNA expression (Panzer et cil., 1993). In the present study, ILip induced
significant IL2 protein production within a day of administration, and although it didn't achieve
statistical significance, due to variation, there was an increase in EL2 protein in the acute studies
within one hour of ILip dosing.
CONCLUSIONS
In conclusion, the present studies have demonstrated that i.art ILip can evoke
mechanical hypersensitivity via actions on afferents innervating the knee joint and may be at
least partly responsible for spontaneous pain via actions on peripheral nerves. This could be
confirmed using anti-ILip treatments, such as Anakinra, a recombinant version of endogenous
ILIRa, following ELip administration in the above studies. Moreover the role of PGs, BK,
Substance P, 5-HT, ATP, NO, or other mediators in ILip-mediated pain could also be proven
using COX, BK, substance P, NO and 5-HT inhibitors, although time and financial constraints
prevented these studies for the purpose of this thesis. However, it is unlikely that ILip is solely
responsible for joint pain and inflammation, for example during RA. DLip evoked the release of
a number of pro- and anti-inflammatory cytokines within a few hours of injection into the knee
joint. However, it must be noted that in comparison to the physiological levels of cytokines
measured in rat knee joints during adjuvant-induced arthritis, the doses administered in the
studies reported in this chapter are pharmacological, therefore not potentially exaggerating the
role of inflammatory protein on the parameters measured. Anti-ILip treatments, such as
Anakinra are now used to treat patients with RA, and although they have proved promising in
reducing overt signs of inflammation and pain, and slowing the progression of the disease and
joint damage, there is a proportion of patients who do not respond. In addition, those who do
respond do not see total resolution of their symptoms. Therefore, a combination of anti-cytokine
drugs may be more efficacious, as mentioned in Chapter 5.
195
Chapter 7: IL6 in joint pain and inflammation
Chapter 7 - The role of IL6 in joint pain and
inflammation
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7.1 INTRODUCTION
IL6 is one of the most abundant cytokines found in both the joints and blood of patients
with active RA, for more information see Section 1.4. It is produced in synovial joints by
lymphocytes, monocytes, fibroblasts (Kishimoto, 1992), synoviocytes (Guerne et al., 1989) and
endothelial cells (Hirano et al., 1988). IL6 acts synergistically with IL1 and TNFa to augment
the production and release of MMPs and increase the production of tissue inhibitors of MMP
from human synovial fibroblasts (Ito et al., 1992). Therefore IL6 may modulate the balance
between MMPs and inhibitors of MMPs at sites of inflammation in RA; it is this imbalance that
may result in joint and cartilage destruction. IL6 is also produced by osteoblasts and
chondrocytes and is induced by pro-inflammatory cytokines (Guerne et al., 1990; Hierl et al.,
1998; Littlewood et al., 1991). In bone, IL6 is an autocrine and paracrine factor that plays a role
in osteoclast-mediated bone resorption (Ishimi et al., 1990; Roodman et al., 1992). However,
IL6 does not appear to have a direct effect in stimulating bone resorption mediated by mature
osteoclasts (Bertolini et al., 1994). In addition, IL6 is responsible for:
■ B-cell growth and differentiation
■ Stimulating B-cell differentiation to plasma cells (Hirano et al., 1986), which may
account for the high levels of rheumatoid factor in RA patients.
■ Stimulating proliferation and differentiation of T lymphocytes into cytotoxic T cells
(Okada et al., 1988)
■ Promoting leukocyte chemotaxis (Taga & Kishimoto, 1997), by inducing the expression
of ICAM-1 and other adhesive ligands.
IL6 knockout mice are protected against joint inflammation and destruction in both CIA and
antigen-induced arthritis (Alonzi et al., 1998; de Hooge et al., 2000; Ohshima et al., 1998). This
protection was seen despite the expression of both TNFa and IL1 in the inflamed synovium
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(Ohshima et cil., 1998), demonstrating the importance of IL6 in these models of disease.
Furthermore, an IL6 receptor- neutralising antibody suppressed the onset and reduced the
severity of CIA in mice (Takagi et al., 1998). IL6 blockade using a monoclonal antibody was
well-tolerated and resulted in significant improvement in clinical scores and laboratory
parameters in a small number of patients with RA (Wendling et al., 1993). A recent therapeutic
trial of an anti-IL6 receptor monoclonal antibody in patients with active RA resulted in a
significant, dose-dependent reduction in disease activity (Choy et al., 2002).
However, there is also evidence that IL6 has anti-inflammatory effects. It can reduce
inflammation by suppressing IL1 and TNFa production and by inducing the release of IL1 Ra
and soluble TNFa receptors in vitro (Taga & Kishimoto, 1997). Hence it has been argued that
IL6 may regulate rather than mediate inflammation. In addition, zymosan-induced arthritis in
IL6-/- mice showed increased cartilage degradation, which occurred in spite of reduced joint
swelling and normal production of IL1, TNFa and NO (van de Loo et al., 1997). IL6 may
therefore have both deleterious and protective effects in inflammatory arthritis. The aims of this
part of the study were:
■ To determine the effects of IL6 on acute and chronic joint swelling, hypersensitivity and
joint destruction
■ To assess the release of other pro- and anti-inflammatory cytokines as a result of i.art IL6
■ To determine the effect of IL6 on primary sensory afferents innervating the normal rat knee
neural activity and sensitivity using in vivo electrophysiological recording.
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7.2 METHODS
All methods were carried out as described in Chapter 2.
Perfusion of the knee joint in anaesthetised rats was carried out as described in Section
2.4. To determine the acute effects of IL6 on the release of pro- and anti-inflammatory cytokine
release, the left knee joints of six normal (untreated) rats were perfused to collect basal samples.
Then recombinant rat IL6 (1 /xg in 100 /xl; n=6) or vehicle (100 /xl sterile saline; n=6) was
perfused into the joint over one minute. One, two, three, four, five, six and seven hours later a
250 /xl sample was collected via perfusion of the joint, the sample was frozen and stored at -20°
C.
To evaluate the effects of IL6 on the cytokine content of the joint over a ten day period,
IL6 (1 /xg in 100 /xl; n=15) or vehicle (100 /xl sterile saline; n=15) were administered via i.art
injection under transient halothane anaesthesia (3% in oxygen). Animals were allowed to
recover, and the ipsilateral (injected) knee joints of three rats were perfused on days 1, 2, 4, 7
and 10 post-IL6 (n=3 per day) or vehicle (n=3 per day). Total inflammatory cell counts of joint
perfusate samples were carried out as described in Section 2.4.2, samples were then frozen and
stored at -20° C and later assayed for a range of nine cytokines (ILla, ELIp, IL2, IL4, IL6, IL10,
GM-CSF, IFNy and TNFa) using the Luminex assay as described in Section 2.4.3.
7.3. RESULTS
7.3.1. EFFECT OF IL6 ON BASAL NEURAL DISCHARGE OF PRIMARY AFFERENT
NERVES
The basal neural discharge frequency of primary afferents innervating normal rat knee
joints was 0.01 ± 0 impulses s"1 (n= 13 rats, 36 units; 78 % of units were inactive at this time).
This increased to 0.03 ± 0.01 impulses s"1 (n= 8 rats; 27 units; 33 % of units were inactive at this
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time) or 0.07 ± 0.04 impulses s"1 (n= 5 rats; 9 units; 45 % of units were inactive at this time) 30
minutes after i.art IL6 (0.1 fig) or vehicle respectively, these values were not significantly
different from each other (/J>0.05, Mann Whitney). Between 30 and 180 minutes after IL6 the
elevated neural discharge frequency increased towards a peak, when the frequency was 0.11 ±
0.05 impulses s"1 (n=8 rats, 27 units), however, this was not significantly different than that of
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Figure 7.1 Basal neural activity (impulses s"1) in fibres of the MAN in normal rat knee joints injected with
IL6 (n=27 units; 8 rats; 0.1 /xg; closed bar) or vehicle (n=9 units; 5 rats; open bar; sterile saline) at time
t=0 (arrow). There was no significant difference between basal neural discharge frequency in IL6- and
vehicle-injected joints at any time (P>0.05, two-way ANOVA)
7.3.2 EFFECT OF IL6 ON THE MECHANICAL THRESHOLD OF PRIMARY
AFFERENT NERVES
The mechanical threshold for activation of primary afferent nerves innervating the
normal rat knee joint was 4.99 ± 0.31 g (n=13 rats, 36 units). Following IL6 there was no
significant difference in the threshold in comparison with vehicle-injected joints (F>0.05, two-
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way ANOVA; see Figure 7.2). The afferents included in this analysis probably include a
mixture of nociceptors and low threshold mechano-sensitive afferents.
IL6 or vehicle (i.art)
2 at t=0
Time post injection (min)
IL6 (n=27 units; 8 rats) □Vehicle (n=9 units; 5 rats)
Figure 7.2 Mechanical threshold of primary afferent nerves in normal rat knee joints injected with IL6
(n=27 units; 8 rats; 0.1 /xg; closed bar) or vehicle (n=9 units; 5 rats; open bar; sterile saline) at time t=0
(arrow). IL6 had no effect on the mechanical threshold to von Frey hairs in comparison with vehicle-
injected joints (P>0.05, two-way ANOVA).
7.3.3 EFFECT OF IL6 ON DISCHARGE FREQUENCY AND ACTION POTENTIAL
COUNT TO MECHANICAL STIMULATION
The evoked response of primary afferents innervating the normal rat knee joints to 0.98,
12.5 and 20.9 g von Frey hairs were 0.12 ± 0.08, 3.34 ± 1.31 and 5.98 ± 2.34 impulses s"1
respectively (n=12 rats; 35 units). Following IL6 (0.1 /xg; n=6) or vehicle (n=6), no significant
changes to the evoked discharge frequency or total action potential count occurred (P>0.05, two-
way ANOVA; see Figure 7.3).
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Figure 7.3 The evoked frequency and total action potential count to five seconds of mechanical
stimulation in the receptive field of a primary afferent innervating normal rat knee joints. Stimulation
with (a) and ( b) 0.98 g, (c ) and (d) 12.5 g and (e) and (f) 20.9 g von Frey hairs in normal joints and
following IL6 (n=20 units; 6 rats; 0.1 /rg; closed bar) or vehicle (n=15 units; 6 rats,; open bar; sterile
saline) at time t=0. IL6 had no effect on the evoked discharge frequency to mechanical stimulation by
these von Frey hairs in comparison with vehicle-injected joints (P>0.05, two-way ANOVA, Bonferroni
post hoc test).
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7.3.4 EFFECT OF IL6 ON JOINT SWELLING AND MECHANICAL
HYPERSENSITIVITY
I.art IL6 had no adverse effects on the animals' general health as demonstrated by the
fact that animals continued to feed and gain weight normally throughout the study (see Figure
7.4a). Three, four, five, six and seven days post-IL6 the body weights of the rats were
significantly higher than day 0 (P<0.05, Kruskal Wallis). There was no significant difference in
body weight between the IL6 and vehicle-injected animals at any time point (P>0.05, 2-way
ANOVA).
Joint swelling
Before the i.art injection, the ipsilateral and contralateral knee joint diameters were 9.1 ±
0.1 mm (n=24) and 9.1 ± 0.0 mm (n=24) respectively, which were not significantly different
(P>0.05, Mann Whitney). Following IL6 (1, 3 or 10 /xg; n=6 at each dose) there was no
significant difference in joint diameter in comparison with those of vehicle-injected joints (n=6)
at any time point (P>0.05, two-way ANOVA; see Figure 7.4b). No changes in contralateral
joint diameters occurred in comparison to the basal values at any time during this study (P>0.05,
Kruskal Wallis).
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Figure 7.4. The (a) body weight and (b) knee joint diameters of IL6- and vehicle-injected rats over a
seven day study. IL6 (1, 3 or 10 /xg; n=6) had no effect on knee joint diameter in comparison with
vehicle-injected (sterile saline) rats at any time point during this study (n=6; * P>0.05, two-way
ANOVA). Statistical analysis was performed to compare the body weight or joint diameter of the two
groups on each day using the two-way ANOVA and a Bonferroni post-hoc test.
Mechanical hypersensitivity measured by the incapacitance tester
Prior to injection of LL6, the weights on the two hind limbs were 52.4 ± 2.3 g (n=24) and
51.3 ± 1.78 g (n=24), with an associated ratio (ipsi:contra) of 1.1 ± 0.0. However, following
administration of 1, 3 and 10 /xg IL6 the weights on the ipsilateral (injected) and contralateral
(uninjected) hind limbs were significantly different from each other until 48 hours post-injection
(P<0.05, Kruskal Wallis; see Figure 7.5 a, b and c). The ratio of the weight distribution between
the hind limbs decreased by 57.4 ± 0.04% (n=6), 69.9 ± 0.1% (n=6) and 51.6 ± 0.1 % (n=6) in
rats treated with 1, 3 and 10 /xg IL6 respectively by four hours post administration. The ratio
remained significantly reduced in comparison with vehicle-injected joints (n=6) until day one
post-IL6 (P<0.05, two-way ANOVA; see Figure 7.5d).
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Figure 7.5 The absolute weight placed on the ipsilateral (injected) and contralateral hind limbs of rats
injected with (a) 1 pg, (b) 3 pg and (c) 10 pg IL6 (n=6) on day 0 after basal measurements were made and
(d) the associated ratio of weight distribution between the hind limbs for IL6- and vehicle-injected (sterile
saline) rats. All doses of IL6 caused significant mechanical hypersensitivity of the joint from two hours
post administration (* P<0.05, two-way ANOVA). Statistical analysis was performed to determine
whether the difference between the weight on the ipsilateral and contralateral hind limbs were
significantly different (a, b, and c) or whether the ratio of weight distribution was significantly reduced in
IL6-injected rats compared with vehicle-injected animals using a two-way ANOVA.
Mechanical hypersensitivity measured by PAD
Before injection of IL6, the ipsilateral and contralateral LWTs were 415.8 ± 22.1 gf
(n=24) and 468.5 ± 49.5 gf (n=24) respectively, which were not significantly different CP>0.05,
Kruskal Wallis; n=6). However, following IL6 (10 pg\ n=6) the ipsilateral LWT was reduced
between five until seven hours post-IL6 in comparison with vehicle-injected rats (n=6; P<0.05,
two-way ANOVA; see Figure 7.6). No changes in the LWT of contralateral joints were
observed at any time during this study (P>0.05, two-way ANOVA, see Table 7.1).
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Figure 7.6 Ipsilateral LWTs for rats injected with 1, 3 or 10 jug IL6 (n=6 at each dose) or vehicle (n=6;
sterile saline; at t=0) following baseline measurements. IL6 (3 ans 10 /xg) evoked a significant decrease in
LWT from five until seven hours post-IL6 in comparison with vehicle-treated rats (* P<0.05, two-way
ANOVA).
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Time (hours) Drug administered i.art into the ipsilateral knee joint at t=0
Vehicle (n=6) 1 ug IL6 (n=6) 3 /xg IL6 (n=6) 10 pg IL6 (n=6)
0 492.0 ± 63.6 525.8 ±48.9 396.2 ±41.7 461.7 ±44.0
3 448.3 ±32.8 409.7 ±51.4 497.0 ±29.9 398.0 ±45.3
5 418.5 ±44.3 494.3 ± 28.0 423.7 ±45.2 422.7 ±43.0
7 430.5 ± 28.7 474.3 ± 70.7 397.8 ± 19.2 384.3 ±36.1
24 595.8 ±43.6 503.2 ± 28.4 441.7 ±35.9 524.0 ±55.0
48 406.8 ± 69.8 474.3 ± 27.4 343.2 ± 29.5 386.7 ±32.2
72 429.2 ± 55.3 555.2 ± 80.3 483.7 ±43.5 408.2 ±49.6
96 67.5 ±49.3 468.2 ±27.7 355.5 ±32.0 521.3 ±10.0
120 455.2 ±93.3 441.7 ±68.3 486.7 ±58.8 392.7 ± 69.6
144 406.5 ±63.1 660.7 ± 36.8 552.0 ±67.3 646.2 ± 146.9
168 473.2 ±36.4 533.8 ±57.0 582.0 ±55.0 533.2 ±73.3
Table 7.1. Contralateral LWTs for IL6- (1, 3 and 10 pg; n-6 at each dose) and vehicle-injected (sterile
saline; n=6) rats. No significant difference in contralateral LWTs occurred between IL6-injected and
vehicle-treated animals at any time during this study (P>0.05, two-way ANOVA). The grey box indicates
the pre-ILip or vehicle baseline values.
7.3.5 EFFECT OF IL6 ON ACUTE CYTOKINE RELEASE IN THE JOINT SPACE
The acute (up to seven hours) effects of IL6 (1 /xg; n=6) on the production of
inflammatory mediators in the joints was investigated and compared with vehicle-injected joints
(n=6). IL6 significantly increased the expression of ILip, IL6 and TNFa in ipsilateral joint
perfusates in comparison with levels in vehicle-injected joints (P<0.05, two-way ANOVA, see
Figure 7.7).
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Figure 7.7 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in normal joints (t=0) perfused with IL6 (1 /tg; closed bars; n=6) or vehicle (sterile saline; open
bars; n=6) and sampled hourly for seven hours post administration. IL6 caused significant increases in
ILip, IL6 and TNFa production in comparison with vehicle-injected joints (* P<0.05 two-way ANOVA).
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7.3.6 EFFECT OF IL6 ON "CHRONIC" CYTOKINE RELEASE AND INFLAMMATORY
CELL INFILTRATION IN THE JOINT SPACE
The "chronic" (up to ten days) effects of IL6 (1 /xg; n=3) on the production of
inflammatory mediators in the joints was investigated and compared with vehicle-injected joints
(n=3). It was found that IL6 significantly increased levels ILla, IL2, IL4 and IL6 in ipsilateral
joint perfusates in comparison with levels in vehicle-injected joints (P<0.05, two-way ANOVA,
see Figure 7.8).
The "chronic" effects of IL6 (1 /xg; n=3) on inflammatory cell infiltration into the joint
space was investigated and compared with vehicle-injected joints (n=3). IL6 had no effect on
the total number of cells in the joint perfusate sample in comparison with levels in contralateral
joints (P>0.05, two-way ANOVA). No cells were detectable at any time during this study.
7.3.7 EFFECT OF IL6 ON HISTOLOGY OF THE NORMAL JOINT
I.art IL6 (1 /xg; n=3 on days 1, 2, 4 and 7) resulted in no detectable cellular infiltrate,
cartilage or bone erosion at any time point during this study (days 1, 2, 4 or 7).
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Figure 7.8 Levels of (a) ILla, (b) ILip, (c) IL2, (d) IL4, (e) IL6, (f) IL10, (g) GM-CSF, (h) IFNy and (i)
TNFa in normal joints (t=0) injected with IL6 (1 p.g\ n-3) or vehicle (sterile saline; 100 /il; n=3) and
sampled daily until ten days post-administration. IL6 resulted in significant increases in ILla, IL2, IL4
and IL6 production in comparison with vehicle-injected joints (* P<0.05, two-way ANOVA).
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Figure 7.9 Summary of histology from (a) and (b) normal (untreated) and (c) and (d) IL6-injected (day 1
post IL6; 1 pg; n=3) rat knee joints. No changes to the joint occurred as a result of IL6 (1 pg; n=3 on days
1,2, 4 and 7). Midline sections stained with H&E.
Abbreviations: JS, joint space; C, cartilage; T, tibia; F, femur; S, synovial membrane; SM, synovial
membrane
Scale bars: (a) 500pm, (b) 250pm, (c) 500pm, (d) 250pm.
7.4 DISCUSSION
IL6 had no significant effect on the activity or sensitivity of primary afferent nerve
fibres innervating the normal rat knee joint at the dose used in this study. It did not affect the
frequency of basal neural discharge, the mechanical threshold, or the frequency of neural
discharge evoked by mechanical stimulation above the threshold for activation. Although IL6
(0.1 pg) had no effect on the activity of peripheral primary afferents, it did induce mechanical
hypersensitivity of the joint when injected at higher doses (1, 3 and 10 pg). Different doses
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were used in the two studies, as the electrophysiological study was carried out first, in which
doses were selected based on existing literature. However, when the behavioural study was
designed an existing behavioural study (unpublished pilot study from our laboratory) and current
literature indicated that 0.1 /rg IL6 had no effect on swelling of hypersensitivity of the joint,
therefore higher doses were chosen.
IL6 AND HYPERSENSITIVITY
In accord with our results, injection of IL6 in a rat hind paw was reported to induce a
dose-dependent mechanical hyperalgesia in both hind paws, although this was greatest in the
ipsilateral paw (Cunha et al., 1992). This mechano-allodynia, which was maximal with 1 ng of
human IL6, reached a plateau between 2 and 3 h after injection, persisted for at least 6 h, and
returned to pre-injection values within 24 h. The dose used in the latter study was lower than the
doses used in the present study, although this may reflect differences between the paw and the
knee joint, or with the different measures of mechanical hypersensitivity used, von Frey hairs, a
punctuate stimulus rather than the more widespread stimulus applied using PAD in the present
study. In a recent study, using the same preparation as that described in this theis, Brenn et al.
(2007) demonstrated that IL6 has the potential to sensitize c-fibres in the joint to mechanical
stimulation, therefore suggesting that IL6 contributes to mechanical hypersensitivity due to an
action on nerve fibres themselves. The latter study administered a coinjection of sILAR, which
may explain the differing results.
Evidence in the literature for a precise role of IL6 is confusing since there have been
pro- and anti-inflammatory effects demonstrated. It has also been reported that
intracerebroventricular injections of IL6 induced thermal hyperalgesia in naive rats (Oka et al.,
1995), whereas intracisternal EL6 had anti-nociceptive effects in an acute orofacial pain model.
However, intra-plantar IL6 had no effect on thermal withdrawal latencies between uninjured rats
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(DeLeo et al., 1996), although it increased mechanical thresholds of inflamed rat hind paws
(Czlonkowski et al., 1993). Studies using EL6 knockout mice have not been conclusive in
establishing the role of endogenous IL6 in nociception. Two studies found no difference in
thermal and mechanical withdrawal latencies of IL6 deficient mice and wild type mice (Bianchi
et al, 1999; Murphy et al., 1999), whilst others report increased thermal thresholds in IL6 -/-
mice (Zhong et al., 1999) or decreased mechanical and thermal thresholds (Xu et al., 1997). The
reasons for the different outcomes of these studies are unclear, although the knockout of IL6
appears to result in compensatory effects such as a threefold increase in TNFa levels (Fattori et
al., 1994).
Moreover, a direct effect of IL6 on the neural activity of DRG cells in rats was not found
by Ozaktay et al. (2006), which is similar to the results in this thesis, although
electrophysiological recording during my studies was from a peripheral primary afferent nerve,
this may be in part due to the lack of sIL6R administered in both studies. The EL6/sIL6R
complex acts agonistically on cells that express the signal transducer molecule gpl30. Previous
in vitro and in vivo studies demonstrate that short exposure to the IL6/sIL6R complex modulates
nociceptors specific release of CGRP thus raising the possibility that IL6 complexed with the
sIL6R coul directly sensitize the nociceptors to noxious stimuli (Obreja, O et al., 2002; Opree &
Kress, 2000).
IL6 AND INJURY
Peripheral nerve-like structures exhibit IL6-like immunoreactivity in normal human skin
and to a greater extent in inflamed skin (Nordlind & Vahlquist, 1999). Furthermore, nerve
injury results in increased levels of IL6 mRNA or LL6-positive cells in rat and mouse sciatic
nerves (Bourde et al., 1996; Cui et al., 2000; Reichert et al., 1996; Zhong & Heumann, 1995).
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However, despite the large amount of literature describing the up-regulation of IL6 following
nerve injury, data on the functional effects of IL6 in sensory processing is limited.
CLINICAL USE OF ANTI-IL6 TREATMENTS
Clinically, five patients treated with a murine anti-EL6 monoclonal antibody (i.v.; 10 mg
day"1) daily for 10 consecutive days showed rapid clinical improvement in pain, morning
stiffness, the number of tender and swollen joints, and reduction in CRP (Wendling et al., 1993).
A recombinant humanised antimonoclonal antibody of the IgGl subtype (MRA) was tested in a
phase I/II double blind, randomised, placebo controlled, single dose trial in patients with RA.
The ACR20 response criterion was met by 50% of patients in the 5mg kg"1 group at week two
and none in the placebo group. Improvement was maintained until week eight. A significant
difference in ACR 20 was also noted between the group receiving 10 mg kg"1 MRA and that
receiving placebo at weeks six and eight (Choy et al., 2002).
IL6 AND JOINT EROSION
As IL6 is known to activate osteoclasts, it has been suggested that it plays a role in the
joint erosion that occurs during RA. However, no effects on bone or cartilage were detected in
the present study, although only one dose of IL6 was studied in an attempt to adhere to the
Home Office's 3Rs and due to financial and time constraints. In contrast, IL6 has been proposed
to have a protective effect on cartilage (Shingu et al., 1995; van de Loo et al., 1997; van den
Berg, 1999), therefore i.art injection of IL6 would not be expected to cause joint damage.
However, an alternative approach to determine if IL6 is involved in joint erosions would be to
treat FCA-injected animals with anti-IL6 drugs and monitor the joint erosions before, during and
after EL6-directed therapy.
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CONCLUSIONS
In conclusion, results from these studies suggest that IL6 is able to produce mechanical
hypersensitivity of the joint, although was not able to induce swelling, joint damage or
alterations in sensitivities of primary afferent fibres. Further work that would add significantly
to this information would include increasing the doses of IL6 administered during
electrophysiological recordings, and co-administration of IL6 receptors in any of the studies
described in this chapter, to investigate whether IL6 was not effective due to the lack of
receptors in the normal joint. Studies similar to those described here but carried out in FCA-
injected rats may have different outcomes if the EL6 R is unregulated during inflammation. In
addition, it must be noted that in comparison to the physiological levels of cytokines measured in
rat knee joints during adjuvant-induced arthritis, the doses administered in the studies reported in
this chapter are pharmacological, therefore not potentially exaggerating the role of inflammatory
protein on the parameters measured.
It should be emphasised that IL6 is not the only molecule that modulates nociceptive
pathways. All members of the "IL6 cytokine family" share the transmembrane signal transducer,
gpl30, resulting in a degree of redundancy (Ito et al., 1998). In addition, other mediators and
cytokines influence pain. Tissue injury elicited by trauma or surgery brings about immediate,
well localised pain. This pain is sustained after the initial injury, implying that substances are
produced to maintain pain. IL-6 is produced in substantial quantities at the site of a surgical
wound (Holzheimer & Steinmetz, 2000), giving an indication that IL6 may well play a dominant
role in the development of pain and inflammation during an immune response.
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The aims of this thesis were to investigate the temporal expression pattern of
inflammatory mediators and cells in the knee joints of rats with adjuvant-induced arthritis, and to
determine the roles of IL1(3 and IL6 in initiating and maintaining joint pain and inflammation
using two novel techniques alongside existing methods.
8.1 DEVELOPMENT OF NOVEL TECHNIQUES
Two novel techniques were developed and validated during this thesis to improve the
study of experimental inflammation and to aid screening of novel drugs designed to treat RA in
humans.
A new behavioural readout which was designed to assess localised, mechanical
hypersensitivity of rodent knee joints was developed. PAD uses similar principles to the clinical
pressure dolorimeter (Langley et al., 1983). The method involved the application of a gradually
increasing squeeze directly across the knee joint until the rodent shows signs of pain or
discomfort, as evidenced by withdrawal of the limb, or rarely vocalisation. At this "end point" a
quantitative value of the maximum force applied prior to limb withdrawal is recorded, and this
value provided an objective LWT. PAD provides a reliable, quantitative measurement of
localised, FCA-induced mechanical hypersensitivity in the knee joint of rats and mice observed
as a decrease in LWTs of around 40% and 60% respectively, compared with the basal values in
normal joints, which were approximately 1045 gf in rats and 400 gf in mice. Moreover, PAD
was able to detect the analgesic action of prednisolone in both species, in addition to analgesia
induced by morphine and celecoxib in rats. A strong correlation was observed between the
weight distribution readout and the PAD measurements in both species, illustrating that PAD is a
simple behavioural test that will be valuable for assessing hypersensitivity in rodent joints with
the particular advantage of assessing the hypersensitivity at the site of the inflammation, in a
similar fashion to the clinical dolorimeter and in contrast to the incapacitance tester.
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The second new technique was designed to collect the "inflammatory soup" within the
joint cavity for subsequent analysis of inflammatory mediator and cell content. This method was
validated by a series of experiments investigating
• whether the experimental protocol resulted in any changes to the cytokine content of the
joint
• whether the method could be used to detect differences between normal and inflamed
knee joints
• whether samples collected via perfusion of the joint contained detectable levels of
inflammatory cells.
It was established that the choice of anaesthetic may play a role in initiating an acute
inflammatory response within the knee joint. It was decided to use urethane for joint perfusion
experiments, based on the results in Section 4.3.1. In addition, it was observed that some
animals showed increased levels of TNFa or IL1 [1 as a result of prolonged (seven hour)
placement of the perfusion needles in the joint, but the changes occurred in only 20% of animals
and were not statistically significant. Furthermore, very little, if any, solution perfused into the
joint is lost into the surrounding tissue, and the perfusate can all be recovered through the
effusion tubes. Combined, this data indicates that the perfusion experimental set up does not
evoke inflammatory reactions, and that the system is efficient, with very little leakage from the
joint cavity.
FCA triggered a significant increase in levels of TNFa and ILip in the inflamed
(ipsilateral) joint. In addition, a biphasic expression pattern of PGE2 following FCA was
observed during a 21 day FCA time course, as well as the possibility that PGE2 is present in
normal joints, although further studies would be required to prove this was not an artefact of the
needle insertion, as described in Chapter 4. Not surprisingly it was found that FCA-injected
joints contained higher levels of inflammatory cells than normal rat knee joints, however, it was
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also noted that contralateral joints contained measurable levels of inflammatory cells, despite the
fact that no overt signs of swelling or hypersensitivity are evident.
This perfusion technique proved to be reliable and consistent; samples were easily
collected from chronically inflamed joints, and no problems were experienced whilst measuring
the cytokine or cell content of the perfusate samples. This technique is therefore a valuable
addition to protocols which use homogenates of entire joints to assess inflammatory mediator
content.
FUTURE DIRECTIONS
PAD could be further validated by using it to assess mechanical hypersensitivity of the
knee joint during other models of inflammatory joint pain, or alternatively for assessing
hypersensitivity in other regions of the body, such as the paw or ankle joints. PAD could be
used as a mechanical stimulator of the knee joint or paw during electrophysiological recording,
either from peripheral afferents, as described in this thesis, or from DRG neurons used elsewhere
(Stanfa & Dickenson, 2004; Urch & Dickenson, 2003). If PAD was applied to measure
hypersensitivity of the paw it could be validated against von Frey thresholds or the Randall and
Selitto analgesymeter (Randall & Selitto, 1957). However, the surface area of the application
pad may require adjustment, as the paw has a smaller surface area than the knee joint and may
be able to withstand higher pressures, i.e. have a higher noxious threshold, in which case a
transducer with a larger force range may be required.
The joint perfusion method could be used for a variety of applications; any mediator
(peptides, other cytokines, chemokines or prostaglandins) within the joint space could be
measured in perfusate samples during FCA-induced arthritis, as well as any other joint
inflammation models, such as CIA or SCW arthritis. In addition, the effectiveness of anti-
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inflammatory, anti-rheumatic or analgesic drugs on these parameters could be assessed, for
example NSAIDs, anti-inflammatory drugs, DMARDs and anti-cytokine agents.
The technique was used here to measure the total inflammatory cell count,
encompassing a range of inflammatory cells, probably including macrophages, lymphocytes and
neutrophils. Perfusate samples could be processed to allow identification of specific cell types,
for example using flow cytometry. Flow cytometry is a method for quantifying components or
structural features of cells primarily by optical means. Since different cell types can be
distinguished by structural features, flow cytometry can be used to count cells of different types
in a mixture (Berner et al., 2000).
The joint perfusion system was applied to here to measure the inflammatory mediator
and cell content of rat joints, although it may be possible to adapt it for use in other species,
including mice. However, the considerably smaller scale of the knee joint may make this
difficult, but smaller needles and more precise placement may make this feat possible. This
technique could be applied to knockout mice lacking specific inflammatory proteins, mediators
or receptors and be used to determine whether downstream processes are affected by this
knockout and to what extent the changes affect the inflammatory response. This would provide
valuable information on the inflammatory cascade and give an indication of further potential
therapeutic targets.
Both techniques could be applied in the future to improve the current level of knowledge
of the inflammatory processes in the knee joint and the effectiveness of novel compounds.
During this thesis, they were used to define the temporal expression patterns of a range of pro-
and anti-inflammatory cytokines over a three week time course of adjuvant induced arthritis in
rats, and to determine the effects of ILlf] and IL6 on the expression of other pro- and anti¬
inflammatory cytokines as well as the influx of immune cells into the joint. In the long term,
this technique could be modified to allow repeated sampling from individual rats, with the
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implantation of an indwelling catheter in the joint that would allow perfusion of the joint under
transient anaesthesia. However, such a device must not cause local inflammation, pain or
discomfort to the rats, or allow infections into the joint. Even further down the line
measurement of inflammatory mediators and cells inside the joint may not require such invasive
procedures. The use of modern imaging with immunofluoresence or radiolabeled inflammatory
mediators may allow identification of specific inflammatory cells or proteins in awake rats
without the need for invasive surgery or procedures. However, current technology and costs
make this unfeasible at this time.
8.2 CYTOKINE EXPRESSION IN INFLAMED JOINTS
Cytokine expression changed with time as FCA-induced arthritis progressed from the acute
to the more "chronic" phase (14-28 days post-FCA). The levels of all nine mediators measured had
substantially increased within a few days of FCA administration. The levels of some cytokines then
stayed elevated, for example ILla, but most peaked in the acute phase and then declined toward
basal levels thereafter. Significant increases in levels of IFla, ILip, IL2 and TNFa occurred in
inflamed joints. Levels of the other cytokines measured were increased in comparison with basal
levels but were not statistically significant. The proportion of inflamed joints that contained
detectable levels of ILla, ILip, IL2, IL6, EL10, GM-CSF, DFNy and TNFa was significantly
increased during the study, suggesting that the majority of joints contain the latter cytokines,
although the absolute levels required to maintain joint inflammation and hypersensitivity are low, or
that other mediators or mechanisms are involved in the more "chronic" phase of the model,
including central mechanisms. In addition, significant correlations between measures of joint
swelling with levels of ILla, ILip, IL4 and IL10 or between mechanical hypersensitivity with levels
of ILla, ILip, IL6 and TNFa in inflamed joints were seen.
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Prednisolone did not affect the absolute levels of cytokines in inflamed joints, although it
reduced the proportion of FCA-injected joints that contained detectable levels of ILla, IL6 and
TNFa whilst significantly reducing the joint swelling over the dosing period. There appeared to be
two populations, "responders" to prednisolone and "non-responders" in terms of cytokine
expression, although all animals dosed with prednisolone showed reduced joint swelling in
comparison to non-drug treated rats. However, in prednisolone "non-responders" the levels of
cytokines measured did not change from pre-treatment levels, despite the reduction in the joint
diameter measurement, indicating that prednisolone has an all-or-none effect on cytokines in this
study.
As well as showing additional information regarding the expression patterns of cytokines
during adjuvant-induced arthritis, close similarity between this animal model of joint inflammation
and human RA have been demonstrated, which endorse the use of this model for studying the
inflammatory process of human RA, and should also improve the confidence in the model to
facilitate preclinical screening of novel compounds, thereby enhancing translation from laboratory to
clinic during the drug development process.
CLINICAL IMPLICATIONS
The fact that there was a proportion of inflamed animals that did not express some of the
key pro-inflammatory cytokines during adjuvant-induced arthritis indicates that the
inflammatory response may vary between rats. It may therefore be the case in humans, and
hence certain anti-cytokine treatments for RA are not effective in all patients (Cohen et al.,
2004; Maini et al., 2006; Smolen & Steiner, 2003), and in those that they are effective, 100%
improvement in the condition is not seen. Compensatory mechanisms may also be responsible
for the latter effects. Anti-TNFa agents, such as etanercept or infliximab show ACR20
responses in 76% (Spencer-Green, 2000) and 53% (Zhang et al., 2006) of RA patients
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respectively; anti-ILip treatments are effective in approximately 40-50% of patients (Bresnihan,
2001; Cohen et al., 2004) and Tocilizumab, an anti-IL6 treatment, shows ACR 20 responses in
approximately 60% of RA patients (Maini et al, 2006). However, when the improvement level
is raised to the ACR 50 or 70 mark, the number of responders decreases in all three treatment
groups.
Combination therapy with IL-IRa and soluble TNFa receptor I in rats with CIA resulted
in an additive effect on clinical and histological parameters when moderate to high efficacious
doses of each protein were administered (Bendele et al., 2000). However, greater-than-additive
effects were seen when an inactive dose of IL-IRa was given in combination with moderately to
minimally active doses of soluble TNFa receptor I. (Bendele et al., 2000), indicating that a
combination approach may prove to have greater effects than any biological agent alone and that
lower doses than either drug alone could be used, thus reducing the cost and potential side
effects of the treatment. Similar studies also show a synergism between other anti-TNFa and
anti-ILl treatments (Zwerina et al., 2004).
LIMITATIONS OF THE DATA
Only the cytokines that were present within the synovial cavity were assayed in the
present study. The levels of ELIp and TNFa were not significantly elevated in comparison with
normal joints after one week of adjuvant-induced arthritis, which is perhaps reflecting a change
in the distribution of these inflammatory proteins within the joint cavity and surrounding tissue.
Furthermore, IL2, EL4, DL6, IL10 and IFNy were never significantly increased above basal (pre-
FCA) levels, which is in contrast to other studies in which entire joint homogenates or the
synovial membranes alone have been assessed (Bush et al., 2001; Schmidt-Weber et al., 1999;
Szekanecz et al., 2000). It is therefore difficult to conclude that ILlp and TNFa are not required
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in the "chronic" phases to maintain adjuvant-induced arthritis, merely that they are not present in
the joint cavity during the "chronic" phase in the present study.
Differential cell counts or flow cytometry were not used to assess what proportion of the
total inflammatory cell population belonged to which cell type. If this was carried out it may
give an indication of which cells could be targeted to treat inflammatory joint disease. In
addition, cells were only detectable on days 7, 10 and 21, indicating that the method is not
sensitive enough to detect inflammatory cells in the perfusates when the levels are low, due to
the fact that the perfusate samples were too dilute. This would be improved by collecting a
smaller, more concentrated sample for cell counting, although a smaller volume means fewer
analyses can be carried out, and perhaps cells, multiple cytokines and PGs could not be
measured in the same samples. These studies were not performed during this thesis as a result of
time and financial restrictions. The later studies in this thesis acted as merely pilot studies, in an
attempt to reduce the Home Office 3 R's. If more time had been available, certain aspects of
these studies would have been taken further and the n numbers increased to make the data more
conclusive.
Ideally, the FCA time course could be conducted by repeated daily sampling from the
same animals under transient anaesthesia, which would reduce the number of animals needed to
conduct a study such as that detailed in Chapter 5. It would also make statistical comparisons
over time more powerful as data from the same individual animals could be compared day to
day. Moreover, AUC values could be calculated for individual animals over a drug-dosing
period which would improve the statistical power of analysis carried out to determine if the drug
affected the cytokine content of joints. However, repeated sampling was not possible during this
thesis as a permanent indwelling catheter or similar device would be required to be surgically
implanted in the rats' knee joints to prevent repeated insertion of needles and therefore repeated
tissue damage and further inflammatory responses. Furthermore, this may lead to infection and
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contamination from the daily sampling; hence at this stage in the development of the technique,
once the knee joint was perfused, the rat was killed.
FUTURE DIRECTIONS
The time course of cytokine release in FCA-injected joints could be repeated with an
alternative inflammatory stimulus and compared with adjuvant arthritis as well as human RA. A
range of nine cytokines was measured during these studies, based on commercially available
kits; however, there is a vast number of cytokines and other mediators, including peptides,
chemokines and PGs that could be assayed in these samples. Ideally higher n values would be
used for the prednisolone treatment study, which may result in more detailed analysis of the
effects of the drugs and a greater statistical power, improving the ability to draw conclusions
from the study, given that it was noted there were two populations, "responders" and "non-
responders", which was not anticipated when the study was designed. Increasing the n numbers
will help gain a better insight into the mechanisms of action of prednisolone and its effectiveness
at reducing the inflammatory mediator content of inflamed joints. Administration of
prednisolone directly into the knee may be successful at reducing the cytokine content of joints
at the dose used, and it would be interesting to compare the results of such experiments with
those from s.c. administration used in the present study. In addition, other anti-inflammatory,
anti-rheumatic, or analgesic drugs could be administered to determine whether they had effects
on the cytokine expression patterns of inflamed joints similar to that seen in the clinic, which
was not the case for prednisolone in this thesis.
An extension of the present study would be to assess the inflammatory mediator content
of whole homogenised joints, and compare the results with the data from the perfusate samples.
This would establish whether a higher proportion of cytokines is evident in the surrounding
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tissues of the joint, rather than in the joint cavity itself, particularly in the "chronic" phases when
levels in the joint cavity appeared to be low.
The effect of prednisolone on levels of cytokines in the knee joint was investigated in
chapter 5, however, it would also be interesting to evaluate the effects of the drug on the levels
of cytokines in the blood, which was not done here to reduce the number of samples required to
assay using the Luminex machine due to the high cost of the kits required to analyse a 96-well
plate. This would establish whether the anti-inflammatory effects of prednisolone are via
systemic reduction of pro-inflammatory mediators, rather than locally within the joint.
8.3 THE ROLES OF IL1B AND IL6 IN JOINT PAIN AND INFLAMMATION
Equal doses of ILip and IL6 had different effects on the sensitivities and activities of
primary afferent nerves innervating the normal rat knee joint. IL1 (3 increased basal discharge
and sensitised the nerve, resulting in a decrease in the mechanical force required to evoke neural
activity when stimulated within the receptive field of the nerve. In contrast, IL6 had no effects
on mechanical threshold or the basal neural activity. When administered at higher doses (1, 3
and 10 pg), both cytokines induced gross mechanical hypersensitivity measured by PAD and the
incapacitance tester, although the response evoked by IL6 was shorter in duration than that
caused by ILip. There was also a difference between the two readouts of mechanical
hypersensitivity used in this study. PAD and the incapacitance tester both detected
hypersensitivity, although that measured by PAD was less well sustained than that measured by
the weight distribution, despite the fact that the two measures correlated well in Chapter 3. This
may be due to the milder nature of joint hypersensitivity evoked by ELip and IL6 in comparison
with FCA (used in chapter 3). In contrast to previous reports, ILip did not cause bone or
cartilage erosion, the formation of pannus or any other structural changes to the joint, although
histology and analysis of joint perfusates showed that it evoked inflammatory cell recruitment
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from day one post-ILip administration. IL6 had no effect on the total inflammatory cell count,
or the joint histology.
IL6 perfused into the joint caused the de novo release of ILip and TNFa within two
hours and additionally the release of ILla, IL2 and IL4 release within a few days. However no
inflammatory cells were detected at any time point post IL6 in joint perfusate samples.
Administration of ILip into the joint evoked increased expression of IL6 and TNFa within one
hour and ILla, IL2 and IL10 within one day and an influx of inflammatory cells within 24 hours
of administration.
CLINICAL IMPLICATIONS
Anti-ILlp and -IL6 treatments may prove to be effective analgesics whilst
simultaneously reducing inflammation. Neither cytokine alone resulted in joint swelling or joint
destruction which is in agreement with other studies and data from Chapter 5, suggesting a
plethora of mediators is required for the full RA phenotype, and hence inhibition of a single
cytokine, although potentially beneficial, will not completely abolish symptoms or totally stop
the progression of the underlying inflammatory disease.
LIMITATIONS OF THE DATA
In order to adhere to the Home Office 3Rs, although three doses of ILip and IL6 were
used during the behavioural study, only one dose was tested in electrophysiological, histology
and joint perfusion experiments. Furthermore, the effect of ILip and IL6 on the sensitivities and
activity of peripheral primary afferents was tested using mechanical stimulation only. More
experiments need to be performed to determine if these agents affected the threshold of neural
activity to thermal or chemical stimulation. The nerve fibres that were recorded were not
characterised to classify them into C- or A5 fibres, which would improve the level of knowledge
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gained from these studies. During the electrophysiological studies NSAIDs could have been
administered to determine if PGs were the intermediate factor causing neural changes following
ILip. When ILip or EL6 were given into the joint only cytokines within the synovial cavity
were analysed, rather than those in the surrounding tissue, which would further our
understanding of the roles of these mediators in joint pain and inflammation.
FUTURE DIRECTIONS
The sensitisation of peripheral nociceptors by cytokines during chronic inflammation of
joints is an area of research that requires much more investigation. The role of the large number
of mediators released during chronic inflammation in the excitation and/or inhibition of
peripheral nociceptors is for the most part unknown. Much of the information that is available
concerning the chemical excitation of joint afferents is extrapolated from experiments on
cutaneous nociceptors or in vitro preparations. Detailed characterisation of joint nociceptors is
necessary to determine whether they have unique pharmacological profiles or are similar to
nociceptors in other regions of the body. There is a vast number of mediators that may play a
role in joint hypersensitivity, all of which play a critical role in cell-cell interactions during
inflammation, and as such may also influence sensory neurons. In the present study ILip or IL6
were administered into the joint; simultaneous administration of their respective receptors in
addition to the protein may increase the number of changes seen in the electrophysiological,
histological and joint perfusion experiments. Administration of an NSAID during
electrophysiological studies investigating the effect of IL1(3 on peripheral sensory neurons
should reveal whether PGs are the only downstream mediators responsible for primary afferent
sensitisation. If sensitisation was still evident, it would suggest that other intermediate
molecules are involved in the sensitisation of nerves innervating the knee joints as a result of
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cytokines and to elucidate this, antagonists of receptors known to be present on primary afferent
nerve endings could be administered during the protocol use in Chapter 6 and 7.
8.4 GENERAL CONCLUSIONS
The primary conclusion that can be drawn from the data presented in this thesis is that
ILip plays a dominant role in the development and maintenance of FCA-induced joint pain and
the associated oedema although to a lesser degree, as i.art IL113 alone was not sufficient to evoke
swelling of the joint. The dose of ILip administered was also not sufficient to cause joint
destruction, despite resulting in an influx of inflammatory cells. The levels of ELip protein are
significantly elevated during adjuvant-induced arthritis, and showed a strong correlation to the
weight distribution readout, a pre-clinical measure of hypersensitivity. In addition, intra¬
articular ILip itself reduces the joint withdrawal threshold and weight carried by the inflamed
limb, measures of evoked and spontaneous mechanical hypersensitivity, when measured by
PAM and the weight distribution readout, respectively. Furthermore, electrophysiological
recording from primary afferent nerves innervating the joint showed that i.art ILip alters the
mechanical threshold for firing and the basal rate of activity, but not the frequency of neural
discharge to a suprathreshold stimulus. However, the role of IL6 still remains unclear; i.art
injection of this inflammatory protein initiated a mild mechanical hypersensitivity, but did not
affect neuronal responses or basal firing rates, not lead to changes to the joint structure or
swelling. However, DL6 protein was present in the synovial fluid of joints from rats with FCA-
induced joint inflammation and these levels were significantly related to the weight distribution
results.
The use of two novel techniques has facilitated the study of cytokines, in particular the
roles of ILip and IL6 in the development of inflammatory joint pain in rodents (see Figure 8.1
for a summary). In addition, the time course of cytokine expression in the joint cavity during
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adjuvant-induced arthritis has been established, which can be used in the future to assay novel
anti-inflammatory or anti-cytokine agents. Moreover, direct links between mechanical
hypersensitivity and ILip and IL6 have been established, suggesting that these are key mediators
involved in the development of joint pain; ILip acts at least in part via direct/indirect effects on
sensory neurons. In accord with previous work, the data presented in this thesis highlights the
fact that multiple cytokines (probably in combination with other mediators) are required for
long-lasting joint pain and inflammation. Therefore a combinatorial approach to treatment is









Sensory nerve / ce||s Cartilage
Figure 8.1 A summary of joint inflammation and the application of the novel joint perfusion technique to
quantify the inflammatory mediator and cell content of the synovial cavity. This technique can be used to
investigate the basic inflammatory processes and to determine the effectiveness of novel anti¬
inflammatory, analgesic or anti-rheumatic drugs on the levels of these mediators. A sensory nerve
innervating the joint is also illustrated to indicate that inflammatory cytokines can act directly on these
nerves, or indirectly via release of other pro-inflammatory and pro-nociceptive agents.
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Mice lacking the TRPV1 receptor develop milder joint inflammation following
FCA
Barton, N.J.1, McQueen,D.S.1, Gauldie,S.D.', Wilson,A.W.2, Clayton,N.M.2,
Chessel,I.P.2
'Division ofNeuroscience, University of Edinburgh, 1 George Sq, EH8 9JZ, UK,
2Neurology CEDD, GlaxoSmithKline R&D Ltd, Harlow, Essex CM19 5AW, UK
The TRPV1 receptor (TRPV1R) is a non-selective ligand-gated cation channel
expressed predominantly by nociceptive sensory neurons (Caterina et al., 1997). The
aim of this study was to determine the role of this receptor in the development and
maintenance of joint inflammation evoked by Freunds Complete Adjuvant (FCA) in a
murine model of chronic unilateral arthritis. The body weights, joint diameters and
weight distribution on hind limbs (Clayton et al., 1997) were measured in male C57BL6
wild type (WT) and TRPV1R-/- mice (Davis et al. 2000). Five C57BL6 WT and 10
TRPV1R-/- mice were injected with FCA (200pg/20pl intra articular) in the left stifle
joint under 3% halothane anaesthesia, as described by Gauldie et al. (2004). Four
C57BL6 WT and 10 TRPV1R-/- mice were injected with vehicle (20 pi heavy liquid
paraffin). Measurements were made three times per week for 30d. Intra-articular FCA
caused an increase in ipsilateral joint diameter in WT mice that was significantly greater
than that observed in TRPV1R-/- mice (P<0.01; MannWhitney U), see Figure 1.
Weight bearing on the hind limbs shifted from equal weight distribution on both joints
towards the untreated joint after FCA injection. The difference between the two joints
was statistically significant in both groups (P<0.05; Mann Whitney U). There were no
significant differences between the strains (P>0.05; Mann Whitney U; Fig. 1).
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Figure 1. Ipsilateral (injected with FCA) and contralateral knee diameters of male (a) TRPVl-/-mice and
(b) WT mice. Weight bearing ofmale (c) TRPV1-/- mice and (d) WT mice.
Our results indicate that TRPVIRs play a key role in the development of inflammation,
in agreement with Keeble et al. (2004). In addition, data from weight distribution on
hind limbs suggest that the TRPVIRs play a role in hyperalgesia following i.art FCA,
however the difference from WT was not statistically significant, probably due to the
variability of the data. In conclusion our data suggests TRPV1R is involved in joint
inflammation and hyperalgesia. However, since neither were completely attenuated in
the knock out mice, it is probable that multiple mediators, receptors and mechanisms are
involved in the development and maintenance of inflammatory joint disease.
Caterina, M.J. et a/.(1997). Nature, 389, 816-24.
Clayton, N.M. et al. (1997) Br JPharmacol 120, 75P
Davis, J.B. et al. (2000). Nature, 405, 183-187
Gauldie S.D. et al. (2004). JNeurosci Methods, 139, 281-291
Keeble, J.E. et al. (2004). Proc British Pharm Soc, pA2 online, 21, 43P
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MICE LACKING THE TRPV1 RECEPTOR DEVELOP A MILDER JOINT
INFLAMMATION FOLLOWING FCA
CiaxoSmithKline
Barton, N.J.1, McQueen,D.S.1, Gauldie,S.D.1, Wilson,A.W.2, Clayton,N.M.2, Chessel,I.P.2
1 Division of Neuroscience, University of Edinburgh, Medical College, 1 George Sq, EH8 9JZ, UK,
2Neurology CEDD, GlaxoSmithKline R&D Ltd, Harlow, Essex CM19 5AW, UK
1.Introduction
The TRPV1 receptor (TRPV1R) is a non-selective ligand-gated cation channel expressed predominantly by
nociceptive sensory neurons (Caterina et a/., 1997).
Aim - Experiments were undertaken to test the hypothesis that the TRPV1 receptor plays a key role in the
development and maintenance of joint inflammation in mice. Inflammation of the stifle (knee) joint was evoked by
Freund's Complete Adjuvant (FCA) in TRPV1R -/- mice (Davis et at, 2000).
2.Methods
The body weights, joint diameters (measured using
digital microcallipers), and weight distribution between
hind limbs - an index of hyperalgesia (Clayton et a I.,
1997) -were measured in male C57BL6 wild type (WT)
and TRPV1R-/- mice (15-25g). Five C57BL6 WT and
10 TRPV1R-/- mice were injected with FCA
(200pg/20pl intra articular, i.art) in the left stifle joint
under 3% halothane anaesthesia, as described by
Gauldie et al. (2004). Four C57BL6 WT and 10
TRPV1R-/- mice were injected with i.art vehicle (20 pi
heavy liquid paraffin). Measurements were made
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In TRPV1-/- (Fig 1A) and C57B6 WT (Fig 1B) mice there
was a significant increase in knee diameter of the injected
joint in comparison with the contralateral limb (P<0.05 for
both WT and TRPV1-/- vs. HLP, Mann Whitney test). The
difference between the WT and the TRPV1-/- injected joints
was statistically significant (P<0.001, Mann-Whitney). This
finding is in agreement with Keeble et al (2004).
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Weight distribution on hind limbs of TRPV1-/- (Fig 2A) and
C57B6 WT (Fig 2B) mice. Weight bearing shifted from equal
distribution on both limbs before FCA towards the untreated
joint after i.art FCA. The difference between the ipsilateral
and the contralateral joints was significant in both groups
(P<0.05, Mann Whitney test). There was a significant
difference between the WT and the TRPV1-/- ipsilateral joints
on day 7, 14 and 28.
Keeble et al (2004) found plasma extravasation from joints
after FCA i.art was reduced in TRPV1-/- in comparison with
WT mice, which is consistent with our data on joint swelling .
4.Summary
•TRPV1R -/- mice develop a milder joint
inflammation following i.art FCA, compared with
WT mice, as measured by joint diameter over 30
days.
• Data from weight distribution on hind limbs
suggest that the TRPV1R also plays a role in
hyperalgesia following i.art FCA, however this is
not statistically significant, probably due to the
small sample size and variability of the data.
• Our data suggests a role for TRPV1R in joint
inflammation and hyperalgesia. Other mediators
and receptors also appear to be involved in
hyperalgesia and allodynia.
THE RELEVANCE OF THE CHILLI PEPPER RECEPTOR IN ARTHRITIS
N. Barton1. D.S.McQueen1, D.Thomson1, A.W.Wilson2. I.P.Chessell2
1Division of Neuroscience, University of Edinburgh, EH8 9JZ, UK.
2Neurology CEDD, GlaxoSmithKline R&D Ltd, Harlow CM19 5AW, UK.
Chilli peppers contain capsaicin, a chemical which interacts with a protein called the capsaicin or
TRPV1 receptor on nerve endings, causing the hot burning sensation associated with eating spicy
foods. Capsaicin also selectively activates a group of sensory nerves responsible for detecting
painful stimuli; TRPV1 receptor expression increase during autoimmune inflammatory disease,
such as rheumatoid arthritis. We are using genetic engineering techniques to study the role of
TRPV1 receptors in a murine model of chronic arthritis. Mild joint inflammation was induced under
general anaesthesia with Freund's Complete Adjuvant in TRPV1 -/- (genetically manipulated to
"knockout" the TRPV1 receptor) and WT (normal) mice. Functional measures of joint inflammation
were made in 20 TRPV1-/- and 9 WT mice. Joint swelling and hypersensitivity were significantly
reduced in the knockout animals compared with the WT. These results indicate that TRPV1
receptors play a key role in the development of joint inflammation, contributing to the
hypersensitivity of arthritis. However, as neither swelling nor hypersensitivity were completely
eliminated in the knock out mice, other mediators must also be involved in the development and
maintenance of arthritis. The study shows that the TRPV1 receptor that is activated by capsaicin
in Chilli's is important in chronic joint pain. Therefore this receptor, together with its as yet
undiscovered endogenous ligand (the substance produced by the body which activates the TRPV1
receptor), are important targets for developing novel anti-inflammatory or analgesic drugs to relieve
the symptoms of arthritis.
GiaxoSmittiKline
The Role of the Chilli Pepper Receptor in Arthritis
N.J.Barton1, D.S.McQueen1, D.Thomson1, A.W.Wilson2, I.P.Chessell2
1Division of Neuroscience, University of Edinburgh, Medical College, 1 George Sq, EH8 9JZ, UK,
2Neurology CEDD, GlaxoSmithKline R&D Ltd, Harlow, Essex CM 19 5AW, UK
J IntroductionChilli Peppers contain capsaicin, a chemical which interacts with TRPV1 receptors on nerve endings, causing the burning
sensation experienced when eating spicy foods. The same receptor also plays an important role in the modulation of the way we
feel pain. TRPV1 receptors are located on 'nociceptors' which are specialised neurones which relay noxious, painful sensations
from the periphery to the spinal cord and then into the brain. The expression of TRPV1 receptors increases during autoimmune
inflammatory diseases, including rheumatoid arthritis. It is therefore likely that this receptor and its mysterious endogenous ligand
are valuable targets for anti-inflammatory or analgesic drugs.
y AimUse a genetically engineered mouse lacking the TRPV1
receptor (Davis et al 2000) to determine the role of TRPV1R in the
development and maintenance of inflammation and
hypersensitivity in a murine model of rheumatoid arthritis.
y MethodsThe body weights, joint diameters (measured using digital
micro callipers), and weight distribution between hind limbs (an
index of hypersensitivity; Clayton et al 1997) were measured in
male C57BL6 wild type (WT; normal) and TRPV1R-/- mice (15-
25g). Five C57BL6 WT and 10 TRPV1R-/- mice were injected with
Freunds Complete Adjuvant (FCA; 200pg in a volume of 20pl intra
articular, i.art) in the left stifle (knee) joint under 3% halothane
anaesthesia, as described by Gauldie et al 2004. Four C57BL6
WT and 10 TRPV1R-/- mice were injected with vehicle (20 pi
heavy liquid paraffin; i.art). Measurements were made three times
per week for 30 days. At the end of the study, both ipsilateral and
contralateral joints were removed, fixed in formalin and processed
for histological staining. Haematoxylin-eosin staining was carried
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Fig 1. In TRPV1-/- (a) and C57B6 WT (b) mice there was a
significant increase in knee diameter of the injected joint in
comparison with the contralateral limb (P<0.05 for both WT and
TRPV1-/- vs. HLP, Mann Whitney test). The difference between
the WT and the TRPV1-/- injected joints was statistically significant
(P<0.001, Mann-Whitney). The inflammation was almost
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Fig 2. Weight distribution on hind limbs of TRPV1-/- (a) and C57B6 WT (b)
mice. Weight bearing shifted from equal distribution on both limbs before
FCA towards the untreated joint after i.art FCA. The difference between
the ipsilateral and the contralateral joints was significant in both groups
(P<0.05, Mann Whitney test). There was a significant difference between
the WT and the TRPV1-/- ipsilateral joints on days 7, 14 and 28.
Fig 3. Haematoxylin-eosin
staining shows a reduced
number of inflammatory cells in
the inflamed joint of the TRPV1-
/- joint in comparison with the
response evoked in WT mice.
Summary
This model of arthritis mimics the pathology of human disease and is
important for developing new anti-inflammatory agents to relieve the
chronic pain of arthritic disease.
We have shown that both joint inflammation and hypersensitivity were
reduced in the knockout animals, suggesting TRPV1 is crucial in their
development in chronic joint pain. However, as neither were completely
attenuated other mechanisms must also play a role in the development
and maintenance of arthritis.
Drugs targeting the Chilli Pepper receptor have the potential to be
peripherally acting anti-inflammatory analgesics, would therefore be anti-
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Intra-articular ILip or IL6 induces hypersensitivity and allodynia in the rat knee joint
N.J.Barton1, I.T.Strickland1, A.J.Reeve2, D.S.McQueen1, I.P. Chessell2
1Division of Neuroscience, University of Edinburgh, 1 George Sq, EH8 9JZ, UK
2Neurology CEDD, GlaxoSmithKline R&D Ltd, Harlow, Essex CM19 5AW, UK
ILip and IL6 are pro-inflammatory cytokines present in high levels in rheumatoid arthritic
joints; their blood concentrations correlate with disease severity (Eastgate et al. 1988;
Houssiau et al. 1988). The aim of this experiment was to determine if exogenous intra¬
articular ILip or IL6 resulted in hypersensitivity or allodynia in the rat. Body weights, knee
joint diameters, weight distribution between hind limbs (Clayton et al., 1997) and the
withdrawal threshold to a discrete pressure applied to the knee joint (PAD; Strickland et al.
2005), a measure of allodynia, were measured in 42 male Wistar rats (150-175g). Animals
were divided into 7 groups, 1, 3 and 10pg ILip or IL6 (rat recombinant; Bioclone Inc, USA)
and vehicle. Rats were transiently anaesthetised with 3% halothane in 02 and a 100pl
injection was made into the left knee joint. Weight distribution and PAM withdrawal
thresholds were measured every 2 hours after surgery for 7 hours and then daily, along with
body weights and knee joint diameters. 2-way ANOVAs were used to assess statistical
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Figure 1. The weight distribution of the ipsilateral hind limb expressed as a percentage of the
contralateral limb for (A) IL1p and vehicle and (B) IL6 and vehicle. When compared to
vehicle, all IL1p doses were significantly lower at t=4h, 6h, 1 d, 2d and 4d, whilst 10 and 3pg
ILip were also significant at t=3d. All doses of IL6 were significantly lower than vehicle at
t=4h, 6h and 1d; 3pg was also significant att=2d.
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Figure 2. The ipsilateral limb withdrawal thresholds for (A) ILip and vehicle and (B) IL6 and
vehicle. When compared to vehicle, 10pg ILip was significantly reduced at t=5h, 7h and 1 d;
3pg 111 p was significant at t=3h; 10pg IL6 was significant at t=5h and 1pg IL6 was significant
at t=1d.
There were no significant differences between the body weights, ipsilateral or contralateral
joint diameters or contralateral PAD withdrawal thresholds of any group at any time point.
This study shows that both ILip and IL6 can cause hypersensitivity and allodynia acutely and
that the decrease in ipsilateral withdrawal threshold resulting from either cytokine is short¬
lived and has returned to baseline after 1day. In contrast, the hypersensitivity of the joint
injected with ILip or IL6, as measured with weight distribution, is more sustained, but that
ILip-induced hypersensitivity has a longer duration than that induced by IL6. However,
neither cytokine induces joint swelling.
Clayton, N.M. et al. (1997) Br J Pharmacol, 120, 75P Eastgate et al. (1988) Lancet, 2, 706-9
Houssiau et al (1988) Arthritis Rheum, 31, 784-8 Strickland et al. (2005) pA2 Online, In Press.
QaxosmrtMhne'ntra-art icu Iar IL1p or IL6 induce acute mechanical
hypersensitivity and allodynia in the rat knee joint
N.J.Barton1. I.T.Strickland1,1.P.Chessell2, A.J.Reeve2, D.S.McQueen1
1 School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK
2Neurology & Gastrointestinal CEDD, GlaxoSmithKline, Harlow, CM19 5AW, UK
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterised by persistent synovitis that results in
progressive joint destruction. It affects approximately 1% of the general population. Most drugs prescribed for RA are non¬
steroidal anti-inflammatory drugs (NSAIDs), to reduce inflammation and the associated pain. Recently disease-modifying anti¬
rheumatic drugs (DMARDs), including anti-cytokine drugs, have shown promising effects clinically.
Interleukin (IL) ip and IL6 are pro-inflammatory cytokines present in high levels in rheumatoid arthritic joints; in addition their
blood concentrations correlate with rheumatoid arthritis disease activity (Eastgate et al. 1988; Houssiau et al. 1988).
2. Aim
The aim of this experiment was to determine whether intra-articular injections of ILip or IL6 cause hypersensitivity or allodynia in
the rat knee (stifle) joint.
3. Methods
•Experiments were performed in accordance with Home Office
regulations and within UK animal welfare guidelines, and received
Local Ethics Committee approval.
Body weights, knee joint diameters (a measure of swelling; measured using
digital microcallipers), the weight distribution between hind limbs (a measure
of hypersensitivity; Clayton et al., 1997; Linton Instruments) and the
withdrawal threshold to a gradually increasing localised pressure applied to
the knee joint (a measure of allodynia; Strickland et al. 2005; PAD), were
measured in 42 male Wistar rats (150-175g). Animals were divided into
seven groups, which were injected with either 1, 3 or 10pg IL1 p or 1, 3 or
10pg IL6 (rat recombinant; Bioclone Inc, USA) or vehicle (sterile saline).
Rats were transiently anaesthetised with 3% halothane in O2 and a 100pl
injection was made into the left knee joint (i.art). Weight distribution and
PAD withdrawal thresholds (WT) were measured every 2 hours after surgery
for 7 hours and then daily, together with body weights and knee joint
diameters. 2-way ANOVAs were used to assess statistical significance
between group means, the null hypothesis was rejected at P<0.05.
4. Results - Joint Swelling
Neither IL1 p or IL6 had any effect on ipsilateral or contralateral joint
diameters, a measure of swelling, at any time point during the study
compared to vehicle-treated animals (P>0.05).
5. Results - Mechanical Hypersensitivity
Both i.art IL1 p and IL6 evoked a mechanical hypersensitivity which was
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Figure 1. The weight distribution of the ipsilateral hind limb expressed as a percentage of the contralateral
limb for (A) IL1(J-injected- and vehicle-injected animals and (B) IL6-injected- and vehicle-injected animals.
When compared to vehicle, the percentage weight distribution between the ipsilateral and contralateral
limbs in all ILip-injected groups was significantly reduced at 4h, 6h, 1day (d), 2d and 4d (P<0.05). The
percentage of weight distribution in all groups injected with IL6 was significantly lower than vehicle at 4h, 6h
dud 1d (P<0.05); 3pg was also significantly lower at 2d (P<0.05).
6. Results - Allodynia
Both i.art IL1 p and IL6 caused a reduction in the ipsilateral limb withdrawal
thresholds to a gradually increasing localised pressure applied across the knee
joint. However this effect was short-lived and only lasted up to 24 hours. The
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Figure 2. The ipsilateral limb withdrawal thresholds for (A) IL1 (3- and vehicle-injected animals and (B) IL6- and
vehicle-injected animals. When compared to vehicle, the ipsilateral limb WT for the group injected with 10pg ILip
was significantly reduced at 5h, 7h and 1d (P<0.05); in addition, the ipsilateral WTs for animals injected with 3pg
111P were significantly decreased at 3h (P<0.05). Animals injected with 10pg IL6 i.art had a significantly reduced
ipsilateral WT at 5h (P<0.05) and those treated with 1pg IL6 had a significantly reduced WT compared to vehicle
at 1d (P<0.05).
7. Summary and Conclusions
a. Neither IL1P or IL6 had any effect on joint swelling
b. This study shows that both IL1 p and IL6 can induce
mechanical hypersensitivity in the rat knee joint
• ILip caused a more sustained effect than IL6
• The hypersensitivity is sustained for 3-4 days
c. Furthermore, both ILip and IL6 can induce allodynia,
as assessed by limb withdrawal threshold to a
localised squeezing of the joints
• This effect by i.art ILip and IL6 was short-lived
• The withdrawal threshold returned to baseline
within 24hours
d. These results suggest that ILip and IL6 may be key
mediators in the development of pain associated with
inflammatory joint diseases.
Clayton, N.M. et al. (1997) Br J Pharmacol, 120, 75P
Eastgate et al. (1988) Lancet, 2, 706-9
Houssiau et al (1988) Arthritis Rheum, 31, 784-8
Strickland et al. (2005) pA2 Online, In Press
A novel behavioural readout for assessing hypersensitivity of knee joints in a
murine model of unilateral arthritis
I.T.Strickland1. N.J.Barton1, H.M.Brash1, D.S.McQueen1, A.J.Reeve2, A.W.Wilson2,
I.P.Chessell2
1 Division ofNeuroscience, College of Medicine and Veterinary Medicine, University
ofEdinburgh, 1 George Square, Edinburgh, EH8 9JZ.
2
Neurology & Gastrointestinal CEDD, GlaxoSmithKline, Harlow,
UK, CM19 5AW
The aim of this study was to develop a new quantitative method for measuring
hypersensitivity of the knee (stifle) joint during a murine model of unilateral arthritis
(Gauldie et al,. 2004). The pressure application measurement device (PAM) is designed
to objectively assess a discrete localised hypersensitivity across the knee joint. The
force applied across a joint under test is measured by a force transducer fitted to the
experimenter's thumb (see Figure 1). A gradually increasing 'squeeze' force was
applied across the joint and by means of calibrated instrumentation the force in grams
applied was recorded. The test endpoint was when the animal withdrew its limb. Male
C57BL6 mice (n=24, 23-27g) were transiently anaesthetised (3% isofluorane with O2 at
1.51.min_1) and a small incision was made over the knee joint to show the patella tendon,
sham (n=8) animals recovered with no further treatment. The remaining 16 animals
were injected with Freund's complete adjuvant (FCA; 20pl, lOmg.mF1) under the
patella tendon into the intra-articular space of the joint. Prior to surgery and for 21 days
following PAM withdrawal threshold, weight bearing (Clayton et al,. 1997), knee
diameter and body weight were recorded. On day 10 the FCA injected animals were
ranked and randomised into two matched groups (n=8) and dosed (s.c.) on days 13-17
with either prednisolone (lmg.kg"1) or vehicle (ethanol 5%, PEG 45% and distilled
water 50%). PAM data were transformed into an area under the curve (AUC) value and
analysed using a Mann-Whitney test, where p<0.05 was considered significant. Results
showed FCA injected animals had significantly lower withdrawal thresholds than sham
on day 3 (p= 0.0001), when compared to day 0, confirming the FCA induced
hypersensitivity. Over days 13-17 the prednisolone treated group had significantly
higher AUC values than the vehicle group (p= 0.0104), compared to day 10, due to a
reversal of hypersensitivity. PAM results correlated significantly with weight bearing
data (r= 0.9, Pearson's correlation). These results show that PAM is a robust tool which
provides an easy to use objective method for localised assessment of knee joint
hypersensitivity in mice, which correlates strongly with a previously accepted
behavioural readout.
Clayton et al,. 1997 Br JPharmacol 120:219P.
Gauldie et al,. 2004 JNeurosci Methods 139(2):281 -291.
Figure 1. Pressure application measurement device (PAM)
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Aim
The aim of this study was to develop and validate a new quantitative method for measuring hypersensitivity of the knee
(stifle) joint in a murine model of unilateral arthritis (Gauldie et at,. 2004).
Introduction
Several behavioural readouts are currently used to assess the hypersensitivity in the joints of arthritic rodents (Clayton et a/,. 1997).
However none of these are able to assess a localised hypersensitivity directly across the arthritic joint. The pressure application measurement
(PAM) device measures and records the force applied across a joint under test using a force transducer fitted to the experimenter's thumb.
Apparatus
PAM apparatus includes a base unit with display screen (Fig. 1 A) and a force transducer, with 5mm diameter application surface, mounted on a unit worn on
the experimenters thumb. Placing the force transducer on one side of the joint and the forefinger on the opposite (Fig. 1B), a gradually increasing 'squeeze' was
applied in a mediolateral plane across a joint. By means of the calibrated instrumentation the force in grams (gf) applied was recorded (max = 500gf). The test
endpoint was when the animal withdrew its limb. The measured forces are quoted in gf (gram force) and may be converted to N (Newton) by multiplying by
9.8159 x 10'3
Fig. 1. (A) PAM device showing the base unit with force display screen and thumb worn force
transducer. (B) Example of how the gradually increasing squeeze' force is applied across a
joint. The transducer is placed on one side of the joint and the forefinger on the opposite.
Methods
Weight distribution over the hind limbs (Clayton et at,. 1997), PAM,
knee joint diameters and body weights were measured in male C57BL6
mice (n=24, 23-27g) for a period of 21 days. Following day 0 recordings the
mice were transiently anaesthetised (3% isofluorane with 02 at 1.5l.min"1)
and a small incision was made over the knee joint to expose the patella
tendon, sham (n=8) animals recovered with no further treatment. The
remaining 16 animals were injected with Freund's complete adjuvant (FCA;
20pl, 10mg.mh1) under the patella tendon into the intra-articular space of
the knee joint (Gauldie et at,. 2004).
On day 10 the FCA injected animals were ranked and randomised into
two matched groups (n=8 per group), based on their level of withdrawal
threshold (gf) as recorded by PAM. The groups were dosed (s.c.) on days
13-17 blindly with either prednisolone (Img.kg-1) or vehicle (ethanol 5%,
PEG 45% and distilled water 50%) one hour before recordings were taken.
All procedures were in accordance with U.K Home Office Regulations.
Data were transformed into an area under the curve (AUC) value during










Fig. 2. Effect of prednisolone (n=8, s c., Img.kg'1, filled circle) or vehicle (open circle) on the FCA
induced hypersensitivity (n=16, I.art., 20pl, all circles) over days 13-17 as measured by the PAM
device. Untreated sham (n=8) animals are represented by open triangles. Day 0 ratios of 1.0 are





PAM withdrawal threshold ratio
(Daily value : Day 0 value)
Fig. 3. Graph showing the correlation between the group mean weight distribution ratio (Ipsilateral:
Contralateral) and the group mean PAM withdrawal threshold ratio (Daily value : Day 0 value) for
days 0-20. Groups are represented as follows; sham (open blue triangles), FCA + vehicle (open
black squares) and FCA + prednisolone (s.c., Img.kg'1, closed black circle).
■ Results showed FCA injected animals had significantly lower withdrawal
thresholds than sham on day 3 (P= 0.0001), when compared to day 0,
confirming the FCA induced a localised hypersensitivity which was
detected using the PAM device.
• During the treatment period (days 13-17) the prednisolone treated group
had significantly higher AUC values, compared to day 10, than the vehicle
group (P= 0.0104). This was due to a reversal of hypersensitivity by
prednisolone which was also observed using the PAM device.
• A strong correlation between the PAM device and weight distribution
results was observed (Pearson's r correlation = 0.9).
Summary and Conclusions
• PAM is a robust instrument which provides an easy to
use, objective method for localised assessment of knee
joint hypersensitivity in mice and correlates strongly with a
previously accepted behavioural readout.
• A second PAM device is currently under development
designed and calibrated for measuring hypersensitivity in
rat knee joints.
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Abstract
The Transient Receptor Potential Vanilloid 1 (TRPV1R) is a ligand-gated, non-selective cation channel expressed predominantly by sensory
neurons. TRPVIRs respond to a variety of noxious stimuli including capsaicin, intense heat and acid. These factors, combined with behavioral
studies, show that TRPVIRs are involved in nociception. The aim of our study was to determine whether TRPVIRs play a role in the
development and maintenance of inflammation and mechanical hyperalgesia by studying the development of unilateral joint inflammation in
TRPV1R-/- mice. Knee joints of TRPV1R-/- or wild-type (WT) mice were injected with FCA (200 pg) under temporary anesthesia, and the
resulting inflammation and hyperalgesia measured for 35 days. Histological analysis was perfonned on joints at the end of the study. TRPV1R-/-
mice developed mild joint swelling which was significantly less than that obtained in WT mice (P < 0.05, Mann-Whitney). The ratio of the
weight distribution between the hind limbs in TRPV1R-/— mice was also significantly less than in WT mice (P < 0.05, Mann Whitney). Neither
swelling nor hypersensitivity was completely absent in the knockout mice, indicating either that other mechanisms are involved or that a
compensatory mechanism operates in TRPV1R—/- mice. These results suggest that TRPV1 receptors are important for the development of joint
inflammation and the associated mechanical hypersensitivity observed in this model.
© 2006 Elsevier Inc. All rights reserved.
Keywords: Arthritis; FCA; TRPV1; Inflammation; Mechanical hyperalgesia
Introduction
The Transient Receptor Potential Vanilloid 1 receptor
(TRPV1R; previously known as VR1 or capsaicin receptor) is
a ligand-gated, non-selective cation channel expressed predom¬
inately by primary nociceptive sensory neurons (Caterina et al.,
1997). It is found on nerves that innervate the skin (Foster and
Ramage, 1981), cornea (Belmonte et al., 1991), mucous
membranes of the mouth (Szolcsanyi and Jancso-Gabor,
1975), muscles (Kaufman et al., 1982), joints (He et al.,
Abbreviations: ANOVA, analysis of variance; CGRP. calcitonin-gene-
rclated peptide; DRG, dorsal root ganglion; EDTA, ethylenediaminetetraacetic
acid; FCA, Freunds Complete Adjuvant; IB4, isolectin B4; PMN, polymor¬
phonuclear neutrophils; SEM, standard error of the mean; TRPV1R. Transient
Receptor Potential Vanilloid 1 receptor; WT, wild type.
* Corresponding author. Fax: +44 131 651 1835.
E-mail address: N.J.Barton@sms.ed.ac.uk (N.J. Barton).
ELSEVIER
1988) and in several visceral organs within the cardiovaseular,
respiratoiy and genitourinary systems (Coleridge and Coler¬
idge, 1977; Maggi et al., 1986). In addition, these receptors are
located in the central nervous system, on small and medium size
dorsal root ganglion (DRG) cells (Caterina et al., 1997; Guo et
al., 1999; Helliwell et al., 1998), whieh co-express isolectin B4
(IB4), P2X3 purinoceptors or neuropeptides (Guo et al., 1999).
Furthermore, TRPVIRs are located on central processes of
DRG cells, in particular, those in superficial laminae of the
dorsal hom (Szallasi, 1995). The TRPV1R is a polymodal
detector of noxious stimuli including capsaicin, the pungent
ingredient in chili peppers, heat above 43°C and extracellular
pH <6 (Caterina et al., 1997). It is also capable of integrating
simultaneous exposure to these stimuli (Tominaga et al., 1998),
making it of fundamental importance in the transduction of
many types of nociceptive input (Szallasi and Blumberg, 1999).
It has been reported that mice lacking TRPVIRs are less
responsive to noxious heat and do not develop inflammation-
0014-4800/$ - see front matter © 2006 Elsevier Inc. All rights reserved,
doi: 10.1016/j.yexmp.2006.04.007
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induced thermal hyperalgesia (Caterina et al., 1997). A selective
reduction in thermal nociceptive input to the spinal cord dorsal
horn (evoked by heating of hind paw) has also been reported,
although this was not the case following partial ligation of the
sciatic nerve (Caterina, 2003). TRPV1R knockout mice show
selective deficits in behavioral assays, including tail immersion,
hot plate and radiant heating of the paw. Heat-evoked
withdrawal at relatively low noxious temperatures was
comparable to that of wild-type littennates, while at tempera¬
tures above 43°C TRPV1R-/- mice displayed a longer
withdrawal latency compared to normal mice, consistent with
impaired thermal nociception (Caterina et al., 2000). This
evidence suggests that TRPVIRs are involved in the peripheral
sensitization ofnociceptors that occurs following inflammation.
In addition, small diameter DRG neurons isolated from
TRPV1R-/- mice lacked many of the capsaicin-, acid- and
heat-gated responses that have been well characterized in these
neurons (Davis et al., 2000). In the intact mouse, these deficits
manifest as reductions in paw licking and inflammation evoked
by intraplantar injection of either capsaicin or resiniferatoxin
(Caterina et al., 2000), demonstrating that TRPVIRs are
essential for vanilloid-evoked inflammation and nociception.
Caterina et al. (2000) reported that there was no decrease in
mechanically evoked input to the spinal dorsal horn in
TRPV1R-/- mice following hind paw inflammation. How¬
ever, no studies to date have investigated the role of the
TRPV1R on mechanical hyperalgesia and inflammation
following experimentally induced murine arthritis, a joint
inflammation. The aim of our study was to test the hypothesis
that TRPV1R on nociceptive sensory nerves is crucial for the
development and maintenance of mechanical hyperalgesia and
joint inflammation in a unilateral model of chronic murine
arthritis induced by FCA. TRPV1 antagonists may have utility
as novel analgesics and hypothetically could deliver efficacy
with a safety profile quite different from the cyclooxygenase-2
inhibitors, some of which carry a potential long-term
cardiovascular liability.
Materials and methods
Experiments were performed in accordance with Home Office Regulations
and within UK animal welfare guidelines and received Local Ethics Committee
approval. Nine male C57 Black 6 (C57BL/6; Charles River, UK) wild-type
(WT) and 20 C57BL/6 male TRPV1R—/— (GlaxoSmithKline, Harlow, UK)
mice (weight range: 15-25 g) were used to investigate the consequence of
TRPVIR—/- on the development of unilateral chronic joint inflammation.
Animals were housed four to a cage in a 12-h light/dark environment and were
given free access to standard animal feed and water for the duration of the study.
Knockout of TRPVIR gene
Homologous recombination in embryonic stem cells was used to generate a
mouse lacking transmembrane domains 2-4 of the TRPVIR gene (i.e. DNA
encoding amino acids 460-555) at GlaxoSmithKline (Harlow, UK; Davis et al.,
2000). Ten male heterozygous (TRPVIR—/+) mice were mated with female
TRPV1R+/+ WT C57BL/6 mice, giving rise to overtly healthy litters in the
expected Mendelian ratios. Homozygous TRPVIR-/- mice were then
generated and crossed to provide a full colony of KO mice for the study.
Genotypes of the mice were confirmed by polymerase chain reaction and gel
electrophoresis, showing absence of the TRPVIR gene.
Induction ofarthritis
Animals were injected with Freunds Complete Adjuvant (FCA; MAFF;
10 mg ml"1 Mycobacterium tuberculosis in paraffin oil plus mannide
monooleate; n - 10 TRPVIR-/- and n - 5 WT) or vehicle (heavy liquid
paraffin oil; « = 10 TRPVIR—/ and n = 4 WT; Gauldie et al., 2004). Briefly,
injections were carried out by transiently anesthetizing the animal (3% halothane
in oxygen) and making a small incision over the left knee joint to allow visual
identification of the patella tendon. Using a 26-gauge needle mounted on a 50-pl
Hamilton syringe, FCA or vehicle (20 pi) was injected under the patella tendon
and directly into the synovial space of the knee joint.
Assessment ofarthritis
Animals were weighed, and their knee joint diameters (left and right) were
measured just below the level of the patella using hand-held micro-callipers
(Mitutoyo, Japan; accuracy ±0.1 mm).
Weight distribution between the animal's hind limbs was measured using an
Incapacitance Tester (Linton Instruments; Clayton et al., 1997), which provides
a measure of hyperalgesia. Measurements were made three times per week by
the same operator.
Histopathology
Animals were killed by cervical dislocation at the end of the study (day 35),
and the left and right knee joints were removed for histology. Joints were excised
by cutting through the femur and tibia with the skin intact and were then fixed in
30 ml of 10% neutral buffered formalin (Sigma) for 3 days. Joints were
decalcified in a saturated solution ofEDTA (ethylenediaminetetraacetic acid) for
up to 3 weeks, processed into paraffin wax and 4 pm sections were cut and
stained with either hematoxylin and eosin or alcoholic toluidine blue. Slides
were then viewed and photographed.
Data analysis and statistics
Results were collated and analyzed using Graph pad Prism and Microsoft
Excel software. Unpaired non-parametric tests were used to analyze the
difference between means of two independent groups. For paired data, the
Mann-Whitney test (non-parametric) was used; for non-paired data, the
Wilcoxon test (non-parametric) was used. To determine differences between the
means ofmore than two groups, a two-way analysis of variance (ANOVA) was
performed and a post hoc test was performed if the result was significant
(Bonferroni multiple comparison). A P value of less than 0.05 was considered
significant, rejecting the null hypothesis that the variation was due to chance. All
data are expressed as mean ± standard error of the mean (SEM).
Results
TRPVlR-null mice were viable and fertile and exhibited a
normal appearance and behaviors
Intra-articular injection of FCA had no adverse effects in
either group of mice as animals continued to feed and gain
weight normally throughout the study. There was no significant
difference in body weight between FCA-injected and vehicle-
injected WT or TRPVIR-/- mice on days 0, 7, 14, 21 and 28
post-FCA (P > 0.05, ANOVA; data not shown).
Development of unilateral arthritis in TRPVIR—/- mice and
WT mice after FCA
Baseline ipsilateral knee joint diameters in WT and
TRPVIR-/- mice averaged 3.6 ± 0.2 mm and 3.8 ± 0.2 mm
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Day
m TRPV1 -/- Ipsilateral, n=10
□ TRPV1+/+ Ipsilateral, n=5
Fig. 1. Ipsilateral inflammation of the knee joint in TRPV1R-/— and WT mice
following FCA. The ipsilateral inflammation, as assessed by swelling, was
significantly less in TRPV1R-7- mice compared to WT on each day post-FCA
(P < 0.05, ANOVA). There was no significant difference between the
ipsilateral joints of the two groups of mice on day 0. Each bar represents the
mean ± SEM. Statistical significance is represented by *. To determine
differences between the means of the ipsilateral joint diameters in the 2 groups
ofmice, on each day, a two-way analysis of variance (ANOVA) was performed
and a post hoc test was performed if the result was significant (Bonferroni
multiple comparison).
respectively; these values were not significantly different
(P > 0.05, Wilcoxon).
An intra-articular injection of FCA into the knee joint
induced inflammation in C57BL/6 WT (n = 5) and TRPV1R—/—
(n = 10) mice, but the response was significantly attenuated in
TRPV1R-/- mice (P < 0.05, ANOVA); this was the case at all
time points in the study (see Fig. 1).
Contralateral joint diameters were not significantly different
from their day 0 values at any time point, either in the WT or the
TRPV1R—/— mice, and there was no significant difference
between the WT and TRPV1R—/— contralateral joint diameters
(P > 0.05, ANOVA).
The joint diameter in the TRPV1R—/— mice was
significantly increased compared to day 0, when measured
on days 7, 14, 21 and 35 (P < 0.05, Mann-Whitney).
However, the swelling in the ipsilateral knee joints of
TRPV1R-/- mice was significantly less than that observed
in WT. The ipsilateral joint's diameter increased by 15.5,
21.1, 18.3 and 16.9% on days 7, 14, 21 and 35 respectively.
The ipsilateral FCA-injected TRPV1R—/— joint diameter on
day 28 did not differ significantly from the corresponding
pre-FCA value (P > 0.05, Mann-Whitney). In contrast, the
ipsilateral joint of WT mice increased in diameter by 61.6,
64.0, 53.4, 52.3 and 48.1% on days 7, 14, 21, 28 and 35
respectively, all of which were significantly different from
day 0 measurements (P < 0.05, Mann-Whitney).
Vehicle-injected joints showed no significant inflammation
in either TRPV1R—/— (/? = 10) or WT mice (n = 4) at any
time point, as compared to the baseline values (P > 0.05,
Mann-Whitney; data not shown). Contralateral joints of
vehicle-injected mice showed no significant difference at any
time point post-injection of FCA (P > 0.05, ANOVA; data not
shown).
Incapacitance following induction of unilateral arthritis by
FCA in TRPV1R—/— and WT mice
Prior to FCA injection (day 0), the ratio of weight
distribution between ipsilateral and contralateral limbs was
1.0 ± 0.05 in TRPV1R—/- mice (n = 10) and 0.94 ± 0.09 in WT
mice (n = 5), and these values were not significantly different
(P < 0.05, Mann Whitney).
The ratio of weight distribution between the hind limbs
for TRPV1R-/- mice decreased by 35% (to 0.65 ± 0.04),
25% (to 0.75 ± 0.14), 17% (to 0.83 ± 0.08), 12% (to
0.88 ± 0.1) and 6% (0.94 ± 0.04) on days 7, 14, 21, 28 and
35 respectively, all of which were significantly different from
the value on day 0 (P < 0.05, Mann Whitney). In contrast,
there was a significantly greater change in weight distribu¬
tion on the hind limbs in WT mice than in TRPV1R-/—
joints at all time points (P < 0.05, Wilcoxon test). From
0.94 ± 0.08, there was a decrease of 67, 60, 45, 44 and 45%
on days 7, 14, 21, 28 and 35 respectively, all of which were
significantly different from day 0 (P < 0.05 Mann Whitney;
see Fig. 2).
Intra-articular injection of vehicle into the left knee joint
in TRPV1R-/— mice (n = 10) and WT mice (n = 4) did not
affect the weight distribution (P > 0.05 Mann-Whitney; data
not shown). The ratios of weight distribution in FCA-injected
TRPV1R—/- to vehicle-injected limbs were significantly
different on days 7, 14, 21 and 28 post-injection
(P < 0.05, ANOVA; data not shown). In addition, compa¬
rison of the ratio of weight distribution in FCA-injected
WT to vehicle-injected WT showed a significant difference





Fig. 2. The ratio of weight distribution on the ipsilateral and contralateral hind
limbs for TRPV1R-/- mice and WT mice is shown. The difference between the
ratios of the 2 groups ofmice was statistically significant at all time points post-
FCA (P< 0.05, ANOVA). TRPV1R-/- mice showed significantly less mecha¬
nical hypersensitivity than WT mice following joint injury, although they still
exhibited some degree off hyperalgesia, as assessed by weight distribution. Each
bar represents the mean ± SEM. Statistical significance is represented by *. To
determine differences between the means of the ratios in the 2 groups ofmice, on
each day, a two-way analysis of variance (ANOVA) was performed and a post
hoc test was performed if the result was significant (Bonferroni multiple
comparison).
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Histopathology
Pathological changes were observed 35 days after a single
dose of FCA into the knee joint ofWT and TRPV1R-7- mice.
All FCA-treated animals had pathological changes in the
injected (left) knee joint. In most cases, there was moderate
hypertrophy of the synovial membrane and the infiltration of a
large number of polymorphonuclear neutrophils (PMN) and
macrophages into the joint space. There was also extensive
inflammation in tissues outside the joint (peri-articular inflam¬
mation) including tendons, ligaments and surrounding muscle.
In many, small amounts of pannus were observed associated
with mild erosion of the articular cartilage and erosion of bone.
Examples of new bone formation were also observed. In a few
instances, mild pathology was noted, including mild thickening
of the synovial membrane, PMN infiltration and peri-articular
inflammation, in the absence of either joint swelling or
hyperalgesia in vehicle-injected joints, likely a result of injury
during injection. There were no differences detected between
the TRPV1R-/- mice and WT mice. The contralateral knee
joint showed no changes in any animal.
Discussion
This study was performed to determine whether TRPV1
receptors are essential for the development and maintenance of
chronic unilateral arthritis in mice. Joint swelling, a measure of
edema, was significantly greater in WT mice than it was in
TRPV1R-/— mice following intra-articular FCA. Furthermore,
mechanical hyperalgesia was reduced in knockout animals
compared to WT.
The animal's weight when standing on the hind limbs was
carried equally by both limbs in the normal state. Following
injection ofFCA, the weight distribution was altered. There was
an increase in weight placed on the contralateral joint and a
corresponding reduction in loading of the ipsilateral joint,
meaning the inflamed limb was being guarded. TRPV1R-/-
rnice do not shift their weight to the contralateral limb to the
same degree as WT mice, a finding that is consistent with
reduced mechanical hyperalgesia.
Although the knee joints of knockout mice were inflamed
following the induction of unilateral arthritis and were swollen
in comparison with the contralateral limb or with vehicle-
injected counterparts, the inflammation was significantly less
than that developed by wild-type mice. This is in agreement
with Keeble et al. (2004) who reported that TRPV1R knockout
mice have decreased plasma extravasation in the knee joints
following induction of experimental arthritis compared to wild-
type mice. Caterina et al. (2000) also reported that TRPV1R-/-
mice develop less paw swelling in response to intraplantar
injection of vanilloid compounds.
The attenuated inflammation we observed in TRPV1R-/-
mice in the present study probably resulted from a reduction in
TRPVlR-induced peptide release from sensory afferent nerves.
Thus, following stimulation by noxious mediators activated by
injection ofFCA, capsaicin-sensitive neurons trigger the release
of neuropeptides from their peripheral tenninals. Substance P
(which triggers plasma extravasation) and calcitonin-gene-
relatcd peptide (CGRP; which stimulates vasodilatation) are the
two main peptides released from capsaicin-sensitive sensory
afferents; without the release of these peptides, the micro-
environment following tissue injury may be quite different in
TRPV1R -/— mice to that in wild-type mice, where release of
peptides results in the recruitment of more serum factors and
inflammatory cells to promote healing at the site of injury.
However, under pathological circumstances, excessive neuro¬
genic peptide release by capsaicin-sensitive afferent neurons is
thought to contribute to the maladaptive inflammation associ¬
ated with several conditions, including arthritis.
Davis et al. (2000) reported that knocking out the TRPV1
receptor eliminated thermal hyperalgesia following carageenan-
induced inflammation. In addition, it has recently been
demonstrated that TRPV 1 receptors were responsible for post¬
operative heat hyperalgesia but were not involved in mechanical
hypersensitivity in a model of incisional pain (Pogatzki-Zahn et
al., 2005). However, this study also showed that neither the
proportion of TRPV 1R immunoreactive neurons in the DRG,
nor the TRPV1R staining in the sciatic nerve, changed in WT
mice following the tail incision. This is in contrast to other
studies using other experimental models of pain. For example,
Carlton and Coggeshall (2001) showed that TRPV1 receptors
function and expression are increased in IB4-positive neurons
following intraplantar FCA (Breese et al., 2005). Approximate¬
ly 17% of unmyelinated C fibers in rat digital nerves
immunostain for TRPV1R, and this proportion increased to
almost 100% 48 h post-FCA inflammation, which would
contribute to the thermal hyperalgesia and peripheral sensitiza¬
tion in inflammatory conditions (Carlton and Coggeshall,
2001). Other studies have shown that there were no differences
between knockout and WT animals in formalin-induced
nocifensive behavior, carageenan-evoked inflammatory me¬
chanical hyperalgesia and partial sciatic nerve lesion-induced
neuropathic mechanical hyperalgesia (Bolcskei et al., 2005).
Several other studies have shown that TRPV 1 receptors are
necessary for the development of thermal inflammatory
hyperalgesia, but as yet, none has identified a role in joint
mechanical hypersensitivity. We found that TRPVlR-null mice
develop less mechanical hypersensitivity in the injected joint, as
shown by the change in their weight distribution between hind
limbs being less marked than in WT animals suggesting less
discomfort in the injected joint and a reduced mechanical
hyperalgesia compared to wild-type mice. It has been reported
that TRPVlR-null mice had normal withdrawal thresholds to
punctuate stimuli applied to the hind paw. In addition, responses
to intense tail pinch were also indistinguishable from those of
wild-type littermates (Caterina et al., 2000). However, TRPV1R
antagonists have been found to have analgesic activity in animal
models of chronic inflammatory and neuropathic pain (Garcia-
Martinez et al., 2002; Pomonis et al., 2003; Walker et al., 2003).
Pre-treatment with the TRPV1 antagonist capsazepine pre¬
vented the development of mechanical hyperalgesia of
capsaicin-injected foot pads in rats, mice and guinea pigs
(Walker et al., 2003). In addition, capsazepine reversed
mechanical hyperalgesia in the guinea pig FCA-injected hind
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paw but had no effect in rats or mice (Walker et al., 2003).
Similarly, in the partial sciatic nerve ligation model of
neuropathic pain, capsazepine was surprisingly effective in
the guinea pig, producing up to 80% reversal of mechanical
hyperalgesia but had no effect in the rat or mouse (Walker et al„
2003).
It would be beneficial to have, in addition to the
incapacitance readout, a measure of hyperalgesia present solely
in the knee joint. This would enable the primary hyperalgesia in
the joint itself, as a result of FCA-injection, to be studied;
whereas the incapacitance tester measures whole limb changes.
We are developing a device to measure the force applied to stifle
joints, which will give significantly more information about
hyperalgesia in the inflamed joint.
The histology showed that there were no major differences
between the WT and TRPV1R-/- mice, which indicates that
the TRPV1 receptor is not involved in initiating the pathological
changes that occurwithin the joint. The receptor appears only to
alter the hypersensitivity and the degree of inflammation that
occurs alongside these structural changes.
In conclusion, our studies suggest that the TRPV1R plays an
important role in the development and maintenance of
inflammation of the joint and also in the mechanical
hypersensitivity developed as a result of FCA injection.
However, as the inflammation and hyperalgesia were not
completely attenuated, it is probable that other mechanisms play
a role in the inflammation processes and/or that, in the absence
of TPRVR, other mediators and receptors may play a
compensatory role. These results have implications for the
future development of novel anti-arthritis drugs targeting the
TRPV1 receptor as such agents may be analgesic as well as anti¬
inflammatory.
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Abstract
Chronic joint pain affects physical well being and can lead to severe psychological and social problems, therefore successful long-term manage¬
ment is highly sought-after. No current behavioural measures of pain used in pre-clinical models mimic the clinical dolorimeter, which provides
an objective measure of joint hypersensitivity. In this study we aim to use a novel behavioural readout alongside an established measure to mimic
the multifactorial measurements taken in the clinic. Using the pressure application measurement (PAM) device a gradually increasing squeeze was
applied across the knee joint of rats until the animal gave an indication of pain or discomfort. PAM and the incapacitance tester were used to detect
joint hypersensitivity in a well-established rodent model of adjuvant-induced arthritis. Subsequently, the analgesic effects of prednisolone (1,3
or lOmgkg-1), morphine (3mgkg~') and celecoxib (15mgkg_l) were assessed. Both PAM and the incapacitance tester detected a reversal of
hypersensitivity 1 h post-drug administration. Furthermore, the two readouts were highly correlated, and power analysis indicated that PAM was
highly reproducible. In conclusion, PAM provides a novel, accurate behavioural tool for detecting a primary mechanical hypersensitivity in a rat
model of chronic inflammatory joint pain.
© 2007 Elsevier B.V. All rights reserved.
Keywords: Rat; hypersensitivity; Joint; Force; Withdrawal; Pressure application
1. Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are preva¬
lent diseases, with estimated incidences of 12.5% (Bedson
et al., 2005) and 0.8% (Symmons, 2005) in the UK adult
population, respectively. Arthritis is associated with chronic,
debilitating pain in the joints. Pain is the most common symptom
of patients seeking medical consultation (Loeser and Melzack,
1999). Chronic joint pain not only affects physical well being,
for instance impairing the ability to work, but can also lead to
severe psychological and social problems as a result of sleep dis¬
turbance, anxiety and depression (Ashburn and Staats, 1999).
Successful long-term management is therefore highly sought-
after.
* Corresponding author. Tel.: +44 131 6511913; fax:+44 131 6511835.
E-mail address: s0093836@sms.ed.ac.uk (I.T. Strickland).
1 Equal contributors.
Rodent models of chronic inflammatory joint hypersensitiv¬
ity have been developed (Chiilingworth and Donaldson, 2003;
Donaldson et al., 1993; Gauldie et al., 2004; Wilson et al., 2006)
to help elucidate the underlying pathophysiology involved in
arthritic conditions by identifying specific key modulators or
receptors involved in the pain process. These models are com¬
monly used as pre-clinical screens for novel analgesics, with
the aim to improve the treatment of chronic joint pain in the
clinic. In order to do this successfully it is essential that results
from pre-clinical models correlate well with observed changes
in the clinic to facilitate the translation of novel treatments into
successful patient pain management.
To date, several behavioural readouts have been used to assess
joint hypersensitivity in animal models, using thermal, mechan¬
ical, or electrical sensory stimuli (for review see Le Bars et
al., 2001). Only the weight distribution readout obtained using
an incapacitance tester (Clayton et al., 1997) has so far been
considered as a fairmeasurement of the persistent chronic hyper-
0165-0270/$ - see front matter © 2007 Elsevier B.V. All rights reserved,
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sensitivity observed in patients. The incapacitance tester is able
to provide an objective, non-evoked assessment of "incident"
pain by measuring the average weight placed on each hind
limb. Naive rodents distribute their weight equally between both
hind limbs under normal conditions (Kobayashi et al., 2003).
However, following induction of joint inflammation, animals
redistribute their weight in order to put less weight through the
affected joint.
Whilst this readout has gone a long way to correlate with the
clinical observation of 'pain on standing' it is only one mea¬
surement of complex pain. In the clinic, patients are scored by a
variety of readouts or tasks, often being subjected to firm squeez¬
ing of affected joints (Ritchie et al., 1968). For instance, using
the pressure dolorimeter (Langley et al., 1983), a localised quan¬
titative measure of hypersensitivity directly around the affected
joint can be measured. Using this device, a gradually increas¬
ing pressure is applied perpendicularly across the joint until the
patient indicates tenderness or pain, at which point a 'sensitivity'
score is recorded. Clinicians are able to summate a number of
quantitative evaluations to assess a patient's level of pain or dis¬
comfort. In this study we aim to use a novel behavioural readout
alongside an already established readout, with a view to bring¬
ing together two quantitative animal evaluations to mimic the
multifactorial measurements taken in the clinic.
Here we describe a novel behavioural readout, for use with
rats, utilising similar principles to the clinical pressure dolorime¬
ter. The pressure application measurement (PAM) device is
designed to apply a gradually increasing squeeze pressure
directly across the kneejoint of rats until the animal gives an indi¬
cation of pain or discomfort. At this point a quantitative value of
the force applied is recorded, giving a similar 'sensitivity' score.
The aim of this study was to determine if PAM was able to
detect a Freund's complete adjuvant (FCA)-induced hypersen¬
sitivity in the knee joints of rats, and subsequently if PAM could
detect a reversal of this hypersensitivity using analgesics known
to be effective in the clinic. A dose-response study using pred¬
nisolone (Pyne et al., 2004), and further studies using morphine
(Caldwell et al., 2002), and celecoxib (Schnitzer et al., 2005),
were performed to investigate the reproducibility and sensitivity
(a)
of PAM, whilst comparing the device with the already estab¬
lished weight distribution readout. Thus enabling an additional,
clinically relevant pain readout to be applied pre-clinically aid¬
ing the translation of novel analgesics from animal to man.
2. Materials and methods
Experiments were performed in accordance with Home
Office regulations and within UK animal welfare guidelines, and
received Local Ethics Committee approval. Adult male Wistar
rats (Charles River, UK; initial weight range 137-284 g) were
used in the study. Animals were housed four to a cage in a 12 h
light/dark environment and were given free access to standard
animal feed and water for the duration of the study. All ani¬
mals were allowed 6 days acclimatisation before the experiment
began and all behavioural tests took place in the same room at
the same time of day. Animals were weighed on each test day
to monitor their general health.
2.1. Behavioural assessment
2.1.1. PAM-knee joint withdrawal threshold measurement
PAM consists of a force transducer mounted on a unit fitted
to the operator's thumb (see Fig. 1). The thumb unit is connected
to a recording base unit containing the control panel and digital
readout display. The apparatus has a force transducer with a
range of 0-1500 g (Honeywell, Farnell, UK) and the diameter
of the circular contact is 8 mm; giving the device a surface area
of 50.3 mm2.
Animals were lightly, but securely held and the operator
placed the thumb unit on one side of the animal's knee joint
and the forefinger on the other. A gradually increasing squeeze
force was applied across the joint at a rate of approximately
300 grams per second ensuring the maximum test duration was
5 s. By means of calibrated instrumentation the force in grams
applied was displayed on the digital screen and recorded. The
test endpoint was when the animal withdrew its limb or showed
any behavioural signs of discomfort or distress, such as freezing
of whisker movement or wriggling. As the animals were lightly
(b)
<>
Fig. 1. Presentation of the pressure application measurement (PAM) device, (a) The portable control unit with digital display and thumb attachment; (b) PAM in use
measuring the limb withdrawal threshold (LWT) of a rat.
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held with their hind limbs suspended, any movements to pull or
twist out of the operator's fingers were obvious. Any motion to
attempt to withdraw from the device was transferred from the
rat limb to the operator's fingers and forearm, and was taken as
an indication of the test end point. On very rare occasions the
first sign of distress was shown as the animal vocalising prior
to limb withdrawal, and on these occasions this was taken as
the test end point. The peak gram force (gf) applied immedi¬
ately prior to limb withdrawal was recorded by the base unit,
and this value was designated the limb withdrawal threshold
(LWT). Three measurements of both the ipsilateral and con¬
tralateral limbs were made at 1 min intervals during which the
animals were returned to their respective cages. The mean LWTs
were calculated.
2.7.2. Incapacitance tester—weight distribution
The weight distribution between the animal's hind limbs was
measured using the incapacitance tester (Linton Instruments,
UK): The apparatus consists of two force transducers capable
of measuring the body weight that the animal places on each
hind limb. Animals were placed on the incapacitance tester with
their hind paws centred on the two force transducers; the average
body weight distribution in grams was calculated over a period
of three seconds. Weight placed through the ipsilateral limb was
expressed as a ratio of the weight placed through the contralateral
limb, with a ratio of 1.0 resulting from equal weight distribution
across both hind limbs. Each animal had three recordings taken
per test day and the mean weight distribution ratio was calculated
for each group.
2.1.3. Knee joint diameter
The knee joint diameters (left and right) were measured
just below the level of the patella using hand-held digital
micro-callipers (Mitutoyo, Japan; accuracy ±0.1 mm), used as
a measure of swelling during the study.
2.2. Arthritis induction
Rats were transiently anaesthetised with 3% halothane in
oxygen. FCA (1 mg ml"1; Sigma, UK) was injected at a volume
of 150 |xl into the joint space of the left knee through the patella
tendon using a sterile 25-gauge needle (B&D Microlance, UK).
Control animals were anaesthetised but received no injection.
The animals were allowed to recover from anaesthesia before
being returned to cages.
2.3. Study design and drug treatment
A pilot study was carried out to determine whether PAM
could detect a window of hypersensitivity following intra¬
articular FCA in comparison with sham animals. The study also
compared values for PAM with those obtained in the same ani¬
mals using the incapacitance tester. Baseline values for body
weight, weight distribution, PAM LWT and knee joint diam¬
eters were measured on day 0, prior to induction of the joint
inflammation, and were repeated two to three times per week
until day 28. No habituation to the PAM device was conducted.
Secondly, a drug-treatment study was carried out, to inves¬
tigate whether PAM was able to detect reversal of this joint
hypersensitivity and how this differed with three types of drug,
an opioid, a steroid and a non-steroidal anti-inflammatory drug
(NSAID). In order to perform a thorough pharmacological
investigation in this study, whilst using the minimum number
of animals, a dose-response relationship to prednisolone was
examined and single top doses of an opioid and an NSAID
were also investigated. A pre-study behavioural assessment was
introduced to habituate the animals to the device. Baseline val¬
ues for body weight, weight distribution, PAM LWT and knee
joint diameters were measured on day 0, prior to induction of
the joint inflammation. Measurements were made two to three
times per week until day 10, when animals were randomly
assigned into treatment groups. Drugs were administered sub-
cutaneously (s.c.) in a volume of 2 ml kg-1 between days 14
and 18. Prednisolone (1, 3 or lOmgkg-1) was dosed once per
day; whereas morphine (3mgkg_1), celecoxib (15mgkg~')
and vehicle (ethanol 5%, PEG 45% and distilled water 50%)
were given twice a day. The dose range of prednisolone used
was decided from published results from the lab (Gauldie et al.,
2004), and single doses ofmorphine and celecoxib were decided
from other studies giving strong positive reversals of hyper¬
sensitivity (Wilson et al., 2006). One hour after blind dosing,
behavioural assessments were made following a strict protocol
in orderto give animals a rest period between the weight distribu¬
tion and the PAM measurements. Briefly, animals were weighed
and had their weight distribution assessed by making three
consecutive readings before being returned to their cage. Ten
minutes later animals had the sensitivity of both the ipsilateral
and contralateral joints assessed using PAM. Three consecutive
readings were taken, with a 1 min interval between each mea¬
surement, where the animal was returned to the cage. Finally the
knee joint diameters were measured. Further behavioural assess¬
ments were carried out once the dosing period was complete, on
days 21, 24 and 28.
2.4. Data analysis
Prior to analysis, an area under the curve (AUC) summary
of each animal's repeatedly measured responses during the
dosing period was calculated. These AUC values were then anal¬
ysed using a one-way analysis of variance (ANOVA) approach.
Measurements taken over several days were analysed using a
repeated measures ANOVA. In both cases, individual groups
were compared using planned comparisons on the predicted
means. Differences between ipsilateral and contralateral sides
were analysed using paired r-tests. In all cases the null hypoth¬
esis was rejected at P<0.05. The data were log transformed
where appropriate to stabilize the variance. Data are expressed
as observed mean ± standard error of the mean (SEM). Statisti¬
cal analyses were carried out using Statistica version 6 (Statsoft,
Tulsa, OK, USA).
Two different power analyses were carried out on the drug
study to investigate the reliability and confidence levels obtained
from the two different readouts in the framework of this exper¬
imental design. In the first, perhaps more standard power
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analysis, the number of animals required to reach a certain power
obtained from an observed drug effect was assessed. For this
analysis, calculations were based on an effect size equivalent to
the observed difference between vehicle and the highest dose of
prednisolone.
In the second analysis, the effect of varying the number of ani¬
mals used, or the numbers of measurements made, on the power
of the experiment was assessed. By calculating the animal and
measurement variance components, for the weight distribution
and PAM LWT responses separately, we investigated the effect
of varying replication of both animals and the measurements on
the statistical power of the treatment comparisons.
3. Results
In both studies, intra-articular injection of FCA had no
adverse effects on the animal's general health as evidenced by
the fact that they continued to feed and gain weight normally
throughout the study. There were no significant differences in
body weights between any of the FCA-injected and sham ani¬
mals at any time point (data not shown).
In both studies there were no significant differences between
the mean PAM LWTs or knee joint diameters of the ipsi-
lateral and contralateral limbs and no significant differences
between treatment groups, prior to FCA injection on day 0
(P>0.05).
3.1. Behavioural evaluation ofFCA-induced
hypersensitivity
3.1.1. Pressure application measurement (PAM)
Prior to induction of joint inflammation (on day 0), the aver¬
age ipsilateral LWT was 710 ±41 gf (n = 16) and the average
contralateral LWT reading was 790±39gf (n= 16). Following
injection of FCA, the average ipsilateral LWT of the treatment
group decreased by 57% to 316±45gf (n = 8), by day 1. This
was significantly lower than both the day 0 value (P < 0.05) and
the sham group at the same time point (P< 0.001; see Fig. 2a).
Despite receiving no further treatment the ipsilateral LWT of
sham animals increased significantly by 57% to 1028±48gf
(n = 8,P< 0.05) on day 1. The average ipsilateral LWT of FCA-
injected rats were significantly lower than sham and contralateral
joints (P<0.05) over the full 28-day time course studied.
3.1.2. Incapacitance tester—weight distribution
The average ratio of weight distribution between ipsilat¬
eral and contralateral limbs in rats was 0.96±0.03 (n= 16)
on day 0. The ratio of weight distribution between the hind
limbs for FCA injected rats decreased by 70% to 0.29 ± 0.05
(n = 8, see Fig. 2b). This was significantly less than sham ani¬
mals (P<0.05), which had a ratio of 1.05 ±0.02 (n = 8) at this
time point. The ratio remained significantly reduced in FCA-
injected animals compared with the sham group up to and
including day 28 (P< 0.001). There were no significant changes
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Fig. 2. (a) The ipsilateral PAM LWTs in gram force and (b) ratio of weight
distribution between the hind limbs of sham (n-8) and FCA-injected (n = 8)
rats over a 28-day pilot study. PAM detected a large window of hypersensitivity,
similar and comparable to that observed with the incapacitance tester. Statistical
significance (P<0.05) is represented by *; statistical analysis carried out to
compare the two groups at each time point using a repeated measures ANOVA.
3.1.3. Joint inflammation
Basal measurements of joint diameter were 9.92 ±0.08 mm
for ipsilateral knees (« = 16), and 9.85 ±0.12 mm for contralat¬
eral knees (n=16). On day 1, the average ipsilateral knee
joint diameter of FCA-injected animals was 13.11 ±0.06mm
(ji = 8), compared with 10.12 ± 0.1 mm (n = 8) in control ani¬
mals. The swelling remained significant compared with sham
animals on days 2, 5, 7 and 9 post-FCA (P< 0.001), how¬
ever, thereafter the values returned towards basal levels, and
no further significant differences were observed (data not
shown).
3.2. Behavioural evaluation of the effect ofa dose range of
prednisolone, and single doses ofmorphine and celecoxib
on the FCA-induced hypersensitivity
3.2.1. Pressure application measurement (PAM)
Measurements were made on days 0, 2, 4, 7 and 10,
to determine that a window of hypersensitivity was present
prior to drug treatment regimes. On each of these days the
ipsilateral PAM LWTs of all FCA-injected animals (n = 47)
were significantly less than those of the sham group (n = 8,
P< 0.0001). On day 10, arthritic rats were randomly assigned
into one of six treatment groups; celecoxib 15mgkg_I
(n = 8), morphine 3mgkg_l (n = 8) or prednisolone 1 (n = 7),
3 (n = 8), or lOmgkg-1 (/; = 8). AUC values were calcu-
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Fig. 3. The (a) ipsilateral PAM LWTs and (c) weight distribution ratios of vehicle and prednisolone treated arthritic rats and the corresponding graphs of AUC values
for the two readouts during the dosing period (b and d). The drug-dosing period was between days 14 and 18 as indicated by the box on the graphs. The incapacitance
tester was able to detect the dose-dependant reduction in hypersensitivity evoked by FCA in groups treated with 1, 3 and lOmgkg"' prednisolone. PAM did not
show a three-point dose-response, instead the 1 and 3 mg kg-1 doses gave similar responses, whereas the 10 mg kg-1 gave a greater reversal. Statistical analysis was
carried out to compare the AUC values for the drug-treated group compared with vehicle; 'Statistical significance (P< 0.05), determined by an ANOVA.
Iated for each individual animal to observe any drug induced
analgesia over the 5-day dosing period. AUC values were
calculated using each animal's day 10 value as a base¬
line to observe changes from day 14 through to day 18.
Results showed that PAM detected a significant analgesic
effect of all drugs administered (P< 0.0001 for morphine,
celecoxib and prednisolone lOmgkg-1, and P<0.05 for
prednisolone 1 and 3mgkg~', compared with vehicle, see
Figs. 3a and 4a).
Further PAM LWT measurements were taken after the ces¬
sation of drug-treatment, on days 21, 24 and 28. In all groups
any analgesic effect of the compound previously administered
was abolished, with there being no significant difference to the
vehicle-treated group.
3.2.2. Incapacitance tester—weight distribution
Measurements were made on days 0, 2, 4, 7 and 10, to
determine a window of hypersensitivity was present prior to
drug treatment regimes. On each of these days the weight
distribution ratio of all FCA-injected animals (n = 47) was
significantly less than those of sham (n = 8, P<0.0001).
AUC values were calculated for the dosing period and
showed that the FCA-induced hypersensitivity was signifi¬
cantly reversed by celecoxib 15mgkg-1 (/; = 8), morphine
3 mg kg-1 (n = 8) and prednisolone at 3 (n = 8) and 10 mg kg-'
(n = 8) (P<0.05, compared with vehicle), but not by 1 mgkg-1
(n = 7) prednisolone (see Figs. 3 and 4c). The weight dis¬
tribution ratio AUC values also revealed a dose related
reversal of hypersensitivity using the incapacitance tester (see
Fig. 3d).
Further measurements made on days 21, 24 and 28, revealed
that the incapacitance tester detected no lasting reversal of hyper¬
sensitivity following the cessation of drug administration with
there being no significant difference between each drug group
and vehicle (P>0.05).
3.2.3. Joint inflammation
Subcutaneous dosing of 3 mg kg-1 morphine or 15mgkg~'
celecoxib had no effect on FCA-induced joint swelling. How¬
ever, prednisolone at 1, 3 and lOmgkg-1 all significantly
reduced the average ipsilateral knee joint diameter, (P<0.05,
compared with vehicle) during the dosing period (data not
shown).
3.2.4. Correlation of the PAM with weight distribution
In order to determine the strength of the correlation between
the results obtained from the two readouts, a Spearman's linear
regression analysis was carried out. The mean PAM ipsilat¬
eral LWT for each group was plotted against the mean ratio
of weight distribution of the same group, with results from all
experimental days included. A strong correlation between the
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Fig. 4. The (a) ipsilateral PAM LWTs and (c) weight distribution ratios of vehicle-, morphine- and celecoxib-treated arthritic rats; and the corresponding graphs of
AUC values for the two readouts during the dosing period (b and d). The drug-dosing period was between days 14 and 18 as indicated by the box on the graphs.
PAM was able to detect the analgesic action of both drugs compared with vehicle. Statistical analysis was carried out to compare the AUC values for the drug-treated
group to that of vehicle-treated animals using an ANOVA; 'Statistical significance (P<0.05).
results obtained from the two different readouts was observed
(see Fig. 5a; Spearman r= 0.91; PcO.OOOl).
3.2.5. Power analysis of rat drug study
The first power analysis performed (Fig. 5b) was calcu¬
lated from the effect size equivalent to the observed difference
between vehicle and the highest dose of prednisolone. Graphi¬
cal results clearly show that in the structure of this experimental
design, where each animal has three measurements taken for
each readout, that a higher statistical power was achieved from
the PAM readout compared with the weight distribution read¬
out. In this experimental design if six animals per group were
used for investigating a hypothesised drug effect equal to the
observed effect, we could expect to achieve approximately 97%
power using the PAM readout, but only 70% power with the
weight distribution readout.
In a second power analysis (data not shown) results revealed
that the statistical power could be greatly increased in the PAM
readout, by increasing the number of measurements taken per
animal from three to five, however increasing the number of
animals used from 8 to 10 showed no real benefit. This was in
contrast to the weight distribution readout, where increasing the
number of animals from 8 to 10 greatly improved the power, but
incfeasing the number of measurements showed no real bene¬
fit. This highlights the benefit of investigating the experimental
design. For PAM we can actually increase the statistical power
of an experiment by increasing the number of measurements
while reducing the number of animals.
4. Discussion
This study has demonstrated the use of a novel behavioural
tool for assessing joint pain in a rat model of experimental
chronic joint inflammation. The results of these studies indi¬
cate that PAM provides a reliable, quantitative measurement
of localised, FCA-induced mechanical hypersensitivity in the
knee joint of rats. PAM was also able to detect the analgesic
action of prednisolone, morphine and celecoxib. Furthermore, a
strong correlation between the weight distribution readout and
the PAM measurements were made, illustrating that PAM is a
simple behavioural test that will be a valuable addition to current
measures for assessing hypersensitivity in the joint.
Clinically, joint pain is assessed either subjectively using
the Ritchie articular index or objectively using a dolorimeter
(Langley et al., 1983; Ritchie et ah, 1968). The Ritchie articu¬
lar index allocates one of four grades of tenderness in patients'
joints: "not tender" (0), "tender" (1), "tender and winced" (2)
and "tender, winced and withdrew" (3). Previous studies car¬
ried out in this laboratory used a similar subjective scale ofjoint
hypersensitivity (Gauldie et ah, 2004). However, a quantitative
measure, which mimics the pressure dolorimeter, would con¬
siderably improve assessments of experimental joint pain by
providing an objective measure. The dolorimeter uses a grad¬
ually increasing force, applied in a perpendicular plane across
the joint margin, to assess localised hypersensitivity of a human
joint. The dolorimeter can be used on different joint types and
has been adopted in clinical studies assessing osteoarthritis
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Fig. 5. (a) The correlation between the absolute ipsilateral LWTs (measured by
PAM) and the ratio of the weight distribution between the hind limbs (measured
by the incapacitance tester) in rats. There was a strong correlation between the
two readouts (Spearman linear correlation factor, r=0.91, P < 0.0001). (b) Anal¬
ysis of the sample sizes required from the PAM and weight distribution (WD)
readouts in triplicate measurements to reach certain statistical power levels.
Results are calculated from an effect size equivalent to the observed difference
between the vehicle group and the lOmgkg"1 prednisolone group and results
are based upon the observed variability in the study.
(Ottillinger et al., 2001) of the knee as well as the pain associated
with fibromyalgia (Gracely et al., 2003). Currently, no objective
measure of joint hypersensitivity is used to assess experimental
arthritic joint pain in laboratory rodents. To that end, PAM was
developed to align pre-clinical measures to those used clinically
and help the translation of animal studies to human conditions.
Calibrated forceps have been used as a means ofmechanical
stimulation during electrophysiological recording (Gracely et
al., 2003; Li and Neugebauer, 2004; Neugebauer and Li, 2002),
or to measure knee joint or paw pain in experimental inflam¬
mation and primary hyperalgesia induced in deep tissues by
inflammation (Han et al., 2005; Luis-Delgado et al., 2006; Yu
et al., 2002). The latter involved direct application of the for¬
ceps to muscle or to the knee joint of rats (Cui et al., 1999;
Skyba et al., 2005). However, although the technique is reported
to be an easy to use, reliable method of assessing nociceptive
withdrawal thresholds, they also show a steady increase in paw
withdrawal threshold over a 9-day period that was highly corre¬
lated to an increase in weight gain over this time (Luis-Delgado
et al., 2006). The authors suggest that the modification of pain
sensitivity was due to increased size of the paw. This problem
does not arise with PAM, as no change in pain threshold occurred
over a 3-week period, despite the animals gaining weight in each
study. In the pilot study a significant increase in LWT was noted
in ipsilateral joints of naive rats and contralateral joints of all
animals. This increase was due to the absence of initial induc¬
tion measurements prior to the start of the study. Subsequently, a
pre-study behavioural assessment was carried out prior to study¬
ing the effect of chosen gold standard analgesics, removing this
initial anomalous result.
The authors in these studies reported several problems with
the forcep style of device, including variation caused by the
operator due to finger placement on the forceps, and inaccurate
values of withdrawal thresholds, as the calibrated reading given
is a function of the force applied by the experimenter and the
resistance offered by the joint. PAM is calibrated directly across
the force transducer and directly records the precise force placed
across the knee joint, up until the point of joint withdrawal. As
PAM uses a single force transducer worn on the experimenters
thumb, the amount of operator variation will only occur in the
placement of the transducer on the knee joint of the animal being
tested. However this is only a minor issue as the large surface
areas of the PAM thumb attachment removes potential inaccu¬
racy in focusing on an exact point on the joint, which happens in
the case of small forcep tips. A further advantage of PAM is the
ability to change the size of the pressure application surface and
the force range of the transducer, allowing the device to be used
in several species as well as the possibility of assessing other
joints and paws.
In this study, PAM proved to be an easy to use device, which
allowed rapid, reproducible measurements, using triplicate mea¬
surements at each time point taken. The absence of a significant
difference between the ipsilateral and contralateral LWT in naive
animals, together with the low variability, indicated that PAM
could use the contralateral joint as an internal control, an idea
originally proposed by Randall and Selitto (1957).
Typical withdrawal thresholds for naive rats were approxi¬
mately 1000 gf. These values are considerably higher than those
seen in the paw using calibrated forceps or the Randall and
Selitto device (Baamonde et al., 2004; Cook and Moore, 2006;
Luis-Delgado et al., 2006; Randall and Selitto, 1957; Walker et
al., 2003) which is probably due to the difference in the size and
gross anatomy of the paw and the knee joint, in addition, the
surface area over which the pressure is applied differs between
the different devices. Pressure exerted onto the skin may activate
nociceptive afferents in several tissues, depending on the surface
area of the object used. Contact with a punctuate object such as a
needle may exclusively activate nerve endings in the skin, in par¬
ticular C fibres. Because deformation of the skin can be achieved
with very small forces (Garell et al., 1996; Garnsworthy et al.,
1988; Khalsa et al., 1997), these stimuli have little effect on
afferents innervating deeper tissues. In contrast, a preferential
activation of deep afferents is possible if pressure is exerted
on a larger area of skin and the contact surface is rounded or
padded (Treede et al., 2002). According to experiments using
topical local anaesthesia, the contribution of cutaneous afferents
to pain evoked by blunt pressure is minor (Kosek et al., 1995).
This evidence adds support to the use of PAM as a measure
of nociceptive activity in deeper tissues such as the joint itself,
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rather than overlying skin. This is in contrast to von Frey hairs,
which as a punctuate stimulus, activate skin afferents rather than
those innervating the joint capsule and surrounding tissues.
Neugebauer and Li (2002) report that pressure stimuli
>50 g mm-2 applied to the knee joint with calibrated forceps was
noxious, as it consistently evoked hind limb withdrawal reflexes
in awake rats. When values in our study were transformed into
an approximate pressure the noxious LWT was ~20gfmm-2.
However, the data from PAM is not routinely presented as a force
per unit area (pressure), as it cannot be assumed that the entire
surface of the disc is in contact with the joint, furthermore in
inflamed joints the deformation of the joint onto the disc is dif¬
ferent to that in naive animals. PAM measurements are therefore
more accurately expressed as a force, in grams.
PAM was able to detect FCA-induced hypersensitivity,
observed as a decrease in LWTs of around 60% compared
with the basal levels in normal joints. This hypersensitivity was
time matched to the significant inflammation observed following
FCA injection. The ability of PAM to detect FCA-evoked hyper¬
sensitivity provides an excellent experimental model in which to
test the analgesic properties of novel compounds over a period
of stable inflammation between days 14 and 18 post-FCA.
Prednisolone, a standard positive control in drug screening
(Pyne et al., 2004), was studied over a 5-day period to check
whether the drug would lead to a resolution of FCA-induced
hypersensitivity as a correlate to the hyperalgesia we would
expect to see in man. PAM detected prednisolone analgesia,
over the 5 days of dosing, which was abolished after dosing
ceased. PAM also showed significant reversal ofevoked mechan¬
ical hypersensitivity in arthritic rats treated with the opioid
morphine and the cyclooxygenase-2 inhibitor, celecoxib, which
was comparable to that seen in the weight distribution readout.
Dose-related reduction of hypersensitivity to prednisolone was
not observed using PAM whereas a dose related analgesia was
observed using the incapacitance tester. When using weight dis¬
tribution, the global effects of each drug on the whole animal are
determined, whereas the PAM device is measuring a localised
effect at the knee joint. This may explain why the PAM results
observed were not dose related, as the doses were sub-threshold
for a dose-response curve to be observed as measured by the
PAM device.
When results are examined strong correlations are seen
between the two behavioural assessments. These results suggest
that both techniques have the ability to detect a joint hypersensi¬
tivity, which can be attenuated using gold-standard analgesics.
PAM has the added advantage of assessing the hypersensitivity
of the joint at the site of the inflammation, in a similar fashion
to the clinical dolorimeter (Langley et al., 1983).
The 3R's play a large part in the planning of in vivo studies,
where the aim is always to reduce the number of animals used, or
refine the techniques involved. In this study we have shown that
PAM measurements can be collected alongside the usual weight
distribution recordings, increasing the information from a sin¬
gle set of animals. The power analysis performed on this study
has shown that PAM has a higher statistical power as a tool for
measuring the efficacy of drugs used to reverse the FCA-induced
hypersensitivity than the weight distribution readout. The power
curves suggest that if PAM were used as a stand-alone readout
in future studies then the number of animals per group could
be reduced from eight to six, without compromising the statis¬
tical power of the study. Potentially PAM could be used to help
reduce the number of animal's required in future joint hyper¬
sensitivity studies, but we are aware that these plots are based
on the variability calculated from a single study. Replication of
these results in further studies would increase the confidence in
the conclusions drawn in this article.
In conclusion, the present study shows that PAM provides a
novel, accurate behavioural tool for detecting a localised primary
mechanical hypersensitivity in a rat model of chronic inflamma¬
tory joint pain. PAM is the first tool designed to measure both
primary and secondary hypersensitivity objectively. It can be
used in various experimental pain models and could be extended
for use in other species. Results from these studies suggest PAM
will aid the screening of novel analgesics designed to improve
chronic inflammatory pain.
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Abstract
Background: The inflammation that accompanies the pain and swelling associated with osteo- and
rheumatoid arthritis is mediated by complex interactions of inflammatory mediators. Cytokines
play a pivotal role in orchestrating many of these processes, including inflammatory cell
recruitment, adhesion and activation. In addition, prostaglandins are secreted into the synovial
cavity and are involved in perpetuation of local inflammation, vasodilatation and vasoconstriction,
and also with bone resorption. Pre-clinical models have been developed in order to correlate to
the human disease and principle among these is the adjuvant-induced arthritis model in the rat.
Methods: We have developed a technique to quantitatively assess the contents of synovial fluid
samples from rat joints. Two needles joined together are inserted into the knee joint of
anaesthetised rats and connected to a Watson-Marlow perfusion pump. Sterile saline is infused and
withdrawn at 100 |il min-1 until a 250 pi sample is collected.
Results: Our results demonstrate up to 125 fold increases in synovial ILIa and ILI (3
concentrations, approximately 30 fold increases in levels of IL6 and IL 10 and a 200-300 fold
elevation in synovial concentrations of TNFa during FCA-induced experimental arthritis. Finally,
this novel technique has demonstrated a dose-response relationship between FCA and the total
cell counts of synovial perfusates.
Conclusion: In summary, this new technique provides a robust method for quantifying
inflammatory mediators and cells from the synovial cavity itself, thereby detailing the inflammatory
processes from within the capsule and excluding those processes occurring in other tissues
surrounding the entire articulation.
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I. Background
Inflammatory joint diseases such as rheumatoid arthritis
(RA) are regulated by complex interactions involving
many mediators, such as prostanoids and cytokines. The
infiltration of cells into the synovial tissue and joint space
is another key characteristic of synovitis, which combined
with release of these mediators and degradative enzymes,
eventually leads to cartilage and bone destruction (for
reviews see [1]).
Measuring the levels of these mediators of inflammation
in the synovial fluid from patients can provide informa¬
tion about the underlying pathophysiology of joint dis¬
ease [2], for example the level of severity and current
activity (3-5] as well as inter-individual variations in dis¬
ease [6] and effectiveness of drug-treatments (for review
see [7]). Furthermore changes occurring in the synovial
fluid can be used as biomarkers of disease; this has already
been demonstrated in RA patients with plasma levels of
inflammatory proteins [8,9],
Human joint fluid samples have been taken and analysed
for inflammatory mediator content from both healthy
volunteers and patients with joint diseases. These studies
revealed the importance ofparticular cytokines, including
Tumour Necrosis Factor (TNF)a, Interleukin (IL) 1(3, and
IL6, which are now targets for disease-modifying anti¬
rheumatic drugs (DMARDs; for review see [10,11]). Fur¬
thermore increases in virtually all the prostanoids have
been detected from these samples [12,13], but notably
Prostaglandin E2 (PGE2), which has been associated with
erosion of bone and cartilage in RA [ 14-17 ].
Although studies have investigated the fluid taken from
joints, most research has focused on the inflammatory
mediators within the synovial membrane, rather than
those released into the intra-articular space. One reason
for this is the technical difficulty of trying to assess
cytokine levels in such a viscous material as synovial fluid.
Several studies have assessed cytokine gene expression lev¬
els in the synovial membrane, rather than the actual pro¬
tein content, both in human clinical samples ] 18,19] and
in animal models of arthritis [20-22], In addition, PGE
synthase, the enzyme responsible for the conversion of
cyclooxygenase-derived PGH2 to PGE2 has been detected
in synovial tissues of patients with RA [23].
The early time course of release of key mediators cannot
be determined using human synovial fluid samples, as
patients rarely report to the clinic until the disease has
progressed and is causing chronic pain and swelling [24].
Even then, repeated sampling from individuals is difficult,
and most patients are prescribed drugs, to improve their
symptoms and quality of life, which interfere with inflam¬
matory regulatory processes and cytokine expression.
Therefore by using animal models of disease, the early
events of inflammation can be elucidated, and the effects
of drugs on inflammatory markers can be measured under
controlled conditions.
Rat adjuvant-induced unilateral arthritis is a well estab¬
lished RA disease model. [25-27] and use of this model
has gone a long way in aiding the understanding of the
time-course of the pathology in clinical RA. The model
closely mimics the pathology ofhuman RA, including his-
topathological changes, cell infiltration, hypersensitivity
and swelling of the affected joint [28-30]. Previous studies
in animal models of joint inflammation have investigated
the time course of cytokine protein or gene expression
using homogenates of whole rat joints or paws post mor¬
tem [20-22,31-33]. A major limitation of these studies is
that such sampling always includes bone, synovial tissue,
synovial fluid and surrounding muscles and connective
tissue, which will not allow the origin of any analytes to
be determined. Others have surgically dissected and lav-
aged knee joints in order to collect the synovial fluid from
dead animals [34-36]. However, this does not allow for
acute repeated sampling from the same animal over a
period of up to a day to determine the affect of drugs on
the levels of inflammatory mediators, or the acute effect of
an inflammatory insult on inflammatory processes in the
synovial cavity, a significant benefit of the perfusion
method described here. A further study used an in vivo
microdialysis procedure to determine the levels of inflam¬
matory mediators in the synovial fluid of rats with adju¬
vant induced polyarthritis [37]. However, the apparatus
used for this had limitations, for example the molecular
weight cut-off of the microdialysis membrane was 50 kD,
and therefore potentially underestimated the levels of
ILip in the joints. Furthermore, this limits the molecules
that could be assessed by this method, which is in contrast
to the present method, in which there is no limit to the
size of molecules collected. The perfusion technique
described in the present study also allows for the collec¬
tion of cells from the joint space. As yet, no studies appear
to have been carried out by perfusing saline through the
intact joint space and collecting samples of cells and
mediators from intact anaesthetised animals. The primary
aim of this study was to develop a perfusion method to
sample only the synovial fluid. A secondary aim was to
study the effects of a joint insult on the intra-articular
cytokine concentrations and cell infiltrate levels associ¬
ated with adjuvant-induced arthritis in the joint space
were also measured, as these are known key mediators in
human RA conditions.
2. Methods
Experiments were performed in accordance with Home
Office regulations and within UK animal welfare guide¬
lines, and received Local Ethics Committee approval.
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Male Wistar rats (Charles River, UK; initial weight ranges
240-290 g) were used. Rats were housed four to a cage in
a 12-h light: dark environment and were given free access
to standard animal feed and water for the duration of the
study.
2.1 Arthritis induction
Briefly, rats (8) were transiently anaesthetised using 3%
halothane in oxygen. The left knee was injected with 150
pi of Freund's Complete Adjuvant (FCA; 1 mg ml1 Myco¬
bacterium tuberculosis, Sigma, UK; i.art). A further 3 rats
received a higher dose of FCA (500 pg), in order to assess
the effect of adjuvant dose on inflammatory cell recruit¬
ment and mediator release into the joint space (100 pi; 5
mg ml-1 Mycobacterium tuberculosis, MAFF, UK; i.art).
Only 3 rats were used for this part of the study, as it was
designed as a pilot study to determine whether differences
in the number of inflammatory cells and mediators
present in the knee joint were evident between normal
animals and those injected with the two doses ofadjuvant
using this new technique. The right joints were untreated.
Animals were then allowed to recover from the anaesthe¬
sia.
2.2 Perfusion of joint space and analysis of samples
2.2.1. The perfusion needles
A needle perfusion system was constructed by binding a
25- and a 23-gauge needle together using epoxy putty,
with the bevels of the needles positioned on the outside
edges facing away from one another (see Figure 1). The
tips of the needles were set 1-1.5 mm apart.
2.2.2. Perfusion of knee joints
Rats were anaesthetised with urethane (ethyl carbamate;
0.6 ml 100 g'1 body weight; 25% wv1 solution; single i.p.
Figure I
The perfusion needles and the perfusion system managing
inflow and outflow from the knee joint space. A Watson-
Marlow pump controlled the rate of saline infusion and sam¬
ple extraction (100 pi mirr1) from the joint. After the knee
was secured to prevent movement of the limb, needles were
inserted into the knee joint through the patella tendon.
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injection). Once fully anaesthetised the animal was laid
on its back on an automated heating blanket (Harvard
Apparatus Limited, UK) and its core body temperature
maintained at 37 °C via a thermistor probe positioned in
the rectum.
The limbs of the rat were flexed over a 20 ml glass vial,
with the patella facing directly upwards for insertion of
the perfusion needles, and the limb was secured in place
with tape. The 23-gauge needle was connected to a
Watson-Marlow roller pump via silicone mbber perfusion
tubing (internal diameter 1 mm, external diameter 4.2
mm, Watson Marlow, UK). Sterile saline was infused at a
constant rate of 100 pi min1. After infusion of 100 pi of
vehicle (sterile saline), the outflow tubing was connected
to the 25-gauge needle, to minimise pressure build-up
within the joint space. Fluid was infused and withdrawn
at a constant rate until a 250 pi basal sample was collected
in a 1.5 ml centrifuge tube. Samples were immediately fro¬
zen at -20 °C.
2.2.3 Cytokine assay ofjoint samples
Luminex assay
Samples from the studies investigating the effects of
anaesthetic on joint cytokine levels (n = 10) and the dif¬
ferences between normal (n = 10), high dose FCA-injected
(n = 3) and low dose FCA- injected joints (n = 8) were ana¬
lysed using a multi-cytokine bead array detection system
capable of detecting rat ILla, ILip, IL2, IL4, 1L6, IL10,
Interferon (IFN) y, Granulocyte Macrophage-Colony
Stimulating Factor (GM-CSF) andTNFa, according to the
manufacturers instructions (Bio-Rad cytokine rat 9-plex,
Biorad, USA). Briefly, a monoclonal antibody directed
against the desired analyte was covalently coupled to dyed
5.5 pm polystyrene beads (2.5 x 106 beads ml"1 cytokine-
!). The conjugated beads were exposed to 50 pi of sample
or standard solutions containing a known amount of
cytokine, in a 96-well filter plate and incubated overnight
at 4°C, protected from light. After a series of washes and
vacuum filtration to remove unbound protein, a bioti-
nylated detection antibody specific for a different epitope
on the analyte was added to the reaction. After incubation,
the unbound antibody was removed; the reaction mixture
was detected by the addition of streptavidin-phycoeryth-
rin (streptavidin-PE), which binds to the biotinylated
detection antibodies. Following a further series ofwashes
and vacuum filtration, the beads were re-suspended in
200 pi 5% BSA in PBS; the plate was stored at 4°C in the
dark until analysis. The reaction mixture was read using a
Luminex Data Collector in a Luminex 100 flow cytometer
(Luminex, USA). The minimum detection limit of the
assay was 2 pg mk1 for each mediator measured. Any val¬
ues lower than these levels were classed as 0 for the pur¬
poses of this study.
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Luminex data analysis
Excel data files were generated containing individual bead
numbers and the associated median fluorescence intensi¬
ties. Standard curves were plotted to calculate the relative
amount of each cytokine in samples, using the aliquoted
serial dilutions of a positive control solution for calibra¬
tion. Unknown sample cytokine concentrations were cal¬
culated from the curve.
ELISA assay
The levels ofTNFa and ILp in samples from studies inves¬
tigating the effects of the needles (n = 6), and leakage of
infusion from the joint cavity (n = 2) were measured using
commercially available ELISA kits that specifically recog¬
nize the rat cytokines (BioSource International,
Camarillo, USA) according to the manufacturer's instruc¬
tions. Briefly, 100 pi aliquots of sample were pipetted into
the wells of a microtiter plate pre-coated with an antibody
specific for rat IL-ip or TNFa and incubated for 3 h at
room temperature. After washing, a different biotinylated
anti-rat IL-ip or TNFa antibody was added and incubated
at ambient temperature for 1 h. Streptavidin-peroxidase
was added and incubated for 30 min. After a third incuba¬
tion and washing to remove all unbound enzyme, colour
was developed by addition of stabilized chromogen
(tetramethylbenzidine), a stop solution added and the
intensity of the coloured product quantified spectropho-
tometrically at 450 nm. The minimum detection limit of
the assay was 2 pg ml'1.
2.3 Study design
2.3.1 Anaesthetic effects
In order to determine what effect anaesthetic agents had
on inflammatory mediators in joints, control experiments
were carried out. Firstly, five naive rats were anaesthetised
with urethane (ethyl carbamate; 0.6 ml 100 g1 body
weight; 25% w v1 solution; single i.p. injection), and five
further rats with sodium pentobarbital (1 ml kg-1 body
weight; 60 mg ml1 solution; single i.p. injection main¬
tained with i.v. 375 pi hr1 20 mg ml'1 solution of pento¬
barbital). No other procedures were carried out for 7
hours, atwhich point perfusion needles were inserted into
both knee joints and a 250 pi sample collected. The sam¬
ple was frozen immediately at -20 °C, and later assayed
using the Luminex assay.
2.3.2 Needle effects
In order to determine what effects inserting the perfusion
needles had on synovial cytokine concentrations, an
experiment was carried out in which six animals were
anaesthetised with urethane (as described above), and the
perfusion needles inserted into both knee joints and held
in position for 7 hours, at which time a 250 pi sample was
collected. The sample was frozen immediately at -20 °C,
and later assayed using an ELISA.
2.3.3 Perfusion effects on the concentration of analyte
Two naive rats were anaesthetised with urethane (as
described above) and a basal sample taken immediately.
Then 1000 pg recombinant rat IL1 (3 (Bioclone, USA) in
100 pi was infused over 1 min. A second sample was
takenl hour later; this was repeated hourly until 7 hours
post-ILip infusion. The samples were frozen and later
assayed for ILip content using an ELISA, to determine if
the sample contained the same amount of ILip that was
initially infused.
2.3.4 Cytokine levels in normal and FCA-injected joints
Basal samples from ipsilateral and contralateral joints of
10 normal animals were compared with basal samples
from 8 rats which had received i.art low dose FCA (150
pg) and 3 that were injected with i.art high dose FCA (500
pg) 14 days earlier. Samples (250 pi) were collected and
frozen for later testing with the Luminex bead array.
2.3.5 Total cell counts
Joint perfusion samples were collected from ten naive rat
knee joints, eight 150 pg FCA-injected ipsilateral and con¬
tralateral joints and three 500 pg FCA-injected ipsilateral
and contralateral joints. Undiluted samples were viewed
by light microscopy in a haemocytometer. If red blood
cells were present, or a high number of inflammatory
cells, samples were diluted in saline, with added Zap-
poglobin, as per the manufacturer's instructions (1 drop
per 20 ml).
2.4 Data Analysis
Data were collected and analysed using Microsoft Excel
and Graphpad Prism software. Results are expressed as
mean ± standard error of the mean (SEM) where appropri¬
ate.
Statistics
The Mann-Whitney U (non-parametric) test was used to
analyse differences between groups, which were not nor¬
mally distributed, or in which the sample size was small.
To determine differences between the means ofmore than
two groups a non-parametric one-way analysis ofvariance
(Kruskal-Wallis) test was performed and a post-hoc test
(Dunn's) undertaken if the test was significant. In all cases
the null hypothesis was rejected at P < 0.05.
3. Results
3.1 Anaesthetic effects
Samples from naive animals (n = 5) which received no
treatment during 7 hours ofurethane anaesthesia, showed
a slight trend for increased levels of cytokines, but the
increases were not statistically significant for ILla, ILip,
IL2, IL4, IL6, IL10, GM-CSF, IFNy, or TNFa compared
with samples taken from rats immediately after adminis¬
tration of anaesthetic (n = 10; P > 0.05, Mann Whitney)
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see Table 1. However, in contrast, animals anaesthetised
with pentobarbital (n = 5), had significantly higher levels
of GM-CSF and TNFa (P < 0.05, Mann Whitney) after 7
hours, in comparison with naive joints, see Table 1.
3. 2 Needle effects
Samples taken from knee joints in which the perfusion
needles had been in place for 7 hours while the animal
was anaesthetised with urethane (n = 6) showed increased
levels ofTNFa, as measured by ELISA, but these were not
statistically significant from basal samples from the same
rats immediately after needle insertion (P > 0.05, Mann
Whitney). ILip levels in two joints increased to approxi¬
mately 40 pg ml-1 over this time period, see Figure 2.
3.3 Perfusion effects on the concentration of analyte
Two joint perfusions were carried out to determine if any
of the infused solution leaked from the joint space prior
to withdrawal of samples. Recombinant rat ILip (1000
pg), a cytokine known to be detectable by ELISA, was
infused into the joint, along with saline, and samples were
collected hourly. In both cases the full amount (1000 pg)
administered was recovered in the first two samples. How¬
ever, a greater amount of ILip was recovered compared to
the initial dose administered; Table 2 shows the results.
3.4 Levels of cytokines in normal and FCA-injected joints
Fourteen days after rats received 150 pg or 500 pg FCA
i.art (n = 8 and 3 respectively), the ipsilateral joint con¬
tained significantly higher levels of ILla, ILip, IL6 and
TNFa compared with samples from naive joints (n = 10),
as measured by the Luminex assay (P < 0.05, Two-way
ANOVA; see Figure 3a). The contralateral joints of rats
injected with 500 pg FCA also contained significantly
higher levels of ILla, ILip, IL6 and TNFa (P <0.05, Two-
way ANOVA; see Figure 3b).
3.5 Total cell counts
Total inflammatory cell counts from normal animals (n =
5) and those injected with FCA (n = 8) 14 days prior to
sampling are shown in Figure 4. Normal joints had no
cells detectable, whereas all others samples had measura¬
ble levels. However, only the 500 pg FCA ipsilateral (n =









Basal (n»6) 7h (n-6)
Figure 2
Levels of (a) TNFa and (b) ILIP from joints immediately after
needle insertion (basal), and 7 hours later. Cytokines were
assayed using an ELISA, and although there was an apparent
increase in TNFa concentrations, to approximately 300 pg
ml"1 in two samples, this was not statistically significant (P >
0.05, Mann Whitney). The horizontal lines on the graphs rep¬
resent the median values in each group.
cells than normal joints (4.8 ± 0.06 x 106 cells ml1; P <
0.05, Mann Whitney). A dose-response relationship was
demonstrated by the total cell count in both ipsilateral
and contralateral joints.
4. Discussion
The main aim of this study was to develop a method for
sampling synovial fluid from the knee joint of anaesthe¬
tized rats. The technique was firstly validated by assessing
whether any inflammatory response was evoked by the
experimental set up, including the anaesthetic or the nee¬
dles themselves; the efficiency of the system was investi¬
gated, i.e. whether any infused solution leaked from the
joint space prior to sample extraction. Once the above fac¬
tors had been assessed, they were taken into consideration
when comparing samples from naive and adjuvant-
injected inflamed joints. Finally, the novel perfusion tech¬
nique was used to quantify inflammatory cell numbers
within the rat synovial cavity. This technique proved to be
reliable and consistent when perfusing the joint cavity,
and regular volumes of sample were easily collected.
There were no problems with measuring protein content
due to high sample viscosity, and this technique is there¬
fore a valuable addition to protocols which use homoge-
nates of entire joints to assess inflammatory mediator
content.
Table I: The effect of anaesthetic on basal levels of cytokines in the joint.
ILla ILip IL2 IL4 IL6 ILI0 GM-CSF IFNy TNFa
Basal (n = 10) 0.8 ± 0.5 1.0 ± 1.0 0.5 ± 0.5 0.2 ± 0.2 2.5 ± 2.5 1.5 ± 1.0 0 ± 0 0.1 ±0.1 0.2 ± 0.2
Mean ± SEM
Urethane (n = 5) 2.6 ± I.I 0±0 0±0 0 ± 0 0±0 0 ± 0 1.0 ± 0.6 0.3 ± 0.3 36.6 ± 20.9
Mean ± SEM
Pentobarbital (n = 5) 1.4 ± 0.7 0.2 ± 0.2 0.1 ± 0.1 0±0 0±0 6.2 ± 6.2 1.7 ± 0.4* 0.1 ± 0.1 44.2 ±21.6*
Mean ± SEM
Levels of nine cytokines in rats anaesthetised for 7 hours with either urethane or pentobarbital, in comparison with samples taken immediately after
urethane anaesthesia (basal). Mann Whitney test were performed to determine differences between each anaesthetic and basal levels. Pentobarbital
anaesthesia resulted in a significant elevation of GM-CSF and TNFa levels; statistical significance P < 0.05 indicated by *.
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Table 2: Perfusion effects on the concentration of analyte.
Animal I Animal 2
ILIp concentration (pg ml-1; 250 pi) Amount of ILI j! (pg) ILip concentration (pg ml"1; 250 pi) Amount of ILip
(Pg)
I hour 2000 500 2000 500
2 hour 2000 500 2000 500
3 hour 200 SO 356 89
4 hour 544 136 216 54
5 hour 350 87.5 210 52.5
6 hour 458 1 14.5 200 50
7 hour 318 79.5
Total (pg) 1467.5 1245.5
ILI p concentrations in each 250 pi sample collected, up to 7 hours post-infusion of ILIp (1000 pg). The amount of ILip protein in each sample was
calculated and summed, to show that little or no leakage from the joint space occurred. In fact, more IL I p was present than was injected, in both
cases as a result of de novo release of endogenous IL I p protein.
It was established that the choice of anaesthetic may play
a role in initiating an inflammatory response within the
knee joints. Urethane, a hypnotic anaesthetic agent com¬
monly used for laboratory animals, resulted in very little
change in any of the mediators measured over a 7 hour
period. In contrast, pentobarbital (pentobarbitone), a
short-acting anaesthetic which must be maintained by i.v
infusion, therefore requiring further surgical preparation
of the animal, induced increases in GM-CSF and TNFa
after continuous administration during the day, perhaps a
result of the surgery of the implanted cannulae. It was
therefore decided to use urethane for experiments, given
that it provides an extended period of anaesthesia with
minimal physiological changes [38], without the need for
invasive surgical preparation. Furthermore, pentobarbital
can cause respiratory depression in rats, whereas urethane
causes minimal cardiopulmonary disturbances [38,39].
Once it was established that urethane anaesthesia had no
adverse effects on the system, it was necessary to evaluate
any inflammatory component as a result of the perfusion
needles themselves, over a sustained time period of 7
hours. It was noted that a few rats developed increased
TNFa or ILip levels as a result of the needles being main¬
tained within the joint. However, the change occurred in






% S 50 J J J( J
□ Normal (n-10)
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■ High dose FCA (n=3)
Figure 3
Levels of ILI a, ILI p, IL6, ILI0 and TNFa in (a) ipsilateral and
(b) contralateral joints of normal rats and those injected with
low (150 pg; n = 8) and high (500 jig; n = 3) dose FCA 14
days earlier. There were negligible levels of any of the media¬
tors measure in naive joints (n = 10), but a significant
increase in the expression of ILI a, ILI p, IL6 and TNFa was
seen in all ipsilateral inflamed joints and in contralateral joints
of rats injected with the high dose FCA (P < 0.05, Two-way
ANOVA; compared with normal joints); statistical signifi¬














The effects of 150 pg (low dose; n = 5) and 500 pg (high
dose; n = 3) FCA on total cell count from joint perfusates.
Naive joints contained no cells (0), whereas all other joints
contained increased levels, although only high dose ipsilateral
joints proved to have significantly raised levels (P < 0.05,
Mann Whitney); statistical significance donated by *.
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the increases in the two mediators did not occur in the
same animals.
This study has demonstrated that very little, if any, solu¬
tion infused into the joint is lost into the surrounding tis¬
sue, and can be recovered in full through the effusion
tubes. This was confirmed by injection of Evans blue dye
into the joint cavity and later dissection of the tissue (data
not shown here). Furthermore, there was an increased
quantity of ILip detected in the perfusate collected.
Although this study was not designed to show the effects
of the protein on the joint, the 1 ng dose of ILip adminis¬
tered resulted in de novo release of natural IL1 p, as shown
by the fact that elevated levels of IL1 were detected, in
addition to the 1 ng dose.
Adjuvant-induced arthritis is a widely used model of
inflammatory joint disease, and will be the primary sub¬
ject of future studies applying this novel perfusion
method. It was therefore important that samples collected
in this way could detect differences between cytokine lev¬
els in naive joints and FCA-treated joints. Levels of all
cytokines measured in this study (ILla, ILip, IL6, IL10
and TNFa) showed dramatic increases 14 days after an
initial inflammatory insult to the joint, including high
and low doses ofFCA. Furthermore, the contralateral joint
of rats injected with the high dose of FCA also had higher
levels of all cytokines measured, illustrating the contralat¬
eral effect also noted in the inflammatory cell count study.
Finally, this study investigated the total number ofwhite
blood cells present in the joint washout samples. Not sur¬
prisingly it was observed that FCA-injected joints con¬
tained higher levels than normal rat knee joints, as
previously shown [40]. However, of particular interest are
the cell counts in contralateral, non-injected limbs. Con¬
tralateral effects arising from a unilateral insult is a well
documented phenomenon. In general, contralateral
changes in behaviour, magnitude of biochemical fluctua¬
tions or histopathological lesions are less than those
observed on the ipsilateral side (for review see [41 ]). Total
cell count data from this study are in agreement with this
finding, and although the lower dose of FCA used here
does not elicit behavioural signs of inflammation or
hypersensitivity in the contralateral joint, there is evi¬
dence of infiltration of inflammatory cells.
5. Conclusion
In summary, we have demonstrated the use of a novel
method for sampling synovial fluid and washing out the
joint cavity to collect the "inflammatory soup", and have
performed assays to measure levels of cytokines during
adjuvant-induced arthritis. This method has the advan¬
tage of enabling the contents of synovial fluid to be inves¬
tigated alone, without the contamination of the
surrounding tissue. We have also revealed its value in
measuring cellular components of inflammation. In con¬
clusion, as this new method of joint perfusion uses anaes¬
thetised animals, acute effects of anti-inflammatory drugs
or novel compounds could be investigated, thus improv¬
ing the knowledge of how novel drug targets are affecting
the inflammatory process.
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